
<html lang="en"     class="pb-page"  data-request-id="20c78701-573c-4cff-89a3-a9fa4276d153"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b00438;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2016.59.issue-20;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective" /></meta><meta name="dc.Creator" content="Luca  Carlino" /></meta><meta name="dc.Creator" content="Giulio  Rastelli" /></meta><meta name="dc.Description" content="Protein kinases play crucial roles in several cell transformation processes and are validated drug targets for many human diseases, including cancer. Nevertheless, most tumors have eluded the effec..." /></meta><meta name="Description" content="Protein kinases play crucial roles in several cell transformation processes and are validated drug targets for many human diseases, including cancer. Nevertheless, most tumors have eluded the effec..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 7, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00438" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00438" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00438" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00438" /></link>
        
    
    

<title>Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00438" /></meta><meta property="og:title" content="Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0007.jpeg" /></meta><meta property="og:description" content="Protein kinases play crucial roles in several cell transformation processes and are validated drug targets for many human diseases, including cancer. Nevertheless, most tumors have eluded the effects of inhibition of a single kinase by activating resistance mechanisms and/or alternative pathways and escape mechanisms. In recent years, multitarget approaches directed toward inhibition of kinases and targets of different families have received increasing attention. In particular, co-targeting kinases and bromodomain epigenetic reader proteins has rapidly emerged as a promising approach to cancer drug development. In this manuscript, we will review the recent discoveries that led to the identification and optimization of dual kinase/bromodomain inhibitors. We will analyze and compare the structural features required for dual inhibition and comment on the potential of this approach in anticancer drug discovery. Moreover, we will introduce computational approaches useful for the identification of dual kinase/bromodomain inhibitors and generate ad hoc pharmacophore and docking models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00438"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00438">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00438&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00438&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00438&amp;href=/doi/10.1021/acs.jmedchem.6b00438" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 9305-9320</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00473" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b00596" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luca++Carlino">Luca Carlino</a></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giulio++Rastelli">Giulio Rastelli</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Life Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: +39 059 2058564. E-mail: <a href="/cdn-cgi/l/email-protection#37505e425b5e581945564443525b5b5e7742595e5a584552195e43"><span class="__cf_email__" data-cfemail="cfa8a6baa3a6a0e1bdaebcbbaaa3a3a68fbaa1a6a2a0bdaae1a6bb">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00438&amp;href=/doi/10.1021%2Facs.jmedchem.6b00438" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 9305–9320</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 25, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 March 2016</li><li><span class="item_label"><b>Published</b> online</span>7 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00438" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00438</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9305%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLuca%2BCarlino%252C%2BGiulio%2BRastelli%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D20%26contentID%3Dacs.jmedchem.6b00438%26title%3DDual%2BKinase-Bromodomain%2BInhibitors%2Bin%2BAnticancer%2BDrug%2BDiscovery%253A%2BA%2BStructural%2Band%2BPharmacological%2BPerspective%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9320%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00438"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2419</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">31</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00438" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;Carlino&quot;},{&quot;first_name&quot;:&quot;Giulio&quot;,&quot;last_name&quot;:&quot;Rastelli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9305-9320&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00438&quot;},&quot;abstract&quot;:&quot;Protein kinases play crucial roles in several cell transformation processes and are validated drug targets for many human diseases, including cancer. Nevertheless, most tumors have eluded the effects of inhibition of a single kinase by activating resistance mechanisms and/or alternative pathways and escape mechanisms. In recent years, multitarget approaches directed toward inhibition of kinases and targets of different families have received increasing attention. In particular, co-targeting kinases and bromodomain epigenetic reader proteins has rapidly emerged as a promising approach to cancer drug development. In this manuscript, we will review the recent discoveries that led to the identification and optimization of dual kinase/bromodomain inhibitors. We will analyze and compare the structural features required for dual inhibition and comment on the potential of this approach in anticancer drug discovery. Moreover, we will introduce computational approaches useful for the identification of dual kinase/bromo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00438&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00438" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00438&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00438" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00438&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00438" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00438&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00438&amp;href=/doi/10.1021/acs.jmedchem.6b00438" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00438" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00438" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00438%26sid%3Dliteratum%253Aachs%26pmid%3D27559828%26genre%3Darticle%26aulast%3DCarlino%26date%3D2016%26atitle%3DDual%2BKinase-Bromodomain%2BInhibitors%2Bin%2BAnticancer%2BDrug%2BDiscovery%253A%2BA%2BStructural%2Band%2BPharmacological%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D20%26spage%3D9305%26epage%3D9320%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/jmcmar.2016.59.issue-20/20161027/jmcmar.2016.59.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Protein kinases play crucial roles in several cell transformation processes and are validated drug targets for many human diseases, including cancer. Nevertheless, most tumors have eluded the effects of inhibition of a single kinase by activating resistance mechanisms and/or alternative pathways and escape mechanisms. In recent years, multitarget approaches directed toward inhibition of kinases and targets of different families have received increasing attention. In particular, co-targeting kinases and bromodomain epigenetic reader proteins has rapidly emerged as a promising approach to cancer drug development. In this manuscript, we will review the recent discoveries that led to the identification and optimization of dual kinase/bromodomain inhibitors. We will analyze and compare the structural features required for dual inhibition and comment on the potential of this approach in anticancer drug discovery. Moreover, we will introduce computational approaches useful for the identification of dual kinase/bromodomain inhibitors and generate ad hoc pharmacophore and docking models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer has become one of the leading causes of death worldwide, with 8.2 million cancer related deaths in 2012 and new cases expected to rise to 22 million in the next 2 decades.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Despite the considerable progress that has been made in cancer therapy, fighting this disease remains a major challenge. In fact, more effective therapeutic approaches are still needed to increase the arsenal of “weapons” at our disposal.</div><div class="NLM_p">In 2002, Cohen defined protein kinases as the “targets of the twenty-first century” based on their involvement in most aspects of cell function and aberrant growth.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Protein kinases represent one of the largest protein families in the entire human genome.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> They are involved in intracellular signaling processes, catalyzing the transfer of the γ-phosphate of ATP to downstream protein substrates.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Kinase activity is regulated by phosphorylation of specific residues involved in the catalytic reaction and is crucial for cellular growth and differentiation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Protein kinases are considered the main actors in several cell transformation processes and human pathologies, including cancer, inflammation, neurological and endocrine disorders, immunodeficiency, and cardiovascular diseases.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Structurally, protein kinases exist in an “on” state, in which the protein displays full phosphorylation capability and a conserved three-dimensional structure with an accessible active site, and an “off” state, in which the protein is inactive and adopts different conformational states depending on the mechanism by which the active site is blocked.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> Protein kinases are formed by two distinct lobes connected by a flexible hinge region. The N-lobe (N-terminal domain) is composed of five-stranded β-sheets and one α helix (αC helix), whereas the C-lobe (C-terminal domain) is mainly composed of α-helices. The active site is located between the two lobes and contains the ATP and substrate binding pockets.</div><div class="NLM_p">Traditionally, the development of kinase inhibitors has been strongly focused on the identification of ATP competitive (type I) inhibitors.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Although many potent type I ligands have been identified, some of which are on the market, focusing on the ATP site proved to have major limitations such as drug resistance due to mutations or the activation of alternative pathways, poor selectivity among kinases due to the high conservation of the ATP binding site, and inhibitor displacement as a result of high intracellular ATP concentrations.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These disadvantages are only partially avoided by the development of new generations of ATP competitors that extend into additional cavities in proximity to the ATP-binding pocket, such as type II inhibitors, which bind to an inactive conformation in which the DFG motif is flipped outward (DFG-out conformation).<a onclick="showRef(event, 'ref11 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref14">(11, 13, 14)</a> Furthermore, truly allosteric compounds targeting allosteric pockets in proximity to the ATP site (type III inhibitors) or other inhibitors that stabilize the protein in an inactive conformation through binding to allosteric sites distal to the ATP binding pocket (type IV inhibitors) have been reported.<a onclick="showRef(event, 'ref12 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref12 ref15 ref16 ref17 ref18">(12, 15-18)</a> However, despite the huge investments and the large arsenal at our disposal, fighting cancer with kinase inhibitors is still severely hampered by the fact that most tumors can escape from inhibition of a single kinase.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This is mainly due to resistance mechanisms, such as the mutation of the target, the activation of surrogate kinases, or the modulation of pathway components.<a onclick="showRef(event, 'ref10 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref10 ref20 ref21 ref22">(10, 20-22)</a> Cancer resistance mechanisms are associated with known protein kinase inhibitors<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> but may also arise from drugs that hit newer anticancer targets, such as bromodomain epigenetic reader proteins (BRDs). For instance, mechanisms leading to BRD inhibitor resistance in leukemia stem cells and in triple-negative breast cancer cells (TNBCs) have been previously reported.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> In leukemia stem cells, resistance may arise through cancer cell adaptation processes that are facilitated by inactivation of the polycomb repressive complex 2 (PRC2) as well as by the presence of a subpopulation of cells with intrinsically increased expression of the WPT/β-catenin pathway. In TNBC, resistance to BRD inhibitors has not been fully explained, although epigenetic mechanisms have been described.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> Newer approaches in drug discovery, comprising drugs able to hit multiple targets, have been proposed as possible solution to these problems. Polypharmacological approaches include the concomitant inhibition of targets involved in the same or in multiple disease pathways.<a onclick="showRef(event, 'ref19 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref19 ref27 ref28 ref29">(19, 27-29)</a> In both cases, rational polypharmacological approaches require a thorough understanding of the disease pathway and target interconnections, which is difficult to achieve and thus remains a major challenge.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p last">In the past years, co-targeting kinases and BRDs has emerged as a promising approach to cancer drug development. In this manuscript, we will review the recent discoveries that led to the identification and optimization of dual kinase/BRD inhibitors. We will analyze and compare the structural features required for dual inhibition and comment on the potential of this approach in anticancer drug discovery. Moreover, we will introduce computational approaches useful for the identification of dual kinase/BRD inhibitors and generate ad hoc pharmacophore and docking models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Intrafamily Polypharmacology in Protein Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multitarget inhibition of cancer-associated kinases (intrafamily polypharmacology) is an established strategy to improve the efficacy and clinical outcome of targeted therapies. Several well-known kinase inhibitors are known to inhibit more than one kinase.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> One example is the well-known anticancer drug imatinib (<b>1</b>, STI-571, Gleevec,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which was released on the market in 2001. This molecule, initially developed to selectively inhibit BCR-ABL for the treatment of chronic myeloid leukemia (CML), was later found to inhibit two related tyrosine kinases: c-Kit for the treatment of gastrointestinal stromal tumor (GIST) and the platelet-derived growth factor receptors (PDGFRs) for the treatment of dermatofibroma sarcoma protuberans.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In fact, several clinically relevant multitarget kinase inhibitors did not result from rational polypharmacological approaches, and in most cases their multitarget activity was discovered only accidentally.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Examples of marketed drugs showing intrafamily polypharmacology are dasatinib (<b>2</b>, BMS-354825, Sprycel,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), another ABL-BCL inhibitor which also inhibits SRC family tyrosine kinases (used against CML and especially for phenotypes resistant to <b>1</b>), and sunitinib (<b>3</b>, SU11248, Sutent,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which is recognized as one of the most promiscuous multikinase inhibitors.<a onclick="showRef(event, 'ref30 ref35'); return false;" href="javascript:void(0);" class="ref ref30 ref35">(30, 35)</a> Moreover, vandetanib (<b>4</b>, ZD6474, Zactima,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) is another example of an intrafamily polypharmacological drug. This compound inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), EGFR, and ErbB2.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In 2010, Shokat et al. designed a compound (<b>5</b>, pp121<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) with dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitory activity.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> PI3K is involved in several diverse cellular functions, such as cell growth, survival and migration, metabolism, and intracellular vesicular transport,<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38-40)</a> whereas mTOR is responsible of the feedback loop activation that inhibits PI3K.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Today, several compounds showing dual PI3K/mTOR inhibitory activity are under evaluation in clinical trials.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Other examples of kinase inhibitors resulting from intrafamily polypharmacology approaches have been reported.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, considering the high sequence and structural similarity among kinases, developing intrafamily polypharmacological drugs able to selectively bind desired combinations of kinases is difficult and generally prone to off-target effects and side effects.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of kinase inhibitors, BET inhibitors, and dual kinase/BET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Bromodomains: Structures and Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">BRDs have recently been discovered as druggable targets in tumorigenesis and inflammatory diseases.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41-43)</a> In vivo, gene transcriptional activation/repression is regulated by modifications to chromatin fibers. Covalent modifications of histones, the basic unit of chromatin, are involved in the so-called epigenetic code, being responsible for the control of chromatin fiber compactness.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Proteins involved in the regulation of this code are classified according to their function: “writers” are proteins that form the code by attaching the covalent flags, such as histone acetyltransferases (HATs) and histone methyltransferases (HMTs); “erasers” are enzymes that remove the covalently bound histone marks from the histones, for example, histone deacetylases (HDACs) and histone demethylases;<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and finally, “readers” are proteins able to read the histone code without introducing any modification to the covalently bound flags, such as plant homeodomains (PHDs) and members of the royal family of methyl-lysine-binding domains.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> BRDs belong to the “readers” class and specifically interact with ε-N-acetylated lysine residues of histone complexes without introducing any modification to the covalently bound flag present on the substrate.<a onclick="showRef(event, 'ref41 ref45'); return false;" href="javascript:void(0);" class="ref ref41 ref45">(41, 45)</a> BRDs fine-tune the activity of transcriptional regulators, chromatin modulators, and chromatin modifying enzymes through surface protein–protein interactions, and for this reason they are considered relevant targets in drug discovery.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49">(46-49)</a></div><div class="NLM_p">BRDs are grouped into eight subfamilies representing 61 diverse BRDs from 46 different proteins.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The crystal structures of more than 40 BRD-containing proteins have been solved and deposited in the Protein Data Bank (PDB). Although their primary sequences share low similarity, all BRDs share a conserved three-dimensional structure, consisting of four α-helices (αZ, αA, αB, and αC) and two loops that contribute to substrate specificity (the BC loop and the ZA loop).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Only three residues (two tyrosine residues and one asparagine) together with a network of structural water molecules forming the so-called ZA channel are conserved features of BRDs and mandatory hot spots for substrate recognition and binding.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Although their involvement in nuclear protein in testis (NUT) midline carcinoma (NMC) was demonstrated in 2001,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> members of the BRD and extraterminal (BET) domain family (BRD2, BRD3, BRD4, and BRDT), a BRD subfamily group that shows two different N-terminal tandem BRDs (BD1 and BD2), received considerable attention in cancer drug discovery only recently.<a onclick="showRef(event, 'ref41 ref48 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref41 ref48 ref51 ref52">(41, 48, 51, 52)</a> The translocation of genes that involve NUT and BRD4 or BRD3 encodes a BRD4/3-NUT protein that blocks the cellular differentiation and inactivates the p53 protein.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Moreover, BRD4-NUT inhibitors (described below) favor epithelial differentiation, tumor reduction, and survival in BRD4-NUT xenograft mice.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In 2011, Sims et al. performed gene expression profiling in LP-1 (human myeloid leukemia) and Raji (Burkitt lymphoma) cell lines treated with known BET inhibitors, demonstrating that the most down-regulated gene was that for c-MYC, a well-known transcription factor involved in several human malignancies, such as Burkitt lymphoma (BL) and acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p last">The first small molecules specifically designed as BET-family selective inhibitors were reported by Knapp et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and Tarakhovsky et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> in 2010. The authors identified a benzodiazepine based inhibitor (<b>6</b>, iBET<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) able to confer protection against bacteria induced sepsis and a thienodiazepine-based inhibitor (<b>7</b>, (+)-JQ1<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) able to induce squamous differentiation and growth arrest in a BRD4-dependent NMC cell line. The crystal structures of <b>6</b> and <b>7</b> in complex with BRD4 were also described.<a onclick="showRef(event, 'ref54 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref56">(54, 56)</a> In 2011, Nicodeme et al. reported another small molecule nanomolar inhibitor of the BET bromodomain family (<b>8</b>, GW841819X,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) containing a benzodiazepine scaffold.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> More recently, several BET inhibitors have been published and evaluated as potential anticancer agents,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> indicating that BRD inhibitors are endowed with significant therapeutic potential.<a onclick="showRef(event, 'ref43 ref49'); return false;" href="javascript:void(0);" class="ref ref43 ref49">(43, 49)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Synergy between Kinase and Bromodomain Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Interestingly, members of the kinase and BET families are known to be involved in the same disease pathways. For example, both JAK kinases and BRD4 demonstrated key roles in multiple myeloma models.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> Moreover, the Fms-related tyrosine kinase 3 (FLT3) and BRD4 are considered important targets in AML.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> In 2014, Bhalla et al. reported a synergistic lethal effect on AML cultured cells as well as AML stem/blast progenitor cells (BPCs) expressing FLT3-ITD mutations by co-treatment with <b>7</b> and known FLT3 inhibitors such as quizartinib (AC220).<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61, 62)</a> Likewise, synergistic effects (in vitro lethality and in vivo activity) of <b>7</b> and ibrutinib (PCI-32765),<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> a covalent inhibitor of Bruton tyrosine kinase (BTK), against mantle cell lymphoma (MCL) were reported.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Interestingly, it was demonstrated that co-treatment with <b>7</b> and ibrutinib has higher efficacy, compared to the treatment with each agent alone, in immune-depleted mice engrafted with human MCL. In the same article, the authors reported for the first time that co-treatment with <b>7</b> and palbociclib (PD-0332991),<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> a known cyclin dependent kinase 4/6 (CDK4/6) selective inhibitor, is synergistically lethal against MCL cultured cells that display in vitro resistance to ibrutinib.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Zhou et al. observed synergistic effects in growth inhibition and induction of apoptosis of HeLa and H1792 (small-cell lung cancer) cell lines after co-treatment with i-CDK9<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> (a selective inhibitor of CDK9 protein) and <b>7</b>, which is responsible for down-regulation of the c-MYC gene.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Moreover, Baker et al. found that the combinatorial treatment with <b>7</b> and known CDK inhibitors, such as flavopiridol (<b>9</b>, HMR-1275,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) or dinaciclib (<b>10</b>, SCH-727965,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), enhances osteosarcoma (OS) cell death up to 50% more than any of those drugs alone.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Moreover, they described the improvement of the OS cells response to the anthracycline antitumor antibiotic doxorubicin (Adriamycin)<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> when co-treated with <b>7</b>. Considering the side effects shown by treatment with doxorubicin,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> therapeutic strategies aimed at reducing its dose while achieving the same level of in vivo activity definitely showed improved tolerability.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The authors also discovered that the <b>7</b> anti-OS activity is c-MYC independent despite the already reported connection between BET inhibition and c-MYC suppression in multiple models.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Finally, synergistic effects between BET inhibitors and inhibitors targeting the PI3K pathway in different tumor types have been recently described.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72-74)</a></div><div class="NLM_p last">Overall, these findings indicate that a combination therapy based on kinase and BET inhibitors may provide significant therapeutic benefit.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Considering the side effects shown by several approved protein kinase inhibitors,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> a specific combination of kinase and BET inhibitors might reduce the kinase inhibitor dose needed to achieve the same pharmacological effect. Moreover, such combinations may help to combat drug resistance, which is a major issue in patients treated with protein kinase inhibitors. Despite the significant therapeutic relevance of combination therapies, several potential advantages of a targeted therapy based on a single drug that hits multiple targets over single-targeted or combination therapy have been described.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27-29)</a> Although combination therapy is more extensively explored in the clinic, both approaches are potentially able to yield drugs or drug combinations with improved safety and efficacy profiles.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Dual Kinase/Bromodomain Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2013, Schönbrunn et al. demonstrated that <b>10</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), a well-known CDK2 inhibitor, interacts with BRDs; these data indicated for the first time that a new generation of BRD inhibitors could be rationally designed by using the chemical space of kinase inhibitors.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Following these discoveries, the rational identification of dual kinase/BRD inhibitors has emerged as a promising interfamily polypharmacology approach against cancer and inflammatory diseases. Compound <b>10</b> has recently advanced to phase III clinical trials for the treatment of refractory chronic lymphocytic leukemia due to its selectivity for CDK1, CDK2, CDK5, and CDK9.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The molecule acts on a broad spectrum of human cancers both in vitro and in vivo; moreover, <b>10</b> has a better in vivo therapeutic index compared to other CDK inhibitors.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The crystal structure of <b>10</b> in complex with CDK2 was released in 2013 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1">4KD1</a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The dual inhibitor binds in the ATP binding pocket of CDK2 (type I inhibitor). Within the structure, the pyrazopyrimidine hydrogen-bonds to the backbone of Leu83 of the hinge region, whereas the hydroxyethyl group interacts with the side chain of the conserved Lys33 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Furthermore, the pyridine <i>N</i>-oxide ring is partially solvent exposed, and the nitroxy group interacts with the side chain of Lys89 and with the backbone carbonyl group of Ile10 through a water-mediated hydrogen bond. The ethyl group is located in the back pocket of the cavity forming extensive hydrophobic and alkyl–aryl interactions with the side chain of Phe80, the gatekeeper residue of CDK2 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Interestingly, the β1 and β2 sheets of the N-lobe are adapted to the small ligand, allowing more extensive hydrophobic interactions involving the side chains of residues Ile10 and Val18.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>10</b> bound to CDK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1">4KD1</a>). <b>10</b> is represented as light green sticks, while the most important residues are represented as gray sticks. The figure also shows the generated pharmacophore model of <b>10</b> inside CDK2 represented as spheres and dots. The hydrogen bond acceptor, donor, aromatic and hydrophobic features are colored in red, blue, brown, and green, respectively. (B) Crystal structure of <b>10</b> bound to BRDT (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KCX">4KCX</a>). <b>10</b> is represented as light green sticks, while the most important residues are shown as light blue sticks. (C) Crystal structure of <b>10</b> bound to BRD4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70">4O70</a>). <b>10</b> is represented as light green sticks, while the most important residues are shown as light green sticks. Water molecules are represented as ball and sticks. Hydrogen bonds are represented as yellow dashed lines, and nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When tested against a panel of 24 BRDs, <b>10</b> showed activity mainly on the BET-BRDs subfamily (BRD2, BRD3, BRD4, BRDT).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Crystal structures of <b>10</b> in complex with BRDT (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KCX">4KCX</a>) and with BRD4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70">4O70</a>) have been reported (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B and <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C).<a onclick="showRef(event, 'ref76 ref78'); return false;" href="javascript:void(0);" class="ref ref76 ref78">(76, 78)</a> Analysis of these crystal structures shows that the ligand can adopt two different binding modes inside BET-BRDs. In both structures <b>10</b> binds in the AcK pocket, i.e., the pocket in which the acetylated lysine of the BRDs substrate interacts with BET proteins. However, in the case of BRDT (BD1), three hydrogen bond interactions mediate the binding with <b>10</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). Two of them are formed between the pyrazopyrimidine group of the ligand and the backbone of Asp57 (one of the two being water-mediated) located in the ZA channel, whereas the third is established by the nitroxy group of the ligand and the side chain of the conserved residue Asn109 located in the BC loop. Hydrophobic contacts are formed with the side chain of Phe52, which belongs to the conserved WPF shelf (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B), with Val56, and with Leu63 and Ile115, located on the ZA loop and on the first turn of the αC helix, respectively. Finally, the hydroxyethyl and the ethyl groups of the drug are solvent exposed.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> On the contrary, <b>10</b> binds BRD4 (BD1) by forming two hydrogen bonds with the side chain of Asn140 (Asn109 in BRDT (BD1)), and the nitroxy group interacts with the backbone of Ile146 (Ile115 in BRDT (BD1)). The ethyl moiety is directed deep inside the cavity, whereas the hydroxyethyl group is exposed to the solvent at the entrance of the ZA channel (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In the latter structure, <b>10</b> adopts a binding mode that is similar to those observed for <b>7</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A) and <b>8</b> in complex with the BRD4 (BD1) protein (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YEL">2YEL</a>, respectively).<a onclick="showRef(event, 'ref54 ref57'); return false;" href="javascript:void(0);" class="ref ref54 ref57">(54, 57)</a> On the other hand, differences can be noted by comparing the crystal structure of BRDT (BD1) in complex with <b>10</b> and the structure of BRDT (BD1) bound to the well-known selective inhibitor <b>7</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLP">4FLP</a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In fact, <b>7</b> interacts with all BET-BRD subfamily members through strong hydrogen bond interactions between the 1,4,5-triazole ring and the conserved Asn109 (Asn140 in BRD4 (BD1)) and Tyr66 (Tyr97 in BRD4 (BD1)) residues (water-molecule-mediated ZA channel), whereas the rest of the compound is mainly involved in hydrophobic contacts (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A).<a onclick="showRef(event, 'ref54 ref79'); return false;" href="javascript:void(0);" class="ref ref54 ref79">(54, 79)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Different binding types identified by Schönbrunn et al. inside BRD4.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> BRD4 is colored according to the inhibitor binding type. BRD4 bound to a type N inhibitor is colored light green. BRD4 bound to type PZA/ZA inhibitors is colored dark blue, whereas BRD4 bound to type I inhibitors is colored dark yellow. This choice has been made to underline the three different binding types that kinase inhibitors might show inside BRDs. (A) Crystal structure of compound <b>7</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a>). The ligand is represented as black sticks. (B) Crystal structure of compound <b>11</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76">4O76</a>). The ligand is represented as green sticks. (C) Crystal structure of compound <b>14</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7F">4O7F</a>). The ligand is represented as purple sticks. (D) Crystal structure of compound <b>13</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a>). The ligand is shown as blue sticks. (E) Crystal structure of compound <b>15</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK">4CFK</a>). The compound is represented as orange sticks. (F) Crystal structure of compound <b>16</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72">4O72</a>). The ligand is shown as yellow sticks. Nonpolar hydrogen atoms are omitted for clarity. Conserved water molecules are represented as ball and sticks, whereas hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The different binding modes of <b>10</b> in BRDT (BD1) and in BRD4 (BD1) are not apparently reflected by differences in BRD inhibitory activity. Indeed, the compound displays an IC<sub>50</sub> in the middle to low micromolar range for both targets (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), as opposed to the nanomolar activity shown by <b>7</b> and <b>8</b>.<a onclick="showRef(event, 'ref54 ref57 ref76'); return false;" href="javascript:void(0);" class="ref ref54 ref57 ref76">(54, 57, 76)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. BRDs and Protein Kinase Inhibitory Activity Data of the Compounds Discussed in This Article<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">bromodomain activity</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">BRD4 (BD1), μM</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">crystal structure</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub>, μM</th><th class="colsep0 rowsep0" align="center">other BETs</th><th class="colsep0 rowsep0" align="center">type</th><th class="colsep0 rowsep0" align="center">targeted kinases (IC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center">BRD4</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRD2/3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P5O">3P5O</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">56</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">0.035</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">54</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YEL">2YEL</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">57</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">ZA</td><td class="colsep0 rowsep0" align="left">CDK1 (30), CDK2 (170), CDK4 (100)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O71">4O71</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref109'); return false;" href="javascript:void(0);" class="ref ref78 ref109">78, 109</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">18.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CDK1 (3), CDK2 (1), CDK5 (1), CDK9 (4)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70">4O70</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1">4KD1</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref68 ref78'); return false;" href="javascript:void(0);" class="ref ref68 ref78">68, 78</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">0.123 ± 0.018</td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">JAK2 (6.25), RET (169), FLT3 (17)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76">4O76</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JI9">4JI9</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref85 ref110'); return false;" href="javascript:void(0);" class="ref ref78 ref85 ref110">78, 85, 110</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">0.164 ± 0.010</td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">JAK2 (6), RET (17), FLT3 (25)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O73">4O73</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JI9">4JI9</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref85 ref110'); return false;" href="javascript:void(0);" class="ref ref78 ref85 ref110">78, 85, 110</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left">0.037 ± 0.003</td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">PZA</td><td class="colsep0 rowsep0" align="left">PLK1 (0.8), PLK2 (3.5), PLK3 (39)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref85 ref111'); return false;" href="javascript:void(0);" class="ref ref78 ref85 ref111">78, 85, 111</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">ZA</td><td class="colsep0 rowsep0" align="left">p38α, p38β (25)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7F">4O7F</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2">4FA2</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref112'); return false;" href="javascript:void(0);" class="ref ref78 ref112">78, 112</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">12.43</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRD2/3</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PI3Kα (2370), PI3Kβ (420), PI3Kδ (1530)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK">4CFK</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">84</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">DNA-PK (14), PI3K (5000), mTOR (1700)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72">4O72</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref113'); return false;" href="javascript:void(0);" class="ref ref78 ref113">78, 113</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">3.424 ± 0.132</td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">p38α (50), p38β (100)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O77">4O77</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5">3ZS5</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref85 ref114'); return false;" href="javascript:void(0);" class="ref ref78 ref85 ref114">78, 85, 114</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3.546 ± 0.178</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PZA</td><td class="colsep0 rowsep0" align="left">RSK (45), RSK3 (18), RSK4 (15), RSK3 (18), RSK2 (24), RSK1 (31)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D9K">5D9K</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">85, 86</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.079 ± 0.003</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PZA</td><td class="colsep0 rowsep0" align="left">PLK1 (0.87), PLK2 (5), PLK3 (56)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FC2">3FC2</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref115'); return false;" href="javascript:void(0);" class="ref ref85 ref115">85, 115</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">9.02</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">EGFR (44), Erbb2 (8730), Erbb4 (24200)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">90</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">0.241</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PI3Kα (34), PI3Kγ (158), mTOR (280), DNA-PK (9)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">95</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">0.277</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PI3Kα (714), PI3Kδ (27), PI3Kγ (1170)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">95</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PZA</td><td class="colsep0 rowsep0" align="left">MPS1 (35)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref116'); return false;" href="javascript:void(0);" class="ref ref85 ref116">85, 116</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ZA</td><td class="colsep0 rowsep0" align="left">PYK2 (11), FAK (1.5)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FZR">3FZR</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref117'); return false;" href="javascript:void(0);" class="ref ref85 ref117">85, 117</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.742 ± 0.076</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ZA</td><td class="colsep0 rowsep0" align="left">mTOR (8), DNA-PK (410), PI3Kδ (100)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT5">4JT5</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref118'); return false;" href="javascript:void(0);" class="ref ref85 ref118">85, 118</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">PZA</td><td class="colsep0 rowsep0" align="left">VEGFR2 (6.3), pan-kinase</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O78">4O78</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CIF">3CIF</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref119'); return false;" href="javascript:void(0);" class="ref ref78 ref119">78, 119</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">ZA</td><td class="colsep0 rowsep0" align="left">p38α, p38β (15.2)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7B">4O7B</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2">4FA2</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref112'); return false;" href="javascript:void(0);" class="ref ref78 ref112">78, 112</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">p38 (50), p38β (500)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5">3ZS5</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85 ref112'); return false;" href="javascript:void(0);" class="ref ref85 ref112">85, 112</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">p38 (140), c-RAF (23), RET, SRC</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7E">4O7E</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5">3ZS5</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref120'); return false;" href="javascript:void(0);" class="ref ref78 ref120">78, 120</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Syk (17), BTK</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O75">4O75</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PIY">3PIY</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref121'); return false;" href="javascript:void(0);" class="ref ref78 ref121">78, 121</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">GSKα (28), GSKβ (94)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7A">4O7A</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L">1Q4L</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref78 ref122 ref123">78, 122, 123</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRDT</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">BRAF, p38α, LOK</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7C">4O7C</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5">3ZS5</a><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78 ref124'); return false;" href="javascript:void(0);" class="ref ref78 ref124">78, 124</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">The table also reports the binding type according to the classification of Schönbrunn et al.,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> the targeted kinases, and the crystal structure PDB codes.</p></div><div class="footnote" id="t1fn1"><sup>b</sup><p class="last">Crystal structures with very similar cocrystallized ligand.</p></div></div></div><div class="NLM_p">On the basis of these pieces of evidence, in 2014, Schönbrunn et al. carried out a cocrystallization screening campaign using the kinase inhibitor libraries from Selleck Chemicals (277 compounds) and Glaxo Smith Kline (published kinase inhibitor set, 304 compounds).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The screen was performed on BRD4 (BD1), selected as a representative member of the BET-BRDs. Of 377 cocrystal structures that were obtained, 194 were analyzed. Among them, 14 crystal structures (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) exhibited interactions of the tested compounds inside the AcK pocket. IC<sub>50</sub> values against BRD4 (BD1) and BRDT (BD1) were determined using differential scanning fluorimetry (DSF) and the AlphaScreen assay (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Most compounds displayed an IC<sub>50</sub> in the middle or middle to low micromolar range on both proteins. Two of them showed an IC<sub>50</sub> in the low micromolar range. Compounds <b>11</b> (TG101209)<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and <b>12</b> (TG101348, fedratinib)<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> are known inhibitors of JAK2.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80, 81)</a> Compound <b>13</b> (BI2536),<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> a well-known Polo-like kinase 1 (PLK1) inhibitor with antitumor activity against relapsed or refractory AML and non-small-cell lung cancer,<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82, 83)</a> showed an IC<sub>50</sub> comparable with those of <b>7</b> and <b>8</b> on both epigenetic targets (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Importantly, the authors defined three main binding modes on the basis of the interactions established by the hinge-binding group and BRD4 (BD1) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Compounds interacting with Asn140 were classified as type N binders (three compounds). <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B show the binding modes of <b>7</b> and <b>11</b>, respectively, taken as representatives of type N binders. Compounds interacting with Pro82 and the ZA channel or with the ZA channel alone were classified as type PZA and ZA, respectively (five compounds). <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D show the binding modes of <b>13</b> and <b>14</b> (SB251527),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> respectively, taken as representatives of this class. Finally, compounds in which the hinge-binding group is not involved in binding interactions were classified as type I (six compounds). <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>F show the binding modes of compounds <b>15</b> (LY294002)<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and <b>16</b> (NU7441),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> respectively, used as representatives.</div><div class="NLM_p">At the same time, Knapp et al. independently reported that 10 known kinase inhibitors were also active on BRD proteins.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Remarkably, four of these were also reported by Schönbrunn et al. (<b>11</b>, <b>12</b>, <b>13</b>, and <b>17</b> (SB202190)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>). Their BRD4 (BD1) inhibitory activity was confirmed by AlphaScreen assays using the temperature shift assay (Δ<i>T</i><sub>m</sub>), and the AlphaScreen dose–response experiments indicated that <b>12</b>, <b>13</b>, and <b>18</b> (BI-D1870 a RSK inhibitor)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> are the most active compounds against BRD4 (BD1), having IC<sub>50</sub> values in the nanomolar range. Moreover, binding constants determined with isothermal titration calorimetry showed that <b>11</b>, <b>12</b>, <b>13</b>, and <b>19</b> (BI6727)<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) have the best <i>K</i><sub>d</sub> values. Finally, the authors demonstrated that <b>12</b> and <b>13</b> suppress c-MYC expression through BET inhibition in multiple myeloma cells.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The BRD4 (BD1) cocrystal structures determined by Knapp et al. for the most active compounds <b>12</b> and <b>13</b> show a binding pattern similar to those of the crystal structures solved by Schönbrunn et al. (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76">4O76</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O73">4O73</a>).<a onclick="showRef(event, 'ref78 ref85'); return false;" href="javascript:void(0);" class="ref ref78 ref85">(78, 85)</a></div><div class="NLM_p">The binding of compound <b>13</b> is characterized by the presence of a hydrogen bond between the carbonyl group of the 2-amino-6-oxodihydropteridine ring and the side chain of Asn140 of BRD4 (BD1) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). The carbonyl group interacts with Tyr97, i.e., the second BRDs conserved residue, through a hydrogen bond with a conserved water molecule present in the ZA channel. The aminopyrimidine moiety interacts with Pro82 (WPF shelf) through a conserved water molecule located at the entrance of the ZA channel. Finally, the 5-ethyl moiety located on the pteridinone group interacts with Leu92, Leu94, and Tyr139 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). In the complex with the PLK1 kinase, the aminopyrimidine of <b>13</b> interacts with the hinge (type I kinase inhibitor), whereas the carbonyl group of the pteridinone moiety interacts with the side chain of Lys82 and the backbone of Asp194 via two water-mediated hydrogen bonds (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The methylpiperidine of <b>13</b> is solvent exposed in both targets.</div><div class="NLM_p">Compound <b>12</b>, a drug that recently entered phase III clinical trials for myelofibrosis,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> interacts with the epigenetic target by adopting a binding mode similar to those of <b>7</b> and <b>8</b>. Similar to <b>8</b>, <b>12</b> displays bidentate interactions between the aminopyridine hinge-binding moiety and the amide group of Asn140 side chain, whereas the other amino group present in the compound hydrogen-bonds with Pro82.</div><div class="NLM_p">In 2015, Fletcher et al. prepared a focused library starting from the most active hit found by Schönbrunn and Knapp groups.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Through structure-based modification of <b>13</b>, the authors identified a new inhibitor with 7-fold increased binding affinity for BRD4 and only slightly reduced affinity for PLK1. The increased affinity was rationalized with docking, which provided a binding pattern similar to that of <b>13</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). The 7-fold improvement in activity was ascribed to the substitution of the cyclopentyl moiety with a 3-bromobenzyl group on the pteridinone scaffold, which shows higher flexibility and allows the compound to reach the WPF shelf of BRD4 (BD1). According to the computational models obtained, the authors were able to rationalize structure–activity relationships around the structure of <b>13</b>, leading to new selective nanomolar BRD4 inhibitors or dual PLK1/BRD4 inhibitors.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">In 2015, Schürer et al. identified a 4-aminoquinazoline compound <b>20</b> (2870<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) as a new dual EGFR/BRD4 inhibitor endowed with nanomolar activity on EGFR and low micromolar activity on BRD4 (BD1) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Remarkably, lapatinib-induced kinome reprogramming ErbB2-positive breast cancer cells are known to be suppressed by the combination of lapatinib<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> with <b>7</b>.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In light of this information, Schürer et al. carried out a virtual screening campaign and selected 24 compounds as potential dual EGFR/BRD4 inhibitors.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> AlphaScreen assays and differential scanning fluorimetry (DSF) experiments performed on the selected compounds showed that several compounds were active on BRD4, and one of them (compound <b>20</b>) showed dual EGFR/BRD4 inhibitory activity. Docking and molecular dynamics suggested a potential binding mode for this dual inhibitor. Compound <b>20</b> is predicted to bind in the AcK pocket of the epigenetic target. In the complex, the hinge binding group of the compound interacts with Asn140 (type N binder), the Ile146 side chain is involved in hydrophobic interactions, and the 2-aryloxyethylamino moiety is partially solvent exposed. In EGFR, compound <b>20</b> is predicted to interact with the hinge region of the kinase (ATP binding pocket, type I inhibitor), showing the typical binding pattern of other well-known 4-aminoquinazoline-based EGFR inhibitors such as lapatinib.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p last">In 2014 another known PI3K inhibitor, compound <b>15</b> in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, has been reported as a dual kinase/BRD ligand.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The compound, based on a chromen-4-one scaffold, showed inhibitory activity against three members of the BETs family (BRD2, BRD3, BRD4). The resolution of the crystal structure of BRD4 (BD1) in complex with <b>15</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK">4CFK</a>) demonstrated that the compound binds into the AcK pocket. The morpholino group binds the hinge residue of the PI3K kinase (Val882), whereas it is solvent exposed in BRD4 (BD1) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E).<a onclick="showRef(event, 'ref84 ref93'); return false;" href="javascript:void(0);" class="ref ref84 ref93">(84, 93)</a> According to the Schönbrunn classification, this compound belongs to type I binders (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In the epigenetic target, the carbonyl group of the chromene scaffold forms water-mediated hydrogen bonds with Asn140 and Tyr97 residues (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> On the basis of the similarity with <b>15</b>, a compound library comprising 41 morpholinothienopyranone derivatives was synthesized and tested against PI3K.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Most compounds inhibited PI3K with nanomolar activities, and more importantly, two of them (compounds <b>21</b> (SF2523)<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and <b>22</b> (SF2535)<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) also inhibited BRD4 (BD1) with nanomolar activities (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95-97)</a> Considering the high structural similarity between the morpholinothienopyranone derivatives and <b>15</b> and considering the similar binding mode displayed by compounds <b>15</b>, <b>21</b>, and <b>22</b> in the PI3K binding site,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> these compounds are likely to display a similar binding mode with the epigenetic target. This is confirmed by the docking experiments described below. Therefore, <b>21</b> and <b>22</b> are likely to interact with BRD4 (BD1) similarly to <b>15</b>, i.e., with the 1,4-dioxane group and the ethyl acetate moiety exposed to solvent.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Computational Approaches for the Design of Dual Kinase/BRD Ligands: Pharmacophore Modeling and Docking</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Considering the large amount of structural information already available on kinases and kinase inhibitors and the growing evidence that kinases and BRDs are suitable and worthy of special consideration for polypharmacology approaches, ligand-based and structure-based computational approaches may be useful to aid the rational identification of more potent dual kinase/BRD inhibitors.</div><div class="NLM_p">Ligand-based approaches are usually related to the identification of active compounds with a certain degree of structural similarity to known ligands. Pharmacophore modeling is another well-known ligand-based approach, which is based on the identification of key structural features responsible for biological activity of a ligand. In the development of a pharmacophore model, binding site information derived from cocrystallized complexes can be incorporated to generate structure-based pharmacophores. Structure-based approaches, e.g., molecular docking, can be used to identify putative hit compounds for selected targets through virtual screening approaches. Moreover, docking can be used for the optimization of already known ligands (hit to lead optimization). Molecular dynamics may help improve conformational sampling in virtual screening. Likewise, more accurate free-energy-based scoring functions can be used to improve binding free energy predictions. Interestingly, ligand-based and structure-based methods may be combined to provide more robust results. Such combination offers the possibility of taking advantage of the peculiar features and strengths of each approach toward the obtainment of possible candidates for polypharmacology.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Pharmacophore Models</h3><div class="NLM_p">The construction of pharmacophore models may be a suitable approach for the identification of new dual kinase/BRD putative inhibitors. According to the three different binding types described by Schönbrunn et al. (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), the three pharmacophore models described below have been built using the Phase software implemented in the Schrödinger suite.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99, 100)</a> The generated pharmacophores can be useful for the identification of new hit compounds through pharmacophore virtual screening and are available upon request to authors.</div><div id="sec6_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Type N Binders</h4><div class="NLM_p">Type N binders are compounds in which the kinase hinge binding moiety interacts with the conserved Asn residue located in the BRDs ZA loop (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Superposition of the BRD4 (BD1) crystal structures shows that compounds belonging to this class (four compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) have good overlap. Taking into consideration the binding mode of the most active N-type BRD4 (BD1) binder (compound <b>11</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76">4O76</a>) as the query structure, a pharmacophore model with four key features was constructed (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). These comprise one hydrogen bond acceptor, one donor, and one aromatic and one hydrophobic feature. Both the acceptor and the donor are required to establish interactions with Asn140 of BRD4 (BD1), and the aromatic and the hydrophobic features are present in all cocrystallized compounds belonging to this group, such as compounds <b>10</b>, <b>11</b>, and <b>12</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The BETs selective ligand <b>7</b> matches the pharmacophore model, although it does not have a donor group in proximity of Asn140 (<a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a>A and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). This lack of bidentate interaction with Asn140 is compensated for by a second acceptor group located on the tetrazole ring that is engaged in a water-mediated hydrogen bond with Tyr97 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A), i.e., the second conserved hot spot among BRDs.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacophore models. (A) Pharmacophore model obtained considering the binding geometries of compound <b>11</b> inside BRD4 (BD1). <b>11</b> is represented as green sticks, whereas <b>7</b> is represented as black sticks. The hydrogen bond donor, acceptor, aromatic and hydrophobic features are shown in blue, red, brown, and green, respectively. (B) Pharmacophore model generated considering the binding geometries of compound <b>13</b> inside BRD4 (BD1). <b>13</b> and <b>14</b> are shown in blue and purple, respectively. The hydrogen bond donor, acceptor, and hydrophobic features are shown in blue, red/orange (second acceptor moiety), and green, respectively. (C) Pharmacophore model carried out considering the binding geometries of compound <b>16</b> inside BRD4 (BD1). Compounds <b>15</b>, <b>16</b>, and <b>29</b> are shown in orange, yellow, and gray sticks, respectively. The hydrogen bond donor, acceptor, and aromatic features are shown in blue, red, and brown, respectively. (D) Refined “N type binder” pharmacophore model with excluded volume features after consideration of the residues forming the AcK binding site of BRD4. In all panels nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Type PZA/ZA Binders</h4><div class="NLM_p last">According to the second binding type described by Schönbrunn et al., compounds of this class (10 compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) have the kinase hinge binding moiety interacting with Pro82 of the WPF shelf and/or with conserved water molecules located at the entrance of the ZA channel (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). The pharmacophore model generated for this class, built on the most active PZA/ZA compound <b>13</b> cocrystallized with BRD4 (BD1) as a query structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a>), shows five key features, i.e., two hydrogen bond acceptors, one hydrogen bond donor, and two hydrophobic features (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). The two acceptor moieties are likely more relevant than the donor, being present in the majority of the compounds of this class (<a class="ref internalNav" href="#fig1" aria-label="Figures 1">Figures 1</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C, and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>D), whereas the hydrophobic features are common to all derivatives. PZA/ZA binders include compounds <b>9</b>, <b>13</b>, <b>14</b>, <b>18</b>, <b>19</b>, <b>23</b> (AZ-3146),<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a><b>24</b> (PF431396),<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a><b>25</b> (PP242),<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a><b>26</b> (GW612286X),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and <b>27</b> (SB284847BT).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Compound <b>9</b>, which is one of the less active inhibitors in the presented data set (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), is the only compound of this class that matches only one feature of the pharmacophore (the hydrogen bond acceptor region, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).</div></div><div id="sec6_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Type I Binders</h4><div class="NLM_p">Type I binders do not interact with the epigenetic target with their kinase hinge binding group (11 compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The pharmacophore model generated from the most active compound of this class (compound <b>16</b>) cocrystallized with BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72">4O72</a>) shows three key features, i.e., a hydrogen bond acceptor, a hydrogen bond acceptor/donor, and an aromatic feature (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). All compounds belonging to this class (i.e., <b>15</b>, <b>16</b>, <b>17</b>, <b>21</b>, <b>22</b>, <b>28</b> (SB203580),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><b>29</b> (SB610251B),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><b>30</b> (fostamatinib),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><b>31</b> (SB409514),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and <b>32</b> (SB614067R)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>) fit the generated pharmacophore model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C).</div><div class="NLM_p last">Overall, the generated pharmacophores encode the main structural features required for each type of binder. These pharmacophores can be improved by adding excluded volume features based on the three-dimensional positions of residues forming the AcK binding site of BRD4, defined as spatial regions off-limits to the ligands. The use of excluded volumes is exemplified for N-type binders in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D. The pharmacophores can be used to help the identification of dual kinase/BET inhibitors starting from the kinase inhibitors chemical space. Furthermore, kinase-based pharmacophores, such as the one proposed in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A, and the BRD pharmacophores described above (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) can be used in combination to allow the identification of potential dual kinase/BRD inhibitors from a wider chemical space. Finally, the pharmacophore models may be useful to classify already known dual kinase/BET inhibitors and may be used for ligand optimization.</div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Docking</h3><div class="NLM_p">Considering that both protein kinase and BRD crystal structures are known, docking methods can be used to predict binding modes and can aid in the identification of dual ligands. Docking can also be used to predict the binding mode of the dual kinase/BET inhibitors for which a crystal structure in complex with the epigenetic target has not yet been determined (i.e., <b>18</b>, <b>21</b>, <b>22</b>, <b>23</b>, <b>24</b>, <b>25</b>, <b>28</b>). Docking experiments performed using the Glide software<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> with default settings and the crystal structure of BRD4 (BD1) in complex with the most active dual inhibitor of the data set (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a>) indicate that the tested compounds overlap fairly well with the cocrystallized reference ligands, reproducing the mandatory interactions inside BRD4 (BD1) according to the three binding types described above (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Therefore, docking may aid in the identification of putative binding modes in BET-BRDs.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking results for selected dual kinase/BRD ligands for which a crystal structure inside BRD4 is not available. As explained in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, BRD4 is colored according to the inhibitor binding type. BRD4 bound to type PZA/ZA inhibitors is colored dark blue, whereas BRD4 bound to type I inhibitors is colored dark yellow. This choice has been made to underline the three different binding types that kinase inhibitors adopt inside BRDs. The compounds are overlapped to the reference crystal structure. Compound <b>13</b> is represented as blue sticks (A–D). Compound <b>15</b> is shown in orange (E, F). Compounds <b>23</b> (A), <b>18</b> (B), <b>24</b> (C), <b>25</b> (D), <b>28</b> (E), <b>21</b> (F), and <b>22</b> (F) are shown in cyan, brown, pink, magenta, light brown, light cyan, and salmon, respectively. Water molecules are displayed as ball and sticks, and nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Virtual screenings made with docking could also help the identification of new classes of BET inhibitors. In recent years, several examples of successful virtual screening campaigns performed on BRD4 have been described.<a onclick="showRef(event, 'ref102 ref103 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref102 ref103 ref104 ref105">(102-105)</a> The first virtual screening investigation specifically directed toward the identification of dual kinase/BRD inhibitors was reported in 2015 by the Schürer group.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> They proposed a multistep virtual screening workflow consisting of the following: (i) identification of potential EGFR inhibitors based on known active compounds through a statistical model trained on thousands of EGFR inhibitors and hundreds of thousands of kinase decoys (ligand-based approach); (ii) docking of the selected compounds on several BRD4 crystal structures (structure-based approach); and (iii) selection of compounds for biological assays based on docking scores and physicochemical properties. Molecular dynamics simulations were also applied to explain the difference in binding affinity of compound <b>20</b> for BRD4 (BD1) and EGFR, concluding that the chemical optimization of <b>20</b> can lead to the generation of new inhibitors with comparable BRD4 and EGFR potency.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p">Computational structure-based approaches can also be used in extensive medicinal chemistry projects to guide the rational modification of known dual inhibitors in which the putative binding modes inside kinase and BRD targets have been characterized using crystallography. As described by Schönbrunn et al., the three different binding types identified in AcK of BRD4 (BD1) may guide the identification of new more potent BET inhibitors or dual kinase/BET inhibitors.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Fletcher et al. reported new dual inhibitors obtained through structural modifications of compound <b>13</b>.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Moreover, selective and more potent BET inhibitors can also be obtained starting from the kinase inhibitor space. For instance, slight modifications of compounds classified as type PZA/ZA can decrease the kinase inhibitory activity. Fletcher et al. described distinct modifications of <b>13</b> that enhanced selectivity and BRD4 inhibitory activity.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Remarkably, because type I binders do not bind the AcK pocket with the kinase hinge binding group, compounds of this class may be easily converted into selective BET inhibitors. Finally, type N binders are intrinsically dual inhibitors because they bind both targets with the hinge-binding group.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">Moreover, structure-based tools supported by experimental approaches may also be used to identify new protein–ligand interactions inside BRDs. It has been reported that residues located on the surface of the epigenetic targets and in close proximity to the AcK pocket are important for substrate specificity of different BRDs and may be exploited as new anchoring points.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> These additional structural features were recently exploited by Wohlwend et al., who designed structural modifications of a reference ligand based on a 4-acylpyrrole scaffold that provided new derivatives with micromolar activity on the epigenetic target.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Moreover, Hoelder et al. performed a structure-based virtual screen on BRD4 followed by rational modification of the discovered hits, resulting in the identification of compounds with significantly improved activity on BET proteins.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Finally, Wang et al. recently identified new selective nanomolar BET inhibitors after an analysis of the cocrystallized structures of BRD4 followed by structural modification of the reference ligands.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p last">In general, identification of new dual kinases BRD inhibitors through computational based approaches should comprise diverse strategies because ligands can bind the AcK pocket with a chemical group that differs from that of the hinge binding motif, which is mandatory for the binding to protein kinases. As described above, the acetyl-lysine mimetic binding group present in the dual inhibitors classified as type I binders can be solvent exposed in kinases. For this reason, any computational workflow aimed at the identification of new dual inhibitors should take into account the three different binding types shown inside BET-BRDs (i.e., N, PZA/ZA, I). For instance, the identification of dual kinase/BRD inhibitors belonging to type N or type PZA/ZA could be achieved by pharmacophore screenings conducted in parallel on kinases and BRDs (type N and/or PZA/ZA queries, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A and <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B), followed by postprocessing with structure-based methods (e.g., docking) to refine the selection of the final hit compounds. On the other hand, computational workflows to identify type I dual ligands would require a definition of the starting chemical space. If the kinase inhibitor chemical space is used, pharmacophore screenings made with the type I pharmacophore query described above (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C) followed by docking would be appropriate. If wider chemical spaces are used, computational approaches should be conducted in series on the targeted kinase and BRD (or vice versa). For type I ligands, this would allow the presence of a hinge binding group and an AcK mimetic group in the same molecule.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Final Remarks and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The identification of small molecules targeting protein kinases has become one of the milestones in the development of anticancer drugs. Over the years, these inhibitors have shown therapeutic limitations mainly resulting from drug resistance, poor selectivity, and off-target effects. In addition, most tumors can elude the effects of inhibiting a single kinase by activating alternative pathways and escape mechanisms.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22">(19-22)</a> For these reasons, in recent years, multitarget inhibition of cancer-associated kinases (intrafamily polypharmacology) as well as multitarget inhibition of kinases and targets belonging to different families (interfamily polypharmacology) gained a foothold in drug discovery.</div><div class="NLM_p">BRDs play a key role in the epigenome and have very recently been discovered as druggable targets. Since then, dual kinase/BRD inhibitors targeting key drivers in a number of cancers have been reported and demonstrate significant potential for the achievement of higher efficacy and more durable response. The first compound (<b>10</b>) showing dual kinase/BET inhibitory activity was identified by Schönbrunn et al. in 2013.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In 2014, the Schönbrunn and Knapp groups identified several compounds with dual kinases/BETs inhibitory activity.<a onclick="showRef(event, 'ref78 ref85'); return false;" href="javascript:void(0);" class="ref ref78 ref85">(78, 85)</a> Among them, four compounds (<b>11</b>, <b>12</b>, <b>13</b>, and <b>17</b>) were reported by both groups. The most active compound, <b>13</b>, is a known inhibitor of the PLK1 kinase, which inhibited BRD4 in the nanomolar range, i.e., with an activity comparable to that of <b>7</b>, the first selective BETs inhibitor. Moreover, from the analysis of the available crystal structures, the dual inhibitors identified so far have been classified into three groups depending on the binding mode of their kinase hinge binding region adopted in BRD4. Although the three different binding types provide a solid foundation for structure-based design of future compounds with putative dual inhibitory activity, the identification of dual kinase/BRD inhibitors is still in the earliest stages. Evidence of this is given by the results of the cocrystallization screening campaign conducted by Schönbrunn et al., according to which even weak inhibitors cocrystallized with BRD4 could represent an excellent starting point for the rational design of high-potency BET inhibitors.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The results obtained so far indicate that there is ample room for discovering new classes of compounds with dual activity in the near future. Moreover, the virtual screening investigations conducted by Schürer et al. demonstrated that wider chemical spaces, i.e., not necessarily those of kinase and BRD inhibitors, can be used to identify new dual kinase/BRD inhibitors.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Additionally, already optimized druglike kinase inhibitors with nanomolar inhibitory activity on BETs, such as <b>13</b>, still show considerable margins for improvement of activity toward BRDs.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Furthermore, all compounds with dual kinases/BRDs inhibitory activity reported so far belong to kinase type I inhibitors. It is conceivable that progress in the discovery of kinase allosteric inhibitors (types III, IV) will provide additional chemical space that once combined with the chemical space accessible to BRD proteins, may lead to dual ligands less prone to drug resistance and with reduced off-target effects. Finally, the presence of seven additional BRD subfamilies in nature, besides the BET-BRDs discussed in this review, will certainly open the way to new interesting target combinations to be exploited for future drug design and discovery investigations.</div><div class="NLM_p">Overall, co-targeting kinases and BRD epigenetic reader proteins is rapidly emerging as a promising approach in cancer drug development. The identification of dual inhibitors is at the early stages but is definitely a promising opportunity to fight cancer in the polypharmacology era. Knapp et al. observed that the rational design of dual kinase/BRD inhibitors is probably more accessible than the design of ligands with dual activity for two rationally chosen kinases (owing to kinase similarities).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> For example, the structural optimization of <b>11</b> and <b>12</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), showing dual FLT3/BETs and JAK/BETs inhibitory activity, respectively, may represent a future strategy against hematological cancers.</div><div class="NLM_p">The fact that dual ligands could be obtained despite that kinases and BRDs have different structures and binding site architectures provides additional confidence that polypharmacological drugs can also be rationally designed for targets that do not share significant structural homology.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> More generally, compounds with a desired polypharmacology profile represent a promising strategy against cancer, mainly due to the capacity to counteract compensatory mechanisms activated by tumor cells leading to drug resistance. Moreover, drugs able to hit specific target combinations represent useful tools to investigate the biochemical pathways involved in cancer and to analyze the effects of altering specific drug nodes. Remarkably, polypharmacological drugs can have several advantages with respect to single target or combination therapies. In addition to a generally higher efficacy and safety, some of these advantages can be summarized as follows: (i) a multitarget drug may show a more predictable pharmacokinetic profile compared to a combination therapy; (ii) acute and delayed toxicities may be reduced by administering a multitarget drug in place of a combination therapy; (iii) drug–drug interactions are avoided; (iv) combination therapies might also lead to negative synergistic effects; (v) a multitarget approach guarantees the simultaneous presence of the molecule in the tissues where the active principle exert its function; and (vi) regulatory agencies usually require the demonstration of the safety of each individual drug before their combination can be tested in humans, thus delaying the assessment of novel combinations.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27-29)</a></div><div class="NLM_p last">Finally, computational methods are useful in predicting the binding mode of known ligands and in identifying new ligands with dual activity using either ligand-based or structure-based methods or a combination of both methods. The recent successes in predicting polypharmacology and the raising numbers of computational approaches available for this purpose will certainly boost the identification and optimization of next-generation compounds with dual kinase/BRD inhibitory activity.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00438" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41881" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41881" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulio Rastelli</span> - <span class="hlFld-Affiliation affiliation">Department
of Life Sciences, University of Modena and
Reggio Emilia, Modena 41125, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#690e001c050006471b081a1d0c050500291c070004061b0c47001d"><span class="__cf_email__" data-cfemail="214648544d484e0f53405255444d4d4861544f484c4e53440f4855">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca Carlino</span> - <span class="hlFld-Affiliation affiliation">Department
of Life Sciences, University of Modena and
Reggio Emilia, Modena 41125, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Luca Carlino</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=BIO-d168e2371-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Luca Carlino</b> obtained his Master’s degree in Chemistry and Pharmaceutical Technologies at the University of Parma, Italy, in 2009. He received his Doctoral degree in Medicinal Chemistry in 2014 under the supervision of Prof. Wolfgang Sippl at the University of Halle/Saale, Germany. His studies were focused on the discovery, using computational techniques, of novel inhibitors of epigenetic targets. In 2015 he moved to the University of Modena and Reggio Emilia, Italy, where he earned a postdoctoral position in the group of Prof. Giulio Rastelli. Currently he is working on the identification of anticancer drugs based on kinase inhibitors with innovative mechanisms of action.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Giulio Rastelli</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=BIO-d168e2376-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giulio Rastelli</b> is Professor in Medicinal Chemistry and Head of the Molecular Modeling and Drug Design laboratory (<a href="http://www.mmddlab.unimore.it" class="extLink">www.mmddlab.unimore.it</a>) of the University of Modena and Reggio Emilia. He received his Ph.D. in Medicinal Chemistry at the University of Modena and Reggio Emilia and has been Research Fellow at the University of California, San Francisco under the supervision of Prof. Daniel Santi and Peter Kollman. His research interests focus on the development and application of computational drug design methodologies to address problems that lie at the interface between chemistry, biology, and medicine. His lab recently developed BEAR, an innovative tool for virtual screening. He collaborates with academic and private institutions for the discovery and development of small-molecule inhibitors of relevant drug targets, with a special focus on cancer.</p></figure></div><div class="ack" id="ACK-d168e2384-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (Grant AIRC IG 15993).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i18" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i18"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> Abbreviations Used</h2><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine 5′-triphosphate</p></td></tr><tr><td class="NLM_term">BRD</td><td class="NLM_def"><p class="first last">bromodomain</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">PCR2</td><td class="NLM_def"><p class="first last">polycomb repressive complex 2</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">VEGFR-2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HMT</td><td class="NLM_def"><p class="first last">histone methyltransferase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">PHD</td><td class="NLM_def"><p class="first last">plant homeodomain</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">NUT</td><td class="NLM_def"><p class="first last">nuclear protein in testis</p></td></tr><tr><td class="NLM_term">NMC</td><td class="NLM_def"><p class="first last">nuclear protein in testis midline carcinoma</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal domain</p></td></tr><tr><td class="NLM_term">BL</td><td class="NLM_def"><p class="first last">Burkitt Lymphoma</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-related tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">BPC</td><td class="NLM_def"><p class="first last">blast progenitor cell</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">bruton tyrosine kinase</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">osteosarcoma</p></td></tr><tr><td class="NLM_term">WPF</td><td class="NLM_def"><p class="first last">Trp-Pro-Phe</p></td></tr><tr><td class="NLM_term">AcK</td><td class="NLM_def"><p class="first last">acetylated lysine</p></td></tr><tr><td class="NLM_term">DSF</td><td class="NLM_def"><p class="first last">differential scanning fluorimetry</p></td></tr><tr><td class="NLM_term">PLK1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">RSK</td><td class="NLM_def"><p class="first last">ribosomal s6 kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 124 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>The Web site of the National Cancer Institute. <a href="http://www.cancer.gov" class="extLink">http://www.cancer.gov</a> (accessed December 22,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Web+site+of+the+National+Cancer+Institute.+http%3A%2F%2Fwww.cancer.gov+%28accessed+December+22%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Protein Kinases--the Major Drug Targets of the Twenty-First Century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+Kinases%2D%2Dthe+Major+Drug+Targets+of+the+Twenty-First+Century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0ljqBxnVEN1aqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520Kinases--the%2520Major%2520Drug%2520Targets%2520of%2520the%2520Twenty-First%2520Century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kostich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laz, T. M.</span><span> </span><span class="NLM_article-title">Human Members of the Eukaryotic Protein Kinase Family</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">research0043.1</span><span class="refDoi"> DOI: 10.1186/gb-2002-3-9-research0043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1186%2Fgb-2002-3-9-research0043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=research0043.1&author=M.+Kostichauthor=J.+Englishauthor=V.+Madisonauthor=F.+Gheyasauthor=L.+Wangauthor=P.+Qiuauthor=J.+Greeneauthor=T.+M.+Laz&title=Human+Members+of+the+Eukaryotic+Protein+Kinase+Family&doi=10.1186%2Fgb-2002-3-9-research0043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fgb-2002-3-9-research0043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2002-3-9-research0043%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DM.%26aulast%3DEnglish%26aufirst%3DJ.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DP.%26aulast%3DGreene%26aufirst%3DJ.%26aulast%3DLaz%26aufirst%3DT.%2BM.%26atitle%3DHuman%2520Members%2520of%2520the%2520Eukaryotic%2520Protein%2520Kinase%2520Family%26jtitle%3DGenome%2520Biol.%26date%3D2002%26volume%3D3%26spage%3Dresearch0043.1%26doi%3D10.1186%2Fgb-2002-3-9-research0043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ubersax, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrell, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">Mechanisms of Specificity in Protein Phosphorylation</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1038/nrm2203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrm2203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17585314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVaktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=530-541&author=J.+A.+Ubersaxauthor=J.+E.+Ferrell&title=Mechanisms+of+Specificity+in+Protein+Phosphorylation&doi=10.1038%2Fnrm2203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of specificity in protein phosphorylation</span></div><div class="casAuthors">Ubersax, Jeffrey A.; Ferrell, James E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">530-541</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A typical protein kinase must recognize between one and a few hundred bona fide phosphorylation sites in a background of ∼700,000 potentially phosphorylatable residues.  Multiple mechanisms have evolved that contribute to this exquisite specificity, including the structure of the catalytic site, local and distal interactions between the kinase and substrate, the formation of complexes with scaffolding and adaptor proteins that spatially regulate the kinase, systems-level competition between substrates, and error-correction mechanisms.  The responsibility for the recognition of substrates by protein kinases appears to be distributed among a large no. of independent, imperfect specificity mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8JmAzBNpuDbVg90H21EOLACvtfcHk0ljqBxnVEN1aqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVaktbw%253D&md5=02ec2d12c8470113daee83923b4f4626</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2203%26sid%3Dliteratum%253Aachs%26aulast%3DUbersax%26aufirst%3DJ.%2BA.%26aulast%3DFerrell%26aufirst%3DJ.%2BE.%26atitle%3DMechanisms%2520of%2520Specificity%2520in%2520Protein%2520Phosphorylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D530%26epage%3D541%26doi%3D10.1038%2Fnrm2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Engh, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossemeyer, D.</span><span> </span><span class="NLM_article-title">The Protein Kinase Activity Modulation Sites: Mechanism for Cellular Regulation - Targets for Therapeutic Intervention</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1016/S0065-2571(00)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0065-2571%2800%2900010-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=121-149&author=R.+A.+Enghauthor=D.+Bossemeyer&title=The+Protein+Kinase+Activity+Modulation+Sites%3A+Mechanism+for+Cellular+Regulation+-+Targets+for+Therapeutic+Intervention&doi=10.1016%2FS0065-2571%2800%2900010-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-2571%2800%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2571%252800%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DBossemeyer%26aufirst%3DD.%26atitle%3DThe%2520Protein%2520Kinase%2520Activity%2520Modulation%2520Sites%253A%2520Mechanism%2520for%2520Cellular%2520Regulation%2520-%2520Targets%2520for%2520Therapeutic%2520Intervention%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2001%26volume%3D41%26spage%3D121%26epage%3D149%26doi%3D10.1016%2FS0065-2571%2800%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Stenberg, K. a E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riikonen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span> </span><span class="NLM_article-title">KinMutBase, a Database of Human Disease-Causing Protein Kinase Mutations</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1093/nar/27.1.362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1093%2Fnar%2F27.1.362" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=362-364&author=K.+a+E.+Stenbergauthor=P.+T.+Riikonenauthor=M.+Vihinen&title=KinMutBase%2C+a+Database+of+Human+Disease-Causing+Protein+Kinase+Mutations&doi=10.1093%2Fnar%2F27.1.362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F27.1.362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F27.1.362%26sid%3Dliteratum%253Aachs%26aulast%3DStenberg%26aufirst%3DK.%2Ba%2BE.%26aulast%3DRiikonen%26aufirst%3DP.%2BT.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DKinMutBase%252C%2520a%2520Database%2520of%2520Human%2520Disease-Causing%2520Protein%2520Kinase%2520Mutations%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1999%26volume%3D27%26spage%3D362%26epage%3D364%26doi%3D10.1093%2Fnar%2F27.1.362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">kuriyan, J.</span><span> </span><span class="NLM_article-title">The Conformational Plasticity of Protein Kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1016/S0092-8674(02)00741-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&author=M.+Huseauthor=J.+kuriyan&title=The+Conformational+Plasticity+of+Protein+Kinases&doi=10.1016%2FS0092-8674%2802%2900741-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0ljHVgYlgdufhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3Dkuriyan%26aufirst%3DJ.%26atitle%3DThe%2520Conformational%2520Plasticity%2520of%2520Protein%2520Kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D275%26epage%3D282%26doi%3D10.1016%2FS0092-8674%2802%2900741-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Engh, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossemeyer, D.</span><span> </span><span class="NLM_article-title">Structural Aspects of Protein Kinase Control-Role of Conformational Flexibility</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/S0163-7258(02)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0163-7258%2802%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12191603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=99-111&author=R.+A.+Enghauthor=D.+Bossemeyer&title=Structural+Aspects+of+Protein+Kinase+Control-Role+of+Conformational+Flexibility&doi=10.1016%2FS0163-7258%2802%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Structural aspects of protein kinase control - role of conformational flexibility</span></div><div class="casAuthors">Engh, Richard A.; Bossemeyer, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 69 refs.  Protein kinases catalyze the phosphotransfer reaction fundamental to most signaling and regulatory processes in the eukaryotic cell.  Abs. control of individual protein kinase activity is, therefore, of utmost importance to signaling fidelity in the cell.  Mechanisms for activity modulation, including complete and reversible inactivation, have been shown by crystal structures of many active and inactive protein kinases.  The structures of inactivated kinases, compared with those of active and catalytically competent kinases, such as the protein kinase A catalytic subunit, highlight recurring structural alterations among a set of elements of the catalytic kinase core.  These 'activity modulation sites' apparently comprise the principal evolved mechanisms for control of enzyme activity in the catalytic domain.  In combination, they enable diverse physiol. regulatory mechanisms operative for most protein kinases.  Identification and characterization of these sites should impact strategies for discovery and design of target-specific therapeutic drugs as the range of structural variations for specific kinases becomes known.  The principal site, the ATP-binding pocket, is the target of many physiol. regulators and also most exptl. or therapeutic inhibitors, which typically block it in a competitive or allosteric fashion.  Co-crystn. studies with protein kinase A and other kinases have revealed binding features of several classes of protein kinase inhibitors.  Ligand-induced structural changes are common and tend to optimize buried surface areas.  The ability to optimize binding energies arising from the hydrophobic effect creates a logarithmic dependence of binding energy on buried surface areas.  Exceptions to this rule arise for specific inhibitor classes, and possibly also as artifacts of structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR98vkrXdrorVg90H21EOLACvtfcHk0ljHVgYlgdufhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShtb0%253D&md5=2dfe832a0577381146b4a177e3d313a4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DBossemeyer%26aufirst%3DD.%26atitle%3DStructural%2520Aspects%2520of%2520Protein%2520Kinase%2520Control-Role%2520of%2520Conformational%2520Flexibility%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D99%26epage%3D111%26doi%3D10.1016%2FS0163-7258%2802%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tückmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the World of Proteins: Conformational Changes in Protein Kinases</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+T%C3%BCckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+World+of+Proteins%3A+Conformational+Changes+in+Protein+Kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0ljlCfSajZsWXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DT%25C3%25BCckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520World%2520of%2520Proteins%253A%2520Conformational%2520Changes%2520in%2520Protein%2520Kinases%26jtitle%3DArch.%2520Pharm.%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0ljlCfSajZsWXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through The “gatekeeper Door”: Exploiting the Active Kinase Conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+The+%E2%80%9Cgatekeeper+Door%E2%80%9D%3A+Exploiting+the+Active+Kinase+Conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation</span></div><div class="casAuthors">Zuccotto, Fabio; Ardini, Elena; Casale, Elena; Angiolini, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2681-2694</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of new kinase inhibitors is still a slow and problematic process.  Generally, type I compds. suffer from widespread cross-reactivity among other members of the kinase target family, and intense medicinal chem. optimization programs are required to modulate their activity.  Also, fierce competition in the development of scaffolds that could mimic ATP has led to a crowded intellectual property space.  The new opportunities opened by the type II compds. created great expectations, as targeting the allosteric site of the ATP pocket offered addnl. opportunities to control selectivity and introduce intellectual property novelty.  However, clin. evaluation of these compds. has highlighted how the acquisition of resistance-causing mutations of the kinase target limits their efficacy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd_iA7sWS-g7Vg90H21EOLACvtfcHk0ljlCfSajZsWXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K&md5=5c6acd058bacfec89b1eff2090f0fe67</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520The%2520%25E2%2580%259Cgatekeeper%2520Door%25E2%2580%259D%253A%2520Exploiting%2520the%2520Active%2520Kinase%2520Conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1021/cb300663j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300663j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=58-70&author=Z.+Fangauthor=C.+Gr%C3%BCtterauthor=D.+Rauh&title=Strategies+for+the+Selective+Regulation+of+Kinases+with+Allosteric+Modulators%3A+Exploiting+Exclusive+Structural+Features&doi=10.1021%2Fcb300663j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span></div><div class="casAuthors">Fang, Zhizhou; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modulation of kinase function has become an important goal in modern drug discovery and chem. biol. research.  In cancer-targeted therapies, kinase inhibitors have been experiencing an upsurge, which can be measured by the increasing no. of kinase inhibitors approved by the FDA in recent years.  However, lack of efficacy, limited selectivity, and the emergence of acquired drug resistance still represent major bottlenecks in the clinic and challenge inhibitor development.  Most known kinase inhibitors target the active kinase and are ATP competitive.  A second class of small org. mols., which address remote sites of the kinase and stabilize enzymically inactive conformations, is rapidly moving to the forefront of kinase inhibitor research.  Such allosteric modulators bind to sites that are less conserved across the kinome and only accessible upon conformational changes.  These mols. are therefore thought to provide various advantages such as higher selectivity and extended drug target residence times.  This review highlights various strategies that have been developed to utilizing exclusive structural features of kinases and thereby modulating their activity allosterically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjxxztmczXrVg90H21EOLACvtfcHk0ljv0q50iuhQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN&md5=50864096bf66229ff74482a9b56847d6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcb300663j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300663j%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStrategies%2520for%2520the%2520Selective%2520Regulation%2520of%2520Kinases%2520with%2520Allosteric%2520Modulators%253A%2520Exploiting%2520Exclusive%2520Structural%2520Features%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D58%26epage%3D70%26doi%3D10.1021%2Fcb300663j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+Approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljv0q50iuhQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520Approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Alexander, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möbitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deane, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Type II Inhibitors Targeting CDK2</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2116</span><span class="NLM_x">–</span> <span class="NLM_lpage">2125</span><span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+M%C3%B6bitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+Inhibitors+Targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0ljv0q50iuhQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DM%25C3%25B6bitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520Inhibitors%2520Targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Palmieri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">αC Helix Displacement As a General Approach for Allosteric Modulation of Protein Kinases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.drudis.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23195331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=407-414&author=L.+Palmieriauthor=G.+Rastelli&title=%CE%B1C+Helix+Displacement+As+a+General+Approach+for+Allosteric+Modulation+of+Protein+Kinases&doi=10.1016%2Fj.drudis.2012.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">αC helix displacement as a general approach for allosteric modulation of protein kinases</span></div><div class="casAuthors">Palmieri, Lorenzo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Owing to their crucial role in the modulation of cell pathways, protein kinases are important targets for several human diseases, including but not limited to cancer.  The classic approach of targeting the ATP active site has recently come up against selectivity issues, which can be considerably reduced by following an allosteric modulation approach.  Being closely related to protein kinase inactivation, allosteric targeting via displacement of the conserved structural αC helix enables a direct and specific modulation mechanism.  A structure-based survey of the allosteric regulation of αC helix conformation in various kinase families is provided, highlighting key allosteric pockets and modulation mechanisms that appear to be more broadly conserved than was previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEv57xKCTibVg90H21EOLACvtfcHk0ljThWrxvpIpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE&md5=f2380fd543155c49602ca99b0c333ffe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3D%25CE%25B1C%2520Helix%2520Displacement%2520As%2520a%2520General%2520Approach%2520for%2520Allosteric%2520Modulation%2520of%2520Protein%2520Kinases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D407%26epage%3D414%26doi%3D10.1016%2Fj.drudis.2012.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Lamba, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, I.</span><span> </span><span class="NLM_article-title">New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2936</span><span class="NLM_x">–</span> <span class="NLM_lpage">2945</span><span class="refDoi"> DOI: 10.2174/138161212800672813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.2174%2F138161212800672813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22571662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2936-2945&author=V.+Lambaauthor=I.+Ghosh&title=New+Directions+in+Targeting+Protein+Kinases%3A+Focusing+Upon+True+Allosteric+and+Bivalent+Inhibitors&doi=10.2174%2F138161212800672813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors</span></div><div class="casAuthors">Lamba, Vandana; Ghosh, Indraneel</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2936-2945</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer.  Protein kinases are typically targeted at the ATP-binding cleft by type I and II inhibitors; however, the high sequence and structural homol. shared by protein kinases, esp. at the ATP-binding site, inherently leads to polypharmacol.  In order to discover or design truly selective protein kinase inhibitors as both pharmacol. reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft.  Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate-binding pocket.  These new classes of inhibitors are often selective, but usually display moderate affinities.  Here, the authors discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes.  These inhibitors have the potential to couple the high affinity and potency of traditional active site-targeted small-mol. inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkIIgeMxhCrrVg90H21EOLACvtfcHk0ljThWrxvpIpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrk%253D&md5=36a44e36709507b5053bfdfe7d09e5e9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F138161212800672813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672813%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DV.%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DNew%2520Directions%2520in%2520Targeting%2520Protein%2520Kinases%253A%2520Focusing%2520Upon%2520True%2520Allosteric%2520and%2520Bivalent%2520Inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2936%26epage%3D2945%26doi%3D10.2174%2F138161212800672813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span> </span><span class="NLM_article-title">Allosteric Small-Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0ljThWrxvpIpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chripkova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrassa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broggini, M.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of the First Allosteric Inhibitors of Cyclin-Dependent Kinase 2</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2305</span><span class="refDoi"> DOI: 10.4161/cc.29295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.4161%2Fcc.29295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24911186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2296-2305&author=G.+Rastelliauthor=A.+Anighoroauthor=M.+Chripkovaauthor=L.+Carrassaauthor=M.+Broggini&title=Structure-Based+Discovery+of+the+First+Allosteric+Inhibitors+of+Cyclin-Dependent+Kinase+2&doi=10.4161%2Fcc.29295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2</span></div><div class="casAuthors">Rastelli, Giulio; Anighoro, Andrew; Chripkova, Martina; Carrassa, Laura; Broggini, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2296-2305</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is currently gaining a foothold in drug discovery.  Recently, the first crystal structure of CDK2 with an open allosteric pocket adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the structure has not yet been exploited for the structure-based design of type III allosteric inhibitors.  In this work we report the results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2.  Using a combination of docking and post-docking analyses made with our tool BEAR, 7 allosteric ligands (hit rate of 20%) with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the micromolar range.  Competition expts. performed in the presence of the ATP-competitive inhibitor staurosporine confirmed that the 7 ligands are truly allosteric, in agreement with their design.  Of these, compd. 2 bound CDK2 with an EC50 value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75-1 breast cancer cells with IC50 values of approx. 20 μM, while compd. 4 had an EC50 value of 71 μM and IC50 values around 4 μM.  Remarkably, the most potent compd. 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells.  Finally, hit expansion through analog search of the most potent inhibitor 4 revealed an addnl. ligand 4g with similar in vitro potency on breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGYE_h0shsbVg90H21EOLACvtfcHk0ljTZc5_vPUAYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF&md5=e790fc2920b61e6b85b5097a49cbc7bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4161%2Fcc.29295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29295%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DChripkova%26aufirst%3DM.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DBroggini%26aufirst%3DM.%26atitle%3DStructure-Based%2520Discovery%2520of%2520the%2520First%2520Allosteric%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25202%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2296%26epage%3D2305%26doi%3D10.4161%2Fcc.29295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0ljTZc5_vPUAYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+Kinase+Domain+Mutations+Confer+Polyclonal+Resistance+to+the+Tyrosine+Kinase+Inhibitor+Imatinib+%28STI571%29+in+Chronic+Phase+and+Blast+Crisis+Chronic+Myeloid+Leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0ljTZc5_vPUAYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520Kinase%2520Domain%2520Mutations%2520Confer%2520Polyclonal%2520Resistance%2520to%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Imatinib%2520%2528STI571%2529%2520in%2520Chronic%2520Phase%2520and%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+Amplification+Leads+to+Gefitinib+Resistance+in+Lung+Cancer+by+Activating+ERBB3+Signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lgqnzElGU9tkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520Amplification%2520Leads%2520to%2520Gefitinib%2520Resistance%2520in%2520Lung%2520Cancer%2520by%2520Activating%2520ERBB3%2520Signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-Family Tyrosine Kinase Inhibitor Therapy by the Kinase-Inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1038/nature05474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature05474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17206155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos12msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-Family+Tyrosine+Kinase+Inhibitor+Therapy+by+the+Kinase-Inactive+HER3&doi=10.1038%2Fnature05474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span></div><div class="casAuthors">Sergina, Natalia V.; Rausch, Megan; Wang, Donghui; Blair, Jimmy; Hann, Byron; Shokat, Kevan M.; Moasser, Mark M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7126</span>),
    <span class="NLM_cas:pages">437-441</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs.  However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo.  The reasons for this are unclear.  Signaling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10).  Here we show that HER3 and consequently PI(3)K/Akt signaling evade inhibition by current HER-family TKIs in vitro and in tumors in vivo.  This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equil., driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction.  These compensatory changes are driven by Akt-mediated neg.-feedback signaling.  Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected.  The exptl. abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumors and the therapeutic promise of this oncoprotein target.  However, because HER3 signaling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signaling effectively.  The biol. marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAgt3f0FqFvbVg90H21EOLACvtfcHk0lgqnzElGU9tkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos12msA%253D%253D&md5=5a060fb2afd7a7308ce3399d8e57f14b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature05474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05474%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-Family%2520Tyrosine%2520Kinase%2520Inhibitor%2520Therapy%2520by%2520the%2520Kinase-Inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441%26doi%3D10.1038%2Fnature05474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zahreddine, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, K. L. B.</span><span> </span><span class="NLM_article-title">Mechanism and Insights into Drug Resistance in Cancer</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3389/fphar.2013.00028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.3389%2Ffphar.2013.00028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23346057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12itbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-8&author=H.+Zahreddineauthor=K.+L.+B.+Borden&title=Mechanism+and+Insights+into+Drug+Resistance+in+Cancer&doi=10.3389%2Ffphar.2013.00028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and insights into drug resistance in cancer</span></div><div class="casAuthors">Zahreddine, Hiba; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance continues to be a major impediment in medical oncol.  Clin., resistance can arise prior to or as a result of cancer therapy.  In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metab., mutation and amplification of drug targets, as well as genetic rewiring which can lead to impaired apoptosis.  Tumor heterogeneity may also contribute to resistance, where small subpopulations of cells may acquire or stochastically already possess some of the features enabling them to emerge under selective drug pressure.  Making the problem even more challenging, some of these resistance pathways lead to multidrug resistance, generating an even more difficult clin. problem to overcome.  We provide examples of these mechanisms and some insights into how understanding these processes can influence the next generation of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJPvNuYanq7Vg90H21EOLACvtfcHk0lgqnzElGU9tkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12itbrL&md5=c616c14c9e4bf015658e396dc527ac67</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00028%26sid%3Dliteratum%253Aachs%26aulast%3DZahreddine%26aufirst%3DH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DMechanism%2520and%2520Insights%2520into%2520Drug%2520Resistance%2520in%2520Cancer%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D8%26doi%3D10.3389%2Ffphar.2013.00028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Shu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witwicki, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabassum, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janiszewska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekram, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peluffo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Santos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">Response and Resistance to BET Bromodomain Inhibitors in Triple-Negative Breast Cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">529</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1038/nature16508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature16508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26735014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=413-417&author=S.+Shuauthor=C.+Y.+Linauthor=H.+H.+Heauthor=R.+M.+Witwickiauthor=D.+P.+Tabassumauthor=J.+M.+Robertsauthor=M.+Janiszewskaauthor=S.+J.+Huhauthor=Y.+Liangauthor=J.+Ryanauthor=E.+Dohertyauthor=H.+Mohammedauthor=H.+Guoauthor=D.+G.+Stoverauthor=M.+B.+Ekramauthor=G.+Peluffoauthor=J.+Brownauthor=C.+D%E2%80%99Santosauthor=I.+E.+Kropauthor=D.+Dillonauthor=M.+McKeownauthor=C.+Ottauthor=J.+Qiauthor=M.+Niauthor=P.+K.+Raoauthor=M.+Duarteauthor=S.+Y.+Wuauthor=C.+M.+Chiangauthor=L.+Andersauthor=R.+A.+Youngauthor=E.+P.+Winerauthor=A.+Letaiauthor=W.+T.+Barryauthor=J.+S.+Carrollauthor=H.+W.+Longauthor=M.+Brownauthor=X.+S.+Liuauthor=C.+A.+Meyerauthor=J.+E.+Bradnerauthor=K.+Polyak&title=Response+and+Resistance+to+BET+Bromodomain+Inhibitors+in+Triple-Negative+Breast+Cancer&doi=10.1038%2Fnature16508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Liang, Yi; Ryan, Jeremy; Doherty, Ernest; Mohammed, Hisham; Guo, Hao; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; D'Santos, Clive; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Rao, Prakash K.; Duarte, Melissa; Wu, Shwu-Yuan; Chiang, Cheng-Ming; Anders, Lars; Young, Richard A.; Winer, Eric P.; Letai, Antony; Barry, William T.; Carroll, Jason S.; Long, Henry W.; Brown, Myles; Shirley Liu, X.; Meyer, Clifford A.; Bradner, James E.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous and clin. aggressive disease for which there is no targeted therapy.  BET bromodomain inhibitors, which have shown efficacy in several models of cancer, have not been evaluated in TNBC.  These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs.  Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clin. investigation and further motivation to understand mechanisms of resistance.  In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation.  BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner.  Proteomic studies of resistant TNBC identify strong assocn. with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase.  Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clin. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5A85pdQDbVg90H21EOLACvtfcHk0lizLMns8ddtNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D&md5=50a03861d9156ee6e344e95c5f5361b9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature16508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16508%26sid%3Dliteratum%253Aachs%26aulast%3DShu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DWitwicki%26aufirst%3DR.%2BM.%26aulast%3DTabassum%26aufirst%3DD.%2BP.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DEkram%26aufirst%3DM.%2BB.%26aulast%3DPeluffo%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DDillon%26aufirst%3DD.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DDuarte%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26aulast%3DAnders%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLong%26aufirst%3DH.%2BW.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DMeyer%26aufirst%3DC.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DResponse%2520and%2520Resistance%2520to%2520BET%2520Bromodomain%2520Inhibitors%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D413%26epage%3D417%26doi%3D10.1038%2Fnature16508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, E. Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ftouni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giotopoulos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. CW.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Wahab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papenfuss, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M. A.</span><span> </span><span class="NLM_article-title">BET Inhibitor Resistance Emerges From Leukaemia Stem Cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nature14888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature14888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2015&pages=538-542&author=C.+Y.+Fongauthor=O.+Gilanauthor=E.+Y.+N.+Lamauthor=A.+F.+Rubinauthor=S.+Ftouniauthor=D.+Tylerauthor=K.+Stanleyauthor=D.+Sinhaauthor=P.+Yehauthor=J.+Morisonauthor=G.+Giotopoulosauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+CW.+Leeauthor=C.+Carpenterauthor=R.+Gregoryauthor=R.+G.+Ramsayauthor=S.+W.+Laneauthor=O.+Abdel-Wahabauthor=T.+Kouzaridesauthor=R.+W.+Johnstoneauthor=S.+J.+Dawsonauthor=B.+J.+P.+Huntlyauthor=R.+K.+Prinjhaauthor=A.+T.+Papenfussauthor=M.+A.+Dawson&title=BET+Inhibitor+Resistance+Emerges+From+Leukaemia+Stem+Cells&doi=10.1038%2Fnature14888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibitor resistance emerges from leukaemia stem cells</span></div><div class="casAuthors">Fong, Chun Yew; Gilan, Omer; Lam, Enid Y. N.; Rubin, Alan F.; Ftouni, Sarah; Tyler, Dean; Stanley, Kym; Sinha, Devbarna; Yeh, Paul; Morison, Jessica; Giotopoulos, George; Lugo, Dave; Jeffrey, Philip; Lee, Stanley Chun-Wei; Carpenter, Christopher; Gregory, Richard; Ramsay, Robert G.; Lane, Steven W.; Abdel-Wahab, Omar; Kouzarides, Tony; Johnstone, Ricky W.; Dawson, Sarah-Jane; Huntly, Brian J. P.; Prinjha, Rab K.; Papenfuss, Anthony T.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">7570</span>),
    <span class="NLM_cas:pages">538-542</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks.  Early clin. trials have shown promise, esp. in acute myeloid leukemia, and therefore the evaluation of resistance mechanisms is crucial to optimize the clin. efficacy of these drugs.  Here we use primary mouse hematopoietic stem and progenitor cells immortalized with the fusion protein MLL-AF9 to generate several single-cell clones that demonstrate resistance, in vitro and in vivo, to the prototypical BET inhibitor, I-BET.  Resistance to I-BET confers cross-resistance to chem. distinct BET inhibitors such as JQ1, as well as resistance to genetic knockdown of BET proteins.  Resistance is not mediated through increased drug efflux or metab., but is shown to emerge from leukemia stem cells both ex vivo and in vivo.  Chromatin-bound BRD4 is globally reduced in resistant cells, whereas the expression of key target genes such as Myc remains unaltered, highlighting the existence of alternative mechanisms to regulate transcription.  We demonstrate that resistance to BET inhibitors, in human and mouse leukemia cells, is in part a consequence of increased Wnt/β-catenin signaling, and neg. regulation of this pathway results in restoration of sensitivity to I-BET in vitro and in vivo.  Together, these findings provide new insights into the biol. of acute myeloid leukemia, highlight potential therapeutic limitations of BET inhibitors, and identify strategies that may enhance the clin. utility of these unique targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Lg1n64SCWrVg90H21EOLACvtfcHk0lizLMns8ddtNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fL&md5=47d1769e077b1c6c92ff52a051368404</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14888%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DC.%2BY.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DRubin%26aufirst%3DA.%2BF.%26aulast%3DFtouni%26aufirst%3DS.%26aulast%3DTyler%26aufirst%3DD.%26aulast%3DStanley%26aufirst%3DK.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DYeh%26aufirst%3DP.%26aulast%3DMorison%26aufirst%3DJ.%26aulast%3DGiotopoulos%26aufirst%3DG.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DS.%2BCW.%26aulast%3DCarpenter%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DR.%26aulast%3DRamsay%26aufirst%3DR.%2BG.%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DDawson%26aufirst%3DS.%2BJ.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DPapenfuss%26aufirst%3DA.%2BT.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DBET%2520Inhibitor%2520Resistance%2520Emerges%2520From%2520Leukaemia%2520Stem%2520Cells%26jtitle%3DNature%26date%3D2015%26volume%3D525%26spage%3D538%26epage%3D542%26doi%3D10.1038%2Fnature14888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Rathert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerdter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deswal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny-Reiterer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jude, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boryn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweifer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakoc, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuber, J.</span><span> </span><span class="NLM_article-title">Transcriptional Plasticity Promotes Primary and Acquired Resistance to BET Inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1038/nature14898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature14898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26367798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2015&pages=543-547&author=P.+Rathertauthor=M.+Rothauthor=T.+Neumannauthor=F.+Muerdterauthor=J.+S.+Roeauthor=M.+Muharauthor=S.+Deswalauthor=S.+Cerny-Reitererauthor=B.+Peterauthor=J.+Judeauthor=T.+Hoffmannauthor=L.+M.+Borynauthor=E.+Axelssonauthor=N.+Schweiferauthor=U.+Tontsch-Gruntauthor=L.+E.+Dowauthor=D.+Gianniauthor=M.+Pearsonauthor=P.+Valentauthor=A.+Starkauthor=N.+Krautauthor=C.+R.+Vakocauthor=J.+Zuber&title=Transcriptional+Plasticity+Promotes+Primary+and+Acquired+Resistance+to+BET+Inhibition&doi=10.1038%2Fnature14898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional plasticity promotes primary and acquired resistance to BET inhibition</span></div><div class="casAuthors">Rathert, Philipp; Roth, Mareike; Neumann, Tobias; Muerdter, Felix; Roe, Jae-Seok; Muhar, Matthias; Deswal, Sumit; Cerny-Reiterer, Sabine; Peter, Barbara; Jude, Julian; Hoffmann, Thomas; Boryn, Lukasz M.; Axelsson, Elin; Schweifer, Norbert; Tontsch-Grunt, Ulrike; Dow, Lukas E.; Gianni, Davide; Pearson, Mark; Valent, Peter; Stark, Alexander; Kraut, Norbert; Vakoc, Christopher R.; Zuber, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">7570</span>),
    <span class="NLM_cas:pages">543-547</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid leukemia (AML), bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue in numerous cancers.  While clin. trials have reported single-agent activity in advanced hematol. malignancies, mechanisms detg. the response to BET inhibition remain poorly understood.  To identify factors involved in primary and acquired BET resistance in leukemia, here we perform a chromatin-focused RNAi screen in a sensitive MLL-AF9;NrasG12D-driven AML mouse model, and investigate dynamic transcriptional profiles in sensitive and resistant mouse and human leukemias.  Our screen shows that suppression of the PRC2 complex, contrary to effects in other contexts, promotes BET inhibitor resistance in AML.  PRC2 suppression does not directly affect the regulation of Brd4-dependent transcripts, but facilitates the remodelling of regulatory pathways that restore the transcription of key targets such as Myc.  Similarly, while BET inhibition triggers acute MYC repression in human leukemias regardless of their sensitivity, resistant leukemias are uniformly characterized by their ability to rapidly restore MYC transcription.  This process involves the activation and recruitment of WNT signaling components, which compensate for the loss of BRD4 and drive resistance in various cancer models.  Dynamic chromatin immunopptn. sequencing and self-transcribing active regulatory region sequencing of enhancer profiles reveal that BET-resistant states are characterized by remodelled regulatory landscapes, involving the activation of a focal MYC enhancer that recruits WNT machinery in response to BET inhibition.  Together, our results identify and validate WNT signaling as a driver and candidate biomarker of primary and acquired BET resistance in leukemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgeY3nFr4GrVg90H21EOLACvtfcHk0lhKnMBje2Qxng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fO&md5=6d6cf4c4123ad6a698b88f02f95a2ebe</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature14898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14898%26sid%3Dliteratum%253Aachs%26aulast%3DRathert%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DNeumann%26aufirst%3DT.%26aulast%3DMuerdter%26aufirst%3DF.%26aulast%3DRoe%26aufirst%3DJ.%2BS.%26aulast%3DMuhar%26aufirst%3DM.%26aulast%3DDeswal%26aufirst%3DS.%26aulast%3DCerny-Reiterer%26aufirst%3DS.%26aulast%3DPeter%26aufirst%3DB.%26aulast%3DJude%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DBoryn%26aufirst%3DL.%2BM.%26aulast%3DAxelsson%26aufirst%3DE.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DDow%26aufirst%3DL.%2BE.%26aulast%3DGianni%26aufirst%3DD.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DZuber%26aufirst%3DJ.%26atitle%3DTranscriptional%2520Plasticity%2520Promotes%2520Primary%2520and%2520Acquired%2520Resistance%2520to%2520BET%2520Inhibition%26jtitle%3DNature%26date%3D2015%26volume%3D525%26spage%3D543%26epage%3D547%26doi%3D10.1038%2Fnature14898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhKnMBje2Qxng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhKnMBje2Qxng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lj9uA2WuQXPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span><span class="refDoi"> DOI: 10.1021/jm901132v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901132v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1413-1437&author=R.+Morphy&title=Selectively+Nonselective+Kinase+Inhibition%3A+Striking+the+Right+Balance&doi=10.1021%2Fjm901132v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1413-1437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Marketed kinase inhibitors (MKIs) can deliver superior efficacy compared to inhibitors with high specificity for a single kinase, and the recent introduction of several MKIs to the market opens the door to a new era of safer and effective anticancer therapy.  The key to combining high efficacy with acceptable safety is to inhibit multiple targets in a selectively nonselective fashion.  Strategies for intentionally designing MKIs are emerging, but the field is still in its infancy and we are as medicinal chemists currently on the steepest part of the learning curve.  MTDD can be time-consuming and expensive, and we need to become more proficient first at identifying disease-relevant target combinations and second at discovering MKIs that combine optimal physicochem. and biol. properties.  Bold and innovative medicinal chem. strategies are required to tackle "difficult combinations" where the disease rationale is compelling but where it is a struggle to combine all the desired attributes of an oral MKI drug into a single mol.  At present it is unclear to what extent MKIs with highly tuned selectivity profiles can be rationally designed, particularly for targets that are unrelated by sequence.  In addn. to the well-known selectivity challenge, the physicochem. property profiles of AT P-competitive MKIs can be inherently challenging and limited scope for patentability can also be a serious hindrance.  On the plus side, the amt. of kinase-specific structural information is growing very rapidly, and ultimately this may reveal distinct features and design rules that enable a medicinal chemist to rationally modify and refine the profile of MKIs.  In addn., increasing SAR knowledge is emerging from large scale panel screening with the binding profiles starting to reveal to medicinal chemists how chem. structure affects cross-reactivity across large parts of the kinome.  The merit of MKIs compared with single kinase inhibitors is a subject of controversy in drug discovery that is unlikely to be resolved in the near future.  At the start of a new MTDD project, a rigorous debate needs to take place as to whether it makes more sense to seek a combination of highly selective agents or a DML.  Many factors need to be taken into account in this decision such as the no., similarity, and promiscuity of the targets in the profile and the disease area.  Conformational plasticity and the occurrence of multiple binding modes complicate the in silico prediction of kinase polypharmacol. based solely upon protein structure.  The use of ligand-based similarity to assess the feasibility of a given combination can add real value.  Currently, serendipity plays a significant role in MKI discovery and many, if not most, MKIs have been discovered by chance during the search for selective inhibitors.  Medicinal chemists need to be alert to the possibilities when a surprising combination is found by chance.  To exploit such serendipity, you need a good appreciation of when you have a sufficiently high quality starting compd. and then you need to be able to make and test sufficient analogs to explore your new disease-based hypothesis.  MKIs are costly to develop and are consequently priced at a premium level, so they will need to show clear improvements in order to get reimbursement.  There have already been problems with reimbursement for some MKIs in some markets due to concerns from funding bodies over insufficient efficacy.  The true value of MKIs relative to other anticancer drugs still has to be established, and the results from recent clin. trials have been mixed.  Despite the broad activity profile of many MKIs, the patient response can be inconsistent and unpredictable.  The identification of predictive biomarkers of response or resistance is a crit. step to ascertain which specific combination of targets produces a significant clin. benefit with respect to specific tumor types.  More clin. feedback is needed to facilitate the design of the next generation of inhibitors with more precisely defined profiles.  Although it might seem immeasurably distant at the present time, the ultimate goal should be to derive the prerequisite knowledge and tools so that MTDD becomes a rational endeavor rather than a black box approach that relies upon serendipity.  This will help banish claims that MKIs are merely dirty, nonspecific drugs with insufficient specificity for treating a wider range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-L-NWmtdikbVg90H21EOLACvtfcHk0lj9uA2WuQXPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF&md5=3c915b5debf9d005993c8ad31c68bc2e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901132v%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelectively%2520Nonselective%2520Kinase%2520Inhibition%253A%2520Striking%2520the%2520Right%2520Balance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1413%26epage%3D1437%26doi%3D10.1021%2Fjm901132v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1182/blood-2004-08-3097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1182%2Fblood-2004-08-3097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15618470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2640-2653&author=M.+Deiningerauthor=E.+Buchdungerauthor=B.+J.+Druker&title=The+Development+of+Imatinib+as+a+Therapeutic+Agent+for+Chronic+Myeloid+Leukemia&doi=10.1182%2Fblood-2004-08-3097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span></div><div class="casAuthors">Deininger, Michael; Buchdunger, Elisabeth; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2640-2653</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML).  Preclin. studies were promising but the results of clin. trials by far exceeded expectations.  Responses in chronic phase are unprecedented, with rates of complete cytogenetic response (CCR) of more than 40% in patients after failure of interferon-α (IFN) and more than 80% in newly diagnosed patients, a level of efficacy that led to regulatory approval in record time.  While most of these responses are stable, resistance to treatment after an initial response is common in more advanced phases of the disease.  Mutations in the kinase domain (KD) of BCR-ABL that impair imatinib binding have been identified as the leading cause of resistance.  Patients with CCR who achieve a profound redn. of BCR-ABL mRNA have a very low risk of disease progression.  However, residual disease usually remains detectable with reverse transcription-polymerase chain reaction (RT-PCR), indicating that disease eradication may pose a significant challenge.  The mechanisms underlying the persistence of minimal residual disease are unknown.  In this manuscript, we review the preclin. and clin. development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRkeS0lKeTObVg90H21EOLACvtfcHk0lj9uA2WuQXPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D&md5=894d4159f7a65f3ae5304249d6ba1e75</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-08-3097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-08-3097%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520Development%2520of%2520Imatinib%2520as%2520a%2520Therapeutic%2520Agent%2520for%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2640%26epage%3D2653%26doi%3D10.1182%2Fblood-2004-08-3097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Novel Selective-Spectrum Kinase Inhibitors in Oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span><span class="refDoi"> DOI: 10.1517/13543784.17.7.1013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1517%2F13543784.17.7.1013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&author=P.+M.+Lorussoauthor=J.+P.+Eder&title=Therapeutic+Potential+of+Novel+Selective-Spectrum+Kinase+Inhibitors+in+Oncology&doi=10.1517%2F13543784.17.7.1013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.7.1013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.7.1013%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520Potential%2520of%2520Novel%2520Selective-Spectrum%2520Kinase%2520Inhibitors%2520in%2520Oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D1028%26doi%3D10.1517%2F13543784.17.7.1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Steinberg, M.</span><span> </span><span class="NLM_article-title">Dasatinib: A Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia and Philadelphia Chromosome—Positive Acute Lymphoblastic Leukemia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2007.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.clinthera.2007.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18158072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=2289-2308&author=M.+Steinberg&title=Dasatinib%3A+A+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+Chronic+Myelogenous+Leukemia+and+Philadelphia+Chromosome%E2%80%94Positive+Acute+Lymphoblastic+Leukemia&doi=10.1016%2Fj.clinthera.2007.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia</span></div><div class="casAuthors">Steinberg, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2289-2308</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22.  The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathol. of chronic myelogenous leukemia (CML).  Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematol. and cytogenetic responses in affected individuals.  The oral TK inhibitor dasatinib was approved in 2006 for use in patients with CML or Philadelphia chromosome-pos. acute lymphoblastic leukemia (ALL) who are unable to tolerate or have not responded to other treatments.  Objective: This paper reviews the available data on dasatinib, including its pharmacokinetic and pharmacodynamic properties, findings of in vitro and in vivo studies, adverse effects, and potential place in therapy.  Methods: Pertinent information was identified through searches of MEDLINE (1966-May 2007), EMBASE (1980-first quarter 2007), and International Pharmaceutical Abstrs. (1970-May 2007) using the terms dasatinib, BMS-354825, chronic myelogenous leukemia, Sprycel, Philadelphia chromosome, and acute lymphoblastic leukemia.  All clin. studies and case reports published at the time of the search were included in this review.  Results: Obsd. mutations in the amino acid sequence of BCR-ABL cause the failure of treatment with existing TK inhibitors.  Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors.  Preliminary results are available from several noncomparative studies of dasatinib in patients who were unable to tolerate or were resistant to previous therapies.  The 5 phases of START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) represent the largest and most comprehensive evaluation of dasatinib in the treatment of patients in all stages of CML or Philadelphia chromosome-pos. ALL who had undergone previous treatment for leukemia.  Dasatanib had the greatest benefit in patients in the chronic phase of CML, with complete hematol. responses in 90% of patients, 52% of whom achieved a major hematol. response.  Compared with those in the chronic phase, patients in the accelerated phase or blast crisis of CML, or with Philadelphia chromosome-pos. ALL had lower responses.  In the START-R trial, which compared the response to dasatinib and high-dose imatinib (800 mg/d), both regimens had comparable ability to induce a complete hematol. response (95% and 93%, resp.), although more patients achieved a major cytogenetic response with dasatinib (32% vs 7%).  Adverse effects include significant myelosuppression.  Dasatinib may have the potential for use in the management of nonleukemic malignancies.  Conclusions: Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors.  It has shown clin. benefit and tolerability in patients in all phases of CML, as well as in those with Philadelphia chromosome-pos. ALL.  Dasatinib illustrates the potential for targeted drug development based on an understanding of the genetic alterations leading to CML and the development of resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8AoiiPuTJrVg90H21EOLACvtfcHk0lhZNFOzFeKmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D&md5=1219cbf8c0a882317a19db3a2c9a4605</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2007.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2007.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DM.%26atitle%3DDasatinib%253A%2520A%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Myelogenous%2520Leukemia%2520and%2520Philadelphia%2520Chromosome%25E2%2580%2594Positive%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DClin.%2520Ther.%26date%3D2007%26volume%3D29%26spage%3D2289%26epage%3D2308%26doi%3D10.1016%2Fj.clinthera.2007.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Tang, P. C.; Todd A. Miller, T. A.; Li, X.; Sun, L.; Wei, C. C.; Shirazian, S.; Liang, C.; Vojkovsky, T.; Nematalla, A. S.; Hawley, M.</span><span> </span><span class="NLM_article-title">Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors</span>. U.S. Patent 6573293, February 15,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=P.+C.+Tang&author=T.+A.+Todd+A.+Miller&author=X.+Li&author=L.+Sun&author=C.+C.+Wei&author=S.+Shirazian&author=C.+Liang&author=T.+Vojkovsky&author=A.+S.+Nematalla&author=M.+Hawley&title=Pyrrole+Substituted+2-Indolinone+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DP.%2BC.%26atitle%3DPyrrole%2520Substituted%25202-Indolinone%2520Protein%2520Kinase%2520Inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-yl- amino)thiazole-5-carboxamide (BMS-354825), a Dual SRC/ABL Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span><span class="refDoi"> DOI: 10.1021/jm049486a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-yl-+amino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+Dual+SRC%2FABL+Kinase+Inhibitor+with+Potent+Antitumor+Activity+in+Preclinical+Assays&doi=10.1021%2Fjm049486a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-yl-%2520amino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520Dual%2520SRC%252FABL%2520Kinase%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Preclinical%2520Assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661%26doi%3D10.1021%2Fjm049486a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Tung, R.</span><span> </span><span class="NLM_article-title">Vandetanib Derivatives</span>. U.S. Patent 20110117084, January 22,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Tung&title=Vandetanib+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTung%26aufirst%3DR.%26atitle%3DVandetanib%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Z.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lhZNFOzFeKmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%2BZ.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Stein, R. C.</span><span> </span><span class="NLM_article-title">Prospects for Phosphoinositide 3-Kinase Inhibition as a Cancer Treatment</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1677/erc.0.0080237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1677%2Ferc.0.0080237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=237-248&author=R.+C.+Stein&title=Prospects+for+Phosphoinositide+3-Kinase+Inhibition+as+a+Cancer+Treatment&doi=10.1677%2Ferc.0.0080237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080237%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%2BC.%26atitle%3DProspects%2520for%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520as%2520a%2520Cancer%2520Treatment%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26spage%3D237%26epage%3D248%26doi%3D10.1677%2Ferc.0.0080237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillermet-Guibert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graupera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilanges, B.</span><span> </span><span class="NLM_article-title">The Emerging Mechanisms of Isoform-Specific PI3K Signalling</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nrm2882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrm2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20379207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=329-341&author=B.+Vanhaesebroeckauthor=J.+Guillermet-Guibertauthor=M.+Grauperaauthor=B.+Bilanges&title=The+Emerging+Mechanisms+of+Isoform-Specific+PI3K+Signalling&doi=10.1038%2Fnrm2882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging mechanisms of isoform-specific PI3K signaling</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Guillermet-Guibert, Julie; Graupera, Mariona; Bilanges, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-341</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3Ks) function early in intracellular signal transduction pathways and affect many biol. functions.  A further level of complexity derives from the existence of eight PI3K isoforms, which are divided into class I, class II and class III PI3Ks.  PI3K signaling has been implicated in metabolic control, immunity, angiogenesis and cardiovascular homeostasis, and is one of the most frequently deregulated pathways in cancer.  PI3K inhibitors have recently entered clin. trials in oncol.  A better understanding of how the different PI3K isoforms are regulated and control signaling could uncover their roles in pathol. and reveal in which disease contexts their blockade could be most beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1WFE8yaCnkrVg90H21EOLACvtfcHk0lhilCAEQiR_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVersrc%253D&md5=d8507e3901857b68bb0a48dc7fea2b5b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrm2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2882%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26aulast%3DGraupera%26aufirst%3DM.%26aulast%3DBilanges%26aufirst%3DB.%26atitle%3DThe%2520Emerging%2520Mechanisms%2520of%2520Isoform-Specific%2520PI3K%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D329%26epage%3D341%26doi%3D10.1038%2Fnrm2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Montfort, R. L. M.</span><span> </span><span class="NLM_article-title">Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-4355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F0008-5472.CAN-09-4355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2146-2157&author=P.+Workmanauthor=P.+a.+Clarkeauthor=F.+I.+Raynaudauthor=R.+L.+M.+Van+Montfort&title=Drugging+the+PI3+Kinome%3A+From+Chemical+Tools+to+Drugs+in+the+Clinic&doi=10.1158%2F0008-5472.CAN-09-4355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-4355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-4355%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2Ba.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DVan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26atitle%3DDrugging%2520the%2520PI3%2520Kinome%253A%2520From%2520Chemical%2520Tools%2520to%2520Drugs%2520in%2520the%2520Clinic%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2146%26epage%3D2157%26doi%3D10.1158%2F0008-5472.CAN-09-4355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Bromodomains as Therapeutic Targets</span> <span class="citation_source-journal">Expert Rev. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1017/S1462399411001992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1017%2FS1462399411001992" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1-21&author=S.+Mullerauthor=P.+Filippakopoulosauthor=S.+Knapp&title=Bromodomains+as+Therapeutic+Targets&doi=10.1017%2FS1462399411001992"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1017%2FS1462399411001992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399411001992%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DBromodomains%2520as%2520Therapeutic%2520Targets%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3D1%26epage%3D21%26doi%3D10.1017%2FS1462399411001992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span> </span><span class="NLM_article-title">Epigenetic Protein Families: A New Frontier for Drug Discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span><span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+Protein+Families%3A+A+New+Frontier+for+Drug+Discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0lhilCAEQiR_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520Protein%2520Families%253A%2520A%2520New%2520Frontier%2520for%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1298</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+Coteauthor=S.+Magnuson&title=Disrupting+Acetyl-Lysine+Recognition%3A+Progress+in+the+Development+of+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0lhhRtoMwodzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DCote%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520Acetyl-Lysine%2520Recognition%253A%2520Progress%2520in%2520the%2520Development%2520of%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Micelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Histone Deacetylases: Structural Determinants of Inhibitor Selectivity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.drudis.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25687212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFehsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=718-735&author=C.+Micelliauthor=G.+Rastelli&title=Histone+Deacetylases%3A+Structural+Determinants+of+Inhibitor+Selectivity&doi=10.1016%2Fj.drudis.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases: structural determinants of inhibitor selectivity</span></div><div class="casAuthors">Micelli, Carmina; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">718-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are epigenetic targets with an important role in cancer, neurodegeneration, inflammation, and metabolic disorders.  Although clin. effective HDAC inhibitors have been developed, the design of inhibitors with the desired isoform(s) selectivity remains a challenge.  Selective inhibitors could help clarify the function of each isoform, and provide therapeutic agents having potentially fewer adverse effects.  Crystal structures of several HDACs have been reported, enabling structure-based drug design and providing important information to understand enzyme function.  Here, we provide a comprehensive review of the structural information available on HDACs, discussing both conserved and isoform-specific structural and mechanistic features.  We focus on distinctive aspects that help rationalize inhibitor selectivity, and provide structure-based recommendations for achieving the desired selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpabCy1anCPVrVg90H21EOLACvtfcHk0lhhRtoMwodzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFehsL4%253D&md5=5deab17c87fd88af9d6d3887449ef575</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DMicelli%26aufirst%3DC.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DHistone%2520Deacetylases%253A%2520Structural%2520Determinants%2520of%2520Inhibitor%2520Selectivity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D718%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keates, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsyte-Lovejoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felletar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingras, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22464331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVamurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=214-231&author=P.+Filippakopoulosauthor=S.+Picaudauthor=M.+Mangosauthor=T.+Keatesauthor=J.+P.+Lambertauthor=D.+Barsyte-Lovejoyauthor=I.+Felletarauthor=R.+Volkmerauthor=S.+M%C3%BCllerauthor=T.+Pawsonauthor=A.+C.+Gingrasauthor=C.+H.+Arrowsmithauthor=S.+Knapp&title=Histone+Recognition+and+Large-Scale+Structural+Analysis+of+the+Human+Bromodomain+Family&doi=10.1016%2Fj.cell.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family</span></div><div class="casAuthors">Filippakopoulos, Panagis; Picaud, Sarah; Mangos, Maria; Keates, Tracy; Lambert, Jean-Philippe; Barsyte-Lovejoy, Dalia; Felletar, Ildiko; Volkmer, Rudolf; Muller, Susanne; Pawson, Tony; Gingras, Anne-Claude; Arrowsmith, Cheryl H.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-231</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks.  The 61 BRDs in the human genome cluster into eight families based on structure/sequence similarity.  Here, we present 29 high-resoln. crystal structures, covering all BRD families.  These proteins are: ASH1L, ATAD2, BAZ2B, BPTF, BRD1, BRD3(1), BRD3(2), BRD4(1), BRD4(2), BRD9, BRDT(1), CECR2, EP300, CREBBP, GCN5L2, KIAA1240, PB1(1), PB1(2), PB1(3), PB1(4), PB1(5), PB1(6), PCAF, PHIP(2), TAF1(2), WDR9(2), BRD4(1).  Comprehensive crossfamily structural anal. identifies conserved and family-specific structural features that are necessary for specific acetylation-dependent substrate recognition.  Screening of more than 30 representative BRDs against systematic histone-peptide arrays identifies new BRD substrates and reveals a strong influence of flanking posttranslational modifications, such as acetylation and phosphorylation, suggesting that BRDs recognize combinations of marks rather than singly acetylated sequences.  We further uncovered a structural mechanism for the simultaneous binding and recognition of diverse diacetyl-contg. peptides by BRD4.  These data provide a foundation for structure-based drug design of specific inhibitors for this emerging target family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2FSIcPoXZLVg90H21EOLACvtfcHk0lhhRtoMwodzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVamurs%253D&md5=05583a01a1cd4c3b59fc59c00e4c4777</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DMangos%26aufirst%3DM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DLambert%26aufirst%3DJ.%2BP.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DVolkmer%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DHistone%2520Recognition%2520and%2520Large-Scale%2520Structural%2520Analysis%2520of%2520the%2520Human%2520Bromodomain%2520Family%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D214%26epage%3D231%26doi%3D10.1016%2Fj.cell.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Portela, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteller, M.</span><span> </span><span class="NLM_article-title">Epigenetic Modifications and Human Disease</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span><span class="refDoi"> DOI: 10.1038/nbt.1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnbt.1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20944598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yjsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1057-1068&author=A.+Portelaauthor=M.+Esteller&title=Epigenetic+Modifications+and+Human+Disease&doi=10.1038%2Fnbt.1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic modifications and human disease</span></div><div class="casAuthors">Portela, Anna; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1057-1068</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetics is one of the most rapidly expanding fields in biol.  The recent characterization of a human DNA methylome at single nucleotide resoln., the discovery of the CpG island shores, the finding of new histone variants and modifications, and the unveiling of genome-wide nucleosome positioning maps highlight the accelerating speed of discovery over the past two years.  Increasing interest in epigenetics has been accompanied by technol. breakthroughs that now make it possible to undertake large-scale epigenomic studies.  These allow the mapping of epigenetic marks, such as DNA methylation, histone modifications and nucleosome positioning, which are crit. for regulating gene and noncoding RNA expression.  In turn, we are learning how aberrant placement of these epigenetic marks and mutations in the epigenetic machinery is involved in disease.  Thus, a comprehensive understanding of epigenetic mechanisms, their interactions and alterations in health and disease, has become a priority in biomedical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmU-oOba01dbVg90H21EOLACvtfcHk0lhhRtoMwodzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yjsLzF&md5=02649d0c2ed862eda90d7bd349871c71</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1685%26sid%3Dliteratum%253Aachs%26aulast%3DPortela%26aufirst%3DA.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DEpigenetic%2520Modifications%2520and%2520Human%2520Disease%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D1057%26epage%3D1068%26doi%3D10.1038%2Fnbt.1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Furdas, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">Inhibition of Bromodomain-Mediated Protein–protein Interactions as a Novel Therapeutic Strategy</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1039/C1MD00201E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1039%2FC1MD00201E" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=123-134&author=S.+D.+Furdasauthor=L.+Carlinoauthor=W.+Sipplauthor=M.+Jung&title=Inhibition+of+Bromodomain-Mediated+Protein%E2%80%93protein+Interactions+as+a+Novel+Therapeutic+Strategy&doi=10.1039%2FC1MD00201E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC1MD00201E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00201E%26sid%3Dliteratum%253Aachs%26aulast%3DFurdas%26aufirst%3DS.%2BD.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Bromodomain-Mediated%2520Protein%25E2%2580%2593protein%2520Interactions%2520as%2520a%2520Novel%2520Therapeutic%2520Strategy%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D123%26epage%3D134%26doi%3D10.1039%2FC1MD00201E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.-M.</span><span> </span><span class="NLM_article-title">Discovery of Chemical Inhibitors of Human Bromodomains</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">11625</span><span class="NLM_x">–</span> <span class="NLM_lpage">11668</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=11625-11668&author=G.+Zhangauthor=S.+G.+Smithauthor=M.-M.+Zhou&title=Discovery+of+Chemical+Inhibitors+of+Human+Bromodomains&doi=10.1021%2Facs.chemrev.5b00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Chemical Inhibitors of Human Bromodomains</span></div><div class="casAuthors">Zhang, Guangtao; Smith, Steven G.; Zhou, Ming-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11625-11668</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-guided drug design strategy has played an important role in the recent discovery and development of bromodomain inhibitors that has yielded a multitude of chemotypes as described in this review.  Going forward, we expect that this structure-based approach will continue to guide medicinal chemists in lead optimization of bromodomain inhibitors and facilitate the efforts to develop new inhibitors for less druggable bromodomains.  Collectively, these emerging new chem. inhibitors will empower our ongoing investigation to better understand the roles of bromodomain proteins in control of gene transcription in human biol. and disease pathol.  These small-mol. inhibitors can also be developed into new epigenetic therapies for new effective treatments of various human diseases including cancer and inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbsgfBguOabVg90H21EOLACvtfcHk0lhx1EgW9bEvUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qurzP&md5=4014c771384b4a768a80644af22c4485</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00205%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26aulast%3DZhou%26aufirst%3DM.-M.%26atitle%3DDiscovery%2520of%2520Chemical%2520Inhibitors%2520of%2520Human%2520Bromodomains%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D11625%26epage%3D11668%26doi%3D10.1021%2Facs.chemrev.5b00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Jennings, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Measures, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">Phenotypic Screening and Fragment-Based Approaches to the Discovery of Small-Molecule Bromodomain Ligands</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.4155/fmc.13.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.4155%2Ffmc.13.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24467243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=179-204&author=L.+E.+Jenningsauthor=A.+R.+Measuresauthor=B.+G.+Wilsonauthor=S.+J.+Conway&title=Phenotypic+Screening+and+Fragment-Based+Approaches+to+the+Discovery+of+Small-Molecule+Bromodomain+Ligands&doi=10.4155%2Ffmc.13.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands</span></div><div class="casAuthors">Jennings, Laura E.; Measures, Angelina R.; Wilson, Brian G.; Conway, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-204</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Bromodomains are protein modules that bind to acetylated lysine residues and hence facilitate protein-protein interactions.  These bromodomain-mediated interactions often play key roles in transcriptional regulation and their dysfunction is implicated in a large no. of diseases.  The discovery of potent and selective small-mol. bromodomain and extra C-terminal domain bromodomain ligands, which show promising results for the treatment of cancers and atherosclerosis, has promoted intense interest in this area.  Here we describe the progress that has been made to date in the discovery of small-mol. bromodomain ligands, with particular emphasis on the roles played by phenotypic screening and fragment-based approaches.  In considering the future of the field we discuss the prospects for development of mol. probes and drugs for the non-bromodomain and extra C-terminal domain bromodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6WhUfE_Ad4rVg90H21EOLACvtfcHk0lhx1EgW9bEvUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCkuro%253D&md5=08c3266ceefe824fde8ef7c400d6bc22</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.197%26sid%3Dliteratum%253Aachs%26aulast%3DJennings%26aufirst%3DL.%2BE.%26aulast%3DMeasures%26aufirst%3DA.%2BR.%26aulast%3DWilson%26aufirst%3DB.%2BG.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DPhenotypic%2520Screening%2520and%2520Fragment-Based%2520Approaches%2520to%2520the%2520Discovery%2520of%2520Small-Molecule%2520Bromodomain%2520Ligands%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D179%26epage%3D204%26doi%3D10.4155%2Ffmc.13.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aster, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubonishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Cin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Atayde, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19)</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)63049-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0002-9440%2810%2963049-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=11733348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhslakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2001&pages=1987-1992&author=C.+A.+Frenchauthor=I.+Miyoshiauthor=J.+C.+Asterauthor=I.+Kubonishiauthor=T.+G.+Krollauthor=P.+Dal+Cinauthor=S.+O.+Vargasauthor=A.+R.+Perez-Ataydeauthor=J.+A.+Fletcher&title=BRD4+Bromodomain+Gene+Rearrangement+in+Aggressive+Carcinoma+with+Translocation+t%2815%3B19%29&doi=10.1016%2FS0002-9440%2810%2963049-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)</span></div><div class="casAuthors">French, Christopher A.; Miyoshi, Isao; Aster, Jon C.; Kubonishi, Ichiro; Kroll, Todd G.; Dal Cin, Paola; Vargas, Sara O.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1987-1992</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Translocation t(15;19)(q13;p13.1) defines a lethal midline carcinoma arising adjacent to respiratory tract in young people.  To characterize mol. alterations responsible for the distinctly aggressive biol. behavior of this cancer, we mapped the chromosome 15 and 19 translocation breakpoints by fluorescence in situ hybridization (FISH) and Southern blotting.  To evaluate preliminarily the frequency, anatomical distribution, and histol. features of t(15;19) cancer, we developed a FISH assay for paraffin sections.  Our findings reveal a novel oncogenic mechanism in which the chromosome 19 translocation breakpoint interrupts the coding sequence of a bromodomain gene, BRD4.  These studies implicate BRD4 as a potential partner in a t(15;19)-assocd. fusion oncogene.  In addn., we localized the chromosome 15 breakpoint to a 9-kb region in each of two cases, thereby identifying several candidate oncogenes which might represent the BRD4 fusion partner.  FISH evaluation of 13 pediatric carcinomas revealed t(15;19) in one of four sinonasal carcinomas, whereas this translocation was not detected in thymic (n = 3), mucoepidermoid (n = 3), laryngeal (n = 2), or nasopharyngeal (n = 1) carcinomas.  Our studies shed light on the oncogenic mechanism underlying t(15;19) and provide further evidence that this highly lethal cancer arises from respiratory mucosa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT-brK2zZWPbVg90H21EOLACvtfcHk0lhx1EgW9bEvUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhslakug%253D%253D&md5=be1d097192c440e4a8ef8c69e1fca43c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963049-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963049-0%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DMiyoshi%26aufirst%3DI.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DKubonishi%26aufirst%3DI.%26aulast%3DKroll%26aufirst%3DT.%2BG.%26aulast%3DDal%2BCin%26aufirst%3DP.%26aulast%3DVargas%26aufirst%3DS.%2BO.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DBRD4%2520Bromodomain%2520Gene%2520Rearrangement%2520in%2520Aggressive%2520Carcinoma%2520with%2520Translocation%2520t%252815%253B19%2529%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D159%26spage%3D1987%26epage%3D1992%26doi%3D10.1016%2FS0002-9440%2810%2963049-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Raux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voitovich, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derviaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebuffet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinquet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillemot, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunel, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, X.</span><span> </span><span class="NLM_article-title">Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1634</span><span class="NLM_x">–</span> <span class="NLM_lpage">1641</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1634-1641&author=B.+Rauxauthor=Y.+Voitovichauthor=C.+Derviauxauthor=A.+Lugariauthor=E.+Rebuffetauthor=S.+Milhasauthor=S.+Prietauthor=T.+Rouxauthor=E.+Trinquetauthor=J.-C.+Guillemotauthor=S.+Knappauthor=J.-M.+Brunelauthor=A.+Y.+Fedorovauthor=Y.+Colletteauthor=P.+Rocheauthor=S.+Betziauthor=S.+Combesauthor=X.+Morelli&title=Exploring+Selective+Inhibition+of+the+First+Bromodomain+of+the+Human+Bromodomain+and+Extra-Terminal+Domain+%28BET%29+Proteins&doi=10.1021%2Facs.jmedchem.5b01708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins</span></div><div class="casAuthors">Raux, Brigitt; Voitovich, Yuliia; Derviaux, Carine; Lugari, Adrien; Rebuffet, Etienne; Milhas, Sabine; Priet, Stephane; Roux, Thomas; Trinquet, Eric; Guillemot, Jean-Claude; Knapp, Stefan; Brunel, Jean-Michel; Fedorov, Alexey Yu.; Collette, Yves; Roche, Philippe; Betzi, Stephane; Combes, Sebastien; Morelli, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1634-1641</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A midthroughput screening follow-up program targeting the first bromodomain of the human BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine deriv. inhibitor.  This compd. binds with an affinity in the low micromolar range yet exerts suitable unexpected selectivity in vitro against the other members of the bromodomain and extra-terminal domain (BET) family.  A structure-based program pinpointed a role of the ZA loop, paving the way for the development of potent and selective BET-BRDi probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQdXvF3r4zLVg90H21EOLACvtfcHk0ljRT-wLdGbe0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKhsr0%253D&md5=fb9cfc20c76f65fcf409370b60aecc0a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01708%26sid%3Dliteratum%253Aachs%26aulast%3DRaux%26aufirst%3DB.%26aulast%3DVoitovich%26aufirst%3DY.%26aulast%3DDerviaux%26aufirst%3DC.%26aulast%3DLugari%26aufirst%3DA.%26aulast%3DRebuffet%26aufirst%3DE.%26aulast%3DMilhas%26aufirst%3DS.%26aulast%3DPriet%26aufirst%3DS.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DGuillemot%26aufirst%3DJ.-C.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBrunel%26aufirst%3DJ.-M.%26aulast%3DFedorov%26aufirst%3DA.%2BY.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DCombes%26aufirst%3DS.%26aulast%3DMorelli%26aufirst%3DX.%26atitle%3DExploring%2520Selective%2520Inhibition%2520of%2520the%2520First%2520Bromodomain%2520of%2520the%2520Human%2520Bromodomain%2520and%2520Extra-Terminal%2520Domain%2520%2528BET%2529%2520Proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1634%26epage%3D1641%26doi%3D10.1021%2Facs.jmedchem.5b01708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Inhibition of BET Bromodomains as a Therapeutic Strategy for Cancer Drug Discovery</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">5501</span><span class="NLM_x">–</span> <span class="NLM_lpage">5516</span><span class="refDoi"> DOI: 10.18632/oncotarget.3551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.18632%2Foncotarget.3551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25849938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5501-5516&author=L.+Fuauthor=M.+Tianauthor=X.+Liauthor=J.+Liauthor=J.+Huangauthor=L.+Ouyangauthor=Y.+Zhangauthor=B.+Liu&title=Inhibition+of+BET+Bromodomains+as+a+Therapeutic+Strategy+for+Cancer+Drug+Discovery&doi=10.18632%2Foncotarget.3551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span></div><div class="casAuthors">Fu Lei-lei; Tian Mao; Li Xiang; Li Jing-jing; Ouyang Liang; Zhang Yonghui; Liu Bo; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5501-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site.  Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT.  BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2.  Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer.  In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBHUaDfXsQehKDYG3bNImrfW6udTcc2eYN1b5naJBVe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D&md5=b3b070170e6da5585f87dffe1d568f47</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3551%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520BET%2520Bromodomains%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Cancer%2520Drug%2520Discovery%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5501%26epage%3D5516%26doi%3D10.18632%2Foncotarget.3551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubonishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grier, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-atayde, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12543779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Klug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=304-307&author=C.+A.+Frenchauthor=I.+Miyoshiauthor=I.+Kubonishiauthor=H.+E.+Grierauthor=A.+R.+Perez-ataydeauthor=J.+A.+Fletcher&title=BRD4-NUT+Fusion+Oncogene%3A+A+Novel+Mechanism+in+Aggressive+Carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma</span></div><div class="casAuthors">French, Christopher A.; Miyoshi, Isao; Kubonishi, Ichiro; Grier, Holcombe E.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-307</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The poorly differentiated carcinoma with t(15;19)(q13,p13.1) is characterized by its highly aggressive, invariably lethal clin. course.  The chromosome 19 translocation breakpoint targets the BRD4 double bromodomain-contg. gene, which functions in regulation of cell cycle progression.  Herein the authors demonstrate that BRD4 is fused with nearly the entire transcript of the novel 15q13 gene, NUT (nuclear protein in testis), forming a 6.4-kb fusion oncogene, BRD4-NUT.  NUT, like BRD4, is predicted to encode a nuclear protein but, unlike the ubiquitous BRD4 transcript, is expressed only in testis.  These findings establish a model to elucidate the oncogenic consequences of unscheduled NUT expression and altered BRD4 function.  Very few fusion oncogenes have been identified in epithelial tumors, and BRD4-NUT is the first fusion oncogene mechanism identified in a highly lethal form of carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTa0K_kBu2pLVg90H21EOLACvtfcHk0ljRT-wLdGbe0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Klug%253D%253D&md5=e927ea5874b2013c7467f981e10d7efd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DMiyoshi%26aufirst%3DI.%26aulast%3DKubonishi%26aufirst%3DI.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DPerez-atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DBRD4-NUT%2520Fusion%2520Oncogene%253A%2520A%2520Novel%2520Mechanism%2520in%2520Aggressive%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D304%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keates, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felletar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0ljbguTUTroV-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.</span><span> </span><span class="NLM_article-title">Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">16669</span><span class="NLM_x">–</span> <span class="NLM_lpage">16674</span><span class="refDoi"> DOI: 10.1073/pnas.1108190108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1073%2Fpnas.1108190108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21949397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16669-16674&author=J.+A.+Mertzauthor=A.+R.+Coneryauthor=B.+M.+Bryantauthor=P.+Sandyauthor=S.+Balasubramanianauthor=D.+A.+Meleauthor=L.+Bergeronauthor=R.+J.+Sims&title=Targeting+MYC+Dependence+in+Cancer+by+Inhibiting+BET+Bromodomains&doi=10.1073%2Fpnas.1108190108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependence in cancer by inhibiting BET bromodomains</span></div><div class="casAuthors">Mertz, Jennifer A.; Conery, Andrew R.; Bryant, Barbara M.; Sandy, Peter; Balasubramanian, Srividya; Mele, Deanna A.; Bergeron, Louise; Sims, Robert J., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16669-16674, S16669/1-S16669/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies.  However, pharmacol. inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions.  Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small mol. inhibitors of the BET family of chromatin adaptors.  MYC transcriptional suppression was obsd. in the context of the natural, chromosomally translocated, and amplified gene locus.  Inhibition of BET bromodomain-promoter interactions and subsequent redn. of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines.  Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors.  MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor.  Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia.  These findings demonstrate that pharmacol. inhibition of MYC is achievable through targeting BET bromodomains.  Such inhibitors may have clin. utility given the widespread pathogenetic role of MYC in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UHj1YB_ikrVg90H21EOLACvtfcHk0ljbguTUTroV-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL&md5=b1f0fd41fa56bbfcbb1ad6c8d48f7f80</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108190108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108190108%26sid%3Dliteratum%253Aachs%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520MYC%2520Dependence%2520in%2520Cancer%2520by%2520Inhibiting%2520BET%2520Bromodomains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D16669%26epage%3D16674%26doi%3D10.1073%2Fpnas.1108190108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Nicodeme, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beinke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marazzi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirilovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span> </span><span class="NLM_article-title">Suppression of Inflammation by a Synthetic Histone Mimic</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span><span class="refDoi"> DOI: 10.1038/nature09589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature09589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21068722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1119-1123&author=E.+Nicodemeauthor=K.+L.+Jeffreyauthor=U.+Schaeferauthor=S.+Beinkeauthor=S.+Dewellauthor=C.+W.+Chungauthor=R.+Chandwaniauthor=I.+Marazziauthor=P.+Wilsonauthor=H.+Costeauthor=J.+Whiteauthor=J.+Kirilovskyauthor=C.+M.+Riceauthor=J.+M.+Loraauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=A.+Tarakhovsky&title=Suppression+of+Inflammation+by+a+Synthetic+Histone+Mimic&doi=10.1038%2Fnature09589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of inflammation by a synthetic histone mimic</span></div><div class="casAuthors">Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe; Beinke, Soren; Dewell, Scott; Chung, Chun-wa; Chandwani, Rohit; Marazzi, Ivan; Wilson, Paul; Coste, Herve; White, Julia; Kirilovsky, Jorge; Rice, Charles M.; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin; Tarakhovsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression.  This response, although vital for immune defense, is frequently deleterious to the host due to the exaggerated prodn. of inflammatory proteins.  The scope of inflammatory responses reflects the activation state of signaling proteins upstream of inflammatory genes as well as signal-induced assembly of nuclear chromatin complexes that support mRNA expression.  Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a crit. step in the regulation of gene expression.  Here we present a novel pharmacol. approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins.  We describe a synthetic compd. (I-BET) that by mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis.  Our findings suggest that synthetic compds. specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxc3_PNaiuKLVg90H21EOLACvtfcHk0lg_nTB8gkA2LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP&md5=0dfccd9d01b87859512bf591e1c5a93c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature09589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09589%26sid%3Dliteratum%253Aachs%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DJeffrey%26aufirst%3DK.%2BL.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DBeinke%26aufirst%3DS.%26aulast%3DDewell%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DChandwani%26aufirst%3DR.%26aulast%3DMarazzi%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DP.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTarakhovsky%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Inflammation%2520by%2520a%2520Synthetic%2520Histone%2520Mimic%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1119%26epage%3D1123%26doi%3D10.1038%2Fnature09589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Chung, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirguet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosmini, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magny, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boursier, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouillot, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusq, J.-M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellibert, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riou, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uings, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, C. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boullay, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimley, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandel, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirilovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicodeme, E.</span><span> </span><span class="NLM_article-title">Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3827</span><span class="NLM_x">–</span> <span class="NLM_lpage">3838</span><span class="refDoi"> DOI: 10.1021/jm200108t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200108t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3827-3838&author=C.-W.+Chungauthor=H.+Costeauthor=J.+H.+Whiteauthor=O.+Mirguetauthor=J.+Wildeauthor=R.+L.+Gosminiauthor=C.+Delvesauthor=S.+M.+Magnyauthor=R.+Woodwardauthor=S.+a+Hughesauthor=E.+V.+Boursierauthor=H.+Flynnauthor=A.+M.+Bouillotauthor=P.+Bamboroughauthor=J.-M.+G.+Brusqauthor=F.+J.+Gellibertauthor=E.+J.+Jonesauthor=A.+M.+Riouauthor=P.+Homesauthor=S.+L.+Martinauthor=I.+J.+Uingsauthor=J.+Toumauthor=C.+a+Clementauthor=A.-B.+Boullayauthor=R.+L.+Grimleyauthor=F.+M.+Blandelauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=J.+Kirilovskyauthor=E.+Nicodeme&title=Discovery+and+Characterization+of+Small+Molecule+Inhibitors+of+the+BET+Family+Bromodomains&doi=10.1021%2Fjm200108t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of small molecule inhibitors of the BET family bromodomains</span></div><div class="casAuthors">Chung, Chun-wa; Coste, Herve; White, Julia H.; Mirguet, Olivier; Wilde, Jonathan; Gosmini, Romain L.; Delves, Chris; Magny, Sylvie M.; Woodward, Robert; Hughes, Stephen A.; Boursier, Eric V.; Flynn, Helen; Bouillot, Anne M.; Bamborough, Paul; Brusq, Jean-Marie G.; Gellibert, Francoise J.; Jones, Emma J.; Riou, Alizon M.; Homes, Paul; Martin, Sandrine L.; Uings, Iain J.; Toum, Jerome; Clement, Catherine A.; Boullay, Anne-Benedicte; Grimley, Rachel L.; Blandel, Florence M.; Prinjha, Rab K.; Lee, Kevin; Kirilovsky, Jorge; Nicodeme, Edwige</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3827-3838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic mechanisms of gene regulation have a profound role in normal development and disease processes.  An integral part of this mechanism occurs through lysine acetylation of histone tails which are recognized by bromodomains.  While the biol. and structural characterization of many bromodomain contg. proteins has advanced considerably, the therapeutic tractability of this protein family is only now becoming understood.  This paper describes the discovery and mol. characterization of potent (nM) small mol. inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4).  By using a combination of phenotypic screening, chemoproteomics, and biophys. studies, we have discovered that the protein-protein interactions between bromodomains and acetylated histones can be antagonized by selective small mols. that bind at the acetylated lysine recognition pocket.  X-ray crystal structures of compds. bound into bromodomains of Brd2 and Brd4 elucidate the mol. interactions of binding and explain the precisely defined stereochem. required for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8VauuYkT5YLVg90H21EOLACvtfcHk0lg_nTB8gkA2LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWnurs%253D&md5=ebc0f6062321dece877259d775f1c19b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm200108t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200108t%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26aulast%3DMirguet%26aufirst%3DO.%26aulast%3DWilde%26aufirst%3DJ.%26aulast%3DGosmini%26aufirst%3DR.%2BL.%26aulast%3DDelves%26aufirst%3DC.%26aulast%3DMagny%26aufirst%3DS.%2BM.%26aulast%3DWoodward%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DS.%2Ba%26aulast%3DBoursier%26aufirst%3DE.%2BV.%26aulast%3DFlynn%26aufirst%3DH.%26aulast%3DBouillot%26aufirst%3DA.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBrusq%26aufirst%3DJ.-M.%2BG.%26aulast%3DGellibert%26aufirst%3DF.%2BJ.%26aulast%3DJones%26aufirst%3DE.%2BJ.%26aulast%3DRiou%26aufirst%3DA.%2BM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%2BL.%26aulast%3DUings%26aufirst%3DI.%2BJ.%26aulast%3DToum%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DC.%2Ba%26aulast%3DBoullay%26aufirst%3DA.-B.%26aulast%3DGrimley%26aufirst%3DR.%2BL.%26aulast%3DBlandel%26aufirst%3DF.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DNicodeme%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Small%2520Molecule%2520Inhibitors%2520of%2520the%2520BET%2520Family%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3827%26epage%3D3838%26doi%3D10.1021%2Fjm200108t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Delmore, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahl, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastritis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilpatrick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paranal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinzel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakoc, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsagel, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span> </span><span class="NLM_article-title">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2011.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21889194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=904-917&author=J.+E.+Delmoreauthor=G.+C.+Issaauthor=M.+E.+Lemieuxauthor=P.+B.+Rahlauthor=J.+Shiauthor=H.+M.+Jacobsauthor=E.+Kastritisauthor=T.+Gilpatrickauthor=R.+M.+Paranalauthor=J.+Qiauthor=M.+Chesiauthor=A.+C.+Schinzelauthor=M.+R.+McKeownauthor=T.+P.+Heffernanauthor=C.+R.+Vakocauthor=P.+L.+Bergsagelauthor=I.+M.+Ghobrialauthor=P.+G.+Richardsonauthor=R.+A.+Youngauthor=W.+C.+Hahnauthor=K.+C.+Andersonauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=C.+S.+Mitsiades&title=BET+Bromodomain+Inhibition+as+a+Therapeutic+Strategy+to+Target+c-Myc&doi=10.1016%2Fj.cell.2011.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span></div><div class="casAuthors">Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E.; Rahl, Peter B.; Shi, Jun-Wei; Jacobs, Hannah M.; Kastritis, Efstathios; Gilpatrick, Timothy; Paranal, Ronald M.; Qi, Jun; Chesi, Marta; Schinzel, Anna C.; McKeown, Michael R.; Heffernan, Timothy P.; Vakoc, Christopher R.; Bergsagel, P. Leif; Ghobrial, Irene M.; Richardson, Paul G.; Young, Richard A.; Hahn, William C.; Anderson, Kenneth C.; Kung, Andrew L.; Bradner, James E.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-917</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist.  Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation.  Using a selective small-mol. bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc.  BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes.  In exptl. models of multiple myeloma, a Myc-dependent hematol. malignancy, JQ1 produces a potent antiproliferative effect assocd. with cell-cycle arrest and cellular senescence.  Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathol. activation of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpevD1QHKmOhLVg90H21EOLACvtfcHk0ljZfNV4EV82CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF&md5=013674b8224214a9a1c8f0b75583a5a6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DIssa%26aufirst%3DG.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DKastritis%26aufirst%3DE.%26aulast%3DGilpatrick%26aufirst%3DT.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DBET%2520Bromodomain%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520c-Myc%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D904%26epage%3D917%26doi%3D10.1016%2Fj.cell.2011.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparks, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvanitis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span> </span><span class="NLM_article-title">INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1593/neo.91192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1593%2Fneo.91192" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=28-38&author=J.+Liauthor=M.+Favataauthor=J.+A.+Kelleyauthor=E.+Caulderauthor=B.+Thomasauthor=X.+Wenauthor=R.+B.+Sparksauthor=A.+Arvanitisauthor=J.+D.+Rogersauthor=A.+P.+Combsauthor=K.+Vaddiauthor=K.+A.+Solomonauthor=P.+A.+Scherleauthor=R.+Newtonauthor=J.+S.+Fridman&title=INCB16562%2C+a+JAK1%2F2+Selective+Inhibitor%2C+Is+Efficacious+against+Multiple+Myeloma+Cells+and+Reverses+the+Protective+Effects+of+Cytokine+and+Stromal+Cell+Support&doi=10.1593%2Fneo.91192"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1593%2Fneo.91192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.91192%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFavata%26aufirst%3DM.%26aulast%3DKelley%26aufirst%3DJ.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DSparks%26aufirst%3DR.%2BB.%26aulast%3DArvanitis%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DJ.%2BD.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26atitle%3DINCB16562%252C%2520a%2520JAK1%252F2%2520Selective%2520Inhibitor%252C%2520Is%2520Efficacious%2520against%2520Multiple%2520Myeloma%2520Cells%2520and%2520Reverses%2520the%2520Protective%2520Effects%2520of%2520Cytokine%2520and%2520Stromal%2520Cell%2520Support%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D28%26epage%3D38%26doi%3D10.1593%2Fneo.91192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD Mutations in FLT3 as a Therapeutic Target in Human Acute Myeloid Leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.-S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+Mutations+in+FLT3+as+a+Therapeutic+Target+in+Human+Acute+Myeloid+Leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0ljZfNV4EV82CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.-S.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520Mutations%2520in%2520FLT3%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Human%2520Acute%2520Myeloid%2520Leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span><span class="refDoi"> DOI: 10.1021/jm9007533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-Butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+Dihydrochloride+%28AC220%29%2C+a+Uniquely+Potent%2C+Selective%2C+and+Efficacious+FMS-Like+Tyrosine+Kinase-3+%28FLT3%29+Inhibitor&doi=10.1021%2Fjm9007533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520Dihydrochloride%2520%2528AC220%2529%252C%2520a%2520Uniquely%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520FMS-Like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816%26doi%3D10.1021%2Fjm9007533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devaraj, S. G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leveque, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portier, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2315</span><span class="NLM_x">–</span> <span class="NLM_lpage">2327</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1535-7163.MCT-14-0258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25053825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2315-2327&author=W.+Fiskusauthor=S.+Sharmaauthor=J.+Qiauthor=B.+Shahauthor=S.+G.+T.+Devarajauthor=C.+Levequeauthor=B.+P.+Portierauthor=S.+P.+Iyerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=BET+Protein+Antagonist+JQ1+Is+Synergistically+Lethal+with+FLT3+Tyrosine+Kinase+Inhibitor+%28TKI%29+and+Overcomes+Resistance+to+FLT3-TKI+in+AML+Cells+Expressing+FLT-ITD&doi=10.1158%2F1535-7163.MCT-14-0258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span></div><div class="casAuthors">Fiskus, Warren; Sharma, Sunil; Qi, Jun; Shah, Bhavin; Devaraj, Santhana G. T.; Leveque, Christopher; Portier, Bryce P.; Iyer, Swaminathan; Bradner, James E.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2315-2327</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and induce apoptosis of human acute myelogenous leukemia (AML) cells, including those expressing FLT3-ITD.  Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34+ human AML blast progenitor cells (BPC) expressing FLT3-ITD.  Concomitantly, as compared with each agent alone, cotreatment with JQ1 and the FLT3-TKI caused greater attenuation of c-MYC, BCL2, and CDK4/6.  Simultaneously, cotreatment with JQ1 and the FLT3-TKI increased the levels of p21, BIM, and cleaved PARP, as well as mediated marked attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels in AML BPCs.  Conversely, cotreatment with JQ1 and FLT3-TKI was significantly less active against CD34+ normal bone marrow progenitor cells.  Knockdown of BRD4 by short hairpin RNA also sensitized AML cells to FLT3-TKI.  JQ1 treatment induced apoptosis of mouse Ba/F3 cells ectopically expressing FLT3-ITD with or without FLT3-TKI-resistant mutations F691L and D835V.  Compared with the parental human AML FLT3-ITD-expressing MOLM13, MOLM13-TKIR cells resistant to AC220 were markedly more sensitive to JQ1-induced apoptosis.  Furthermore, cotreatment with JQ1 and the pan-histone deacetylase inhibitor (HDI) panobinostat synergistically induced apoptosis of FLT3-TKI-resistant MOLM13-TKIR and MV4-11-TKIR cells.  Collectively, these findings support the rationale for detg. the in vivo activity of combined therapy with BA and FLT3-TKI against human AML cells expressing FLT3-ITD or with BA and HDI against AML cells resistant to FLT3-TKI.  Mol Cancer Ther; 13(10); 2315-27. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PTZkTs8dmLVg90H21EOLACvtfcHk0lhdD6FTzt0UEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI&md5=86b07b19b740ed314bd042a472507766</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0258%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%2BT.%26aulast%3DLeveque%26aufirst%3DC.%26aulast%3DPortier%26aufirst%3DB.%2BP.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DBET%2520Protein%2520Antagonist%2520JQ1%2520Is%2520Synergistically%2520Lethal%2520with%2520FLT3%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529%2520and%2520Overcomes%2520Resistance%2520to%2520FLT3-TKI%2520in%2520AML%2520Cells%2520Expressing%2520FLT-ITD%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2315%26epage%3D2327%26doi%3D10.1158%2F1535-7163.MCT-14-0258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&issue=1&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lhdD6FTzt0UEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Sun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakshe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coarfa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devaraj, S. G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saenz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Synergistic Activity of BET Protein Antagonist-Based Combinations in Mantle Cell Lymphoma Cells Sensitive or Resistant to Ibrutinib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1182/blood-2015-04-639542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1182%2Fblood-2015-04-639542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1565-1574&author=B.+Sunauthor=B.+Shahauthor=W.+Fiskusauthor=J.+Qiauthor=K.+Rajapaksheauthor=C.+Coarfaauthor=L.+Liauthor=S.+G.+T.+Devarajauthor=S.+Sharmaauthor=L.+Zhangauthor=M.+L.+Wangauthor=D.+T.+Saenzauthor=S.+Kriegerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=Synergistic+Activity+of+BET+Protein+Antagonist-Based+Combinations+in+Mantle+Cell+Lymphoma+Cells+Sensitive+or+Resistant+to+Ibrutinib&doi=10.1182%2Fblood-2015-04-639542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-04-639542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-04-639542%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DRajapakshe%26aufirst%3DK.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%2BT.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DSaenz%26aufirst%3DD.%2BT.%26aulast%3DKrieger%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DSynergistic%2520Activity%2520of%2520BET%2520Protein%2520Antagonist-Based%2520Combinations%2520in%2520Mantle%2520Cell%2520Lymphoma%2520Cells%2520Sensitive%2520or%2520Resistant%2520to%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1565%26epage%3D1574%26doi%3D10.1182%2Fblood-2015-04-639542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Lu, J.</span><span> </span><span class="NLM_article-title">Palbociclib: A First-in-Class CDK4/CDK6 Inhibitor for the Treatment of Hormone-Receptor Positive Advanced Breast Cancer</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="refDoi"> DOI: 10.1186/s13045-015-0194-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1186%2Fs13045-015-0194-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26264704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC287it1Kltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=98&author=J.+Lu&title=Palbociclib%3A+A+First-in-Class+CDK4%2FCDK6+Inhibitor+for+the+Treatment+of+Hormone-Receptor+Positive+Advanced+Breast+Cancer&doi=10.1186%2Fs13045-015-0194-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer</span></div><div class="casAuthors">Lu Janice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy.  In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy.  This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeKTdzfqi8kjdblLE_E9PWfW6udTcc2eZx5HGiSkWZ57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287it1Kltw%253D%253D&md5=a731e76c3e3a0f4bb7610d9dd180a844</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0194-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0194-5%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DPalbociclib%253A%2520A%2520First-in-Class%2520CDK4%252FCDK6%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Hormone-Receptor%2520Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D98%26doi%3D10.1186%2Fs13045-015-0194-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arias, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faure, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisburd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span> </span><span class="NLM_article-title">Compensatory Induction of MYC Expression by Sustained CDK9 Inhibition via a BRD4-Dependent Mechanism</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.7554/eLife.06535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.7554%2FeLife.06535" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-26&author=H.+Luauthor=Y.+Xueauthor=G.+K.+Yuauthor=C.+Ariasauthor=J.+Linauthor=S.+Fongauthor=M.+Faureauthor=B.+Weisburdauthor=X.+Jiauthor=A.+Mercierauthor=J.+Suttonauthor=K.+Luoauthor=Z.+Gaoauthor=Q.+Zhou&title=Compensatory+Induction+of+MYC+Expression+by+Sustained+CDK9+Inhibition+via+a+BRD4-Dependent+Mechanism&doi=10.7554%2FeLife.06535"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.7554%2FeLife.06535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.06535%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DArias%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DWeisburd%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DMercier%26aufirst%3DA.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DCompensatory%2520Induction%2520of%2520MYC%2520Expression%2520by%2520Sustained%2520CDK9%2520Inhibition%2520via%2520a%2520BRD4-Dependent%2520Mechanism%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D26%26doi%3D10.7554%2FeLife.06535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Arguello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterry, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalavar, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koss, W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stinson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvord, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klabansky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2282</span><span class="NLM_x">–</span> <span class="NLM_lpage">2490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1998&pages=2282-2490&author=F.+Arguelloauthor=M.+Alexanderauthor=J.+A.+Sterryauthor=G.+Tudorauthor=E.+M.+Smithauthor=N.+T.+Kalavarauthor=J.+F.+Greeneauthor=W.+Kossauthor=C.+D.+Morganauthor=S.+F.+Stinsonauthor=T.+J.+Sifordauthor=W.+G.+Alvordauthor=R.+L.+Klabanskyauthor=E.+A.+Sausville&title=Flavopiridol+Induces+Apoptosis+of+Normal+Lymphoid+Cells%2C+Causes+Immunosuppression%2C+and+Has+Potent+Antitumor+Activity+In+Vivo+Against+Human+Leukemia+and+Lymphoma+Xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArguello%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DSterry%26aufirst%3DJ.%2BA.%26aulast%3DTudor%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DKalavar%26aufirst%3DN.%2BT.%26aulast%3DGreene%26aufirst%3DJ.%2BF.%26aulast%3DKoss%26aufirst%3DW.%26aulast%3DMorgan%26aufirst%3DC.%2BD.%26aulast%3DStinson%26aufirst%3DS.%2BF.%26aulast%3DSiford%26aufirst%3DT.%2BJ.%26aulast%3DAlvord%26aufirst%3DW.%2BG.%26aulast%3DKlabansky%26aufirst%3DR.%2BL.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DFlavopiridol%2520Induces%2520Apoptosis%2520of%2520Normal%2520Lymphoid%2520Cells%252C%2520Causes%2520Immunosuppression%252C%2520and%2520Has%2520Potent%2520Antitumor%2520Activity%2520In%2520Vivo%2520Against%2520Human%2520Leukemia%2520and%2520Lymphoma%2520Xenografts%26jtitle%3DBlood%26date%3D1998%26volume%3D91%26spage%3D2282%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Parry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanahan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabhavalkar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paruch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oft, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees, E. M.</span><span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+Novel+and+Potent+Cyclin-Dependent+Kinase+Inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0ljQMqptANSMbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Baker, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannettino, A. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkley, C. R.</span><span> </span><span class="NLM_article-title">BET Inhibitors Induce Apoptosis through a MYC Independent Mechanism and Synergise with CDK Inhibitors to Kill Osteosarcoma Cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10120</span><span class="refDoi"> DOI: 10.1038/srep10120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsrep10120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25944566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10120&author=E.+K.+Bakerauthor=S.+Taylorauthor=A.+Gupteauthor=P.+P.+Sharpauthor=M.+Waliaauthor=N.+C.+Walshauthor=A.+C.+W.+Zannettinoauthor=A.+M.+Chalkauthor=C.+J.+Burnsauthor=C.+R.+Walkley&title=BET+Inhibitors+Induce+Apoptosis+through+a+MYC+Independent+Mechanism+and+Synergise+with+CDK+Inhibitors+to+Kill+Osteosarcoma+Cells&doi=10.1038%2Fsrep10120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells</span></div><div class="casAuthors">Baker, Emma K.; Taylor, Scott; Gupte, Ankita; Sharp, Phillip P.; Walia, Mannu; Walsh, Nicole C.; Zannettino, Andrew C. W.; Chalk, Alistair M.; Burns, Christopher J.; Walkley, Carl R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10120</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osteosarcoma (OS) survival rates have plateaued in part due to a lack of new therapeutic options.  Here we demonstrate that bromodomain inhibitors (BETi), JQ1, I-BET151, I-BET762, exert potent anti-tumor activity against primary and established OS cell lines, mediated by inhibition of BRD4.  Strikingly, unlike previous observations in long-term established human OS cell lines, the antiproliferative activity of JQ1 in primary OS cells was driven by the induction of apoptosis, not cell cycle arrest.  In further contrast, JQ1 activity in OS was mediated independently of MYC downregulation.  We identified that JQ1 suppresses the transcription factor FOSL1 by displacement of BRD4 from its locus.  Loss of FOSL1 phenocopied the antiproliferative effects of JQ1, identifying FOSL1 suppression as a potential novel therapeutic approach for OS.  As a monotherapy JQ1 demonstrated significant anti-tumor activity in vivo in an OS graft model.  Further, combinatorial treatment approaches showed that JQ1 increased the sensitivity of OS cells to doxorubicin and induced potent synergistic activity when rationally combined with CDK inhibitors.  The greater level of activity achieved with the combination of BETi with CDK inhibitors demonstrates the efficacy of this combination therapy.  Taken together, our studies show that BET inhibitors are a promising new therapeutic for OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiy0tg8DWClLVg90H21EOLACvtfcHk0lj91l-OZoGTsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrsL7I&md5=c95d487ed91b342bd426413430ba36ee</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fsrep10120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10120%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DE.%2BK.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGupte%26aufirst%3DA.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWalia%26aufirst%3DM.%26aulast%3DWalsh%26aufirst%3DN.%2BC.%26aulast%3DZannettino%26aufirst%3DA.%2BC.%2BW.%26aulast%3DChalk%26aufirst%3DA.%2BM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DWalkley%26aufirst%3DC.%2BR.%26atitle%3DBET%2520Inhibitors%2520Induce%2520Apoptosis%2520through%2520a%2520MYC%2520Independent%2520Mechanism%2520and%2520Synergise%2520with%2520CDK%2520Inhibitors%2520to%2520Kill%2520Osteosarcoma%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10120%26doi%3D10.1038%2Fsrep10120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Tacar, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sriamornsak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dass, C. R.</span><span> </span><span class="NLM_article-title">Doxorubicin: an Update on Anticancer Molecular Action, Toxicity and Novel Drug Delivery Systems</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1111/j.2042-7158.2012.01567.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.2042-7158.2012.01567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23278683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=157-170&author=O.+Tacarauthor=P.+Sriamornsakauthor=C.+R.+Dass&title=Doxorubicin%3A+an+Update+on+Anticancer+Molecular+Action%2C+Toxicity+and+Novel+Drug+Delivery+Systems&doi=10.1111%2Fj.2042-7158.2012.01567.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems</span></div><div class="casAuthors">Tacar, Oktay; Sriamornsak, Pornsak; Dass, Crispin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-170</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Objectives The frontline drug doxorubicin has been used for treating cancer for over 30 years.  While providing a cure in select cases, doxorubicin causes toxicity to most major organs, esp. life-threatening cardiotoxicity, which forces the treatment to become dose-limiting.  Key findings Doxorubicin is known to bind to DNA-assocd. enzymes, intercalate with DNA base pairs, and target multiple mol. targets to produce a range of cytotoxic effects.  For instance, it causes the activation of various mol. signals from AMPK (AMP-activated protein kinase inducing apoptosis) to influence the Bcl-2/Bax apoptosis pathway.  By altering the Bcl-2/Bax ratio, downstream activation of different caspases can occur resulting in apoptosis.  Doxorubicin also induces apoptosis and necrosis in healthy tissue causing toxicity in the brain, liver, kidney and heart.  Over the years, many studies have been conducted to devise a drug delivery system that would eliminate these adverse affects including liposomes, hydrogel and nanoparticulate systems, and we highlight the pros and cons of these drug delivery systems.  Summary Overall the future for the continued use of doxorubicin clin. against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chem., delivery and toxicity.  Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ULJ-J2uxgrVg90H21EOLACvtfcHk0lj91l-OZoGTsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGitb4%253D&md5=fca40d4f8ee61dcdd6216a694cf44548</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2012.01567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2012.01567.x%26sid%3Dliteratum%253Aachs%26aulast%3DTacar%26aufirst%3DO.%26aulast%3DSriamornsak%26aufirst%3DP.%26aulast%3DDass%26aufirst%3DC.%2BR.%26atitle%3DDoxorubicin%253A%2520an%2520Update%2520on%2520Anticancer%2520Molecular%2520Action%252C%2520Toxicity%2520and%2520Novel%2520Drug%2520Delivery%2520Systems%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D157%26epage%3D170%26doi%3D10.1111%2Fj.2042-7158.2012.01567.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Janeway, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grier, H. E.</span><span> </span><span class="NLM_article-title">Sequelae of Osteosarcoma Medical Therapy: a Review of Rare Acute Toxicities and Late Effects</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span><span class="refDoi"> DOI: 10.1016/S1470-2045(10)70062-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1470-2045%2810%2970062-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20347613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsVCntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=670-678&author=K.+A.+Janewayauthor=H.+E.+Grier&title=Sequelae+of+Osteosarcoma+Medical+Therapy%3A+a+Review+of+Rare+Acute+Toxicities+and+Late+Effects&doi=10.1016%2FS1470-2045%2810%2970062-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects</span></div><div class="casAuthors">Janeway Katherine A; Grier Holcombe E</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">670-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the introduction of multi-agent chemotherapy for osteosarcoma over 30 years ago, overall survival has exceeded 50%.  A clear understanding of the acute complications and late effects of osteosarcoma therapy is required to care effectively for patients with osteosarcoma undergoing active treatment, and for the increasing number of osteosarcoma survivors.  There has now been sufficient cumulative experience treating patients with osteosarcoma with active anti-osteosarcoma chemotherapy agents, high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, and etoposide to recognise and understand rare toxicities associated with these agents, and to identify the late effects of osteosarcoma therapy.  Late effects and rare toxicities of osteosarcoma include cardiac toxicity, acute and chronic nephrotoxicity, neurotoxicity, hearing loss, infertility, and second malignant neoplasms.  Reducing the complications of osteosarcoma therapy is an important goal that will require the identification of clear prognostic indicators, the development of biologically-based therapies, and improved antidotes for the active anti-osteosarcoma cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS1i4bhTL7itbHMBt0mMIXfW6udTcc2ealZsFHg9NWmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsVCntQ%253D%253D&md5=198e9dc9d8d00a77edc5d743b2d53efe</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970062-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970062-0%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26atitle%3DSequelae%2520of%2520Osteosarcoma%2520Medical%2520Therapy%253A%2520a%2520Review%2520of%2520Rare%2520Acute%2520Toxicities%2520and%2520Late%2520Effects%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D670%26epage%3D678%26doi%3D10.1016%2FS1470-2045%2810%2970062-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doan, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forscher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span> </span><span class="NLM_article-title">Synergistic Effect of JQ1 and Rapamycin for Treatment of Human Osteosarcoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">2055</span><span class="NLM_x">–</span> <span class="NLM_lpage">2064</span><span class="refDoi"> DOI: 10.1002/ijc.29269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fijc.29269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25307878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislegt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=2055-2064&author=D.+H.+Leeauthor=J.+Qiauthor=J.+E.+Bradnerauthor=J.+W.+Saidauthor=N.+B.+Doanauthor=C.+Forscherauthor=H.+Yangauthor=H.+P.+Koeffler&title=Synergistic+Effect+of+JQ1+and+Rapamycin+for+Treatment+of+Human+Osteosarcoma&doi=10.1002%2Fijc.29269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma</span></div><div class="casAuthors">Lee, Dhong Hyun; Qi, Jun; Bradner, James E.; Said, Jonathan W.; Doan, Ngan B.; Forscher, Charles; Yang, Henry; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2055-2064</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Bromodomain and extra terminal domain (BET) proteins are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones.  JQ1, a BET protein inhibitor, has antiproliferative activity against many cancers, mainly through inhibition of c-MYC and upregulation of p21.  In this research, we investigated the use of JQ1 for human osteosarcoma (OS) treatment.  JQ1 significantly inhibited the proliferation and survival of OS cells inducing G1 cell cycle arrest, premature senescence, but little effect on apoptosis.  Interestingly, c-MYC protein levels in JQ1-treated cells remained unchanged, whereas the upregulation of p21 protein was still observable.  Although effective in vitro, JQ1 alone failed to reduce the size of the MNNG/HOS xenografts in immunocompromised mice.  To overcome the resistance of OS cells to JQ1 treatment, we combined JQ1 with rapamycin, an mammalian target of rapamycin (mTOR) inhibitor.  JQ1 and rapamycin synergistically inhibited the growth and survival of OS cells in vitro and in vivo.  We also identified that RUNX2 is a direct target of bromodomain-contg. protein 4 (BRD4) inhibition by JQ1 in OS cells.  Chromatin immunopptn. (ChIP) showed that enrichment of BRD4 protein around RUNX2 transcription start sites diminished with JQ1 treatment in MNNG/HOS cells.  Overexpression of RUNX2 protected JQ1-sensitive OS cells from the effect of JQ1, and siRNA-mediated inhibition of RUNX2 sensitized the same cells to JQ1.  In conclusion, our findings suggest that JQ1, in combination with rapamycin, is an effective chemotherapeutic option for OS treatment.  We also show that inhibition of RUNX2 expression by JQ1 partly explains the antiproliferative activity of JQ1 in OS cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0-M1_Sb11LVg90H21EOLACvtfcHk0liou7G5jPDAMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislegt70%253D&md5=71971e482ce634ae9de6047e94557460</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fijc.29269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29269%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DSaid%26aufirst%3DJ.%2BW.%26aulast%3DDoan%26aufirst%3DN.%2BB.%26aulast%3DForscher%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DSynergistic%2520Effect%2520of%2520JQ1%2520and%2520Rapamycin%2520for%2520Treatment%2520of%2520Human%2520Osteosarcoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D2055%26epage%3D2064%26doi%3D10.1002%2Fijc.29269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Stratikopoulos, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dendy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabolcs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaykin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, R.</span><span> </span><span class="NLM_article-title">Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">851</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.ccell.2015.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26058079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=837-851&author=E.+E.+Stratikopoulosauthor=M.+Dendyauthor=M.+Szabolcsauthor=A.+J.+Khaykinauthor=C.+Lefebvreauthor=M.+M.+Zhouauthor=R.+Parsons&title=Kinase+and+BET+Inhibitors+Together+Clamp+Inhibition+of+PI3K+Signaling+and+Overcome+Resistance+to+Therapy&doi=10.1016%2Fj.ccell.2015.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy</span></div><div class="casAuthors">Stratikopoulos, Elias E.; Dendy, Meaghan; Szabolcs, Matthias; Khaykin, Alan J.; Lefebvre, Celine; Zhou, Ming-Ming; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">837-851</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Unsustained enzyme inhibition is a barrier to targeted therapy for cancer.  Here, resistance to a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was assocd. with feedback activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC.  Inhibitors of bromodomain and extra terminal domain (BET) proteins also failed to affect tumor growth.  Interestingly, BET inhibitors lowered PI3K signaling and dissocd. BRD4 from chromatin at regulatory regions of insulin receptor and EGFR family RTKs to reduce their expression.  Combined PI3K and BET inhibition induced cell death, tumor regression, and clamped inhibition of PI3K signaling in a broad range of tumor cell lines to provide a strategy to overcome resistance to kinase inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmdX2xaXkHjbVg90H21EOLACvtfcHk0liou7G5jPDAMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejurbK&md5=91cca562c9bff9e11e94535916583867</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DStratikopoulos%26aufirst%3DE.%2BE.%26aulast%3DDendy%26aufirst%3DM.%26aulast%3DSzabolcs%26aufirst%3DM.%26aulast%3DKhaykin%26aufirst%3DA.%2BJ.%26aulast%3DLefebvre%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DKinase%2520and%2520BET%2520Inhibitors%2520Together%2520Clamp%2520Inhibition%2520of%2520PI3K%2520Signaling%2520and%2520Overcome%2520Resistance%2520to%2520Therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D837%26epage%3D851%26doi%3D10.1016%2Fj.ccell.2015.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tinsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meja, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khwaja, A.</span><span> </span><span class="NLM_article-title">Synergistic Induction of Cell Death in Haematological Malignancies by Combined Phosphoinositide-3-Kinase and BET Bromodomain Inhibition</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1111/bjh.13283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fbjh.13283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25640480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC2MrhsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=275-278&author=S.+Tinsleyauthor=K.+Mejaauthor=C.+Shepherdauthor=A.+Khwaja&title=Synergistic+Induction+of+Cell+Death+in+Haematological+Malignancies+by+Combined+Phosphoinositide-3-Kinase+and+BET+Bromodomain+Inhibition&doi=10.1111%2Fbjh.13283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition</span></div><div class="casAuthors">Tinsley Steven; Meja Koremu; Shepherd Clare; Khwaja Asim</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcfO8VmViEKF1C8OJBvdfbfW6udTcc2ebVsQ-fVQE4dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrhsVKmsg%253D%253D&md5=1bd85235d6627429aeac4ddf745cd266</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13283%26sid%3Dliteratum%253Aachs%26aulast%3DTinsley%26aufirst%3DS.%26aulast%3DMeja%26aufirst%3DK.%26aulast%3DShepherd%26aufirst%3DC.%26aulast%3DKhwaja%26aufirst%3DA.%26atitle%3DSynergistic%2520Induction%2520of%2520Cell%2520Death%2520in%2520Haematological%2520Malignancies%2520by%2520Combined%2520Phosphoinositide-3-Kinase%2520and%2520BET%2520Bromodomain%2520Inhibition%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D170%26spage%3D275%26epage%3D278%26doi%3D10.1111%2Fbjh.13283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Widakowich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-12-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1634%2Ftheoncologist.12-12-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18165622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1443-1455&author=C.+Widakowichauthor=G.+de+Castroauthor=E.+de+Azambujaauthor=P.+Dinhauthor=A.+Awada&title=Review%3A+Side+Effects+of+Approved+Molecular+Targeted+Therapies+in+Solid+Cancers&doi=10.1634%2Ftheoncologist.12-12-1443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Review: side effects of approved molecular targeted therapies in solid cancers</span></div><div class="casAuthors">Widakowich, Christian; de Castro, Gilberto, Jr.; de Azambuja, Evandro; Dinh, Phuong; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1443-1455</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Major advances have been achieved in the field of biol. based therapies for cancer in the last few years, and some of the recently approved mol.-targeted therapies are now being used in daily clin. practice.  These mol. targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function.  In general, targeted mol. therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities.  In this article, we review the toxicity and safety of various small mols. and monoclonal antibodies used in solid tumors, with discussion of the pathophysiol., correlation with response, and strategies for prevention and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQLiiHG_Az7Vg90H21EOLACvtfcHk0li8XApuCRc2oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D&md5=56e9026df40a921510114079777e84b7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-12-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-12-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWidakowich%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DDinh%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DReview%253A%2520Side%2520Effects%2520of%2520Approved%2520Molecular%2520Targeted%2520Therapies%2520in%2520Solid%2520Cancers%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1443%26epage%3D1455%26doi%3D10.1634%2Ftheoncologist.12-12-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olesen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schönbrunn, E.</span><span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2360</span><span class="NLM_x">–</span> <span class="NLM_lpage">2365</span><span class="refDoi"> DOI: 10.1021/cb4003283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4003283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2rtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2360-2365&author=M.+P.+Martinauthor=S.+H.+Olesenauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Cyclin-Dependent+Kinase+Inhibitor+Dinaciclib+Interacts+with+the+Acetyl-Lysine+Recognition+Site+of+Bromodomains&doi=10.1021%2Fcb4003283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains</span></div><div class="casAuthors">Martin, Mathew P.; Olesen, Sanne H.; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2360-2365</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. proteins are considered atypical kinases, but their potential to interact with kinase inhibitors is unknown.  Dinaciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), which recently advanced to Phase III clin. trials for the treatment of leukemia.  The authors detd. the crystal structure of dinaciclib in complex with CDK2 at 1.7 Å resoln., revealing an elaborate network of binding interactions in the ATP site, which explains the extraordinary potency and selectivity of this inhibitor.  Remarkably, dinaciclib also interacted with the acetyl-lysine recognition site of the bromodomain testis-specific protein BRDT, a member of the BET family of bromodomains.  The binding mode of dinaciclib to BRDT at 2.0 Å resoln. suggests that general kinase inhibitors (hinge binders) possess a previously unrecognized potential to act as protein-protein inhibitors of bromodomains.  The findings may provide a new structural framework for the design of next-generation bromodomain inhibitors using the vast chem. space of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonrxl9QUxkE7Vg90H21EOLACvtfcHk0li8XApuCRc2oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2rtbvN&md5=1ae089e8e571ad11aadcdc4a1a5769b5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fcb4003283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4003283%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitor%2520Dinaciclib%2520Interacts%2520with%2520the%2520Acetyl-Lysine%2520Recognition%2520Site%2520of%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D2360%26epage%3D2365%26doi%3D10.1021%2Fcb4003283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitors Move into Phase III</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">892</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span><span class="refDoi"> DOI: 10.1038/nrd3908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd3908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=892-894&author=M.+Guha&title=Cyclin-Dependent+Kinase+Inhibitors+Move+into+Phase+III&doi=10.1038%2Fnrd3908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrd3908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3908%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitors%2520Move%2520into%2520Phase%2520III%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D892%26epage%3D894%26doi%3D10.1038%2Fnrd3908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Ember, S. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olesen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schönbrunn, E.</span><span> </span><span class="NLM_article-title">Acetyl-Lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1171</span><span class="refDoi"> DOI: 10.1021/cb500072z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500072z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1160-1171&author=S.+W.+J.+Emberauthor=J.+Y.+Zhuauthor=S.+H.+Olesenauthor=M.+P.+Martinauthor=A.+Beckerauthor=N.+Berndtauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Acetyl-Lysine+Binding+Site+of+Bromodomain-Containing+Protein+4+%28BRD4%29+Interacts+with+Diverse+Kinase+Inhibitors&doi=10.1021%2Fcb500072z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span></div><div class="casAuthors">Ember, Stuart W. J.; Zhu, Jin-Yi; Olesen, Sanne H.; Martin, Mathew P.; Becker, Andreas; Berndt, Norbert; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1171</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research.  In co-crystn. screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and characterized 14 kinase inhibitors (10 distinct chem. scaffolds) as ligands of the KAc binding site.  Among these, the PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 displayed strongest inhibitory potential against BRD4 (IC50 = 25 nM and 130 nM, resp.) and high selectivity for BET bromodomains.  Comparative structural anal. revealed markedly different binding modes of kinase hinge-binding scaffolds in the KAc binding site, suggesting that BET proteins are potential off-targets of diverse kinase inhibitors.  Combined, these findings provide a new structural framework for the rational design of next-generation BET-selective and dual-activity BET-kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0X1hjt7cBbVg90H21EOLACvtfcHk0lhvEPCKS23C5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D&md5=5ca37df00cdaa0ba81c0cb4a0f70ba5d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fcb500072z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500072z%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DAcetyl-Lysine%2520Binding%2520Site%2520of%2520Bromodomain-Containing%2520Protein%25204%2520%2528BRD4%2529%2520Interacts%2520with%2520Diverse%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1160%26epage%3D1171%26doi%3D10.1021%2Fcb500072z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Matzuk, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agno, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span> </span><span class="NLM_article-title">Small-Molecule Inhibition of BRDT for Male Contraception</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2012.06.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22901802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aktrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2012&pages=673-684&author=M.+M.+Matzukauthor=M.+R.+McKeownauthor=P.+Filippakopoulosauthor=Q.+Liauthor=L.+Maauthor=J.+E.+Agnoauthor=M.+E.+Lemieuxauthor=S.+Picaudauthor=R.+N.+Yuauthor=J.+Qiauthor=S.+Knappauthor=J.+E.+Bradner&title=Small-Molecule+Inhibition+of+BRDT+for+Male+Contraception&doi=10.1016%2Fj.cell.2012.06.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibition of BRDT for Male Contraception</span></div><div class="casAuthors">Matzuk, Martin M.; McKeown, Michael R.; Filippakopoulos, Panagis; Li, Qinglei; Ma, Lang; Agno, Julio E.; Lemieux, Madeleine E.; Picaud, Sarah; Yu, Richard N.; Qi, Jun; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">673-684</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A pharmacol. approach to male contraception remains a longstanding challenge in medicine.  Toward this objective, the authors explored the spermatogenic effects of a selective small-mol. inhibitor (JQ1) of the bromodomain and extraterminal (BET) subfamily of epigenetic reader proteins.  Here, the authors report potent inhibition of the testis-specific member BRDT, which is essential for chromatin remodeling during spermatogenesis.  Biochem. and crystallog. studies confirm that occupancy of the BRDT acetyl-lysine binding pocket by JQ1 prevents recognition of acetylated histone H4.  Treatment of mice with JQ1 reduced seminiferous tubule area, testis size, and spermatozoa no. and motility without affecting hormone levels.  Although JQ1-treated males mate normally, inhibitory effects of JQ1 evident at the spermatocyte and round spermatid stages cause a complete and reversible contraceptive effect.  These data establish a new contraceptive that can cross the blood:testis boundary and inhibit bromodomain activity during spermatogenesis, providing a lead compd. targeting the male germ cell for contraception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVWUgXTC77Vg90H21EOLACvtfcHk0lhvEPCKS23C5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aktrbO&md5=ccfa1b443c156612714e4b7f88590041</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DMatzuk%26aufirst%3DM.%2BM.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DAgno%26aufirst%3DJ.%2BE.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%2BN.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520BRDT%2520for%2520Male%2520Contraception%26jtitle%3DCell%26date%3D2012%26volume%3D150%26spage%3D673%26epage%3D684%26doi%3D10.1016%2Fj.cell.2012.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimlinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haug, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halling, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkumar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span> </span><span class="NLM_article-title">TG101209, a Novel JAK2 Inhibitor, Has Significant in Vitro Activity in Multiple Myeloma and Displays Preferential Cytotoxicity for CD45+ Myeloma Cells</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span><span class="refDoi"> DOI: 10.1002/ajh.21785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fajh.21785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20652971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Sqtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2010&pages=675-686&author=V.+Ramakrishnanauthor=T.+Kimlingerauthor=J.+Haugauthor=M.+Timmauthor=L.+Wellikauthor=T.+Hallingauthor=A.+Pardananiauthor=A.+Tefferiauthor=S.+V.+Rajkumarauthor=S.+Kumar&title=TG101209%2C+a+Novel+JAK2+Inhibitor%2C+Has+Significant+in+Vitro+Activity+in+Multiple+Myeloma+and+Displays+Preferential+Cytotoxicity+for+CD45%2B+Myeloma+Cells&doi=10.1002%2Fajh.21785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells</span></div><div class="casAuthors">Ramakrishnan, Vijay; Kimlinger, Teresa; Haug, Jessica; Timm, Michael; Wellik, Linda; Halling, Timothy; Pardanani, Animesh; Tefferi, Ayalew; Rajkumar, Sundararasan Vincent; Kumar, Shaji</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">675-686</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Interaction of myeloma cells with the bone marrow microenvironment is mediated in large part through different cytokines, esp. VEGF and IL6.  These cytokines, esp. IL6, leads to upregulation of the JAK/STAT pathway in myeloma cell, contributing to increased proliferation, decreased apoptosis, and acquired drug resistance.  Here, we examd. the preclin. activity of a novel JAK2 inhibitor TG101209.  TG101209 induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines.  The induction of cytotoxicity was assocd. with inhibition of cell cycle progression and induction of apoptosis in myeloma cell lines and patient-derived plasma cells.  Evaluation of U266 cell lines and patient cells, which have a mix of CD45 pos. and neg. cells, demonstrated more profound cytotoxicity and antiproliferative activity of the drug on the CD45+ population relative to the CD45- cells.  Exploring the mechanism of action of TG101209 indicated downregulation of pJak2, pStat3, and Bcl-xl levels with upregulation of pErk and pAkt levels Indicating cross talk between signaling pathways.  TG101209, when used in combination with the PI3K inhibitor LY294002, demonstrated synergistic cytotoxicity against myeloma cells.  Our results provide the rationale for clin. evaluation of TG101209 alone or in combination with PI3K/Akt inhibitors in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiSxKDxqSHLVg90H21EOLACvtfcHk0lhvEPCKS23C5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Sqtb7I&md5=127140bd409441550327c0e32eb67fc3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fajh.21785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21785%26sid%3Dliteratum%253Aachs%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DKimlinger%26aufirst%3DT.%26aulast%3DHaug%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DWellik%26aufirst%3DL.%26aulast%3DHalling%26aufirst%3DT.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DRajkumar%26aufirst%3DS.%2BV.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DTG101209%252C%2520a%2520Novel%2520JAK2%2520Inhibitor%252C%2520Has%2520Significant%2520in%2520Vitro%2520Activity%2520in%2520Multiple%2520Myeloma%2520and%2520Displays%2520Preferential%2520Cytotoxicity%2520for%2520CD45%252B%2520Myeloma%2520Cells%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2010%26volume%3D85%26spage%3D675%26epage%3D686%26doi%3D10.1002%2Fajh.21785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+Selective+JAK2+Inhibitor%2C+in+Treatment+of+a+Murine+Model+of+JAK2V617F-Induced+Polycythemia+Vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lg5dfr4J6ZhDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520Selective%2520JAK2%2520Inhibitor%252C%2520in%2520Treatment%2520of%2520a%2520Murine%2520Model%2520of%2520JAK2V617F-Induced%2520Polycythemia%2520Vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lénárt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssák, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gürtler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Krss%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+In+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0lg5dfr4J6ZhDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKrss%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurie, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyorffy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munzert, G.</span><span> </span><span class="NLM_article-title">A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together with Pemetrexed in Previously Treated Patients with Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.cllc.2012.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cllc.2012.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22658814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFSktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=19-27&author=P.+M.+Ellisauthor=Q.+S.+Chuauthor=N.+Leighlauthor=S.+A.+Laurieauthor=H.+Fritschauthor=B.+Gaschler-Markefskiauthor=S.+Gyorffyauthor=G.+Munzert&title=A+Phase+I+Open-Label+Dose-Escalation+Study+of+Intravenous+BI+2536+Together+with+Pemetrexed+in+Previously+Treated+Patients+with+Non-Small-Cell+Lung+Cancer&doi=10.1016%2Fj.cllc.2012.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Ellis, Peter M.; Chu, Quincy S.; Leighl, Natasha; Laurie, Scott A.; Fritsch, Holger; Gaschler-Markefski, Birgit; Gyorffy, Steve; Munzert, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1.  This open-label, phase I study investigated the max. tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with std.-dose pemetrexed in previously treated advanced or metastatic non-small-cell lung cancer.  A std. 3 + 3 design was used.  The patients received 500 mg/m2 pemetrexed and escalating doses of BI 2536 on day 1 every 3 wk.  The primary objective was the MTD of BI 2536 combined with pemetrexed.  Secondary endpoints were response rate (Response Evaluation Criteria in Solid Tumors), overall safety, and PK.  Forty-one patients received BI 2536 (100-325 mg).  Two dose-limiting toxicities (DLT) occurred at BI 2536 325 mg (grade 3 pruritus and rash; grade 4 neutropenia).  Therefore, the MTD for BI 2536 in combination with pemetrexed was 300 mg.  After expanding the MTD dose level, 3 addnl. patients experienced DLTs, which resulted in expansion of the 250 mg cohort, in which 4 of the 13 addnl. patients experienced DLTs.  Therefore, the recommended dose of BI 2536 was 200 mg.  Most frequently reported drug-related adverse events were fatigue (71%), nausea (37%), and rash (34%).  Two patients had durable confirmed partial responses; 21 (54%) patients had stable disease after the treatment cycle 2.  PK anal. showed that BI 2536 and pemetrexed exposure were not altered when coadministered.  BI 2536 200 mg combined with std.-dose pemetrexed has an acceptable safety profile in relapsed non-small-cell lung cancer.  The antitumor activity obsd. is encouraging and supports further investigation of Plk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwPCdEZCOOD7Vg90H21EOLACvtfcHk0ljJH7ngZuA6yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFSktrrI&md5=35a269b8c6c75aba0578ea3bfc441d43</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2012.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2012.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DChu%26aufirst%3DQ.%2BS.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DGyorffy%26aufirst%3DS.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Open-Label%2520Dose-Escalation%2520Study%2520of%2520Intravenous%2520BI%25202536%2520Together%2520with%2520Pemetrexed%2520in%2520Previously%2520Treated%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2013%26volume%3D14%26spage%3D19%26epage%3D27%26doi%3D10.1016%2Fj.cllc.2012.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Dittmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitski, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fälth Savitski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewes, G.</span><span> </span><span class="NLM_article-title">The Commonly Used PI3-Kinase Probe LY294002 is an Inhibitor of BET Bromodomains</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1021/cb400789e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400789e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=495-502&author=A.+Dittmannauthor=T.+Wernerauthor=C.+W.+Chungauthor=M.+M.+Savitskiauthor=M.+F%C3%A4lth+Savitskiauthor=P.+Grandiauthor=C.+Hopfauthor=M.+Lindonauthor=G.+Neubauerauthor=R.+K.+Prinjhaauthor=M.+Bantscheffauthor=G.+Drewes&title=The+Commonly+Used+PI3-Kinase+Probe+LY294002+is+an+Inhibitor+of+BET+Bromodomains&doi=10.1021%2Fcb400789e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span></div><div class="casAuthors">Dittmann, Antje; Werner, Thilo; Chung, Chun-Wa; Savitski, Mikhail M.; Faelth Savitski, Maria; Grandi, Paola; Hopf, Carsten; Lindon, Matthew; Neubauer, Gitte; Prinjha, Rabinder K.; Bantscheff, Marcus; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A commonly used small-mol. probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002.  Quant. chemoproteomic profiling shows that LY294002 and LY303511, a close analog devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.  Both compds. competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell exts.  X-ray crystallog. shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbIVXFQARTKLVg90H21EOLACvtfcHk0ljJH7ngZuA6yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO&md5=13435c7d6a6747dc5699e3c3865c8243</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fcb400789e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400789e%26sid%3Dliteratum%253Aachs%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DF%25C3%25A4lth%2BSavitski%26aufirst%3DM.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThe%2520Commonly%2520Used%2520PI3-Kinase%2520Probe%2520LY294002%2520is%2520an%2520Inhibitor%2520of%2520BET%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D495%26epage%3D502%26doi%3D10.1021%2Fcb400789e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&author=P.+Ciceriauthor=S.+M%C3%BCllerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+a+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0lgDNOp9eEs4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2Ba%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Sapkota, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">BI-D1870 is a Specific Inhibitor of the p90 RSK (Ribosomal S6 Kinase) Isoforms in Vitro and in Vivo</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1042/BJ20061088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1042%2FBJ20061088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2007&pages=29-38&author=G.+P.+Sapkotaauthor=L.+Cummingsauthor=F.+S.+Newellauthor=C.+Armstrongauthor=J.+Bainauthor=M.+Frodinauthor=M.+Grauertauthor=M.+Hoffmannauthor=G.+Schnappauthor=M.+Steegmaierauthor=P.+Cohenauthor=D.+R.+Alessi&title=BI-D1870+is+a+Specific+Inhibitor+of+the+p90+RSK+%28Ribosomal+S6+Kinase%29+Isoforms+in+Vitro+and+in+Vivo&doi=10.1042%2FBJ20061088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1042%2FBJ20061088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20061088%26sid%3Dliteratum%253Aachs%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26aulast%3DCummings%26aufirst%3DL.%26aulast%3DNewell%26aufirst%3DF.%2BS.%26aulast%3DArmstrong%26aufirst%3DC.%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DFrodin%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DSchnapp%26aufirst%3DG.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DBI-D1870%2520is%2520a%2520Specific%2520Inhibitor%2520of%2520the%2520p90%2520RSK%2520%2528Ribosomal%2520S6%2520Kinase%2529%2520Isoforms%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D401%26spage%3D29%26epage%3D38%26doi%3D10.1042%2FBJ20061088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span> </span><span class="NLM_article-title">Selectivity-Determining Residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.+H.+Ding&title=Selectivity-Determining+Residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0lgDNOp9eEs4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%2BH.%26atitle%3DSelectivity-Determining%2520Residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shorr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1200/JCO.2010.32.8021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1200%2FJCO.2010.32.8021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21220608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlelsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=789-796&author=A.+Pardananiauthor=J.+R.+Gotlibauthor=C.+Jamiesonauthor=J.+E.+Cortesauthor=M.+Talpazauthor=R.+M.+Stoneauthor=M.+H.+Silvermanauthor=D.+G.+Gillilandauthor=J.+Shorrauthor=A.+Tefferi&title=Safety+and+Efficacy+of+TG101348%2C+a+Selective+JAK2+Inhibitor%2C+in+Myelofibrosis&doi=10.1200%2FJCO.2010.32.8021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Pardanani, Animesh; Gotlib, Jason R.; Jamieson, Catriona; Cortes, Jorge E.; Talpaz, Moshe; Stone, Richard M.; Silverman, Michael H.; Gilliland, D. Gary; Shorr, Jolene; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-796</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Myelofibrosis is a myeloid malignancy assocd. with anemia, splenomegaly, and constitutional symptoms.  Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-mol. Janus kinase 2 (JAK2) inhibitor.  Patients and Methods In a multicenter phase I trial, oral TG101348 was administered once a day to patients with high- or intermediate-risk primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.  Results Fifty-nine patients were treated, including 28 in the dose-escalation phase.  The max.-tolerated dose was 680 mg/d, and dose-limiting toxicity was a reversible and asymptomatic increase in the serum amylase level.  Forty-three patients (73%) continued treatment beyond six cycles; the median cumulative exposure to TG101348 was 380 days.  Adverse events included nausea, vomiting, diarrhea, anemia, and thrombocytopenia; corresponding grades 3 to 4 incidence rates were 3%, 3%, 10%, 35%, and 24%.  TG101348 treatment had modest effect on serum cytokine levels, but greater than half of the patients with early satiety, night sweats, fatigue, pruritus, and cough achieved rapid and durable improvement in these symptoms.  By six and 12 cycles of treatment, 39% and 47% of patients, resp., had achieved a spleen response per International Working Group criteria.  The majority of patients with leukocytosis or thrombocytosis at baseline (n = 28 and n = 10, resp.) achieved normalization of blood counts after six (57% and 90%, resp.) and 12 (56% and 88%, resp.) cycles.  A significant decrease in JAK2 V617F allele burden was obsd. at 6 mo in mutation-pos. patients (n = 51; P = .04), particularly in the subgroup with allele burden greater than 20% (n = 23; P < .01); the decrease was durable at 12 mo.  Conclusion TG101348 is well tolerated and produces significant redn. in disease burden and durable clin. benefit in patients with myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH4BD7RVGmfLVg90H21EOLACvtfcHk0ljsO1k3kMkrmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlelsL0%253D&md5=8b69a31d9dcf09b3b121e477f98d103b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.8021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.8021%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DGotlib%26aufirst%3DJ.%2BR.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSilverman%26aufirst%3DM.%2BH.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DShorr%26aufirst%3DJ.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520TG101348%252C%2520a%2520Selective%2520JAK2%2520Inhibitor%252C%2520in%2520Myelofibrosis%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D789%26epage%3D796%26doi%3D10.1200%2FJCO.2010.32.8021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanning, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountain, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheenstra, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strovel, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=764-769&author=L.+Chenauthor=J.+L.+Yapauthor=M.+Yoshiokaauthor=M.+E.+Lanningauthor=R.+N.+Fountainauthor=M.+Rajeauthor=J.+A.+Scheenstraauthor=J.+W.+Strovelauthor=S.+Fletcher&title=BRD4+Structure%E2%80%93Activity+Relationships+of+Dual+PLK1+Kinase%2FBRD4+Bromodomain+Inhibitor+BI-2536&doi=10.1021%2Facsmedchemlett.5b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span></div><div class="casAuthors">Chen, Lijia; Yap, Jeremy L.; Yoshioka, Makoto; Lanning, Maryanna E.; Fountain, Rachel N.; Raje, Mithun; Scheenstra, Jacob A.; Strovel, Jeffrey W.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">764-769</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused library of analogs of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepd. and then analyzed for BRD4 and PLK1 inhibitory activities.  Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiety afforded the most potent BRD4 inhibitor of the series (39j) with a Ki = 8.7 nM, which was equipotent against PLK1.  The superior affinity of 39j over the parental compd. to BRD4 possibly derives from improved interactions with the WPF shelf.  Meanwhile, substitution of the pyrimidine NH with an oxygen atom reversed the PLK1/BRD4 selectivity to convert BI-2536 into a BRD4-selective inhibitor, likely owing to the loss of a crit. hydrogen bond in PLK1.  We believe further fine-tuning will furnish a BRD4 "magic bullet" or an even more potent PLK1/BRD4 dual inhibitor toward the expansion and improved efficacy of the chemotherapy arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5UnNSmf1L17Vg90H21EOLACvtfcHk0ljsO1k3kMkrmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D&md5=f39070e652bca20c03a3bc5fe070a7fc</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DYoshioka%26aufirst%3DM.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DFountain%26aufirst%3DR.%2BN.%26aulast%3DRaje%26aufirst%3DM.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DStrovel%26aufirst%3DJ.%2BW.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DBRD4%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Dual%2520PLK1%2520Kinase%252FBRD4%2520Bromodomain%2520Inhibitor%2520BI-2536%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D764%26epage%3D769%26doi%3D10.1021%2Facsmedchemlett.5b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Allen, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ember, S. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbrunn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schürer, S. C.</span><span> </span><span class="NLM_article-title">Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">16924</span><span class="refDoi"> DOI: 10.1038/srep16924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsrep16924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26596901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFentrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16924&author=B.+K.+Allenauthor=S.+Mehtaauthor=S.+W.+J.+Emberauthor=E.+Schonbrunnauthor=N.+Ayadauthor=S.+C.+Sch%C3%BCrer&title=Large-Scale+Computational+Screening+Identifies+First+in+Class+Multitarget+Inhibitor+of+EGFR+Kinase+and+BRD4&doi=10.1038%2Fsrep16924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4</span></div><div class="casAuthors">Allen, Bryce K.; Mehta, Saurabh; Ember, Stewart W. J.; Schonbrunn, Ernst; Ayad, Nagi; Schurer, Stephan C.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16924</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common.  One way to overcome resistance is to target orthogonal cancer-promoting pathways.  Bromo and Extra-Terminal (BET) domain proteins, which belong to the family of epigenetic readers, have recently emerged as promising therapeutic targets in multiple cancers.  The development of multitarget drugs that inhibit kinase and BET proteins therefore may be a promising strategy to overcome tumor resistance and prolong therapeutic efficacy in the clinic.  We developed a general computational screening approach to identify novel dual kinase/bromodomain inhibitors from millions of com. available small mols.  Our method integrated machine learning using big datasets of kinase inhibitors and structure-based drug design.  Here we describe the computational methodol., including validation and characterization of our models and their application and integration into a scalable virtual screening pipeline.  We screened over 6 million com. available compds. and selected 24 for testing in BRD4 and EGFR biochem. assays.  We identified several novel BRD4 inhibitors, among them a first in class dual EGFR-BRD4 inhibitor.  Our studies suggest that this computational screening approach may be broadly applicable for identifying dual kinase/BET inhibitors with potential for treating various cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2LBJWDL9se7Vg90H21EOLACvtfcHk0liHvsKBTC_dMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFentrrI&md5=341f9fedbdfd9e66829e5c43d602d510</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fsrep16924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16924%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DB.%2BK.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DAyad%26aufirst%3DN.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26atitle%3DLarge-Scale%2520Computational%2520Screening%2520Identifies%2520First%2520in%2520Class%2520Multitarget%2520Inhibitor%2520of%2520EGFR%2520Kinase%2520and%2520BRD4%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16924%26doi%3D10.1038%2Fsrep16924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Burris, A. H.,  III</span><span> </span><span class="NLM_article-title">Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1634/theoncologist.9-suppl_3-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1634%2Ftheoncologist.9-suppl_3-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15163842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=10-15&author=A.+H.+Burris&title=Dual+Kinase+Inhibition+in+the+Treatment+of+Breast+Cancer%3A+Initial+Experience+with+the+EGFR%2FErbB-2+Inhibitor+Lapatinib&doi=10.1634%2Ftheoncologist.9-suppl_3-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib</span></div><div class="casAuthors">Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">10-15</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Dual inhibition of ErbB-1 (EGFR) and ErbB-2 (HER-2) tyrosine kinases has been found to exert greater biol. effects in the inhibition of signaling pathways promoting cancer cell proliferation and survival than inhibition of either receptor alone.  The novel dual EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; Research Triangle Park, NC) has been shown to inhibit tumor cell growth in vitro and in xenograft models for a variety of human tumors.  Preliminary findings in a phase I study of lapatinib in patients with solid tumors indicate doses up to 1,800 mg per day are well tolerated.  No grade 4 toxicities were obsd. and only two of 43 patients had grade 3 toxicity (diarrhea).  Clin. activity of lapatinib was obsd. in these patients; nine patients with a variety of tumors remained on study for ≥4 mo, one with a complete response (head and neck cancer).  In a phase IB study in pretreated metastatic cancer patients with disease that could be biopsied, grade 1 or 2 diarrhea and rash were the most common adverse events.  Three patients with breast cancer refractory to trastuzumab (Herceptin; Genentech, Inc.; South San Francisco, CA) had partial responses and 12 patients with a variety of tumors had stable disease.  Assessment of biol. correlates in these patients indicates that increased tumor cell apoptosis on the terminal deoxynucleotide transferase-mediated dUTP nick-end labeling assay correlates with clin. response.  Lapatinib currently is being evaluated in phase II and phase III trials in patients with metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynMnAi22a_rVg90H21EOLACvtfcHk0liHvsKBTC_dMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFOju7g%253D&md5=b1b91091896f42356f369ba20f6c39de</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.9-suppl_3-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.9-suppl_3-10%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DA.%2BH.%26atitle%3DDual%2520Kinase%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520Breast%2520Cancer%253A%2520Initial%2520Experience%2520with%2520the%2520EGFR%252FErbB-2%2520Inhibitor%2520Lapatinib%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D10%26epage%3D15%26doi%3D10.1634%2Ftheoncologist.9-suppl_3-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Stuhlmiller, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistowski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, K. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuther, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuan, P.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. L.</span><span> </span><span class="NLM_article-title">Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.celrep.2015.03.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25865888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVCjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=390-404&author=T.+J.+Stuhlmillerauthor=S.+M.+Millerauthor=J.+S.+Zawistowskiauthor=K.+Nakamuraauthor=A.+S.+Beltranauthor=J.+S.+Duncanauthor=S.+P.+Angusauthor=K.+A.+L.+Collinsauthor=D.+A.+Grangerauthor=R.+A.+Reutherauthor=L.+M.+Gravesauthor=S.+M.+Gomezauthor=P.-F.+Kuanauthor=J.+S.+Parkerauthor=X.+Chenauthor=N.+Sciakyauthor=L.+A.+Careyauthor=H.+S.+Earpauthor=J.+Jinauthor=G.+L.+Johnson&title=Inhibition+of+Lapatinib-Induced+Kinome+Reprogramming+in+ERBB2-Positive+Breast+Cancer+by+Targeting+BET+Family+Bromodomains&doi=10.1016%2Fj.celrep.2015.03.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains</span></div><div class="casAuthors">Stuhlmiller, Timothy J.; Miller, Samantha M.; Zawistowski, Jon S.; Nakamura, Kazuhiro; Beltran, Adriana S.; Duncan, James S.; Angus, Steven P.; Collins, Kyla A. L.; Granger, Deborah A.; Reuther, Rachel A.; Graves, Lee M.; Gomez, Shawn M.; Kuan, Pei-Fen; Parker, Joel S.; Chen, Xin; Sciaky, Noah; Carey, Lisa A.; Earp, H. Shelton; Jin, Jian; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-404</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Therapeutics that target ERBB2, such as lapatinib, often provide initial clin. benefit, but resistance frequently develops.  Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activation of multiple tyrosine kinases.  The heterogeneity of induced kinases prevents their targeting by a single kinase inhibitor, underscoring the challenge of predicting effective kinase inhibitor combination therapies.  We hypothesized that, to make the tumor response to single kinase inhibitors durable, the adaptive kinome response itself must be inhibited.  Genetic and chem. inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.  Combining inhibitors of kinases and chromatin readers prevents kinome adaptation by blocking transcription, generating a durable response to lapatinib, and overcoming the dilemma of heterogeneity in the adaptive response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroE3zQ9yBs3LVg90H21EOLACvtfcHk0lhx5ACT9xyHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVCjsr4%253D&md5=c1f91643c2ff7034d7c44aa93653ab27</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DS.%2BM.%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DCollins%26aufirst%3DK.%2BA.%2BL.%26aulast%3DGranger%26aufirst%3DD.%2BA.%26aulast%3DReuther%26aufirst%3DR.%2BA.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DGomez%26aufirst%3DS.%2BM.%26aulast%3DKuan%26aufirst%3DP.-F.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DInhibition%2520of%2520Lapatinib-Induced%2520Kinome%2520Reprogramming%2520in%2520ERBB2-Positive%2520Breast%2520Cancer%2520by%2520Targeting%2520BET%2520Family%2520Bromodomains%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D390%26epage%3D404%26doi%3D10.1016%2Fj.celrep.2015.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+Determinants+of+Phosphoinositide+3-Kinase+Inhibition+by+Wortmannin%2C+LY294002%2C+Quercetin%2C+Myricetin%2C+and+Staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lhx5ACT9xyHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520Determinants%2520of%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520by%2520Wortmannin%252C%2520LY294002%252C%2520Quercetin%252C%2520Myricetin%252C%2520and%2520Staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Morales, G. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlich, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newblom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durden, D. L.</span><span> </span><span class="NLM_article-title">Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-B]pyran-7-Ones Designed as next Generation PI3K Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1922</span><span class="NLM_x">–</span> <span class="NLM_lpage">1939</span><span class="refDoi"> DOI: 10.1021/jm301522m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301522m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1922-1939&author=G.+a+Moralesauthor=J.+R.+Garlichauthor=J.+Suauthor=X.+Pengauthor=J.+Newblomauthor=K.+Weberauthor=D.+L.+Durden&title=Synthesis+and+Cancer+Stem+Cell-Based+Activity+of+Substituted+5-Morpholino-7H-thieno%5B3%2C2-B%5Dpyran-7-Ones+Designed+as+next+Generation+PI3K+Inhibitors&doi=10.1021%2Fjm301522m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm301522m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301522m%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DG.%2Ba%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DNewblom%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DK.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DSynthesis%2520and%2520Cancer%2520Stem%2520Cell-Based%2520Activity%2520of%2520Substituted%25205-Morpholino-7H-thieno%255B3%252C2-B%255Dpyran-7-Ones%2520Designed%2520as%2520next%2520Generation%2520PI3K%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1922%26epage%3D1939%26doi%3D10.1021%2Fjm301522m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span>SignalRX Pharmaceuticals. Product Candidates, PI3K Pipeline. 2015. <a href="http://www.signalrx.com/signal-Rx/product-candidates/pi3k/" class="extLink">http://www.signalrx.com/signal-Rx/product-candidates/pi3k/</a> (accessed January 16,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SignalRX+Pharmaceuticals.+Product+Candidates%2C+PI3K+Pipeline.+2015.+http%3A%2F%2Fwww.signalrx.com%2Fsignal-Rx%2Fproduct-candidates%2Fpi3k%2F+%28accessed+January+16%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Singh, A. R.; Joshi, S.; Garlich, J. R.; Morales, G. A.; Durden, D. L.</span><span> </span><span class="NLM_article-title">Dual PI3K/BRD4 (Kinase/Epigenetic) Inhibitors for Maximal MYC Control in Cancer Therapeutics</span>. AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Philadelphia, PA, September 14–17,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract A27. <a href="http://mct.aacrjournals.org/content/14/7_Supplement/A27.abstract/" class="extLink">http://mct.aacrjournals.org/content/14/7_Supplement/A27.abstract/</a> (accessed January 16, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+R.+Singh&author=S.+Joshi&author=J.+R.+Garlich&author=G.+A.+Morales&author=D.+L.+Durden&title=Dual+PI3K%2FBRD4+%28Kinase%2FEpigenetic%29+Inhibitors+for+Maximal+MYC+Control+in+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BR.%26atitle%3DDual%2520PI3K%252FBRD4%2520%2528Kinase%252FEpigenetic%2529%2520Inhibitors%2520for%2520Maximal%2520MYC%2520Control%2520in%2520Cancer%2520Therapeutics%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Morales, G. A.; Weber, K. T.; Newblom, J. M.; Peng, X.; Su, J.; Garlich, J. R.</span><span> </span><span class="NLM_article-title">Thienopyranones as Kinase Inhibitors</span>. U.S. Patent 8557807, October 15,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+A.+Morales&author=K.+T.+Weber&author=J.+M.+Newblom&author=X.+Peng&author=J.+Su&author=J.+R.+Garlich&title=Thienopyranones+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DG.%2BA.%26atitle%3DThienopyranones%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, L.</span><span> </span><span class="NLM_article-title">Computational Polypharmacology Comes of Age</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.3389/fphar.2015.00157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.3389%2Ffphar.2015.00157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26283966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=157&author=G.+Rastelliauthor=L.+Pinzi&title=Computational+Polypharmacology+Comes+of+Age&doi=10.3389%2Ffphar.2015.00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Computational polypharmacology comes of age</span></div><div class="casAuthors">Rastelli, Giulio; Pinzi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/4</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the predicting drug polypharmacol., the raising no. of computational strategies, frameworks developed at testify that computational polypharmacol. has come of age and increasingly important role in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiapZ3lz9l4rVg90H21EOLACvtfcHk0lj8k_ycnTtqdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI&md5=4444f48a7d9c80f30a4d9dbf3f6ba2be</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00157%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DPinzi%26aufirst%3DL.%26atitle%3DComputational%2520Polypharmacology%2520Comes%2520of%2520Age%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D157%26doi%3D10.3389%2Ffphar.2015.00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Dixon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smondyrev, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening: 1. Methodology and Preliminary Results</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span><span class="refDoi"> DOI: 10.1007/s10822-006-9087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1007%2Fs10822-006-9087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17124629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCksbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=647-671&author=S.+L.+Dixonauthor=A.+M.+Smondyrevauthor=E.+H.+Knollauthor=S.+N.+Raoauthor=D.+E.+Shawauthor=R.+A.+Friesner&title=PHASE%3A+A+New+Engine+for+Pharmacophore+Perception%2C+3D+QSAR+Model+Development%2C+and+3D+Database+Screening%3A+1.+Methodology+and+Preliminary+Results&doi=10.1007%2Fs10822-006-9087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">PHASE: A new design for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results</span></div><div class="casAuthors">Dixon, Steven L.; Smondyrev, Alexander M.; Knoll, Eric H.; Rao, Shashidhar N.; Shaw, David E.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10/11</span>),
    <span class="NLM_cas:pages">647-671</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We introduce PHASE, a highly flexible system for common pharmacophore identification and assessment, 3D QSAR model development, and 3D database creation and searching.  The primary workflows and tasks supported by PHASE are described, and details of the underlying scientific methodologies are provided. Using results from previously published investigations, PHASE is compared directly to other ligand-based software for its ability to identify target pharmacophores, rationalize structure-activity data, and predict activities of external compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof5WS3oFk3MLVg90H21EOLACvtfcHk0lj8k_ycnTtqdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCksbvE&md5=512f55e6e3c3dfbae3fc94886482b69a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1007%2Fs10822-006-9087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-006-9087-6%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DS.%2BL.%26aulast%3DSmondyrev%26aufirst%3DA.%2BM.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DRao%26aufirst%3DS.%2BN.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DPHASE%253A%2520A%2520New%2520Engine%2520for%2520Pharmacophore%2520Perception%252C%25203D%2520QSAR%2520Model%2520Development%252C%2520and%25203D%2520Database%2520Screening%253A%25201.%2520Methodology%2520and%2520Preliminary%2520Results%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2006%26volume%3D20%26spage%3D647%26epage%3D671%26doi%3D10.1007%2Fs10822-006-9087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Dixon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smondyrev, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. N.</span><span> </span><span class="NLM_article-title">PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2006.00384.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.1747-0285.2006.00384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=16784462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVeqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=370-372&author=S.+L.+Dixonauthor=A.+M.+Smondyrevauthor=S.+N.+Rao&title=PHASE%3A+A+Novel+Approach+to+Pharmacophore+Modeling+and+3D+Database+Searching&doi=10.1111%2Fj.1747-0285.2006.00384.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approach to pharmacophore modeling and 3D database searching</span></div><div class="casAuthors">Dixon, Steven L.; Smondyrev, Alexander M.; Rao, Shashidhar N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">370-372</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Pharmacophore modeling and 3D database searching are now recognized as integral components of lead discovery and lead optimization, and the continuing need for improved pharmacophore-based tools has driven the development of PHASE.  PHASE pharmacophore and 3D QSAR models provide a means for rationalizing structure-activity data, predicting the activity of new compds., and efficiently extg. actives from a prototypical database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50KpRHTGgAbVg90H21EOLACvtfcHk0ljgn_4StIqvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVeqsbg%253D&md5=30d06fe99776e203eed35b0f774bbe64</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2006.00384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2006.00384.x%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DS.%2BL.%26aulast%3DSmondyrev%26aufirst%3DA.%2BM.%26aulast%3DRao%26aufirst%3DS.%2BN.%26atitle%3DPHASE%253A%2520A%2520Novel%2520Approach%2520to%2520Pharmacophore%2520Modeling%2520and%25203D%2520Database%2520Searching%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D370%26epage%3D372%26doi%3D10.1111%2Fj.1747-0285.2006.00384.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Friesner, R. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+a+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+a+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+New+Approach+for+Rapid%2C+Accurate+Docking+and+Scoring.+1.+Method+and+Assessment+of+Docking+Accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0ljgn_4StIqvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2Ba%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2Ba%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520New%2520Approach%2520for%2520Rapid%252C%2520Accurate%2520Docking%2520and%2520Scoring.%25201.%2520Method%2520and%2520Assessment%2520of%2520Docking%2520Accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Muvva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singam, E. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raman, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, V.</span><span> </span><span class="NLM_article-title">Structure-Based Virtual Screening of Novel, High-Affinity BRD4 Inhibitors</span> <span class="citation_source-journal">Mol. BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2397</span><span class="refDoi"> DOI: 10.1039/C4MB00243A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1039%2FC4MB00243A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24976024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOis7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=2384-2397&author=C.+Muvvaauthor=E.+R.+A.+Singamauthor=S.+S.+Ramanauthor=V.+Subramanian&title=Structure-Based+Virtual+Screening+of+Novel%2C+High-Affinity+BRD4+Inhibitors&doi=10.1039%2FC4MB00243A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based virtual screening of novel, high-affinity BRD4 inhibitors</span></div><div class="casAuthors">Muvva, Charuvaka; Singam, E. R. Azhagiya; Raman, S. Sundar; Subramanian, V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2384-2397</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are a diverse family of evolutionarily conserved protein-interaction modules.  Among various members of the bromodomain and extra terminal domain family, BRD4 is found to be an important target for many diseases such as cancer, acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, etc.  Therefore, in this study an attempt has been made to screen compds. from NCI Diversity, Drug Bank and Toslab Databases targeting the Kac binding site of BRD4 using mol. docking, mol. dynamics simulations, MM-PB/GBSA binding free energy calcns. and steered mol. dynamics simulations.  Using virtual screening and docking, we have identified 11 inhibitors.  These new inhibitors exhibit binding energy values higher than that of the (+)JQ1 inhibitor which is effective against BRD4.  However, due to the toxicity of (+)JQ1, the designing of new inhibitors becomes significantly important.  Thus, these new 11 ligands were systematically analyzed using other computational investigations.  Results reveal that the compds. ZINC01411240, ZINC19632618 and ZINC04818522 could be potential drug candidates for targeting BRD4.  It can also be seen from the results that there is a linear relationship between the results obtained from the SMD simulation and free energy obtained from the MM-PBSA/GBSA approach.  This study clearly illustrates that the steered mol. dynamics can be effectively used for the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3go7Pz1QUrVg90H21EOLACvtfcHk0ljgn_4StIqvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOis7nP&md5=81005695a0cb0efa88b6b7fefaa768c7</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1039%2FC4MB00243A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MB00243A%26sid%3Dliteratum%253Aachs%26aulast%3DMuvva%26aufirst%3DC.%26aulast%3DSingam%26aufirst%3DE.%2BR.%2BA.%26aulast%3DRaman%26aufirst%3DS.%2BS.%26aulast%3DSubramanian%26aufirst%3DV.%26atitle%3DStructure-Based%2520Virtual%2520Screening%2520of%2520Novel%252C%2520High-Affinity%2520BRD4%2520Inhibitors%26jtitle%3DMol.%2520BioSyst.%26date%3D2014%26volume%3D10%26spage%3D2384%26epage%3D2397%26doi%3D10.1039%2FC4MB00243A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Duffy, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsia, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharenko, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesner, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLure, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshminarasimhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D. B.</span><span> </span><span class="NLM_article-title">Discovery of a New Chemical Series of BRD4(1) Inhibitors Using Protein-Ligand Docking and Structure-Guided Design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2818</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2015.04.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2818-2823&author=B.+C.+Duffyauthor=S.+Liuauthor=G.+S.+Martinauthor=R.+Wangauthor=M.+M.+Hsiaauthor=H.+Zhaoauthor=C.+Guoauthor=M.+Ellisauthor=J.+F.+Quinnauthor=O.+A.+Kharenkoauthor=K.+Norekauthor=E.+M.+Gesnerauthor=P.+R.+Youngauthor=K.+G.+McLureauthor=G.+S.+Wagnerauthor=D.+Lakshminarasimhanauthor=A.+Whiteauthor=R.+K.+Sutoauthor=H.+C.+Hansenauthor=D.+B.+Kitchen&title=Discovery+of+a+New+Chemical+Series+of+BRD4%281%29+Inhibitors+Using+Protein-Ligand+Docking+and+Structure-Guided+Design&doi=10.1016%2Fj.bmcl.2015.04.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.107%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DB.%2BC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DHsia%26aufirst%3DM.%2BM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DEllis%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DKharenko%26aufirst%3DO.%2BA.%26aulast%3DNorek%26aufirst%3DK.%26aulast%3DGesner%26aufirst%3DE.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DMcLure%26aufirst%3DK.%2BG.%26aulast%3DWagner%26aufirst%3DG.%2BS.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DSuto%26aufirst%3DR.%2BK.%26aulast%3DHansen%26aufirst%3DH.%2BC.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Chemical%2520Series%2520of%2520BRD4%25281%2529%2520Inhibitors%2520Using%2520Protein-Ligand%2520Docking%2520and%2520Structure-Guided%2520Design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2818%26epage%3D2823%26doi%3D10.1016%2Fj.bmcl.2015.04.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartenmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Discovery of BRD4 Bromodomain Inhibitors by Fragment-Based High-Throughput Docking</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2496</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2014.04.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2493-2496&author=H.+Zhaoauthor=L.+Gartenmannauthor=J.+Dongauthor=D.+Spiliotopoulosauthor=A.+Caflisch&title=Discovery+of+BRD4+Bromodomain+Inhibitors+by+Fragment-Based+High-Throughput+Docking&doi=10.1016%2Fj.bmcl.2014.04.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGartenmann%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520BRD4%2520Bromodomain%2520Inhibitors%2520by%2520Fragment-Based%2520High-Throughput%2520Docking%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2493%26epage%3D2496%26doi%3D10.1016%2Fj.bmcl.2014.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Discovery of Benzo[cd]indol-2(1H)-Ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization and Biological Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01511</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01511" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1565-1579&author=X.+Xueauthor=Y.+Zhangauthor=Z.+Liuauthor=M.+Songauthor=Y.+Xingauthor=Q.+Xiangauthor=Z.+Wangauthor=Z.-C.+Tuauthor=Y.+Zhouauthor=K.+Dingauthor=Y.+Xu&title=Discovery+of+Benzo%5Bcd%5Dindol-2%281H%29-Ones+as+Potent+and+Specific+BET+Bromodomain+Inhibitors%3A+Structure-Based+Virtual+Screening%2C+Optimization+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.5b01511"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01511%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Benzo%255Bcd%255Dindol-2%25281H%2529-Ones%2520as%2520Potent%2520and%2520Specific%2520BET%2520Bromodomain%2520Inhibitors%253A%2520Structure-Based%2520Virtual%2520Screening%252C%2520Optimization%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1565%26epage%3D1579%26doi%3D10.1021%2Facs.jmedchem.5b01511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Hügle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostrovskyi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breit, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einsle, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlwend, D.</span><span> </span><span class="NLM_article-title">4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1518</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1518-1530&author=M.+H%C3%BCgleauthor=X.+Lucasauthor=G.+Weitzelauthor=D.+Ostrovskyiauthor=B.+Breitauthor=S.+Gerhardtauthor=O.+Einsleauthor=S.+G%C3%BCntherauthor=D.+Wohlwend&title=4-Acyl+Pyrrole+Derivatives+Yield+Novel+Vectors+for+Designing+Inhibitors+of+the+Acetyl-Lysine+Recognition+Site+of+BRD4%281%29&doi=10.1021%2Facs.jmedchem.5b01267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1)</span></div><div class="casAuthors">Huegle, Martin; Lucas, Xavier; Weitzel, Gerhard; Ostrovskyi, Dmytro; Breit, Bernhard; Gerhardt, Stefan; Einsle, Oliver; Guenther, Stefan; Wohlwend, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1518-1530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several human diseases, including cancer, show altered signaling pathways resulting from changes in the activity levels of epigenetic modulators.  In the past few years, small-mol. inhibitors against specific modulators, including the bromodomain and extra-terminal (BET) bromodomain family of acetylation readers, have shown early promise in the treatment of the genetically defined midline carcinoma and hematopoietic malignancies.  We have recently developed a novel potent inhibitor of BET proteins, 1 (XD14), which exerts a strong inhibitory potential on the proliferation of specific leukemia cell lines.  In the study presented here, we designed analogs of 1 to study the potential of substitutions on the 4-acyl pyrrole backbone to occupy addnl. sites within the substrate recognition site of BRD4(1).  The compds. were profiled using ITC, DSF, and X-ray crystallog.  We could introduce several substitutions that address previously untargeted areas of the substrate recognition site.  This work may substantially contribute to the development of therapeutics with increased target specificity against BRD4-related malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwg6psp_B35bVg90H21EOLACvtfcHk0lhT_LsobwOkvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yksA%253D%253D&md5=07296d23042a3ce2f2ecc1b6ae691e30</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01267%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCgle%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DX.%26aulast%3DWeitzel%26aufirst%3DG.%26aulast%3DOstrovskyi%26aufirst%3DD.%26aulast%3DBreit%26aufirst%3DB.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DEinsle%26aufirst%3DO.%26aulast%3DG%25C3%25BCnther%26aufirst%3DS.%26aulast%3DWohlwend%26aufirst%3DD.%26atitle%3D4-Acyl%2520Pyrrole%2520Derivatives%2520Yield%2520Novel%2520Vectors%2520for%2520Designing%2520Inhibitors%2520of%2520the%2520Acetyl-Lysine%2520Recognition%2520Site%2520of%2520BRD4%25281%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1518%26epage%3D1530%26doi%3D10.1021%2Facs.jmedchem.5b01267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Vidler, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8073</span><span class="NLM_x">–</span> <span class="NLM_lpage">8088</span><span class="refDoi"> DOI: 10.1021/jm4011302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOjurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8073-8088&author=L.+R.+Vidlerauthor=P.+Filippakopoulosauthor=O.+Fedorovauthor=S.+Picaudauthor=S.+Martinauthor=M.+Tomsettauthor=H.+Woodwardauthor=N.+Brownauthor=S.+Knappauthor=S.+Hoelder&title=Discovery+of+Novel+Small-Molecule+Inhibitors+of+BRD4+Using+Structure-Based+Virtual+Screening&doi=10.1021%2Fjm4011302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening</span></div><div class="casAuthors">Vidler, Lewis R.; Filippakopoulos, Panagis; Fedorov, Oleg; Picaud, Sarah; Martin, Sarah; Tomsett, Michael; Woodward, Hannah; Brown, Nathan; Knapp, Stefan; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8073-8088</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are epigenetic readers that recognize acetylated-lysine (KAc) on proteins and are implicated in a no. of diseases.  We describe a virtual screening approach to identify BRD inhibitors.  Key elements of this approach are the extensive design and use of substructure queries to compile a set of com. available compds. featuring novel putative KAc mimetics and docking this set for final compd. selection.  We describe the validation of this approach by applying it to the first BRD of BRD4.  The selection and testing of 143 compds. lead to the discovery of six novel hits, including four unprecedented KAc mimetics.  We solved the crystal structure of four hits, detd. their binding mode, and improved their potency through synthesis and the purchase of derivs.  This work provides a validated virtual screening approach that is applicable to other BRDs and describes novel KAc mimetics that can be further explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow5yj8bnohUbVg90H21EOLACvtfcHk0ljdafgvD6X1Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOjurrI&md5=c1f76e4838713335be7a93ebe4c68701</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm4011302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011302%26sid%3Dliteratum%253Aachs%26aulast%3DVidler%26aufirst%3DL.%2BR.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DTomsett%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Small-Molecule%2520Inhibitors%2520of%2520BRD4%2520Using%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8073%26epage%3D8088%26doi%3D10.1021%2Fjm4011302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Ran, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meagher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaswamy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4927</span><span class="NLM_x">–</span> <span class="NLM_lpage">4939</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4927-4939&author=X.+Ranauthor=Y.+Zhaoauthor=L.+Liuauthor=L.+Baiauthor=C.+Y.+Yangauthor=B.+Zhouauthor=J.+L.+Meagherauthor=K.+Chinnaswamyauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-Based+Design+of+%CE%B3-Carboline+Analogues+as+Potent+and+Specific+BET+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors</span></div><div class="casAuthors">Ran, Xu; Zhao, Yujun; Liu, Liu; Bai, Longchuan; Yang, Chao-Yie; Zhou, Bing; Meagher, Jennifer L.; Chinnaswamy, Krishnapriya; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4927-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of bromodomain and extra terminal proteins (BET), including BRD2, BRD3, and BRD4 proteins have therapeutic potential for the treatment of human cancers and other diseases and conditions.  In this paper, the authors report the design, synthesis, and evaluation of γ-carboline-contg. compds. as a new class of small-mol. BET inhibitors.  The most potent inhibitor I (RX-37) obtained from this study binds to BET bromodomain proteins (BRD2, BRD3, and BRD4) with Ki values of 3.2-24.7 nM and demonstrates high selectivity over other non-BET bromodomain-contg. proteins.  Compd. I potently and selectively inhibits cell growth in human acute leukemia cell lines harboring the rearranged mixed lineage leukemia 1 gene.  The authors have detd. a cocrystal structure of I in complex with BRD4 BD2 at 1.4 Å resoln., which provides a solid structural basis for the compd.'s high binding affinity and for its further structure-based optimization.  Compd. I represents a promising lead compd. for the development of a new class of therapeutics for the treatment of human cancer and other conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-VCfWLBWYLVg90H21EOLACvtfcHk0ljdafgvD6X1Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7rM&md5=e6e150169812e439c1d7d91416eb3ee9</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00613%26sid%3Dliteratum%253Aachs%26aulast%3DRan%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-Based%2520Design%2520of%2520%25CE%25B3-Carboline%2520Analogues%2520as%2520Potent%2520and%2520Specific%2520BET%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4927%26epage%3D4939%26doi%3D10.1021%2Facs.jmedchem.5b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Misra, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Activity of N-aryl-2-aminothiazoles: Potent Pan Inhibitors of Cyclin-Dependent Kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2973</span><span class="NLM_x">–</span> <span class="NLM_lpage">2977</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2004.02.105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2973-2977&author=R.+J.+Misraauthor=H.+J.+Xiaoauthor=D.+K.+Williamsauthor=K.+S.+Kimauthor=S.+Luauthor=K.+A.+Kellerauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=J.+S.+Tokarskiauthor=J.+S.+Sackauthor=S.+D.+Kimballauthor=F.+J.+Leeauthor=K.+R.+Webster&title=Synthesis+and+Biological+Activity+of+N-aryl-2-aminothiazoles%3A+Potent+Pan+Inhibitors+of+Cyclin-Dependent+Kinases&doi=10.1016%2Fj.bmcl.2004.02.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.105%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BJ.%26aulast%3DXiao%26aufirst%3DH.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DLee%26aufirst%3DF.%2BJ.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520N-aryl-2-aminothiazoles%253A%2520Potent%2520Pan%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2973%26epage%3D2977%26doi%3D10.1016%2Fj.bmcl.2004.02.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">TG101209, a Small Molecule JAK2-Selective Kinase Inhibitor Potently Inhibits Myeloproliferative Disorder-Associated JAK2V617F and MPLW515L/K Mutations</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1668</span><span class="refDoi"> DOI: 10.1038/sj.leu.2404750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsj.leu.2404750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17541402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1658-1668&author=A.+Pardananiauthor=J.+Hoodauthor=T.+Lashoauthor=R.+L.+Levineauthor=M.+B.+Martinauthor=G.+Noronhaauthor=C.+Finkeauthor=C.+C.+Makauthor=R.+Mesaauthor=H.+Zhuauthor=R.+Sollauthor=D.+G.+Gillilandauthor=A.+Tefferi&title=TG101209%2C+a+Small+Molecule+JAK2-Selective+Kinase+Inhibitor+Potently+Inhibits+Myeloproliferative+Disorder-Associated+JAK2V617F+and+MPLW515L%2FK+Mutations&doi=10.1038%2Fsj.leu.2404750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations</span></div><div class="casAuthors">Pardanani, A.; Hood, J.; Lasho, T.; Levine, R. L.; Martin, M. B.; Noronha, G.; Finke, C.; Mak, C. C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D. G.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1658-1668</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis.  The authors developed TG101209, an orally bioavailable small mol. that potently inhibits JAK2 (IC50 = 6 nM), FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC50 = 169 nM).  TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of ∼200 nM.  In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209-induced cell cycle arrest and apoptosis, and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3.  Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model.  Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFcz0joQsNbVg90H21EOLACvtfcHk0ljdafgvD6X1Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D&md5=784ff4ff7d65097052d9d864c90e8138</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404750%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BB.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DTG101209%252C%2520a%2520Small%2520Molecule%2520JAK2-Selective%2520Kinase%2520Inhibitor%2520Potently%2520Inhibits%2520Myeloproliferative%2520Disorder-Associated%2520JAK2V617F%2520and%2520MPLW515L%252FK%2520Mutations%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1658%26epage%3D1668%26doi%3D10.1038%2Fsj.leu.2404750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Lénárt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipp, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J. M.</span><span> </span><span class="NLM_article-title">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cub.2006.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17291761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=304-315&author=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Steegmaierauthor=B.+Di+Fioreauthor=J.+J.+Lippauthor=M.+Hoffmannauthor=W.+J.+Rettigauthor=N.+Krautauthor=J.+M.+Peters&title=The+Small-Molecule+Inhibitor+BI+2536+Reveals+Novel+Insights+into+Mitotic+Roles+of+Polo-like+Kinase+1&doi=10.1016%2Fj.cub.2006.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span></div><div class="casAuthors">Lenart, Peter; Petronczki, Mark; Steegmaier, Martin; Di Fiore, Barbara; Lipp, Jesse J.; Hoffmann, Matthias; Rettig, Wolfgang J.; Kraut, Norbert; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensively to further understanding of mitotic mechanisms and as potential targets for cancer therapy.  Cdk1 and Aurora kinase studies have been facilitated by small-mol. inhibitors, but few if any potent Plk1 inhibitors have been identified.  We describe the cellular effects of a novel compd., BI 2536, a potent and selective inhibitor of Plk1.  The fact that BI 2536 blocks Plk1 activity fully and instantaneously enabled us to study controversial and unknown functions of Plk1.  Cells treated with BI 2536 are delayed in prophase but eventually import Cdk1-cyclin B into the nucleus, enter prometaphase, and degrade cyclin A, although BI 2536 prevents degrdn. of the APC/C inhibitor Emi1.  BI 2536-treated cells lack prophase microtubule asters and thus polymerize mitotic microtubules only after nuclear-envelope breakdown and form monopolar spindles that do not stably attach to kinetochores.  Mad2 accumulates at kinetochores, and cells arrest with an activated spindle-assembly checkpoint.  BI 2536 prevents Plk1's enrichment at kinetochores and centrosomes, and when added to metaphase cells, it induces detachment of microtubules from kinetochores and leads to spindle collapse.  Our results suggest that Plk1's accumulation at centrosomes and kinetochores depends on its own activity and that this activity is required for maintaining centrosome and kinetochore function.  Our data also show that Plk1 is not required for prophase entry, but delays transition to prometaphase, and that Emi1 destruction in prometaphase is not essential for APC/C-mediated cyclin A degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmCcyKwjrX7Vg90H21EOLACvtfcHk0li8rh8T-KFdxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D&md5=4f0bc426138f64db93e17bf10a5f4db9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DB.%26aulast%3DLipp%26aufirst%3DJ.%2BJ.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Small-Molecule%2520Inhibitor%2520BI%25202536%2520Reveals%2520Novel%2520Insights%2520into%2520Mitotic%2520Roles%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.cub.2006.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Boehm, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bower, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span> </span><span class="NLM_article-title">Phenoxypyrimidine Inhibitors of p38α Kinase: Synthesis and Statistical Evaluation of the p38 Inhibitory Potencies of a Series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00163-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0960-894X%2801%2900163-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1123-1126&issue=9&author=J.+C.+Boehmauthor=M.+J.+Bowerauthor=T.+F.+Gallagherauthor=S.+Kassisauthor=S.+R.+Johnsonauthor=J.+R.+Adams&title=Phenoxypyrimidine+Inhibitors+of+p38%CE%B1+Kinase%3A+Synthesis+and+Statistical+Evaluation+of+the+p38+Inhibitory+Potencies+of+a+Series+of+1-%28piperidin-4-yl%29-4-%284-fluorophenyl%29-5-%282-phenoxypyrimidin-4-yl%29+imidazoles&doi=10.1016%2FS0960-894X%2801%2900163-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900163-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900163-9%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DJ.%2BC.%26aulast%3DBower%26aufirst%3DM.%2BJ.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DKassis%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26atitle%3DPhenoxypyrimidine%2520Inhibitors%2520of%2520p38%25CE%25B1%2520Kinase%253A%2520Synthesis%2520and%2520Statistical%2520Evaluation%2520of%2520the%2520p38%2520Inhibitory%2520Potencies%2520of%2520a%2520Series%2520of%25201-%2528piperidin-4-yl%2529-4-%25284-fluorophenyl%2529-5-%25282-phenoxypyrimidin-4-yl%2529%2520imidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D9%26spage%3D1123%26epage%3D1126%26doi%3D10.1016%2FS0960-894X%2801%2900163-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Leahy, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigoreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span> </span><span class="NLM_article-title">Identification of a Highly Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor (NU7441) by Screening of Chromenone Libraries</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6083</span><span class="NLM_x">–</span> <span class="NLM_lpage">6087</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2004.09.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15546735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps1Okurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=6083-6087&issue=24&author=J.+J.+J.+Leahyauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=I.+R.+Hardcastleauthor=C.+Richardsonauthor=L.+Rigoreauauthor=G.+C.+M.+Smith&title=Identification+of+a+Highly+Potent+and+Selective+DNA-Dependent+Protein+Kinase+%28DNA-PK%29+Inhibitor+%28NU7441%29+by+Screening+of+Chromenone+Libraries&doi=10.1016%2Fj.bmcl.2004.09.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries</span></div><div class="casAuthors">Leahy, Justin J. J.; Golding, Bernard T.; Griffin, Roger J.; Hardcastle, Ian R.; Richardson, Caroline; Rigoreau, Laurent; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6083-6087</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A soln.-phase multiple-parallel synthesis approach was employed for the prepn. of 6-, 7- and 8-aryl-substituted chromenone libraries, which were screened as inhibitors of the DNA repair enzyme DNA-dependent protein kinase (DNA-PK).  These studies resulted in the identification of 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (I; NU7441) as a highly potent and selective DNA-PK inhibitor (IC50 = 14 nM), exhibiting ATP-competitive inhibition kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIxqS9nsWG9rVg90H21EOLACvtfcHk0li8rh8T-KFdxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps1Okurg%253D&md5=f2a980013b9943f93a6c9e5f6897cf8a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.060%26sid%3Dliteratum%253Aachs%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26atitle%3DIdentification%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520DNA-Dependent%2520Protein%2520Kinase%2520%2528DNA-PK%2529%2520Inhibitor%2520%2528NU7441%2529%2520by%2520Screening%2520of%2520Chromenone%2520Libraries%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D24%26spage%3D6083%26epage%3D6087%26doi%3D10.1016%2Fj.bmcl.2004.09.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Davies, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caivano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0lg9-NNO6WGt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Rudolph, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3094</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+A+Polo-like+Kinase+Inhibitor+with+Improved+Pharmacokinetic+Profile+and+Broad+Antitumor+Activity&doi=10.1158%2F1078-0432.CCR-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0lg9-NNO6WGt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520A%2520Polo-like%2520Kinase%2520Inhibitor%2520with%2520Improved%2520Pharmacokinetic%2520Profile%2520and%2520Broad%2520Antitumor%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26doi%3D10.1158%2F1078-0432.CCR-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Hewitt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tighe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santaguida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musacchio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span> </span><span class="NLM_article-title">Sustained Mps1 Activity is Required in Mitosis to Recruit O-Mad2 to the Mad1–C-Mad2 Core Complex</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1083/jcb.201002133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1083%2Fjcb.201002133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20624899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2010&pages=25-34&author=L.+Hewittauthor=A.+Tigheauthor=S.+Santaguidaauthor=A.+M.+Whiteauthor=C.+D.+Jonesauthor=A.+Musacchioauthor=S.+Greenauthor=S.+S.+Taylor&title=Sustained+Mps1+Activity+is+Required+in+Mitosis+to+Recruit+O-Mad2+to+the+Mad1%E2%80%93C-Mad2+Core+Complex&doi=10.1083%2Fjcb.201002133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex</span></div><div class="casAuthors">Hewitt, Laura; Tighe, Anthony; Santaguida, Stefano; White, Anne M.; Jones, Clifford D.; Musacchio, Andrea; Green, Stephen; Taylor, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mps1 is an essential component of the spindle assembly checkpoint.  In this study, we describe a novel Mps1 inhibitor, AZ3146, and use it to probe the role of Mps1's catalytic activity during mitosis.  When Mps1 is inhibited before mitotic entry, subsequent recruitment of Mad1 and Mad2 to kinetochores is abolished.  However, if Mps1 is inhibited after mitotic entry, the Mad1-C-Mad2 core complex remains kinetochore bound, but O-Mad2 is not recruited to the core.  Although inhibiting Mps1 also interferes with chromosome alignment, we see no obvious effect on aurora B activity.  In contrast, kinetochore recruitment of centromere protein E (CENP-E), a kinesin-related motor protein, is severely impaired.  Strikingly, inhibition of Mps1 significantly increases its own abundance at kinetochores.  Furthermore, we show that Mps1 can dimerize and transphosphorylate in cells.  We propose a model whereby Mps1 transphosphorylation results in its release from kinetochores, thus facilitating recruitment of O-Mad2 and CENP-E and thereby simultaneously promoting checkpoint signaling and chromosome congression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40BfrYS2Vu7Vg90H21EOLACvtfcHk0lg9-NNO6WGt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D&md5=2b95cfba4b228bada877bdb6dc95be1f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201002133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201002133%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DL.%26aulast%3DTighe%26aufirst%3DA.%26aulast%3DSantaguida%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DSustained%2520Mps1%2520Activity%2520is%2520Required%2520in%2520Mitosis%2520to%2520Recruit%2520O-Mad2%2520to%2520the%2520Mad1%25E2%2580%2593C-Mad2%2520Core%2520Complex%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D190%26spage%3D25%26epage%3D34%26doi%3D10.1083%2Fjcb.201002133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Allen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, P.</span><span> </span><span class="NLM_article-title">Emerging Targets in Osteoporosis Disease Modification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4332</span><span class="NLM_x">–</span> <span class="NLM_lpage">4353</span><span class="refDoi"> DOI: 10.1021/jm9018756</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018756" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVyht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4332-4353&author=J.+G.+Allenauthor=C.+Fotschauthor=P.+Babij&title=Emerging+Targets+in+Osteoporosis+Disease+Modification&doi=10.1021%2Fjm9018756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Targets in Osteoporosis Disease Modification</span></div><div class="casAuthors">Allen, John G.; Fotsch, Christopher; Babij, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4332-4353</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolnqRUQFya4bVg90H21EOLACvtfcHk0liO4eTPFJJVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVyht74%253D&md5=78e247d0cddbbba4635209fa030d688f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm9018756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018756%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DBabij%26aufirst%3DP.%26atitle%3DEmerging%2520Targets%2520in%2520Osteoporosis%2520Disease%2520Modification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4332%26epage%3D4353%26doi%3D10.1021%2Fjm9018756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Z.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0liO4eTPFJJVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%2BZ.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span><span class="refDoi"> DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0liO4eTPFJJVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claiborne, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libby, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitzenberger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selnick, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancheck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanlon, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofsess, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orevillo, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolando, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahly, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2180</span><span class="NLM_x">–</span> <span class="NLM_lpage">2190</span><span class="refDoi"> DOI: 10.1021/jm9805236</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9805236" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADyaK1MXjt1aqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2180-2190&author=N.+J.+Livertonauthor=J.+W.+Butcherauthor=C.+F.+Claiborneauthor=D.+A.+Claremonauthor=B.+E.+Libbyauthor=K.+T.+Nguyenauthor=S.+M.+Pitzenbergerauthor=H.+G.+Selnickauthor=G.+R.+Smithauthor=A.+Tebbenauthor=J.+P.+Vaccaauthor=S.+L.+Vargaauthor=L.+Agarwalauthor=K.+Dancheckauthor=A.+J.+Forsythauthor=D.+S.+Fletcherauthor=B.+Frantzauthor=W.+A.+Hanlonauthor=C.+F.+Harperauthor=S.+J.+Hofsessauthor=M.+Kosturaauthor=J.+Linauthor=S.+Luellauthor=E.+A.+O%E2%80%99Neillauthor=C.+J.+Orevilloauthor=M.+Pangauthor=J.+Parsonsauthor=A.+Rolandoauthor=Y.+Sahlyauthor=D.+M.+Viscoauthor=S.+J.+O%E2%80%99Keefe&title=Design+and+Synthesis+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Tetrasubstituted+Imidazole+Inhibitors+of+p38+Mitogen-Activated+Protein+Kinase&doi=10.1021%2Fjm9805236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase</span></div><div class="casAuthors">Liverton, Nigel J.; Butcher, John W.; Claiborne, Christopher F.; Claremon, David A.; Libby, Brian E.; Nguyen, Kevin T.; Pitzenberger, Steven M.; Selnick, Harold G.; Smith, Garry R.; Tebben, Andrew; Vacca, Joseph P.; Varga, Sandor L.; Agarwal, Lily; Dancheck, Kim; Forsyth, Amy J.; Fletcher, Daniel S.; Frantz, Betsy; Hanlon, William A.; Harper, Coral F.; Hofsess, Scott J.; Kostura, Matthew; Lin, Jiunn; Luell, Sylvie; O'Neill, Edward A.; Orevillo, Chad J.; Pang, Margaret; Parsons, Janey; Rolando, Anna; Sahly, Yousif; Visco, Denise M.; O'Keefe, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2180-2190</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-α (TNF-α) release and an animal model of rheumatoid arthritis.  The SAR leading to the development of selectivity against c-Raf and JNK2α1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a 2-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aq. soly.  In general, oral bioavailability of this class of compds. was found to be poor unless the imidazole was methylated on nitrogen.  This work led to identification of 4-[1-methyl-2-(4-piperidinyl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]-2-pyridinamine sulfate salt, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-α from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCz5nW0Ifnt7Vg90H21EOLACvtfcHk0lix8ziuFcDxEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjt1aqsrY%253D&md5=1a8e8710ce6ab0c3928077a29029938d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm9805236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9805236%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DLibby%26aufirst%3DB.%2BE.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DPitzenberger%26aufirst%3DS.%2BM.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DVarga%26aufirst%3DS.%2BL.%26aulast%3DAgarwal%26aufirst%3DL.%26aulast%3DDancheck%26aufirst%3DK.%26aulast%3DForsyth%26aufirst%3DA.%2BJ.%26aulast%3DFletcher%26aufirst%3DD.%2BS.%26aulast%3DFrantz%26aufirst%3DB.%26aulast%3DHanlon%26aufirst%3DW.%2BA.%26aulast%3DHarper%26aufirst%3DC.%2BF.%26aulast%3DHofsess%26aufirst%3DS.%2BJ.%26aulast%3DKostura%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuell%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%2BA.%26aulast%3DOrevillo%26aufirst%3DC.%2BJ.%26aulast%3DPang%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DRolando%26aufirst%3DA.%26aulast%3DSahly%26aufirst%3DY.%26aulast%3DVisco%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Tetrasubstituted%2520Imidazole%2520Inhibitors%2520of%2520p38%2520Mitogen-Activated%2520Protein%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2180%26epage%3D2190%26doi%3D10.1021%2Fjm9805236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Padilla, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowrie, L. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O-Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span> </span><span class="NLM_article-title">Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1677</span><span class="NLM_x">–</span> <span class="NLM_lpage">1692</span><span class="refDoi"> DOI: 10.1021/jm301720p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301720p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFaqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1677-1692&author=F.+Padillaauthor=N.+Bhagirathauthor=S.+Chenauthor=R.+Chiaoauthor=D.+M.+Goldsteinauthor=J.+C.+Hermannauthor=J.+Hsuauthor=J.+J.+Kennedy-Smithauthor=A.+Kuglstatterauthor=C.+Liaoauthor=W.+Liuauthor=L.+E.+Lowrieauthor=K.+C.+Lukauthor=S.+M.+Lynchauthor=J.+M.+Menkeauthor=L.+Niuauthor=T.+D.+Owensauthor=C.+O-Yangauthor=A.+Railkarauthor=R.+C.+Schoenfeldauthor=M.+Sladeauthor=S.+Steinerauthor=Y.+C.+Tanauthor=A.+G.+Villasenorauthor=C.+Wangauthor=J.+Wannerauthor=W.+Xieauthor=D.+Xuauthor=X.+Zhangauthor=M.+Zhouauthor=M.+C.+Lucas&title=Pyrrolopyrazines+as+Selective+Spleen+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Fjm301720p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Padilla, Fernando; Bhagirath, Niala; Chen, Shaoqing; Chiao, Eric; Goldstein, David M.; Hermann, Johannes C.; Hsu, Jonathan; Kennedy-Smith, Joshua J.; Kuglstatter, Andreas; Liao, Cheng; Liu, Wenjian; Lowrie, Lee E., Jr.; Luk, Kin Chun; Lynch, Stephen M.; Menke, John; Niu, Linghao; Owens, Timothy D.; O-Yang, Counde; Railkar, Aruna; Schoenfeld, Ryan C.; Slade, Michelle; Steiner, Sandra; Tan, Yun-Chou; Villasenor, Armando G.; Wang, Ce; Wanner, Jutta; Xie, Wenwei; Xu, Daigen; Zhang, Xiaohu; Zhou, Mingyan; Lucas, Matthew C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1677-1692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochem. properties and human whole blood potencies.  Ultimately, the mouse model revealed unexpected toxicity of compd. I that precluded the further advancement of this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPn6yiWDGRMbVg90H21EOLACvtfcHk0lix8ziuFcDxEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFaqurs%253D&md5=2ab3e28de06e6300547d2a474bd14aef</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm301720p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301720p%26sid%3Dliteratum%253Aachs%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChiao%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLowrie%26aufirst%3DL.%2BE.%26aulast%3DLuk%26aufirst%3DK.%2BC.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DMenke%26aufirst%3DJ.%2BM.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DO-Yang%26aufirst%3DC.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWanner%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26atitle%3DPyrrolopyrazines%2520as%2520Selective%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1677%26epage%3D1692%26doi%3D10.1021%2Fjm301720p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Taha, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bustanji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ghussein, M. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalloum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Masri, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, N.</span><span> </span><span class="NLM_article-title">Pharmacophore Modeling, Quantitative Structure–Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2062</span><span class="NLM_x">–</span> <span class="NLM_lpage">2077</span><span class="refDoi"> DOI: 10.1021/jm7009765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2062-2077&author=M.+O.+Tahaauthor=Y.+Bustanjiauthor=M.+A.+S.+Al-Ghusseinauthor=M.+Mohammadauthor=H.+Zalloumauthor=I.+M.+Al-Masriauthor=N.+Atallah&title=Pharmacophore+Modeling%2C+Quantitative+Structure%E2%80%93Activity+Relationship+Analysis%2C+and+in+Silico+Screening+Reveal+Potent+Glycogen+Synthase+Kinase-3%CE%B2+Inhibitory+Activities+for+Cimetidine%2C+Hydroxychloroquine%2C+and+Gemifloxacin&doi=10.1021%2Fjm7009765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin</span></div><div class="casAuthors">Taha, Mutasem O.; Bustanji, Yasser; Al-Ghussein, Mohamed A. S.; Mohammad, Mohammad; Zalloum, Hiba; Al-Masri, Ihab M.; Atallah, Naji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2062-2077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacophoric space of glycogen synthase kinase-3β (GSK-3β) was explored using two diverse sets of inhibitors.  Subsequently, genetic algorithm and multiple linear regression anal. were employed to select optimal combination of pharmacophores and physicochem. descriptors that access self-consistent and predictive quant. structure-activity relationship (QSAR) against 132 training compds. (r2123 = 0.663, F = 24.6, r2LOO = 0.592, r2PRESS against 29 external test inhibitors = 0.695).  Two orthogonal pharmacophores emerged in the QSAR, suggesting the existence of at least two distinct binding modes accessible to ligands within GSK-3β binding pocket.  The validity of the QSAR equation and the assocd. pharmacophores was established by the identification of three nanomolar GSK-3β inhibitors retrieved from our inhouse-built structural database of established drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin.  Docking studies supported the binding modes suggested by the pharmacophore/QSAR anal.  In addn. to being excellent leads for subsequent optimization, the anti-GSK-3β activities of these drugs should have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEh_csUf5KYLVg90H21EOLACvtfcHk0lgiPHR8KA0i-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOnur0%253D&md5=60a909c0c66603e68e29bddfb3518a36</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm7009765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009765%26sid%3Dliteratum%253Aachs%26aulast%3DTaha%26aufirst%3DM.%2BO.%26aulast%3DBustanji%26aufirst%3DY.%26aulast%3DAl-Ghussein%26aufirst%3DM.%2BA.%2BS.%26aulast%3DMohammad%26aufirst%3DM.%26aulast%3DZalloum%26aufirst%3DH.%26aulast%3DAl-Masri%26aufirst%3DI.%2BM.%26aulast%3DAtallah%26aufirst%3DN.%26atitle%3DPharmacophore%2520Modeling%252C%2520Quantitative%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Analysis%252C%2520and%2520in%2520Silico%2520Screening%2520Reveal%2520Potent%2520Glycogen%2520Synthase%2520Kinase-3%25CE%25B2%2520Inhibitory%2520Activities%2520for%2520Cimetidine%252C%2520Hydroxychloroquine%252C%2520and%2520Gemifloxacin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2062%26epage%3D2077%26doi%3D10.1021%2Fjm7009765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieffine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalisz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M.</span><span> </span><span class="NLM_article-title">Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1016/j.jmb.2003.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.jmb.2003.08.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2003&pages=393-407&issue=2&author=J.+A.+Bertrandauthor=S.+Thieffineauthor=A.+Vulpettiauthor=C.+Cristianiauthor=B.+Valsasinaauthor=S.+Knappauthor=H.+M.+Kaliszauthor=M.+Flocco&title=Structural+Characterization+of+the+GSK-3%CE%B2+Active+Site+Using+Selective+and+Non-selective+ATP-mimetic+Inhibitors&doi=10.1016%2Fj.jmb.2003.08.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKalisz%26aufirst%3DH.%2BM.%26aulast%3DFlocco%26aufirst%3DM.%26atitle%3DStructural%2520Characterization%2520of%2520the%2520GSK-3%25CE%25B2%2520Active%2520Site%2520Using%2520Selective%2520and%2520Non-selective%2520ATP-mimetic%2520Inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D333%26issue%3D2%26spage%3D393%26epage%3D407%26doi%3D10.1016%2Fj.jmb.2003.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamford, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaiba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, J. GA.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The Identification of Potent, Selective and CNS Penetrant Furan-Based Inhibitors of B-Raf Kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4373</span><span class="NLM_x">–</span> <span class="NLM_lpage">4376</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2008.06.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4373-4376&issue=15&author=A.+K.+Takleauthor=M.+J.+Bamfordauthor=S.+Daviesauthor=R.+P.+Davisauthor=D.+K.+Deanauthor=A.+Gaibaauthor=E.+A.+Irvingauthor=F.+D.+Kingauthor=A.+Naylorauthor=C.+A.+Parrauthor=A.+M.+Rayauthor=A.+D.+Reithauthor=B.+B.+Smithauthor=P.+C.+Statonauthor=J.+GA.+Steadmanauthor=T.+O.+Steanauthor=D.+M.+Wilson&title=The+Identification+of+Potent%2C+Selective+and+CNS+Penetrant+Furan-Based+Inhibitors+of+B-Raf+Kinase&doi=10.1016%2Fj.bmcl.2008.06.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DIrving%26aufirst%3DE.%2BA.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DRay%26aufirst%3DA.%2BM.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DB.%2BB.%26aulast%3DStaton%26aufirst%3DP.%2BC.%26aulast%3DSteadman%26aufirst%3DJ.%2BGA.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520Identification%2520of%2520Potent%252C%2520Selective%2520and%2520CNS%2520Penetrant%2520Furan-Based%2520Inhibitors%2520of%2520B-Raf%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D15%26spage%3D4373%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2008.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 31 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lina Humbeck, Jette Pretzel, Saskia Spitzer, <span class="NLM_string-name hlFld-ContribAuthor">Oliver Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 1255-1265. <a href="https://doi.org/10.1021/acschembio.1c00323" title="DOI URL">https://doi.org/10.1021/acschembio.1c00323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.1c00323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.1c00323%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ban%252BUnexpected%252BSimilarity%252Bin%252BLigand%252BBinding%252Bbetween%252BBRD4%252Band%252BPPAR%2525CE%2525B3%26aulast%3DHumbeck%26aufirst%3DLina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D07062021%26date%3D28062021%26volume%3D16%26issue%3D7%26spage%3D1255%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pan Tang, Jifa Zhang, Jie Liu, Cheng-Ming Chiang, <span class="NLM_string-name hlFld-ContribAuthor">Liang Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2419-2435. <a href="https://doi.org/10.1021/acs.jmedchem.0c01487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BBromodomain%252Band%252BExtraterminal%252BProteins%252Bfor%252BDrug%252BDiscovery%25253A%252BFrom%252BCurrent%252BProgress%252Bto%252BTechnological%252BDevelopment%26aulast%3DTang%26aufirst%3DPan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26082020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2419%26epage%3D2435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kaikai Lv, Weicong Chen, Danqi Chen, Jie Mou, Huijie Zhang, Tiantian Fan, Yanlian Li, Danyan Cao, Xin Wang, Lin Chen, Jingkang Shen, Dongsheng Pei, <span class="NLM_string-name hlFld-ContribAuthor">Bing Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9787-9802. <a href="https://doi.org/10.1021/acs.jmedchem.0c00962" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00962%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Band%252BEvaluation%252Bof%252B6-%252528Pyrimidin-2-ylamino%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-ones%252Bas%252BPolypharmacological%252BInhibitors%252Bof%252BBET%252Band%252BKinases%26aulast%3DLv%26aufirst%3DKaikai%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D26082020%26date%3D11082020%26volume%3D63%26issue%3D17%26spage%3D9787%26epage%3D9802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rezaul Md Karim, Alice Chan, Jin-Yi Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Ernst Schönbrunn</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3227-3237. <a href="https://doi.org/10.1021/acs.jmedchem.9b01980" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01980</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01980%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bof%252BInhibitor%252BSelectivity%252Bin%252Bthe%252BBRD7%25252F9%252BSubfamily%252Bof%252BBromodomains%26aulast%3DKarim%26aufirst%3DRezaul%2BMd%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28112019%26date%3D06032020%26date%3D24022020%26volume%3D63%26issue%3D6%26spage%3D3227%26epage%3D3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 372-390. <a href="https://doi.org/10.1021/acs.jcim.9b00821" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BTarget%252BAssociations%252Bfor%252BPolypharmacology%252Bfrom%252BAnalysis%252Bof%252BCrystallographic%252BLigands%252Bof%252Bthe%252BProtein%252BData%252BBank%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D20092019%26date%3D19122019%26date%3D04122019%26volume%3D60%26issue%3D1%26spage%3D372%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela
S. Carlson, Huarui Cui, Anand Divakaran, Jorden A. Johnson, Ryan M. Brunner, William C. K. Pomerantz, <span class="NLM_string-name hlFld-ContribAuthor">Joseph J. Topczewski</span>. </span><span class="cited-content_cbyCitation_article-title">Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (9)
                                     , 1296-1301. <a href="https://doi.org/10.1021/acsmedchemlett.9b00227" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00227%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSystematically%252BMitigating%252Bthe%252Bp38%2525CE%2525B1%252BActivity%252Bof%252BTriazole-based%252BBET%252BInhibitors%26aulast%3DCarlson%26aufirst%3DAngela%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20052019%26date%3D02082019%26date%3D07082019%26date%3D02082019%26volume%3D10%26issue%3D9%26spage%3D1296%26epage%3D1301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Reza Abazari, Ali Reza Mahjoub, Farangis Ataei, Ali Morsali, Cameron L. Carpenter-Warren, Kayhan Mehdizadeh, <span class="NLM_string-name hlFld-ContribAuthor">Alexandra M. Z. Slawin</span>. </span><span class="cited-content_cbyCitation_article-title">Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (21)
                                     , 13364-13379. <a href="https://doi.org/10.1021/acs.inorgchem.8b01955" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.8b01955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.8b01955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.8b01955%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DChitosan%252BImmobilization%252Bon%252BBio-MOF%252BNanostructures%25253A%252BA%252BBiocompatible%252BpH-Responsive%252BNanocarrier%252Bfor%252BDoxorubicin%252BRelease%252Bon%252BMCF-7%252BCell%252BLines%252Bof%252BHuman%252BBreast%252BCancer%26aulast%3DAbazari%26aufirst%3DReza%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D17102018%26volume%3D57%26issue%3D21%26spage%3D13364%26epage%3D13379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anand Divakaran, Siva K. Talluri, Alex M. Ayoub, Neeraj K. Mishra, Huarui Cui, John C. Widen, Norbert Berndt, Jin-Yi Zhu, Angela S. Carlson, Joseph J. Topczewski, Ernst K. Schonbrunn, Daniel A. Harki, <span class="NLM_string-name hlFld-ContribAuthor">William C. K. Pomerantz</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase–Bromodomain Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9316-9334. <a href="https://doi.org/10.1021/acs.jmedchem.8b01248" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01248%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252BBasis%252Bfor%252Bthe%252BN-Terminal%252BBromodomain-and-Extra-Terminal-Family%252BSelectivity%252Bof%252Ba%252BDual%252BKinase%2525E2%252580%252593Bromodomain%252BInhibitor%26aulast%3DDivakaran%26aufirst%3DAnand%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07082018%26date%3D16102018%26date%3D25092018%26volume%3D61%26issue%3D20%26spage%3D9316%26epage%3D9334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaonan Shi, Xi Chen, Muhua Wang, Xinying Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xuesen Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective Synthesis of Acylated N-Heterocycles via the Cascade Reactions of Saturated Cyclic Amines with 2-Oxo-2-arylacetic Acids. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (12)
                                     , 6524-6533. <a href="https://doi.org/10.1021/acs.joc.8b00805" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00805%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRegioselective%252BSynthesis%252Bof%252BAcylated%252BN-Heterocycles%252Bvia%252Bthe%252BCascade%252BReactions%252Bof%252BSaturated%252BCyclic%252BAmines%252Bwith%252B2-Oxo-2-arylacetic%252BAcids%26aulast%3DShi%26aufirst%3DXiaonan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30032018%26date%3D24052018%26date%3D14052018%26volume%3D83%26issue%3D12%26spage%3D6524%26epage%3D6533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulun  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Tan</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The ups, downs and new trends of IDO1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104815. <a href="https://doi.org/10.1016/j.bioorg.2021.104815" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bups%25252C%252Bdowns%252Band%252Bnew%252Btrends%252Bof%252BIDO1%252Binhibitors%26aulast%3DChen%26aufirst%3DShulun%26date%3D2021%26volume%3D110%26spage%3D104815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharon  Rossiter</span>, <span class="hlFld-ContribAuthor ">Mehrnoosh  Ostovar</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Pteridines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00040-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00040-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00040-8%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BPteridines%26aulast%3DRossiter%26aufirst%3DSharon%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kendra R.  Vann</span>, <span class="hlFld-ContribAuthor ">Dhananjaya  Pal</span>, <span class="hlFld-ContribAuthor ">Guillermo A.  Morales</span>, <span class="hlFld-ContribAuthor ">Adam M.  Burgoyne</span>, <span class="hlFld-ContribAuthor ">Donald L.  Durden</span>, <span class="hlFld-ContribAuthor ">Tatiana G.  Kutateladze</span>. </span><span class="cited-content_cbyCitation_article-title">Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-68964-6" title="DOI URL">https://doi.org/10.1038/s41598-020-68964-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-68964-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-68964-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDesign%252Bof%252Bthienopyranone-based%252BBET%252Binhibitors%252Bthat%252Bbind%252Bmultiple%252Bsynthetic%252Blethality%252Btargets%26aulast%3DVann%26aufirst%3DKendra%2BR.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam M.  Burgoyne</span>, <span class="hlFld-ContribAuthor ">Kendra R.  Vann</span>, <span class="hlFld-ContribAuthor ">Shweta  Joshi</span>, <span class="hlFld-ContribAuthor ">Guillermo A.  Morales</span>, <span class="hlFld-ContribAuthor ">Francisco M.  Vega</span>, <span class="hlFld-ContribAuthor ">Alok  Singh</span>, <span class="hlFld-ContribAuthor ">Dhananjaya  Pal</span>, <span class="hlFld-ContribAuthor ">Aran B.  Merati</span>, <span class="hlFld-ContribAuthor ">Tatiana G.  Kutateladze</span>, <span class="hlFld-ContribAuthor ">Donald L.  Durden</span>. </span><span class="cited-content_cbyCitation_article-title">A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Cell Discovery</span><span> <strong>2020,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41421-020-0181-z" title="DOI URL">https://doi.org/10.1038/s41421-020-0181-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41421-020-0181-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41421-020-0181-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Discovery%26atitle%3DA%252Btriple%252Baction%252BCDK4%25252F6-PI3K-BET%252Binhibitor%252Bwith%252Baugmented%252Bcancer%252Bcell%252Bcytotoxicity%26aulast%3DBurgoyne%26aufirst%3DAdam%2BM.%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adel S.  El-Azab</span>, <span class="hlFld-ContribAuthor ">Alaa A.-M.  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Nawaf A.  AlSaif</span>, <span class="hlFld-ContribAuthor ">Hamad M.  Alkahtani</span>, <span class="hlFld-ContribAuthor ">Mohammed M.  Alanazi</span>, <span class="hlFld-ContribAuthor ">Ahmad J.  Obaidullah</span>, <span class="hlFld-ContribAuthor ">Razan O.  Eskandrani</span>, <span class="hlFld-ContribAuthor ">Amal  Alharbi</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104345. <a href="https://doi.org/10.1016/j.bioorg.2020.104345" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104345%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAntitumor%252Bactivity%25252C%252Bmultitarget%252Bmechanisms%25252C%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bquinazoline%252Bderivatives%252Bbased%252Bon%252Ba%252Bbenzenesulfonamide%252Bscaffold%25253A%252BCell%252Bcycle%252Banalysis%26aulast%3DEl-Azab%26aufirst%3DAdel%2BS.%26date%3D2020%26volume%3D104%26spage%3D104345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalie  Timme</span>, <span class="hlFld-ContribAuthor ">Youjia  Han</span>, <span class="hlFld-ContribAuthor ">Shuai  Liu</span>, <span class="hlFld-ContribAuthor ">Hailemichael O.  Yosief</span>, <span class="hlFld-ContribAuthor ">Heathcliff Dorado  García</span>, <span class="hlFld-ContribAuthor ">Yi  Bei</span>, <span class="hlFld-ContribAuthor ">Filippos  Klironomos</span>, <span class="hlFld-ContribAuthor ">Ian C.  MacArthur</span>, <span class="hlFld-ContribAuthor ">Annabell  Szymansky</span>, <span class="hlFld-ContribAuthor ">Jennifer  von Stebut</span>, <span class="hlFld-ContribAuthor ">Victor  Bardinet</span>, <span class="hlFld-ContribAuthor ">Constantin  Dohna</span>, <span class="hlFld-ContribAuthor ">Annette  Künkele</span>, <span class="hlFld-ContribAuthor ">Jana  Rolff</span>, <span class="hlFld-ContribAuthor ">Patrick  Hundsdörfer</span>, <span class="hlFld-ContribAuthor ">Andrej  Lissat</span>, <span class="hlFld-ContribAuthor ">Georg  Seifert</span>, <span class="hlFld-ContribAuthor ">Angelika  Eggert</span>, <span class="hlFld-ContribAuthor ">Johannes H.  Schulte</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Anton G.  Henssen</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (2)
                                     , 221-232. <a href="https://doi.org/10.1016/j.tranon.2019.09.013" title="DOI URL">https://doi.org/10.1016/j.tranon.2019.09.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2019.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2019.09.013%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DSmall-Molecule%252BDual%252BPLK1%252Band%252BBRD4%252BInhibitors%252Bare%252BActive%252BAgainst%252BPreclinical%252BModels%252Bof%252BPediatric%252BSolid%252BTumors%26aulast%3DTimme%26aufirst%3DNatalie%26date%3D2020%26volume%3D13%26issue%3D2%26spage%3D221%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Tian  Lu</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Feilong  Zhou</span>, <span class="hlFld-ContribAuthor ">Xilin  Lyu</span>, <span class="hlFld-ContribAuthor ">Biling  Xu</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Kaixian  Chen</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111633. <a href="https://doi.org/10.1016/j.ejmech.2019.111633" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111633%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Bstructural%252Binsight%25252C%252Band%252Bbioactivities%252Bof%252BBY27%252Bas%252Ba%252Bselective%252Binhibitor%252Bof%252Bthe%252Bsecond%252Bbromodomains%252Bof%252BBET%252Bproteins%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2019%26volume%3D182%26spage%3D111633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea G.  Cochran</span>, <span class="hlFld-ContribAuthor ">Andrew R.  Conery</span>, <span class="hlFld-ContribAuthor ">Robert J.  Sims</span>. </span><span class="cited-content_cbyCitation_article-title">Bromodomains: a new target class for drug development. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2019,</strong> <em>18 </em>
                                    (8)
                                     , 609-628. <a href="https://doi.org/10.1038/s41573-019-0030-7" title="DOI URL">https://doi.org/10.1038/s41573-019-0030-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DBromodomains%25253A%252Ba%252Bnew%252Btarget%252Bclass%252Bfor%2525C2%2525A0drug%252Bdevelopment%26aulast%3DCochran%26aufirst%3DAndrea%2BG.%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D8%26spage%3D609%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simona  Sestito</span>, <span class="hlFld-ContribAuthor ">Simona  Rapposelli</span>. </span><span class="cited-content_cbyCitation_article-title">A patent update on PDK1 inhibitors (2015-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (4)
                                     , 271-282. <a href="https://doi.org/10.1080/13543776.2019.1597852" title="DOI URL">https://doi.org/10.1080/13543776.2019.1597852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1597852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1597852%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Bupdate%252Bon%252BPDK1%252Binhibitors%252B%2525282015-present%252529%26aulast%3DSestito%26aufirst%3DSimona%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D271%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Xue  Zhu</span>, <span class="hlFld-ContribAuthor ">Jian-Ru  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2019,</strong> <em>511 </em>
                                    (3)
                                     , 559-565. <a href="https://doi.org/10.1016/j.bbrc.2019.02.080" title="DOI URL">https://doi.org/10.1016/j.bbrc.2019.02.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2019.02.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2019.02.080%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DSF2523%252Binhibits%252Bhuman%252Bchondrosarcoma%252Bcell%252Bgrowth%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DZhu%26aufirst%3DJia-Xue%26date%3D2019%26volume%3D511%26issue%3D3%26spage%3D559%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehrosh  Pervaiz</span>, <span class="hlFld-ContribAuthor ">Pankaj  Mishra</span>, <span class="hlFld-ContribAuthor ">Stefan  Günther</span>. </span><span class="cited-content_cbyCitation_article-title">Bromodomains: Promising Targets for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 347-381. <a href="https://doi.org/10.1002/9783527809257.ch13" title="DOI URL">https://doi.org/10.1002/9783527809257.ch13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527809257.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527809257.ch13%26sid%3Dliteratum%253Aachs%26atitle%3DBromodomains%25253A%252BPromising%252BTargets%252Bfor%252BDrug%252BDiscovery%26aulast%3DPervaiz%26aufirst%3DMehrosh%26date%3D2019%26date%3D2019%26spage%3D347%26epage%3D381%26pub%3DWiley%26atitle%3DEpigenetic%252BDrug%252BDiscovery%26aulast%3DSippl%26aufirst%3DWolfgang%26date%3D2019%26date%3D2019%26volume%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William C. K.  Pomerantz</span>, <span class="hlFld-ContribAuthor ">Jorden A.  Johnson</span>, <span class="hlFld-ContribAuthor ">Peter D.  Ycas</span>. </span><span class="cited-content_cbyCitation_article-title">Applied Biophysics for Bromodomain Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 287-337. <a href="https://doi.org/10.1007/7355_2019_79" title="DOI URL">https://doi.org/10.1007/7355_2019_79</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2019_79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2019_79%26sid%3Dliteratum%253Aachs%26atitle%3DApplied%252BBiophysics%252Bfor%252BBromodomain%252BDrug%252BDiscovery%26aulast%3DPomerantz%26aufirst%3DWilliam%2BC.%2BK.%26date%3D2019%26date%3D2019%26spage%3D287%26epage%3D337%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChemical%252BEpigenetics%26aulast%3DMai%26aufirst%3DAntonello%26date%3D2020%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fazeela Mahaboob Begum  S.M.</span>, <span class="hlFld-ContribAuthor ">Kalai  Chitra</span>, <span class="hlFld-ContribAuthor ">Benin  Joseph</span>, <span class="hlFld-ContribAuthor ">Raji  Sundararajan</span>, <span class="hlFld-ContribAuthor ">Hemalatha  S.</span>. </span><span class="cited-content_cbyCitation_article-title">Gelidiella acerosa inhibits lung cancer proliferation. </span><span class="cited-content_cbyCitation_journal-name">BMC Complementary and Alternative Medicine</span><span> <strong>2018,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12906-018-2165-1" title="DOI URL">https://doi.org/10.1186/s12906-018-2165-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12906-018-2165-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12906-018-2165-1%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Complementary%2520and%2520Alternative%2520Medicine%26atitle%3DGelidiella%252Bacerosa%252Binhibits%252Blung%252Bcancer%252Bproliferation%26aulast%3DS.M.%26aufirst%3DFazeela%2BMahaboob%2BBegum%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liyan  Duan</span>, <span class="hlFld-ContribAuthor ">Kequn  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>, <span class="hlFld-ContribAuthor ">Junyan  Xie</span>, <span class="hlFld-ContribAuthor ">Xiang  Luo</span>, <span class="hlFld-ContribAuthor ">Qiaozi  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Two new metal coordination polymers: anticancer activity in endometrial carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Inorganic and Nano-Metal Chemistry</span><span> <strong>2018,</strong> <em>48 </em>
                                    (4-5)
                                     , 257-261. <a href="https://doi.org/10.1080/24701556.2018.1513529" title="DOI URL">https://doi.org/10.1080/24701556.2018.1513529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/24701556.2018.1513529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F24701556.2018.1513529%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520and%2520Nano-Metal%2520Chemistry%26atitle%3DTwo%252Bnew%252Bmetal%252Bcoordination%252Bpolymers%25253A%252Banticancer%252Bactivity%252Bin%252Bendometrial%252Bcarcinoma%26aulast%3DDuan%26aufirst%3DLiyan%26date%3D2018%26date%3D2018%26volume%3D48%26issue%3D4-5%26spage%3D257%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reza  Abazari</span>, <span class="hlFld-ContribAuthor ">Ali  Reza Mahjoub</span>, <span class="hlFld-ContribAuthor ">Alexandra M.Z.  Slawin</span>, <span class="hlFld-ContribAuthor ">Cameron L.  Carpenter-Warren</span>. </span><span class="cited-content_cbyCitation_article-title">Morphology- and size-controlled synthesis of a metal-organic framework under ultrasound irradiation: An efficient carrier for pH responsive release of anti-cancer drugs and their applicability for adsorption of amoxicillin from aqueous solution. </span><span class="cited-content_cbyCitation_journal-name">Ultrasonics Sonochemistry</span><span> <strong>2018,</strong> <em>42 </em>, 594-608. <a href="https://doi.org/10.1016/j.ultsonch.2017.12.032" title="DOI URL">https://doi.org/10.1016/j.ultsonch.2017.12.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ultsonch.2017.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ultsonch.2017.12.032%26sid%3Dliteratum%253Aachs%26jtitle%3DUltrasonics%2520Sonochemistry%26atitle%3DMorphology-%252Band%252Bsize-controlled%252Bsynthesis%252Bof%252Ba%252Bmetal-organic%252Bframework%252Bunder%252Bultrasound%252Birradiation%25253A%252BAn%252Befficient%252Bcarrier%252Bfor%252BpH%252Bresponsive%252Brelease%252Bof%252Banti-cancer%252Bdrugs%252Band%252Btheir%252Bapplicability%252Bfor%252Badsorption%252Bof%252Bamoxicillin%252Bfrom%252Baqueous%252Bsolution%26aulast%3DAbazari%26aufirst%3DReza%26date%3D2018%26volume%3D42%26spage%3D594%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luciana  Scotti</span>, <span class="hlFld-ContribAuthor ">Hamilton Mitsugu  Ishiki</span>, <span class="hlFld-ContribAuthor ">Marcelo Cavalcante  Duarte</span>, <span class="hlFld-ContribAuthor ">Tiago Branquinho  Oliveira</span>, <span class="hlFld-ContribAuthor ">Marcus T.  Scotti</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Approaches in Multitarget Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 327-345. <a href="https://doi.org/10.1007/978-1-4939-7899-1_16" title="DOI URL">https://doi.org/10.1007/978-1-4939-7899-1_16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7899-1_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7899-1_16%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BApproaches%252Bin%252BMultitarget%252BDrug%252BDiscovery%26aulast%3DScotti%26aufirst%3DLuciana%26date%3D2018%26date%3D2018%26spage%3D327%26epage%3D345%26pub%3DSpringer%2520New%2520York%26atitle%3DComputational%252BToxicology%26aulast%3DNicolotti%26aufirst%3DOrazio%26date%3D2018%26volume%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Xianghong  Guan</span>, <span class="hlFld-ContribAuthor ">Jiewei  Jiang</span>, <span class="hlFld-ContribAuthor ">Gunda I.  Georg</span>. </span><span class="cited-content_cbyCitation_article-title">BRDT Inhibitors for Male Contraceptive Drug Discovery: Current Status. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 287-315. <a href="https://doi.org/10.1007/978-981-13-0773-7_11" title="DOI URL">https://doi.org/10.1007/978-981-13-0773-7_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-13-0773-7_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-13-0773-7_11%26sid%3Dliteratum%253Aachs%26atitle%3DBRDT%252BInhibitors%252Bfor%252BMale%252BContraceptive%252BDrug%252BDiscovery%25253A%252BCurrent%252BStatus%26aulast%3DMiao%26aufirst%3DZhenyuan%26date%3D2018%26date%3D2018%26spage%3D287%26epage%3D315%26pub%3DSpringer%2520Singapore%26atitle%3DTargeting%252BProtein-Protein%252BInteractions%252Bby%252BSmall%252BMolecules%26aulast%3DSheng%26aufirst%3DChunquan%26date%3D2018%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XVI, 2016. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-254. <a href="https://doi.org/10.1016/bs.aihch.2018.02.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXVI%25252C%252B2016%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2018%26spage%3D173%26epage%3D254%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Bistrović</span>, <span class="hlFld-ContribAuthor ">Luka  Krstulović</span>, <span class="hlFld-ContribAuthor ">Anja  Harej</span>, <span class="hlFld-ContribAuthor ">Petra  Grbčić</span>, <span class="hlFld-ContribAuthor ">Mirela  Sedić</span>, <span class="hlFld-ContribAuthor ">Sanja  Koštrun</span>, <span class="hlFld-ContribAuthor ">Sandra Kraljević  Pavelić</span>, <span class="hlFld-ContribAuthor ">Miroslav  Bajić</span>, <span class="hlFld-ContribAuthor ">Silvana  Raić-Malić</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1616-1634. <a href="https://doi.org/10.1016/j.ejmech.2017.10.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzimidazole%252Bamidines%252Bas%252Bpotent%252Bmulti-target%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DBistrovi%25C4%2587%26aufirst%3DAndrea%26date%3D2018%26volume%3D143%26spage%3D1616%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Shen</span>, <span class="hlFld-ContribAuthor ">Minjun  Jiang</span>, <span class="hlFld-ContribAuthor ">Jinxian  Pu</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2018,</strong> <em>495 </em>
                                    (1)
                                     , 567-573. <a href="https://doi.org/10.1016/j.bbrc.2017.11.062" title="DOI URL">https://doi.org/10.1016/j.bbrc.2017.11.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2017.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2017.11.062%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DDual%252Binhibition%252Bof%252BBRD4%252Band%252BPI3K%252Bby%252BSF2523%252Bsuppresses%252Bhuman%252Bprostate%252Bcancer%252Bcell%252Bgrowth%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DShen%26aufirst%3DGang%26date%3D2018%26volume%3D495%26issue%3D1%26spage%3D567%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua  Zhu</span>, <span class="hlFld-ContribAuthor ">Jia-Hui  Mao</span>, <span class="hlFld-ContribAuthor ">Yin  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Hua  Gu</span>, <span class="hlFld-ContribAuthor ">Xiao-Dong  Pan</span>, <span class="hlFld-ContribAuthor ">Yuxi  Shan</span>, <span class="hlFld-ContribAuthor ">Bing  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (58)
                                     , 98471-98481. <a href="https://doi.org/10.18632/oncotarget.21432" title="DOI URL">https://doi.org/10.18632/oncotarget.21432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.21432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.21432%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDual%252Binhibition%252Bof%252BBRD4%252Band%252BPI3K-AKT%252Bby%252BSF2523%252Bsuppresses%252Bhuman%252Brenal%252Bcell%252Bcarcinoma%252Bcell%252Bgrowth%26aulast%3DZhu%26aufirst%3DHua%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D58%26spage%3D98471%26epage%3D98481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of kinase inhibitors, BET inhibitors, and dual kinase/BET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>10</b> bound to CDK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1">4KD1</a>). <b>10</b> is represented as light green sticks, while the most important residues are represented as gray sticks. The figure also shows the generated pharmacophore model of <b>10</b> inside CDK2 represented as spheres and dots. The hydrogen bond acceptor, donor, aromatic and hydrophobic features are colored in red, blue, brown, and green, respectively. (B) Crystal structure of <b>10</b> bound to BRDT (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KCX">4KCX</a>). <b>10</b> is represented as light green sticks, while the most important residues are shown as light blue sticks. (C) Crystal structure of <b>10</b> bound to BRD4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70">4O70</a>). <b>10</b> is represented as light green sticks, while the most important residues are shown as light green sticks. Water molecules are represented as ball and sticks. Hydrogen bonds are represented as yellow dashed lines, and nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Different binding types identified by Schönbrunn et al. inside BRD4.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> BRD4 is colored according to the inhibitor binding type. BRD4 bound to a type N inhibitor is colored light green. BRD4 bound to type PZA/ZA inhibitors is colored dark blue, whereas BRD4 bound to type I inhibitors is colored dark yellow. This choice has been made to underline the three different binding types that kinase inhibitors might show inside BRDs. (A) Crystal structure of compound <b>7</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a>). The ligand is represented as black sticks. (B) Crystal structure of compound <b>11</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76">4O76</a>). The ligand is represented as green sticks. (C) Crystal structure of compound <b>14</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7F">4O7F</a>). The ligand is represented as purple sticks. (D) Crystal structure of compound <b>13</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74">4O74</a>). The ligand is shown as blue sticks. (E) Crystal structure of compound <b>15</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK">4CFK</a>). The compound is represented as orange sticks. (F) Crystal structure of compound <b>16</b> inside BRD4 (BD1) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72">4O72</a>). The ligand is shown as yellow sticks. Nonpolar hydrogen atoms are omitted for clarity. Conserved water molecules are represented as ball and sticks, whereas hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacophore models. (A) Pharmacophore model obtained considering the binding geometries of compound <b>11</b> inside BRD4 (BD1). <b>11</b> is represented as green sticks, whereas <b>7</b> is represented as black sticks. The hydrogen bond donor, acceptor, aromatic and hydrophobic features are shown in blue, red, brown, and green, respectively. (B) Pharmacophore model generated considering the binding geometries of compound <b>13</b> inside BRD4 (BD1). <b>13</b> and <b>14</b> are shown in blue and purple, respectively. The hydrogen bond donor, acceptor, and hydrophobic features are shown in blue, red/orange (second acceptor moiety), and green, respectively. (C) Pharmacophore model carried out considering the binding geometries of compound <b>16</b> inside BRD4 (BD1). Compounds <b>15</b>, <b>16</b>, and <b>29</b> are shown in orange, yellow, and gray sticks, respectively. The hydrogen bond donor, acceptor, and aromatic features are shown in blue, red, and brown, respectively. (D) Refined “N type binder” pharmacophore model with excluded volume features after consideration of the residues forming the AcK binding site of BRD4. In all panels nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/medium/jm-2016-00438m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking results for selected dual kinase/BRD ligands for which a crystal structure inside BRD4 is not available. As explained in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, BRD4 is colored according to the inhibitor binding type. BRD4 bound to type PZA/ZA inhibitors is colored dark blue, whereas BRD4 bound to type I inhibitors is colored dark yellow. This choice has been made to underline the three different binding types that kinase inhibitors adopt inside BRDs. The compounds are overlapped to the reference crystal structure. Compound <b>13</b> is represented as blue sticks (A–D). Compound <b>15</b> is shown in orange (E, F). Compounds <b>23</b> (A), <b>18</b> (B), <b>24</b> (C), <b>25</b> (D), <b>28</b> (E), <b>21</b> (F), and <b>22</b> (F) are shown in cyan, brown, pink, magenta, light brown, light cyan, and salmon, respectively. Water molecules are displayed as ball and sticks, and nonpolar hydrogen atoms are omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-20/acs.jmedchem.6b00438/20161021/images/large/jm-2016-00438m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00438&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 124 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>The Web site of the National Cancer Institute. <a href="http://www.cancer.gov" class="extLink">http://www.cancer.gov</a> (accessed December 22,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Web+site+of+the+National+Cancer+Institute.+http%3A%2F%2Fwww.cancer.gov+%28accessed+December+22%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Protein Kinases--the Major Drug Targets of the Twenty-First Century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+Kinases%2D%2Dthe+Major+Drug+Targets+of+the+Twenty-First+Century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lhV3vE-0gM6Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520Kinases--the%2520Major%2520Drug%2520Targets%2520of%2520the%2520Twenty-First%2520Century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kostich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laz, T. M.</span><span> </span><span class="NLM_article-title">Human Members of the Eukaryotic Protein Kinase Family</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">research0043.1</span><span class="refDoi"> DOI: 10.1186/gb-2002-3-9-research0043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1186%2Fgb-2002-3-9-research0043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=research0043.1&author=M.+Kostichauthor=J.+Englishauthor=V.+Madisonauthor=F.+Gheyasauthor=L.+Wangauthor=P.+Qiuauthor=J.+Greeneauthor=T.+M.+Laz&title=Human+Members+of+the+Eukaryotic+Protein+Kinase+Family&doi=10.1186%2Fgb-2002-3-9-research0043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fgb-2002-3-9-research0043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2002-3-9-research0043%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DM.%26aulast%3DEnglish%26aufirst%3DJ.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DP.%26aulast%3DGreene%26aufirst%3DJ.%26aulast%3DLaz%26aufirst%3DT.%2BM.%26atitle%3DHuman%2520Members%2520of%2520the%2520Eukaryotic%2520Protein%2520Kinase%2520Family%26jtitle%3DGenome%2520Biol.%26date%3D2002%26volume%3D3%26spage%3Dresearch0043.1%26doi%3D10.1186%2Fgb-2002-3-9-research0043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ubersax, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrell, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">Mechanisms of Specificity in Protein Phosphorylation</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1038/nrm2203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrm2203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17585314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVaktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=530-541&author=J.+A.+Ubersaxauthor=J.+E.+Ferrell&title=Mechanisms+of+Specificity+in+Protein+Phosphorylation&doi=10.1038%2Fnrm2203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of specificity in protein phosphorylation</span></div><div class="casAuthors">Ubersax, Jeffrey A.; Ferrell, James E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">530-541</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A typical protein kinase must recognize between one and a few hundred bona fide phosphorylation sites in a background of ∼700,000 potentially phosphorylatable residues.  Multiple mechanisms have evolved that contribute to this exquisite specificity, including the structure of the catalytic site, local and distal interactions between the kinase and substrate, the formation of complexes with scaffolding and adaptor proteins that spatially regulate the kinase, systems-level competition between substrates, and error-correction mechanisms.  The responsibility for the recognition of substrates by protein kinases appears to be distributed among a large no. of independent, imperfect specificity mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8JmAzBNpuDbVg90H21EOLACvtfcHk0lhV3vE-0gM6Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVaktbw%253D&md5=02ec2d12c8470113daee83923b4f4626</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2203%26sid%3Dliteratum%253Aachs%26aulast%3DUbersax%26aufirst%3DJ.%2BA.%26aulast%3DFerrell%26aufirst%3DJ.%2BE.%26atitle%3DMechanisms%2520of%2520Specificity%2520in%2520Protein%2520Phosphorylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D530%26epage%3D541%26doi%3D10.1038%2Fnrm2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Engh, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossemeyer, D.</span><span> </span><span class="NLM_article-title">The Protein Kinase Activity Modulation Sites: Mechanism for Cellular Regulation - Targets for Therapeutic Intervention</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1016/S0065-2571(00)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0065-2571%2800%2900010-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=121-149&author=R.+A.+Enghauthor=D.+Bossemeyer&title=The+Protein+Kinase+Activity+Modulation+Sites%3A+Mechanism+for+Cellular+Regulation+-+Targets+for+Therapeutic+Intervention&doi=10.1016%2FS0065-2571%2800%2900010-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-2571%2800%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2571%252800%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DBossemeyer%26aufirst%3DD.%26atitle%3DThe%2520Protein%2520Kinase%2520Activity%2520Modulation%2520Sites%253A%2520Mechanism%2520for%2520Cellular%2520Regulation%2520-%2520Targets%2520for%2520Therapeutic%2520Intervention%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2001%26volume%3D41%26spage%3D121%26epage%3D149%26doi%3D10.1016%2FS0065-2571%2800%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Stenberg, K. a E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riikonen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span> </span><span class="NLM_article-title">KinMutBase, a Database of Human Disease-Causing Protein Kinase Mutations</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1093/nar/27.1.362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1093%2Fnar%2F27.1.362" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=362-364&author=K.+a+E.+Stenbergauthor=P.+T.+Riikonenauthor=M.+Vihinen&title=KinMutBase%2C+a+Database+of+Human+Disease-Causing+Protein+Kinase+Mutations&doi=10.1093%2Fnar%2F27.1.362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F27.1.362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F27.1.362%26sid%3Dliteratum%253Aachs%26aulast%3DStenberg%26aufirst%3DK.%2Ba%2BE.%26aulast%3DRiikonen%26aufirst%3DP.%2BT.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DKinMutBase%252C%2520a%2520Database%2520of%2520Human%2520Disease-Causing%2520Protein%2520Kinase%2520Mutations%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1999%26volume%3D27%26spage%3D362%26epage%3D364%26doi%3D10.1093%2Fnar%2F27.1.362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">kuriyan, J.</span><span> </span><span class="NLM_article-title">The Conformational Plasticity of Protein Kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1016/S0092-8674(02)00741-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&author=M.+Huseauthor=J.+kuriyan&title=The+Conformational+Plasticity+of+Protein+Kinases&doi=10.1016%2FS0092-8674%2802%2900741-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0lgeVpxTqMrbjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3Dkuriyan%26aufirst%3DJ.%26atitle%3DThe%2520Conformational%2520Plasticity%2520of%2520Protein%2520Kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D275%26epage%3D282%26doi%3D10.1016%2FS0092-8674%2802%2900741-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Engh, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossemeyer, D.</span><span> </span><span class="NLM_article-title">Structural Aspects of Protein Kinase Control-Role of Conformational Flexibility</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/S0163-7258(02)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0163-7258%2802%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12191603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=99-111&author=R.+A.+Enghauthor=D.+Bossemeyer&title=Structural+Aspects+of+Protein+Kinase+Control-Role+of+Conformational+Flexibility&doi=10.1016%2FS0163-7258%2802%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Structural aspects of protein kinase control - role of conformational flexibility</span></div><div class="casAuthors">Engh, Richard A.; Bossemeyer, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 69 refs.  Protein kinases catalyze the phosphotransfer reaction fundamental to most signaling and regulatory processes in the eukaryotic cell.  Abs. control of individual protein kinase activity is, therefore, of utmost importance to signaling fidelity in the cell.  Mechanisms for activity modulation, including complete and reversible inactivation, have been shown by crystal structures of many active and inactive protein kinases.  The structures of inactivated kinases, compared with those of active and catalytically competent kinases, such as the protein kinase A catalytic subunit, highlight recurring structural alterations among a set of elements of the catalytic kinase core.  These 'activity modulation sites' apparently comprise the principal evolved mechanisms for control of enzyme activity in the catalytic domain.  In combination, they enable diverse physiol. regulatory mechanisms operative for most protein kinases.  Identification and characterization of these sites should impact strategies for discovery and design of target-specific therapeutic drugs as the range of structural variations for specific kinases becomes known.  The principal site, the ATP-binding pocket, is the target of many physiol. regulators and also most exptl. or therapeutic inhibitors, which typically block it in a competitive or allosteric fashion.  Co-crystn. studies with protein kinase A and other kinases have revealed binding features of several classes of protein kinase inhibitors.  Ligand-induced structural changes are common and tend to optimize buried surface areas.  The ability to optimize binding energies arising from the hydrophobic effect creates a logarithmic dependence of binding energy on buried surface areas.  Exceptions to this rule arise for specific inhibitor classes, and possibly also as artifacts of structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR98vkrXdrorVg90H21EOLACvtfcHk0lgeVpxTqMrbjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShtb0%253D&md5=2dfe832a0577381146b4a177e3d313a4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DBossemeyer%26aufirst%3DD.%26atitle%3DStructural%2520Aspects%2520of%2520Protein%2520Kinase%2520Control-Role%2520of%2520Conformational%2520Flexibility%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D99%26epage%3D111%26doi%3D10.1016%2FS0163-7258%2802%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tückmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the World of Proteins: Conformational Changes in Protein Kinases</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+T%C3%BCckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+World+of+Proteins%3A+Conformational+Changes+in+Protein+Kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0lgeVpxTqMrbjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DT%25C3%25BCckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520World%2520of%2520Proteins%253A%2520Conformational%2520Changes%2520in%2520Protein%2520Kinases%26jtitle%3DArch.%2520Pharm.%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0ljRgZgCvOFfSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through The “gatekeeper Door”: Exploiting the Active Kinase Conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+The+%E2%80%9Cgatekeeper+Door%E2%80%9D%3A+Exploiting+the+Active+Kinase+Conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation</span></div><div class="casAuthors">Zuccotto, Fabio; Ardini, Elena; Casale, Elena; Angiolini, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2681-2694</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of new kinase inhibitors is still a slow and problematic process.  Generally, type I compds. suffer from widespread cross-reactivity among other members of the kinase target family, and intense medicinal chem. optimization programs are required to modulate their activity.  Also, fierce competition in the development of scaffolds that could mimic ATP has led to a crowded intellectual property space.  The new opportunities opened by the type II compds. created great expectations, as targeting the allosteric site of the ATP pocket offered addnl. opportunities to control selectivity and introduce intellectual property novelty.  However, clin. evaluation of these compds. has highlighted how the acquisition of resistance-causing mutations of the kinase target limits their efficacy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd_iA7sWS-g7Vg90H21EOLACvtfcHk0ljRgZgCvOFfSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K&md5=5c6acd058bacfec89b1eff2090f0fe67</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520The%2520%25E2%2580%259Cgatekeeper%2520Door%25E2%2580%259D%253A%2520Exploiting%2520the%2520Active%2520Kinase%2520Conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1021/cb300663j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300663j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=58-70&author=Z.+Fangauthor=C.+Gr%C3%BCtterauthor=D.+Rauh&title=Strategies+for+the+Selective+Regulation+of+Kinases+with+Allosteric+Modulators%3A+Exploiting+Exclusive+Structural+Features&doi=10.1021%2Fcb300663j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span></div><div class="casAuthors">Fang, Zhizhou; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modulation of kinase function has become an important goal in modern drug discovery and chem. biol. research.  In cancer-targeted therapies, kinase inhibitors have been experiencing an upsurge, which can be measured by the increasing no. of kinase inhibitors approved by the FDA in recent years.  However, lack of efficacy, limited selectivity, and the emergence of acquired drug resistance still represent major bottlenecks in the clinic and challenge inhibitor development.  Most known kinase inhibitors target the active kinase and are ATP competitive.  A second class of small org. mols., which address remote sites of the kinase and stabilize enzymically inactive conformations, is rapidly moving to the forefront of kinase inhibitor research.  Such allosteric modulators bind to sites that are less conserved across the kinome and only accessible upon conformational changes.  These mols. are therefore thought to provide various advantages such as higher selectivity and extended drug target residence times.  This review highlights various strategies that have been developed to utilizing exclusive structural features of kinases and thereby modulating their activity allosterically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjxxztmczXrVg90H21EOLACvtfcHk0ljRgZgCvOFfSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN&md5=50864096bf66229ff74482a9b56847d6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcb300663j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300663j%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStrategies%2520for%2520the%2520Selective%2520Regulation%2520of%2520Kinases%2520with%2520Allosteric%2520Modulators%253A%2520Exploiting%2520Exclusive%2520Structural%2520Features%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D58%26epage%3D70%26doi%3D10.1021%2Fcb300663j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+Approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljRgZgCvOFfSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520Approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Alexander, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möbitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deane, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Type II Inhibitors Targeting CDK2</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2116</span><span class="NLM_x">–</span> <span class="NLM_lpage">2125</span><span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+M%C3%B6bitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+Inhibitors+Targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0liFwE66tm0vgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DM%25C3%25B6bitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520Inhibitors%2520Targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Palmieri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">αC Helix Displacement As a General Approach for Allosteric Modulation of Protein Kinases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.drudis.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23195331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=407-414&author=L.+Palmieriauthor=G.+Rastelli&title=%CE%B1C+Helix+Displacement+As+a+General+Approach+for+Allosteric+Modulation+of+Protein+Kinases&doi=10.1016%2Fj.drudis.2012.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">αC helix displacement as a general approach for allosteric modulation of protein kinases</span></div><div class="casAuthors">Palmieri, Lorenzo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Owing to their crucial role in the modulation of cell pathways, protein kinases are important targets for several human diseases, including but not limited to cancer.  The classic approach of targeting the ATP active site has recently come up against selectivity issues, which can be considerably reduced by following an allosteric modulation approach.  Being closely related to protein kinase inactivation, allosteric targeting via displacement of the conserved structural αC helix enables a direct and specific modulation mechanism.  A structure-based survey of the allosteric regulation of αC helix conformation in various kinase families is provided, highlighting key allosteric pockets and modulation mechanisms that appear to be more broadly conserved than was previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEv57xKCTibVg90H21EOLACvtfcHk0liFwE66tm0vgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE&md5=f2380fd543155c49602ca99b0c333ffe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3D%25CE%25B1C%2520Helix%2520Displacement%2520As%2520a%2520General%2520Approach%2520for%2520Allosteric%2520Modulation%2520of%2520Protein%2520Kinases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D407%26epage%3D414%26doi%3D10.1016%2Fj.drudis.2012.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Lamba, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, I.</span><span> </span><span class="NLM_article-title">New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2936</span><span class="NLM_x">–</span> <span class="NLM_lpage">2945</span><span class="refDoi"> DOI: 10.2174/138161212800672813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.2174%2F138161212800672813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22571662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2936-2945&author=V.+Lambaauthor=I.+Ghosh&title=New+Directions+in+Targeting+Protein+Kinases%3A+Focusing+Upon+True+Allosteric+and+Bivalent+Inhibitors&doi=10.2174%2F138161212800672813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors</span></div><div class="casAuthors">Lamba, Vandana; Ghosh, Indraneel</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2936-2945</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer.  Protein kinases are typically targeted at the ATP-binding cleft by type I and II inhibitors; however, the high sequence and structural homol. shared by protein kinases, esp. at the ATP-binding site, inherently leads to polypharmacol.  In order to discover or design truly selective protein kinase inhibitors as both pharmacol. reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft.  Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate-binding pocket.  These new classes of inhibitors are often selective, but usually display moderate affinities.  Here, the authors discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes.  These inhibitors have the potential to couple the high affinity and potency of traditional active site-targeted small-mol. inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkIIgeMxhCrrVg90H21EOLACvtfcHk0liFwE66tm0vgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrk%253D&md5=36a44e36709507b5053bfdfe7d09e5e9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F138161212800672813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672813%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DV.%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DNew%2520Directions%2520in%2520Targeting%2520Protein%2520Kinases%253A%2520Focusing%2520Upon%2520True%2520Allosteric%2520and%2520Bivalent%2520Inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2936%26epage%3D2945%26doi%3D10.2174%2F138161212800672813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span> </span><span class="NLM_article-title">Allosteric Small-Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0liCZnSDqgUq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chripkova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrassa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broggini, M.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of the First Allosteric Inhibitors of Cyclin-Dependent Kinase 2</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2305</span><span class="refDoi"> DOI: 10.4161/cc.29295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.4161%2Fcc.29295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24911186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2296-2305&author=G.+Rastelliauthor=A.+Anighoroauthor=M.+Chripkovaauthor=L.+Carrassaauthor=M.+Broggini&title=Structure-Based+Discovery+of+the+First+Allosteric+Inhibitors+of+Cyclin-Dependent+Kinase+2&doi=10.4161%2Fcc.29295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2</span></div><div class="casAuthors">Rastelli, Giulio; Anighoro, Andrew; Chripkova, Martina; Carrassa, Laura; Broggini, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2296-2305</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is currently gaining a foothold in drug discovery.  Recently, the first crystal structure of CDK2 with an open allosteric pocket adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the structure has not yet been exploited for the structure-based design of type III allosteric inhibitors.  In this work we report the results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2.  Using a combination of docking and post-docking analyses made with our tool BEAR, 7 allosteric ligands (hit rate of 20%) with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the micromolar range.  Competition expts. performed in the presence of the ATP-competitive inhibitor staurosporine confirmed that the 7 ligands are truly allosteric, in agreement with their design.  Of these, compd. 2 bound CDK2 with an EC50 value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75-1 breast cancer cells with IC50 values of approx. 20 μM, while compd. 4 had an EC50 value of 71 μM and IC50 values around 4 μM.  Remarkably, the most potent compd. 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells.  Finally, hit expansion through analog search of the most potent inhibitor 4 revealed an addnl. ligand 4g with similar in vitro potency on breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGYE_h0shsbVg90H21EOLACvtfcHk0liCZnSDqgUq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF&md5=e790fc2920b61e6b85b5097a49cbc7bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4161%2Fcc.29295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29295%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DChripkova%26aufirst%3DM.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DBroggini%26aufirst%3DM.%26atitle%3DStructure-Based%2520Discovery%2520of%2520the%2520First%2520Allosteric%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25202%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2296%26epage%3D2305%26doi%3D10.4161%2Fcc.29295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0liCZnSDqgUq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+Kinase+Domain+Mutations+Confer+Polyclonal+Resistance+to+the+Tyrosine+Kinase+Inhibitor+Imatinib+%28STI571%29+in+Chronic+Phase+and+Blast+Crisis+Chronic+Myeloid+Leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0lii2PD8w4nydw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520Kinase%2520Domain%2520Mutations%2520Confer%2520Polyclonal%2520Resistance%2520to%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Imatinib%2520%2528STI571%2529%2520in%2520Chronic%2520Phase%2520and%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+Amplification+Leads+to+Gefitinib+Resistance+in+Lung+Cancer+by+Activating+ERBB3+Signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lii2PD8w4nydw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520Amplification%2520Leads%2520to%2520Gefitinib%2520Resistance%2520in%2520Lung%2520Cancer%2520by%2520Activating%2520ERBB3%2520Signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-Family Tyrosine Kinase Inhibitor Therapy by the Kinase-Inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1038/nature05474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature05474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17206155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos12msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-Family+Tyrosine+Kinase+Inhibitor+Therapy+by+the+Kinase-Inactive+HER3&doi=10.1038%2Fnature05474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span></div><div class="casAuthors">Sergina, Natalia V.; Rausch, Megan; Wang, Donghui; Blair, Jimmy; Hann, Byron; Shokat, Kevan M.; Moasser, Mark M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7126</span>),
    <span class="NLM_cas:pages">437-441</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs.  However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo.  The reasons for this are unclear.  Signaling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10).  Here we show that HER3 and consequently PI(3)K/Akt signaling evade inhibition by current HER-family TKIs in vitro and in tumors in vivo.  This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equil., driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction.  These compensatory changes are driven by Akt-mediated neg.-feedback signaling.  Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected.  The exptl. abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumors and the therapeutic promise of this oncoprotein target.  However, because HER3 signaling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signaling effectively.  The biol. marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAgt3f0FqFvbVg90H21EOLACvtfcHk0lii2PD8w4nydw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos12msA%253D%253D&md5=5a060fb2afd7a7308ce3399d8e57f14b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature05474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05474%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-Family%2520Tyrosine%2520Kinase%2520Inhibitor%2520Therapy%2520by%2520the%2520Kinase-Inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441%26doi%3D10.1038%2Fnature05474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zahreddine, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, K. L. B.</span><span> </span><span class="NLM_article-title">Mechanism and Insights into Drug Resistance in Cancer</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3389/fphar.2013.00028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.3389%2Ffphar.2013.00028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23346057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12itbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-8&author=H.+Zahreddineauthor=K.+L.+B.+Borden&title=Mechanism+and+Insights+into+Drug+Resistance+in+Cancer&doi=10.3389%2Ffphar.2013.00028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and insights into drug resistance in cancer</span></div><div class="casAuthors">Zahreddine, Hiba; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance continues to be a major impediment in medical oncol.  Clin., resistance can arise prior to or as a result of cancer therapy.  In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metab., mutation and amplification of drug targets, as well as genetic rewiring which can lead to impaired apoptosis.  Tumor heterogeneity may also contribute to resistance, where small subpopulations of cells may acquire or stochastically already possess some of the features enabling them to emerge under selective drug pressure.  Making the problem even more challenging, some of these resistance pathways lead to multidrug resistance, generating an even more difficult clin. problem to overcome.  We provide examples of these mechanisms and some insights into how understanding these processes can influence the next generation of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJPvNuYanq7Vg90H21EOLACvtfcHk0lgVeHVCyhrZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12itbrL&md5=c616c14c9e4bf015658e396dc527ac67</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00028%26sid%3Dliteratum%253Aachs%26aulast%3DZahreddine%26aufirst%3DH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DMechanism%2520and%2520Insights%2520into%2520Drug%2520Resistance%2520in%2520Cancer%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D8%26doi%3D10.3389%2Ffphar.2013.00028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Shu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witwicki, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabassum, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janiszewska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekram, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peluffo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Santos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">Response and Resistance to BET Bromodomain Inhibitors in Triple-Negative Breast Cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">529</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1038/nature16508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature16508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26735014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=413-417&author=S.+Shuauthor=C.+Y.+Linauthor=H.+H.+Heauthor=R.+M.+Witwickiauthor=D.+P.+Tabassumauthor=J.+M.+Robertsauthor=M.+Janiszewskaauthor=S.+J.+Huhauthor=Y.+Liangauthor=J.+Ryanauthor=E.+Dohertyauthor=H.+Mohammedauthor=H.+Guoauthor=D.+G.+Stoverauthor=M.+B.+Ekramauthor=G.+Peluffoauthor=J.+Brownauthor=C.+D%E2%80%99Santosauthor=I.+E.+Kropauthor=D.+Dillonauthor=M.+McKeownauthor=C.+Ottauthor=J.+Qiauthor=M.+Niauthor=P.+K.+Raoauthor=M.+Duarteauthor=S.+Y.+Wuauthor=C.+M.+Chiangauthor=L.+Andersauthor=R.+A.+Youngauthor=E.+P.+Winerauthor=A.+Letaiauthor=W.+T.+Barryauthor=J.+S.+Carrollauthor=H.+W.+Longauthor=M.+Brownauthor=X.+S.+Liuauthor=C.+A.+Meyerauthor=J.+E.+Bradnerauthor=K.+Polyak&title=Response+and+Resistance+to+BET+Bromodomain+Inhibitors+in+Triple-Negative+Breast+Cancer&doi=10.1038%2Fnature16508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Liang, Yi; Ryan, Jeremy; Doherty, Ernest; Mohammed, Hisham; Guo, Hao; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; D'Santos, Clive; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Rao, Prakash K.; Duarte, Melissa; Wu, Shwu-Yuan; Chiang, Cheng-Ming; Anders, Lars; Young, Richard A.; Winer, Eric P.; Letai, Antony; Barry, William T.; Carroll, Jason S.; Long, Henry W.; Brown, Myles; Shirley Liu, X.; Meyer, Clifford A.; Bradner, James E.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous and clin. aggressive disease for which there is no targeted therapy.  BET bromodomain inhibitors, which have shown efficacy in several models of cancer, have not been evaluated in TNBC.  These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs.  Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clin. investigation and further motivation to understand mechanisms of resistance.  In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation.  BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner.  Proteomic studies of resistant TNBC identify strong assocn. with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase.  Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clin. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5A85pdQDbVg90H21EOLACvtfcHk0lgVeHVCyhrZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D&md5=50a03861d9156ee6e344e95c5f5361b9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature16508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16508%26sid%3Dliteratum%253Aachs%26aulast%3DShu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DWitwicki%26aufirst%3DR.%2BM.%26aulast%3DTabassum%26aufirst%3DD.%2BP.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DEkram%26aufirst%3DM.%2BB.%26aulast%3DPeluffo%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DDillon%26aufirst%3DD.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DDuarte%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26aulast%3DAnders%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLong%26aufirst%3DH.%2BW.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DMeyer%26aufirst%3DC.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DResponse%2520and%2520Resistance%2520to%2520BET%2520Bromodomain%2520Inhibitors%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D413%26epage%3D417%26doi%3D10.1038%2Fnature16508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, E. Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ftouni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giotopoulos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. CW.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Wahab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papenfuss, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M. A.</span><span> </span><span class="NLM_article-title">BET Inhibitor Resistance Emerges From Leukaemia Stem Cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nature14888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature14888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2015&pages=538-542&author=C.+Y.+Fongauthor=O.+Gilanauthor=E.+Y.+N.+Lamauthor=A.+F.+Rubinauthor=S.+Ftouniauthor=D.+Tylerauthor=K.+Stanleyauthor=D.+Sinhaauthor=P.+Yehauthor=J.+Morisonauthor=G.+Giotopoulosauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+CW.+Leeauthor=C.+Carpenterauthor=R.+Gregoryauthor=R.+G.+Ramsayauthor=S.+W.+Laneauthor=O.+Abdel-Wahabauthor=T.+Kouzaridesauthor=R.+W.+Johnstoneauthor=S.+J.+Dawsonauthor=B.+J.+P.+Huntlyauthor=R.+K.+Prinjhaauthor=A.+T.+Papenfussauthor=M.+A.+Dawson&title=BET+Inhibitor+Resistance+Emerges+From+Leukaemia+Stem+Cells&doi=10.1038%2Fnature14888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibitor resistance emerges from leukaemia stem cells</span></div><div class="casAuthors">Fong, Chun Yew; Gilan, Omer; Lam, Enid Y. N.; Rubin, Alan F.; Ftouni, Sarah; Tyler, Dean; Stanley, Kym; Sinha, Devbarna; Yeh, Paul; Morison, Jessica; Giotopoulos, George; Lugo, Dave; Jeffrey, Philip; Lee, Stanley Chun-Wei; Carpenter, Christopher; Gregory, Richard; Ramsay, Robert G.; Lane, Steven W.; Abdel-Wahab, Omar; Kouzarides, Tony; Johnstone, Ricky W.; Dawson, Sarah-Jane; Huntly, Brian J. P.; Prinjha, Rab K.; Papenfuss, Anthony T.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">7570</span>),
    <span class="NLM_cas:pages">538-542</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks.  Early clin. trials have shown promise, esp. in acute myeloid leukemia, and therefore the evaluation of resistance mechanisms is crucial to optimize the clin. efficacy of these drugs.  Here we use primary mouse hematopoietic stem and progenitor cells immortalized with the fusion protein MLL-AF9 to generate several single-cell clones that demonstrate resistance, in vitro and in vivo, to the prototypical BET inhibitor, I-BET.  Resistance to I-BET confers cross-resistance to chem. distinct BET inhibitors such as JQ1, as well as resistance to genetic knockdown of BET proteins.  Resistance is not mediated through increased drug efflux or metab., but is shown to emerge from leukemia stem cells both ex vivo and in vivo.  Chromatin-bound BRD4 is globally reduced in resistant cells, whereas the expression of key target genes such as Myc remains unaltered, highlighting the existence of alternative mechanisms to regulate transcription.  We demonstrate that resistance to BET inhibitors, in human and mouse leukemia cells, is in part a consequence of increased Wnt/β-catenin signaling, and neg. regulation of this pathway results in restoration of sensitivity to I-BET in vitro and in vivo.  Together, these findings provide new insights into the biol. of acute myeloid leukemia, highlight potential therapeutic limitations of BET inhibitors, and identify strategies that may enhance the clin. utility of these unique targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Lg1n64SCWrVg90H21EOLACvtfcHk0lgVeHVCyhrZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fL&md5=47d1769e077b1c6c92ff52a051368404</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14888%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DC.%2BY.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DRubin%26aufirst%3DA.%2BF.%26aulast%3DFtouni%26aufirst%3DS.%26aulast%3DTyler%26aufirst%3DD.%26aulast%3DStanley%26aufirst%3DK.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DYeh%26aufirst%3DP.%26aulast%3DMorison%26aufirst%3DJ.%26aulast%3DGiotopoulos%26aufirst%3DG.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DS.%2BCW.%26aulast%3DCarpenter%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DR.%26aulast%3DRamsay%26aufirst%3DR.%2BG.%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DDawson%26aufirst%3DS.%2BJ.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DPapenfuss%26aufirst%3DA.%2BT.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DBET%2520Inhibitor%2520Resistance%2520Emerges%2520From%2520Leukaemia%2520Stem%2520Cells%26jtitle%3DNature%26date%3D2015%26volume%3D525%26spage%3D538%26epage%3D542%26doi%3D10.1038%2Fnature14888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Rathert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerdter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deswal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny-Reiterer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jude, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boryn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweifer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakoc, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuber, J.</span><span> </span><span class="NLM_article-title">Transcriptional Plasticity Promotes Primary and Acquired Resistance to BET Inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">525</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1038/nature14898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature14898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26367798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=525&publication_year=2015&pages=543-547&author=P.+Rathertauthor=M.+Rothauthor=T.+Neumannauthor=F.+Muerdterauthor=J.+S.+Roeauthor=M.+Muharauthor=S.+Deswalauthor=S.+Cerny-Reitererauthor=B.+Peterauthor=J.+Judeauthor=T.+Hoffmannauthor=L.+M.+Borynauthor=E.+Axelssonauthor=N.+Schweiferauthor=U.+Tontsch-Gruntauthor=L.+E.+Dowauthor=D.+Gianniauthor=M.+Pearsonauthor=P.+Valentauthor=A.+Starkauthor=N.+Krautauthor=C.+R.+Vakocauthor=J.+Zuber&title=Transcriptional+Plasticity+Promotes+Primary+and+Acquired+Resistance+to+BET+Inhibition&doi=10.1038%2Fnature14898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional plasticity promotes primary and acquired resistance to BET inhibition</span></div><div class="casAuthors">Rathert, Philipp; Roth, Mareike; Neumann, Tobias; Muerdter, Felix; Roe, Jae-Seok; Muhar, Matthias; Deswal, Sumit; Cerny-Reiterer, Sabine; Peter, Barbara; Jude, Julian; Hoffmann, Thomas; Boryn, Lukasz M.; Axelsson, Elin; Schweifer, Norbert; Tontsch-Grunt, Ulrike; Dow, Lukas E.; Gianni, Davide; Pearson, Mark; Valent, Peter; Stark, Alexander; Kraut, Norbert; Vakoc, Christopher R.; Zuber, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">525</span>
        (<span class="NLM_cas:issue">7570</span>),
    <span class="NLM_cas:pages">543-547</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid leukemia (AML), bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue in numerous cancers.  While clin. trials have reported single-agent activity in advanced hematol. malignancies, mechanisms detg. the response to BET inhibition remain poorly understood.  To identify factors involved in primary and acquired BET resistance in leukemia, here we perform a chromatin-focused RNAi screen in a sensitive MLL-AF9;NrasG12D-driven AML mouse model, and investigate dynamic transcriptional profiles in sensitive and resistant mouse and human leukemias.  Our screen shows that suppression of the PRC2 complex, contrary to effects in other contexts, promotes BET inhibitor resistance in AML.  PRC2 suppression does not directly affect the regulation of Brd4-dependent transcripts, but facilitates the remodelling of regulatory pathways that restore the transcription of key targets such as Myc.  Similarly, while BET inhibition triggers acute MYC repression in human leukemias regardless of their sensitivity, resistant leukemias are uniformly characterized by their ability to rapidly restore MYC transcription.  This process involves the activation and recruitment of WNT signaling components, which compensate for the loss of BRD4 and drive resistance in various cancer models.  Dynamic chromatin immunopptn. sequencing and self-transcribing active regulatory region sequencing of enhancer profiles reveal that BET-resistant states are characterized by remodelled regulatory landscapes, involving the activation of a focal MYC enhancer that recruits WNT machinery in response to BET inhibition.  Together, our results identify and validate WNT signaling as a driver and candidate biomarker of primary and acquired BET resistance in leukemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgeY3nFr4GrVg90H21EOLACvtfcHk0lhKvSuwygAacA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeiu7fO&md5=6d6cf4c4123ad6a698b88f02f95a2ebe</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature14898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14898%26sid%3Dliteratum%253Aachs%26aulast%3DRathert%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DNeumann%26aufirst%3DT.%26aulast%3DMuerdter%26aufirst%3DF.%26aulast%3DRoe%26aufirst%3DJ.%2BS.%26aulast%3DMuhar%26aufirst%3DM.%26aulast%3DDeswal%26aufirst%3DS.%26aulast%3DCerny-Reiterer%26aufirst%3DS.%26aulast%3DPeter%26aufirst%3DB.%26aulast%3DJude%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DBoryn%26aufirst%3DL.%2BM.%26aulast%3DAxelsson%26aufirst%3DE.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DDow%26aufirst%3DL.%2BE.%26aulast%3DGianni%26aufirst%3DD.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DZuber%26aufirst%3DJ.%26atitle%3DTranscriptional%2520Plasticity%2520Promotes%2520Primary%2520and%2520Acquired%2520Resistance%2520to%2520BET%2520Inhibition%26jtitle%3DNature%26date%3D2015%26volume%3D525%26spage%3D543%26epage%3D547%26doi%3D10.1038%2Fnature14898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhKvSuwygAacA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhKvSuwygAacA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lhVCHP8ONhRwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span><span class="refDoi"> DOI: 10.1021/jm901132v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901132v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1413-1437&author=R.+Morphy&title=Selectively+Nonselective+Kinase+Inhibition%3A+Striking+the+Right+Balance&doi=10.1021%2Fjm901132v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1413-1437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Marketed kinase inhibitors (MKIs) can deliver superior efficacy compared to inhibitors with high specificity for a single kinase, and the recent introduction of several MKIs to the market opens the door to a new era of safer and effective anticancer therapy.  The key to combining high efficacy with acceptable safety is to inhibit multiple targets in a selectively nonselective fashion.  Strategies for intentionally designing MKIs are emerging, but the field is still in its infancy and we are as medicinal chemists currently on the steepest part of the learning curve.  MTDD can be time-consuming and expensive, and we need to become more proficient first at identifying disease-relevant target combinations and second at discovering MKIs that combine optimal physicochem. and biol. properties.  Bold and innovative medicinal chem. strategies are required to tackle "difficult combinations" where the disease rationale is compelling but where it is a struggle to combine all the desired attributes of an oral MKI drug into a single mol.  At present it is unclear to what extent MKIs with highly tuned selectivity profiles can be rationally designed, particularly for targets that are unrelated by sequence.  In addn. to the well-known selectivity challenge, the physicochem. property profiles of AT P-competitive MKIs can be inherently challenging and limited scope for patentability can also be a serious hindrance.  On the plus side, the amt. of kinase-specific structural information is growing very rapidly, and ultimately this may reveal distinct features and design rules that enable a medicinal chemist to rationally modify and refine the profile of MKIs.  In addn., increasing SAR knowledge is emerging from large scale panel screening with the binding profiles starting to reveal to medicinal chemists how chem. structure affects cross-reactivity across large parts of the kinome.  The merit of MKIs compared with single kinase inhibitors is a subject of controversy in drug discovery that is unlikely to be resolved in the near future.  At the start of a new MTDD project, a rigorous debate needs to take place as to whether it makes more sense to seek a combination of highly selective agents or a DML.  Many factors need to be taken into account in this decision such as the no., similarity, and promiscuity of the targets in the profile and the disease area.  Conformational plasticity and the occurrence of multiple binding modes complicate the in silico prediction of kinase polypharmacol. based solely upon protein structure.  The use of ligand-based similarity to assess the feasibility of a given combination can add real value.  Currently, serendipity plays a significant role in MKI discovery and many, if not most, MKIs have been discovered by chance during the search for selective inhibitors.  Medicinal chemists need to be alert to the possibilities when a surprising combination is found by chance.  To exploit such serendipity, you need a good appreciation of when you have a sufficiently high quality starting compd. and then you need to be able to make and test sufficient analogs to explore your new disease-based hypothesis.  MKIs are costly to develop and are consequently priced at a premium level, so they will need to show clear improvements in order to get reimbursement.  There have already been problems with reimbursement for some MKIs in some markets due to concerns from funding bodies over insufficient efficacy.  The true value of MKIs relative to other anticancer drugs still has to be established, and the results from recent clin. trials have been mixed.  Despite the broad activity profile of many MKIs, the patient response can be inconsistent and unpredictable.  The identification of predictive biomarkers of response or resistance is a crit. step to ascertain which specific combination of targets produces a significant clin. benefit with respect to specific tumor types.  More clin. feedback is needed to facilitate the design of the next generation of inhibitors with more precisely defined profiles.  Although it might seem immeasurably distant at the present time, the ultimate goal should be to derive the prerequisite knowledge and tools so that MTDD becomes a rational endeavor rather than a black box approach that relies upon serendipity.  This will help banish claims that MKIs are merely dirty, nonspecific drugs with insufficient specificity for treating a wider range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-L-NWmtdikbVg90H21EOLACvtfcHk0lhVCHP8ONhRwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF&md5=3c915b5debf9d005993c8ad31c68bc2e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901132v%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelectively%2520Nonselective%2520Kinase%2520Inhibition%253A%2520Striking%2520the%2520Right%2520Balance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1413%26epage%3D1437%26doi%3D10.1021%2Fjm901132v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1182/blood-2004-08-3097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1182%2Fblood-2004-08-3097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15618470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2640-2653&author=M.+Deiningerauthor=E.+Buchdungerauthor=B.+J.+Druker&title=The+Development+of+Imatinib+as+a+Therapeutic+Agent+for+Chronic+Myeloid+Leukemia&doi=10.1182%2Fblood-2004-08-3097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span></div><div class="casAuthors">Deininger, Michael; Buchdunger, Elisabeth; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2640-2653</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML).  Preclin. studies were promising but the results of clin. trials by far exceeded expectations.  Responses in chronic phase are unprecedented, with rates of complete cytogenetic response (CCR) of more than 40% in patients after failure of interferon-α (IFN) and more than 80% in newly diagnosed patients, a level of efficacy that led to regulatory approval in record time.  While most of these responses are stable, resistance to treatment after an initial response is common in more advanced phases of the disease.  Mutations in the kinase domain (KD) of BCR-ABL that impair imatinib binding have been identified as the leading cause of resistance.  Patients with CCR who achieve a profound redn. of BCR-ABL mRNA have a very low risk of disease progression.  However, residual disease usually remains detectable with reverse transcription-polymerase chain reaction (RT-PCR), indicating that disease eradication may pose a significant challenge.  The mechanisms underlying the persistence of minimal residual disease are unknown.  In this manuscript, we review the preclin. and clin. development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRkeS0lKeTObVg90H21EOLACvtfcHk0lhVCHP8ONhRwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D&md5=894d4159f7a65f3ae5304249d6ba1e75</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-08-3097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-08-3097%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520Development%2520of%2520Imatinib%2520as%2520a%2520Therapeutic%2520Agent%2520for%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2640%26epage%3D2653%26doi%3D10.1182%2Fblood-2004-08-3097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Novel Selective-Spectrum Kinase Inhibitors in Oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span><span class="refDoi"> DOI: 10.1517/13543784.17.7.1013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1517%2F13543784.17.7.1013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&author=P.+M.+Lorussoauthor=J.+P.+Eder&title=Therapeutic+Potential+of+Novel+Selective-Spectrum+Kinase+Inhibitors+in+Oncology&doi=10.1517%2F13543784.17.7.1013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.7.1013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.7.1013%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520Potential%2520of%2520Novel%2520Selective-Spectrum%2520Kinase%2520Inhibitors%2520in%2520Oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D1028%26doi%3D10.1517%2F13543784.17.7.1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Steinberg, M.</span><span> </span><span class="NLM_article-title">Dasatinib: A Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia and Philadelphia Chromosome—Positive Acute Lymphoblastic Leukemia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2007.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.clinthera.2007.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18158072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=2289-2308&author=M.+Steinberg&title=Dasatinib%3A+A+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+Chronic+Myelogenous+Leukemia+and+Philadelphia+Chromosome%E2%80%94Positive+Acute+Lymphoblastic+Leukemia&doi=10.1016%2Fj.clinthera.2007.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia</span></div><div class="casAuthors">Steinberg, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2289-2308</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22.  The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathol. of chronic myelogenous leukemia (CML).  Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematol. and cytogenetic responses in affected individuals.  The oral TK inhibitor dasatinib was approved in 2006 for use in patients with CML or Philadelphia chromosome-pos. acute lymphoblastic leukemia (ALL) who are unable to tolerate or have not responded to other treatments.  Objective: This paper reviews the available data on dasatinib, including its pharmacokinetic and pharmacodynamic properties, findings of in vitro and in vivo studies, adverse effects, and potential place in therapy.  Methods: Pertinent information was identified through searches of MEDLINE (1966-May 2007), EMBASE (1980-first quarter 2007), and International Pharmaceutical Abstrs. (1970-May 2007) using the terms dasatinib, BMS-354825, chronic myelogenous leukemia, Sprycel, Philadelphia chromosome, and acute lymphoblastic leukemia.  All clin. studies and case reports published at the time of the search were included in this review.  Results: Obsd. mutations in the amino acid sequence of BCR-ABL cause the failure of treatment with existing TK inhibitors.  Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors.  Preliminary results are available from several noncomparative studies of dasatinib in patients who were unable to tolerate or were resistant to previous therapies.  The 5 phases of START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) represent the largest and most comprehensive evaluation of dasatinib in the treatment of patients in all stages of CML or Philadelphia chromosome-pos. ALL who had undergone previous treatment for leukemia.  Dasatanib had the greatest benefit in patients in the chronic phase of CML, with complete hematol. responses in 90% of patients, 52% of whom achieved a major hematol. response.  Compared with those in the chronic phase, patients in the accelerated phase or blast crisis of CML, or with Philadelphia chromosome-pos. ALL had lower responses.  In the START-R trial, which compared the response to dasatinib and high-dose imatinib (800 mg/d), both regimens had comparable ability to induce a complete hematol. response (95% and 93%, resp.), although more patients achieved a major cytogenetic response with dasatinib (32% vs 7%).  Adverse effects include significant myelosuppression.  Dasatinib may have the potential for use in the management of nonleukemic malignancies.  Conclusions: Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors.  It has shown clin. benefit and tolerability in patients in all phases of CML, as well as in those with Philadelphia chromosome-pos. ALL.  Dasatinib illustrates the potential for targeted drug development based on an understanding of the genetic alterations leading to CML and the development of resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8AoiiPuTJrVg90H21EOLACvtfcHk0ljJUy7wiV7iJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D&md5=1219cbf8c0a882317a19db3a2c9a4605</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2007.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2007.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DM.%26atitle%3DDasatinib%253A%2520A%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Myelogenous%2520Leukemia%2520and%2520Philadelphia%2520Chromosome%25E2%2580%2594Positive%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DClin.%2520Ther.%26date%3D2007%26volume%3D29%26spage%3D2289%26epage%3D2308%26doi%3D10.1016%2Fj.clinthera.2007.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Tang, P. C.; Todd A. Miller, T. A.; Li, X.; Sun, L.; Wei, C. C.; Shirazian, S.; Liang, C.; Vojkovsky, T.; Nematalla, A. S.; Hawley, M.</span><span> </span><span class="NLM_article-title">Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors</span>. U.S. Patent 6573293, February 15,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=P.+C.+Tang&author=T.+A.+Todd+A.+Miller&author=X.+Li&author=L.+Sun&author=C.+C.+Wei&author=S.+Shirazian&author=C.+Liang&author=T.+Vojkovsky&author=A.+S.+Nematalla&author=M.+Hawley&title=Pyrrole+Substituted+2-Indolinone+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DP.%2BC.%26atitle%3DPyrrole%2520Substituted%25202-Indolinone%2520Protein%2520Kinase%2520Inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-yl- amino)thiazole-5-carboxamide (BMS-354825), a Dual SRC/ABL Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span><span class="refDoi"> DOI: 10.1021/jm049486a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-yl-+amino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+Dual+SRC%2FABL+Kinase+Inhibitor+with+Potent+Antitumor+Activity+in+Preclinical+Assays&doi=10.1021%2Fjm049486a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-yl-%2520amino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520Dual%2520SRC%252FABL%2520Kinase%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Preclinical%2520Assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661%26doi%3D10.1021%2Fjm049486a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Tung, R.</span><span> </span><span class="NLM_article-title">Vandetanib Derivatives</span>. U.S. Patent 20110117084, January 22,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Tung&title=Vandetanib+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTung%26aufirst%3DR.%26atitle%3DVandetanib%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Z.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lj3kPrwqyRXZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%2BZ.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Stein, R. C.</span><span> </span><span class="NLM_article-title">Prospects for Phosphoinositide 3-Kinase Inhibition as a Cancer Treatment</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1677/erc.0.0080237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1677%2Ferc.0.0080237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=237-248&author=R.+C.+Stein&title=Prospects+for+Phosphoinositide+3-Kinase+Inhibition+as+a+Cancer+Treatment&doi=10.1677%2Ferc.0.0080237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080237%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%2BC.%26atitle%3DProspects%2520for%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520as%2520a%2520Cancer%2520Treatment%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26spage%3D237%26epage%3D248%26doi%3D10.1677%2Ferc.0.0080237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillermet-Guibert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graupera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilanges, B.</span><span> </span><span class="NLM_article-title">The Emerging Mechanisms of Isoform-Specific PI3K Signalling</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nrm2882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrm2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20379207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=329-341&author=B.+Vanhaesebroeckauthor=J.+Guillermet-Guibertauthor=M.+Grauperaauthor=B.+Bilanges&title=The+Emerging+Mechanisms+of+Isoform-Specific+PI3K+Signalling&doi=10.1038%2Fnrm2882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging mechanisms of isoform-specific PI3K signaling</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Guillermet-Guibert, Julie; Graupera, Mariona; Bilanges, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-341</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3Ks) function early in intracellular signal transduction pathways and affect many biol. functions.  A further level of complexity derives from the existence of eight PI3K isoforms, which are divided into class I, class II and class III PI3Ks.  PI3K signaling has been implicated in metabolic control, immunity, angiogenesis and cardiovascular homeostasis, and is one of the most frequently deregulated pathways in cancer.  PI3K inhibitors have recently entered clin. trials in oncol.  A better understanding of how the different PI3K isoforms are regulated and control signaling could uncover their roles in pathol. and reveal in which disease contexts their blockade could be most beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1WFE8yaCnkrVg90H21EOLACvtfcHk0lj3kPrwqyRXZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVersrc%253D&md5=d8507e3901857b68bb0a48dc7fea2b5b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrm2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2882%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26aulast%3DGraupera%26aufirst%3DM.%26aulast%3DBilanges%26aufirst%3DB.%26atitle%3DThe%2520Emerging%2520Mechanisms%2520of%2520Isoform-Specific%2520PI3K%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D329%26epage%3D341%26doi%3D10.1038%2Fnrm2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Montfort, R. L. M.</span><span> </span><span class="NLM_article-title">Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-4355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F0008-5472.CAN-09-4355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2146-2157&author=P.+Workmanauthor=P.+a.+Clarkeauthor=F.+I.+Raynaudauthor=R.+L.+M.+Van+Montfort&title=Drugging+the+PI3+Kinome%3A+From+Chemical+Tools+to+Drugs+in+the+Clinic&doi=10.1158%2F0008-5472.CAN-09-4355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-4355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-4355%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2Ba.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DVan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26atitle%3DDrugging%2520the%2520PI3%2520Kinome%253A%2520From%2520Chemical%2520Tools%2520to%2520Drugs%2520in%2520the%2520Clinic%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2146%26epage%3D2157%26doi%3D10.1158%2F0008-5472.CAN-09-4355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Bromodomains as Therapeutic Targets</span> <span class="citation_source-journal">Expert Rev. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1017/S1462399411001992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1017%2FS1462399411001992" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1-21&author=S.+Mullerauthor=P.+Filippakopoulosauthor=S.+Knapp&title=Bromodomains+as+Therapeutic+Targets&doi=10.1017%2FS1462399411001992"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1017%2FS1462399411001992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399411001992%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DBromodomains%2520as%2520Therapeutic%2520Targets%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3D1%26epage%3D21%26doi%3D10.1017%2FS1462399411001992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span> </span><span class="NLM_article-title">Epigenetic Protein Families: A New Frontier for Drug Discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span><span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+Protein+Families%3A+A+New+Frontier+for+Drug+Discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0lgVBXMMqlwUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520Protein%2520Families%253A%2520A%2520New%2520Frontier%2520for%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1298</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+Coteauthor=S.+Magnuson&title=Disrupting+Acetyl-Lysine+Recognition%3A+Progress+in+the+Development+of+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0lgVBXMMqlwUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DCote%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520Acetyl-Lysine%2520Recognition%253A%2520Progress%2520in%2520the%2520Development%2520of%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Micelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Histone Deacetylases: Structural Determinants of Inhibitor Selectivity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.drudis.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25687212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFehsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=718-735&author=C.+Micelliauthor=G.+Rastelli&title=Histone+Deacetylases%3A+Structural+Determinants+of+Inhibitor+Selectivity&doi=10.1016%2Fj.drudis.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases: structural determinants of inhibitor selectivity</span></div><div class="casAuthors">Micelli, Carmina; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">718-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are epigenetic targets with an important role in cancer, neurodegeneration, inflammation, and metabolic disorders.  Although clin. effective HDAC inhibitors have been developed, the design of inhibitors with the desired isoform(s) selectivity remains a challenge.  Selective inhibitors could help clarify the function of each isoform, and provide therapeutic agents having potentially fewer adverse effects.  Crystal structures of several HDACs have been reported, enabling structure-based drug design and providing important information to understand enzyme function.  Here, we provide a comprehensive review of the structural information available on HDACs, discussing both conserved and isoform-specific structural and mechanistic features.  We focus on distinctive aspects that help rationalize inhibitor selectivity, and provide structure-based recommendations for achieving the desired selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpabCy1anCPVrVg90H21EOLACvtfcHk0lg04gJj0xatiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFehsL4%253D&md5=5deab17c87fd88af9d6d3887449ef575</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DMicelli%26aufirst%3DC.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DHistone%2520Deacetylases%253A%2520Structural%2520Determinants%2520of%2520Inhibitor%2520Selectivity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D718%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keates, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsyte-Lovejoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felletar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingras, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22464331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVamurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=214-231&author=P.+Filippakopoulosauthor=S.+Picaudauthor=M.+Mangosauthor=T.+Keatesauthor=J.+P.+Lambertauthor=D.+Barsyte-Lovejoyauthor=I.+Felletarauthor=R.+Volkmerauthor=S.+M%C3%BCllerauthor=T.+Pawsonauthor=A.+C.+Gingrasauthor=C.+H.+Arrowsmithauthor=S.+Knapp&title=Histone+Recognition+and+Large-Scale+Structural+Analysis+of+the+Human+Bromodomain+Family&doi=10.1016%2Fj.cell.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family</span></div><div class="casAuthors">Filippakopoulos, Panagis; Picaud, Sarah; Mangos, Maria; Keates, Tracy; Lambert, Jean-Philippe; Barsyte-Lovejoy, Dalia; Felletar, Ildiko; Volkmer, Rudolf; Muller, Susanne; Pawson, Tony; Gingras, Anne-Claude; Arrowsmith, Cheryl H.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-231</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks.  The 61 BRDs in the human genome cluster into eight families based on structure/sequence similarity.  Here, we present 29 high-resoln. crystal structures, covering all BRD families.  These proteins are: ASH1L, ATAD2, BAZ2B, BPTF, BRD1, BRD3(1), BRD3(2), BRD4(1), BRD4(2), BRD9, BRDT(1), CECR2, EP300, CREBBP, GCN5L2, KIAA1240, PB1(1), PB1(2), PB1(3), PB1(4), PB1(5), PB1(6), PCAF, PHIP(2), TAF1(2), WDR9(2), BRD4(1).  Comprehensive crossfamily structural anal. identifies conserved and family-specific structural features that are necessary for specific acetylation-dependent substrate recognition.  Screening of more than 30 representative BRDs against systematic histone-peptide arrays identifies new BRD substrates and reveals a strong influence of flanking posttranslational modifications, such as acetylation and phosphorylation, suggesting that BRDs recognize combinations of marks rather than singly acetylated sequences.  We further uncovered a structural mechanism for the simultaneous binding and recognition of diverse diacetyl-contg. peptides by BRD4.  These data provide a foundation for structure-based drug design of specific inhibitors for this emerging target family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2FSIcPoXZLVg90H21EOLACvtfcHk0lg04gJj0xatiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVamurs%253D&md5=05583a01a1cd4c3b59fc59c00e4c4777</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DMangos%26aufirst%3DM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DLambert%26aufirst%3DJ.%2BP.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DVolkmer%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DHistone%2520Recognition%2520and%2520Large-Scale%2520Structural%2520Analysis%2520of%2520the%2520Human%2520Bromodomain%2520Family%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D214%26epage%3D231%26doi%3D10.1016%2Fj.cell.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Portela, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteller, M.</span><span> </span><span class="NLM_article-title">Epigenetic Modifications and Human Disease</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span><span class="refDoi"> DOI: 10.1038/nbt.1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnbt.1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20944598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yjsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1057-1068&author=A.+Portelaauthor=M.+Esteller&title=Epigenetic+Modifications+and+Human+Disease&doi=10.1038%2Fnbt.1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic modifications and human disease</span></div><div class="casAuthors">Portela, Anna; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1057-1068</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetics is one of the most rapidly expanding fields in biol.  The recent characterization of a human DNA methylome at single nucleotide resoln., the discovery of the CpG island shores, the finding of new histone variants and modifications, and the unveiling of genome-wide nucleosome positioning maps highlight the accelerating speed of discovery over the past two years.  Increasing interest in epigenetics has been accompanied by technol. breakthroughs that now make it possible to undertake large-scale epigenomic studies.  These allow the mapping of epigenetic marks, such as DNA methylation, histone modifications and nucleosome positioning, which are crit. for regulating gene and noncoding RNA expression.  In turn, we are learning how aberrant placement of these epigenetic marks and mutations in the epigenetic machinery is involved in disease.  Thus, a comprehensive understanding of epigenetic mechanisms, their interactions and alterations in health and disease, has become a priority in biomedical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmU-oOba01dbVg90H21EOLACvtfcHk0lhnbNQ01k9-ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yjsLzF&md5=02649d0c2ed862eda90d7bd349871c71</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1685%26sid%3Dliteratum%253Aachs%26aulast%3DPortela%26aufirst%3DA.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DEpigenetic%2520Modifications%2520and%2520Human%2520Disease%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D1057%26epage%3D1068%26doi%3D10.1038%2Fnbt.1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Furdas, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">Inhibition of Bromodomain-Mediated Protein–protein Interactions as a Novel Therapeutic Strategy</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1039/C1MD00201E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1039%2FC1MD00201E" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=123-134&author=S.+D.+Furdasauthor=L.+Carlinoauthor=W.+Sipplauthor=M.+Jung&title=Inhibition+of+Bromodomain-Mediated+Protein%E2%80%93protein+Interactions+as+a+Novel+Therapeutic+Strategy&doi=10.1039%2FC1MD00201E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC1MD00201E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00201E%26sid%3Dliteratum%253Aachs%26aulast%3DFurdas%26aufirst%3DS.%2BD.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Bromodomain-Mediated%2520Protein%25E2%2580%2593protein%2520Interactions%2520as%2520a%2520Novel%2520Therapeutic%2520Strategy%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D123%26epage%3D134%26doi%3D10.1039%2FC1MD00201E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.-M.</span><span> </span><span class="NLM_article-title">Discovery of Chemical Inhibitors of Human Bromodomains</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">11625</span><span class="NLM_x">–</span> <span class="NLM_lpage">11668</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=11625-11668&author=G.+Zhangauthor=S.+G.+Smithauthor=M.-M.+Zhou&title=Discovery+of+Chemical+Inhibitors+of+Human+Bromodomains&doi=10.1021%2Facs.chemrev.5b00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Chemical Inhibitors of Human Bromodomains</span></div><div class="casAuthors">Zhang, Guangtao; Smith, Steven G.; Zhou, Ming-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11625-11668</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-guided drug design strategy has played an important role in the recent discovery and development of bromodomain inhibitors that has yielded a multitude of chemotypes as described in this review.  Going forward, we expect that this structure-based approach will continue to guide medicinal chemists in lead optimization of bromodomain inhibitors and facilitate the efforts to develop new inhibitors for less druggable bromodomains.  Collectively, these emerging new chem. inhibitors will empower our ongoing investigation to better understand the roles of bromodomain proteins in control of gene transcription in human biol. and disease pathol.  These small-mol. inhibitors can also be developed into new epigenetic therapies for new effective treatments of various human diseases including cancer and inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbsgfBguOabVg90H21EOLACvtfcHk0lg8QLB7fanGTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qurzP&md5=4014c771384b4a768a80644af22c4485</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00205%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26aulast%3DZhou%26aufirst%3DM.-M.%26atitle%3DDiscovery%2520of%2520Chemical%2520Inhibitors%2520of%2520Human%2520Bromodomains%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D11625%26epage%3D11668%26doi%3D10.1021%2Facs.chemrev.5b00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Jennings, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Measures, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">Phenotypic Screening and Fragment-Based Approaches to the Discovery of Small-Molecule Bromodomain Ligands</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.4155/fmc.13.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.4155%2Ffmc.13.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24467243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=179-204&author=L.+E.+Jenningsauthor=A.+R.+Measuresauthor=B.+G.+Wilsonauthor=S.+J.+Conway&title=Phenotypic+Screening+and+Fragment-Based+Approaches+to+the+Discovery+of+Small-Molecule+Bromodomain+Ligands&doi=10.4155%2Ffmc.13.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands</span></div><div class="casAuthors">Jennings, Laura E.; Measures, Angelina R.; Wilson, Brian G.; Conway, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-204</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Bromodomains are protein modules that bind to acetylated lysine residues and hence facilitate protein-protein interactions.  These bromodomain-mediated interactions often play key roles in transcriptional regulation and their dysfunction is implicated in a large no. of diseases.  The discovery of potent and selective small-mol. bromodomain and extra C-terminal domain bromodomain ligands, which show promising results for the treatment of cancers and atherosclerosis, has promoted intense interest in this area.  Here we describe the progress that has been made to date in the discovery of small-mol. bromodomain ligands, with particular emphasis on the roles played by phenotypic screening and fragment-based approaches.  In considering the future of the field we discuss the prospects for development of mol. probes and drugs for the non-bromodomain and extra C-terminal domain bromodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6WhUfE_Ad4rVg90H21EOLACvtfcHk0lg8QLB7fanGTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCkuro%253D&md5=08c3266ceefe824fde8ef7c400d6bc22</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.197%26sid%3Dliteratum%253Aachs%26aulast%3DJennings%26aufirst%3DL.%2BE.%26aulast%3DMeasures%26aufirst%3DA.%2BR.%26aulast%3DWilson%26aufirst%3DB.%2BG.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DPhenotypic%2520Screening%2520and%2520Fragment-Based%2520Approaches%2520to%2520the%2520Discovery%2520of%2520Small-Molecule%2520Bromodomain%2520Ligands%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D179%26epage%3D204%26doi%3D10.4155%2Ffmc.13.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aster, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubonishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Cin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Atayde, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19)</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)63049-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0002-9440%2810%2963049-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=11733348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhslakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2001&pages=1987-1992&author=C.+A.+Frenchauthor=I.+Miyoshiauthor=J.+C.+Asterauthor=I.+Kubonishiauthor=T.+G.+Krollauthor=P.+Dal+Cinauthor=S.+O.+Vargasauthor=A.+R.+Perez-Ataydeauthor=J.+A.+Fletcher&title=BRD4+Bromodomain+Gene+Rearrangement+in+Aggressive+Carcinoma+with+Translocation+t%2815%3B19%29&doi=10.1016%2FS0002-9440%2810%2963049-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)</span></div><div class="casAuthors">French, Christopher A.; Miyoshi, Isao; Aster, Jon C.; Kubonishi, Ichiro; Kroll, Todd G.; Dal Cin, Paola; Vargas, Sara O.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1987-1992</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Translocation t(15;19)(q13;p13.1) defines a lethal midline carcinoma arising adjacent to respiratory tract in young people.  To characterize mol. alterations responsible for the distinctly aggressive biol. behavior of this cancer, we mapped the chromosome 15 and 19 translocation breakpoints by fluorescence in situ hybridization (FISH) and Southern blotting.  To evaluate preliminarily the frequency, anatomical distribution, and histol. features of t(15;19) cancer, we developed a FISH assay for paraffin sections.  Our findings reveal a novel oncogenic mechanism in which the chromosome 19 translocation breakpoint interrupts the coding sequence of a bromodomain gene, BRD4.  These studies implicate BRD4 as a potential partner in a t(15;19)-assocd. fusion oncogene.  In addn., we localized the chromosome 15 breakpoint to a 9-kb region in each of two cases, thereby identifying several candidate oncogenes which might represent the BRD4 fusion partner.  FISH evaluation of 13 pediatric carcinomas revealed t(15;19) in one of four sinonasal carcinomas, whereas this translocation was not detected in thymic (n = 3), mucoepidermoid (n = 3), laryngeal (n = 2), or nasopharyngeal (n = 1) carcinomas.  Our studies shed light on the oncogenic mechanism underlying t(15;19) and provide further evidence that this highly lethal cancer arises from respiratory mucosa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT-brK2zZWPbVg90H21EOLACvtfcHk0lhsgHQvItS99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhslakug%253D%253D&md5=be1d097192c440e4a8ef8c69e1fca43c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963049-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963049-0%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DMiyoshi%26aufirst%3DI.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DKubonishi%26aufirst%3DI.%26aulast%3DKroll%26aufirst%3DT.%2BG.%26aulast%3DDal%2BCin%26aufirst%3DP.%26aulast%3DVargas%26aufirst%3DS.%2BO.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DBRD4%2520Bromodomain%2520Gene%2520Rearrangement%2520in%2520Aggressive%2520Carcinoma%2520with%2520Translocation%2520t%252815%253B19%2529%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D159%26spage%3D1987%26epage%3D1992%26doi%3D10.1016%2FS0002-9440%2810%2963049-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Raux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voitovich, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derviaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebuffet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinquet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillemot, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunel, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, X.</span><span> </span><span class="NLM_article-title">Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1634</span><span class="NLM_x">–</span> <span class="NLM_lpage">1641</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1634-1641&author=B.+Rauxauthor=Y.+Voitovichauthor=C.+Derviauxauthor=A.+Lugariauthor=E.+Rebuffetauthor=S.+Milhasauthor=S.+Prietauthor=T.+Rouxauthor=E.+Trinquetauthor=J.-C.+Guillemotauthor=S.+Knappauthor=J.-M.+Brunelauthor=A.+Y.+Fedorovauthor=Y.+Colletteauthor=P.+Rocheauthor=S.+Betziauthor=S.+Combesauthor=X.+Morelli&title=Exploring+Selective+Inhibition+of+the+First+Bromodomain+of+the+Human+Bromodomain+and+Extra-Terminal+Domain+%28BET%29+Proteins&doi=10.1021%2Facs.jmedchem.5b01708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins</span></div><div class="casAuthors">Raux, Brigitt; Voitovich, Yuliia; Derviaux, Carine; Lugari, Adrien; Rebuffet, Etienne; Milhas, Sabine; Priet, Stephane; Roux, Thomas; Trinquet, Eric; Guillemot, Jean-Claude; Knapp, Stefan; Brunel, Jean-Michel; Fedorov, Alexey Yu.; Collette, Yves; Roche, Philippe; Betzi, Stephane; Combes, Sebastien; Morelli, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1634-1641</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A midthroughput screening follow-up program targeting the first bromodomain of the human BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine deriv. inhibitor.  This compd. binds with an affinity in the low micromolar range yet exerts suitable unexpected selectivity in vitro against the other members of the bromodomain and extra-terminal domain (BET) family.  A structure-based program pinpointed a role of the ZA loop, paving the way for the development of potent and selective BET-BRDi probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQdXvF3r4zLVg90H21EOLACvtfcHk0lhsgHQvItS99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKhsr0%253D&md5=fb9cfc20c76f65fcf409370b60aecc0a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01708%26sid%3Dliteratum%253Aachs%26aulast%3DRaux%26aufirst%3DB.%26aulast%3DVoitovich%26aufirst%3DY.%26aulast%3DDerviaux%26aufirst%3DC.%26aulast%3DLugari%26aufirst%3DA.%26aulast%3DRebuffet%26aufirst%3DE.%26aulast%3DMilhas%26aufirst%3DS.%26aulast%3DPriet%26aufirst%3DS.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DGuillemot%26aufirst%3DJ.-C.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBrunel%26aufirst%3DJ.-M.%26aulast%3DFedorov%26aufirst%3DA.%2BY.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DCombes%26aufirst%3DS.%26aulast%3DMorelli%26aufirst%3DX.%26atitle%3DExploring%2520Selective%2520Inhibition%2520of%2520the%2520First%2520Bromodomain%2520of%2520the%2520Human%2520Bromodomain%2520and%2520Extra-Terminal%2520Domain%2520%2528BET%2529%2520Proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1634%26epage%3D1641%26doi%3D10.1021%2Facs.jmedchem.5b01708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Inhibition of BET Bromodomains as a Therapeutic Strategy for Cancer Drug Discovery</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">5501</span><span class="NLM_x">–</span> <span class="NLM_lpage">5516</span><span class="refDoi"> DOI: 10.18632/oncotarget.3551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.18632%2Foncotarget.3551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25849938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5501-5516&author=L.+Fuauthor=M.+Tianauthor=X.+Liauthor=J.+Liauthor=J.+Huangauthor=L.+Ouyangauthor=Y.+Zhangauthor=B.+Liu&title=Inhibition+of+BET+Bromodomains+as+a+Therapeutic+Strategy+for+Cancer+Drug+Discovery&doi=10.18632%2Foncotarget.3551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span></div><div class="casAuthors">Fu Lei-lei; Tian Mao; Li Xiang; Li Jing-jing; Ouyang Liang; Zhang Yonghui; Liu Bo; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5501-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site.  Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT.  BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2.  Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer.  In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBHUaDfXsQehKDYG3bNImrfW6udTcc2eYyMdR-FvQqv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D&md5=b3b070170e6da5585f87dffe1d568f47</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3551%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520BET%2520Bromodomains%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Cancer%2520Drug%2520Discovery%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5501%26epage%3D5516%26doi%3D10.18632%2Foncotarget.3551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubonishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grier, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-atayde, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=12543779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Klug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=304-307&author=C.+A.+Frenchauthor=I.+Miyoshiauthor=I.+Kubonishiauthor=H.+E.+Grierauthor=A.+R.+Perez-ataydeauthor=J.+A.+Fletcher&title=BRD4-NUT+Fusion+Oncogene%3A+A+Novel+Mechanism+in+Aggressive+Carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma</span></div><div class="casAuthors">French, Christopher A.; Miyoshi, Isao; Kubonishi, Ichiro; Grier, Holcombe E.; Perez-Atayde, Antonio R.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-307</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The poorly differentiated carcinoma with t(15;19)(q13,p13.1) is characterized by its highly aggressive, invariably lethal clin. course.  The chromosome 19 translocation breakpoint targets the BRD4 double bromodomain-contg. gene, which functions in regulation of cell cycle progression.  Herein the authors demonstrate that BRD4 is fused with nearly the entire transcript of the novel 15q13 gene, NUT (nuclear protein in testis), forming a 6.4-kb fusion oncogene, BRD4-NUT.  NUT, like BRD4, is predicted to encode a nuclear protein but, unlike the ubiquitous BRD4 transcript, is expressed only in testis.  These findings establish a model to elucidate the oncogenic consequences of unscheduled NUT expression and altered BRD4 function.  Very few fusion oncogenes have been identified in epithelial tumors, and BRD4-NUT is the first fusion oncogene mechanism identified in a highly lethal form of carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTa0K_kBu2pLVg90H21EOLACvtfcHk0lj3PKFw3b3e7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Klug%253D%253D&md5=e927ea5874b2013c7467f981e10d7efd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DMiyoshi%26aufirst%3DI.%26aulast%3DKubonishi%26aufirst%3DI.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DPerez-atayde%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DBRD4-NUT%2520Fusion%2520Oncogene%253A%2520A%2520Novel%2520Mechanism%2520in%2520Aggressive%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D304%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keates, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felletar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0lj3PKFw3b3e7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.</span><span> </span><span class="NLM_article-title">Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">16669</span><span class="NLM_x">–</span> <span class="NLM_lpage">16674</span><span class="refDoi"> DOI: 10.1073/pnas.1108190108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1073%2Fpnas.1108190108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21949397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16669-16674&author=J.+A.+Mertzauthor=A.+R.+Coneryauthor=B.+M.+Bryantauthor=P.+Sandyauthor=S.+Balasubramanianauthor=D.+A.+Meleauthor=L.+Bergeronauthor=R.+J.+Sims&title=Targeting+MYC+Dependence+in+Cancer+by+Inhibiting+BET+Bromodomains&doi=10.1073%2Fpnas.1108190108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependence in cancer by inhibiting BET bromodomains</span></div><div class="casAuthors">Mertz, Jennifer A.; Conery, Andrew R.; Bryant, Barbara M.; Sandy, Peter; Balasubramanian, Srividya; Mele, Deanna A.; Bergeron, Louise; Sims, Robert J., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16669-16674, S16669/1-S16669/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies.  However, pharmacol. inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions.  Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small mol. inhibitors of the BET family of chromatin adaptors.  MYC transcriptional suppression was obsd. in the context of the natural, chromosomally translocated, and amplified gene locus.  Inhibition of BET bromodomain-promoter interactions and subsequent redn. of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines.  Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors.  MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor.  Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia.  These findings demonstrate that pharmacol. inhibition of MYC is achievable through targeting BET bromodomains.  Such inhibitors may have clin. utility given the widespread pathogenetic role of MYC in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UHj1YB_ikrVg90H21EOLACvtfcHk0lh4JjgH6PRzfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL&md5=b1f0fd41fa56bbfcbb1ad6c8d48f7f80</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108190108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108190108%26sid%3Dliteratum%253Aachs%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520MYC%2520Dependence%2520in%2520Cancer%2520by%2520Inhibiting%2520BET%2520Bromodomains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D16669%26epage%3D16674%26doi%3D10.1073%2Fpnas.1108190108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Nicodeme, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beinke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marazzi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirilovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span> </span><span class="NLM_article-title">Suppression of Inflammation by a Synthetic Histone Mimic</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span><span class="refDoi"> DOI: 10.1038/nature09589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature09589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21068722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1119-1123&author=E.+Nicodemeauthor=K.+L.+Jeffreyauthor=U.+Schaeferauthor=S.+Beinkeauthor=S.+Dewellauthor=C.+W.+Chungauthor=R.+Chandwaniauthor=I.+Marazziauthor=P.+Wilsonauthor=H.+Costeauthor=J.+Whiteauthor=J.+Kirilovskyauthor=C.+M.+Riceauthor=J.+M.+Loraauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=A.+Tarakhovsky&title=Suppression+of+Inflammation+by+a+Synthetic+Histone+Mimic&doi=10.1038%2Fnature09589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of inflammation by a synthetic histone mimic</span></div><div class="casAuthors">Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe; Beinke, Soren; Dewell, Scott; Chung, Chun-wa; Chandwani, Rohit; Marazzi, Ivan; Wilson, Paul; Coste, Herve; White, Julia; Kirilovsky, Jorge; Rice, Charles M.; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin; Tarakhovsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression.  This response, although vital for immune defense, is frequently deleterious to the host due to the exaggerated prodn. of inflammatory proteins.  The scope of inflammatory responses reflects the activation state of signaling proteins upstream of inflammatory genes as well as signal-induced assembly of nuclear chromatin complexes that support mRNA expression.  Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a crit. step in the regulation of gene expression.  Here we present a novel pharmacol. approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins.  We describe a synthetic compd. (I-BET) that by mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis.  Our findings suggest that synthetic compds. specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxc3_PNaiuKLVg90H21EOLACvtfcHk0lh4JjgH6PRzfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP&md5=0dfccd9d01b87859512bf591e1c5a93c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature09589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09589%26sid%3Dliteratum%253Aachs%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DJeffrey%26aufirst%3DK.%2BL.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DBeinke%26aufirst%3DS.%26aulast%3DDewell%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DChandwani%26aufirst%3DR.%26aulast%3DMarazzi%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DP.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTarakhovsky%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Inflammation%2520by%2520a%2520Synthetic%2520Histone%2520Mimic%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1119%26epage%3D1123%26doi%3D10.1038%2Fnature09589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Chung, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coste, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirguet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosmini, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magny, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boursier, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouillot, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusq, J.-M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellibert, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riou, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uings, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, C. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boullay, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimley, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandel, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirilovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicodeme, E.</span><span> </span><span class="NLM_article-title">Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3827</span><span class="NLM_x">–</span> <span class="NLM_lpage">3838</span><span class="refDoi"> DOI: 10.1021/jm200108t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200108t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3827-3838&author=C.-W.+Chungauthor=H.+Costeauthor=J.+H.+Whiteauthor=O.+Mirguetauthor=J.+Wildeauthor=R.+L.+Gosminiauthor=C.+Delvesauthor=S.+M.+Magnyauthor=R.+Woodwardauthor=S.+a+Hughesauthor=E.+V.+Boursierauthor=H.+Flynnauthor=A.+M.+Bouillotauthor=P.+Bamboroughauthor=J.-M.+G.+Brusqauthor=F.+J.+Gellibertauthor=E.+J.+Jonesauthor=A.+M.+Riouauthor=P.+Homesauthor=S.+L.+Martinauthor=I.+J.+Uingsauthor=J.+Toumauthor=C.+a+Clementauthor=A.-B.+Boullayauthor=R.+L.+Grimleyauthor=F.+M.+Blandelauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=J.+Kirilovskyauthor=E.+Nicodeme&title=Discovery+and+Characterization+of+Small+Molecule+Inhibitors+of+the+BET+Family+Bromodomains&doi=10.1021%2Fjm200108t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of small molecule inhibitors of the BET family bromodomains</span></div><div class="casAuthors">Chung, Chun-wa; Coste, Herve; White, Julia H.; Mirguet, Olivier; Wilde, Jonathan; Gosmini, Romain L.; Delves, Chris; Magny, Sylvie M.; Woodward, Robert; Hughes, Stephen A.; Boursier, Eric V.; Flynn, Helen; Bouillot, Anne M.; Bamborough, Paul; Brusq, Jean-Marie G.; Gellibert, Francoise J.; Jones, Emma J.; Riou, Alizon M.; Homes, Paul; Martin, Sandrine L.; Uings, Iain J.; Toum, Jerome; Clement, Catherine A.; Boullay, Anne-Benedicte; Grimley, Rachel L.; Blandel, Florence M.; Prinjha, Rab K.; Lee, Kevin; Kirilovsky, Jorge; Nicodeme, Edwige</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3827-3838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic mechanisms of gene regulation have a profound role in normal development and disease processes.  An integral part of this mechanism occurs through lysine acetylation of histone tails which are recognized by bromodomains.  While the biol. and structural characterization of many bromodomain contg. proteins has advanced considerably, the therapeutic tractability of this protein family is only now becoming understood.  This paper describes the discovery and mol. characterization of potent (nM) small mol. inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4).  By using a combination of phenotypic screening, chemoproteomics, and biophys. studies, we have discovered that the protein-protein interactions between bromodomains and acetylated histones can be antagonized by selective small mols. that bind at the acetylated lysine recognition pocket.  X-ray crystal structures of compds. bound into bromodomains of Brd2 and Brd4 elucidate the mol. interactions of binding and explain the precisely defined stereochem. required for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8VauuYkT5YLVg90H21EOLACvtfcHk0lhDx0TLHMYdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWnurs%253D&md5=ebc0f6062321dece877259d775f1c19b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm200108t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200108t%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26aulast%3DMirguet%26aufirst%3DO.%26aulast%3DWilde%26aufirst%3DJ.%26aulast%3DGosmini%26aufirst%3DR.%2BL.%26aulast%3DDelves%26aufirst%3DC.%26aulast%3DMagny%26aufirst%3DS.%2BM.%26aulast%3DWoodward%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DS.%2Ba%26aulast%3DBoursier%26aufirst%3DE.%2BV.%26aulast%3DFlynn%26aufirst%3DH.%26aulast%3DBouillot%26aufirst%3DA.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBrusq%26aufirst%3DJ.-M.%2BG.%26aulast%3DGellibert%26aufirst%3DF.%2BJ.%26aulast%3DJones%26aufirst%3DE.%2BJ.%26aulast%3DRiou%26aufirst%3DA.%2BM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%2BL.%26aulast%3DUings%26aufirst%3DI.%2BJ.%26aulast%3DToum%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DC.%2Ba%26aulast%3DBoullay%26aufirst%3DA.-B.%26aulast%3DGrimley%26aufirst%3DR.%2BL.%26aulast%3DBlandel%26aufirst%3DF.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DNicodeme%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Small%2520Molecule%2520Inhibitors%2520of%2520the%2520BET%2520Family%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3827%26epage%3D3838%26doi%3D10.1021%2Fjm200108t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Delmore, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahl, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastritis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilpatrick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paranal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinzel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakoc, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsagel, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span> </span><span class="NLM_article-title">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2011.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21889194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=904-917&author=J.+E.+Delmoreauthor=G.+C.+Issaauthor=M.+E.+Lemieuxauthor=P.+B.+Rahlauthor=J.+Shiauthor=H.+M.+Jacobsauthor=E.+Kastritisauthor=T.+Gilpatrickauthor=R.+M.+Paranalauthor=J.+Qiauthor=M.+Chesiauthor=A.+C.+Schinzelauthor=M.+R.+McKeownauthor=T.+P.+Heffernanauthor=C.+R.+Vakocauthor=P.+L.+Bergsagelauthor=I.+M.+Ghobrialauthor=P.+G.+Richardsonauthor=R.+A.+Youngauthor=W.+C.+Hahnauthor=K.+C.+Andersonauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=C.+S.+Mitsiades&title=BET+Bromodomain+Inhibition+as+a+Therapeutic+Strategy+to+Target+c-Myc&doi=10.1016%2Fj.cell.2011.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span></div><div class="casAuthors">Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E.; Rahl, Peter B.; Shi, Jun-Wei; Jacobs, Hannah M.; Kastritis, Efstathios; Gilpatrick, Timothy; Paranal, Ronald M.; Qi, Jun; Chesi, Marta; Schinzel, Anna C.; McKeown, Michael R.; Heffernan, Timothy P.; Vakoc, Christopher R.; Bergsagel, P. Leif; Ghobrial, Irene M.; Richardson, Paul G.; Young, Richard A.; Hahn, William C.; Anderson, Kenneth C.; Kung, Andrew L.; Bradner, James E.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-917</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist.  Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation.  Using a selective small-mol. bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc.  BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes.  In exptl. models of multiple myeloma, a Myc-dependent hematol. malignancy, JQ1 produces a potent antiproliferative effect assocd. with cell-cycle arrest and cellular senescence.  Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathol. activation of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpevD1QHKmOhLVg90H21EOLACvtfcHk0lhDx0TLHMYdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF&md5=013674b8224214a9a1c8f0b75583a5a6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DIssa%26aufirst%3DG.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DKastritis%26aufirst%3DE.%26aulast%3DGilpatrick%26aufirst%3DT.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DBET%2520Bromodomain%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520c-Myc%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D904%26epage%3D917%26doi%3D10.1016%2Fj.cell.2011.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparks, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvanitis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span> </span><span class="NLM_article-title">INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1593/neo.91192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1593%2Fneo.91192" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=28-38&author=J.+Liauthor=M.+Favataauthor=J.+A.+Kelleyauthor=E.+Caulderauthor=B.+Thomasauthor=X.+Wenauthor=R.+B.+Sparksauthor=A.+Arvanitisauthor=J.+D.+Rogersauthor=A.+P.+Combsauthor=K.+Vaddiauthor=K.+A.+Solomonauthor=P.+A.+Scherleauthor=R.+Newtonauthor=J.+S.+Fridman&title=INCB16562%2C+a+JAK1%2F2+Selective+Inhibitor%2C+Is+Efficacious+against+Multiple+Myeloma+Cells+and+Reverses+the+Protective+Effects+of+Cytokine+and+Stromal+Cell+Support&doi=10.1593%2Fneo.91192"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1593%2Fneo.91192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.91192%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFavata%26aufirst%3DM.%26aulast%3DKelley%26aufirst%3DJ.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DSparks%26aufirst%3DR.%2BB.%26aulast%3DArvanitis%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DJ.%2BD.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26atitle%3DINCB16562%252C%2520a%2520JAK1%252F2%2520Selective%2520Inhibitor%252C%2520Is%2520Efficacious%2520against%2520Multiple%2520Myeloma%2520Cells%2520and%2520Reverses%2520the%2520Protective%2520Effects%2520of%2520Cytokine%2520and%2520Stromal%2520Cell%2520Support%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D28%26epage%3D38%26doi%3D10.1593%2Fneo.91192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD Mutations in FLT3 as a Therapeutic Target in Human Acute Myeloid Leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.-S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+Mutations+in+FLT3+as+a+Therapeutic+Target+in+Human+Acute+Myeloid+Leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0liGMJ80x4MQVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.-S.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520Mutations%2520in%2520FLT3%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Human%2520Acute%2520Myeloid%2520Leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span><span class="refDoi"> DOI: 10.1021/jm9007533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-Butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+Dihydrochloride+%28AC220%29%2C+a+Uniquely+Potent%2C+Selective%2C+and+Efficacious+FMS-Like+Tyrosine+Kinase-3+%28FLT3%29+Inhibitor&doi=10.1021%2Fjm9007533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520Dihydrochloride%2520%2528AC220%2529%252C%2520a%2520Uniquely%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520FMS-Like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816%26doi%3D10.1021%2Fjm9007533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devaraj, S. G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leveque, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portier, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2315</span><span class="NLM_x">–</span> <span class="NLM_lpage">2327</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1535-7163.MCT-14-0258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25053825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2315-2327&author=W.+Fiskusauthor=S.+Sharmaauthor=J.+Qiauthor=B.+Shahauthor=S.+G.+T.+Devarajauthor=C.+Levequeauthor=B.+P.+Portierauthor=S.+P.+Iyerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=BET+Protein+Antagonist+JQ1+Is+Synergistically+Lethal+with+FLT3+Tyrosine+Kinase+Inhibitor+%28TKI%29+and+Overcomes+Resistance+to+FLT3-TKI+in+AML+Cells+Expressing+FLT-ITD&doi=10.1158%2F1535-7163.MCT-14-0258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span></div><div class="casAuthors">Fiskus, Warren; Sharma, Sunil; Qi, Jun; Shah, Bhavin; Devaraj, Santhana G. T.; Leveque, Christopher; Portier, Bryce P.; Iyer, Swaminathan; Bradner, James E.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2315-2327</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and induce apoptosis of human acute myelogenous leukemia (AML) cells, including those expressing FLT3-ITD.  Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34+ human AML blast progenitor cells (BPC) expressing FLT3-ITD.  Concomitantly, as compared with each agent alone, cotreatment with JQ1 and the FLT3-TKI caused greater attenuation of c-MYC, BCL2, and CDK4/6.  Simultaneously, cotreatment with JQ1 and the FLT3-TKI increased the levels of p21, BIM, and cleaved PARP, as well as mediated marked attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels in AML BPCs.  Conversely, cotreatment with JQ1 and FLT3-TKI was significantly less active against CD34+ normal bone marrow progenitor cells.  Knockdown of BRD4 by short hairpin RNA also sensitized AML cells to FLT3-TKI.  JQ1 treatment induced apoptosis of mouse Ba/F3 cells ectopically expressing FLT3-ITD with or without FLT3-TKI-resistant mutations F691L and D835V.  Compared with the parental human AML FLT3-ITD-expressing MOLM13, MOLM13-TKIR cells resistant to AC220 were markedly more sensitive to JQ1-induced apoptosis.  Furthermore, cotreatment with JQ1 and the pan-histone deacetylase inhibitor (HDI) panobinostat synergistically induced apoptosis of FLT3-TKI-resistant MOLM13-TKIR and MV4-11-TKIR cells.  Collectively, these findings support the rationale for detg. the in vivo activity of combined therapy with BA and FLT3-TKI against human AML cells expressing FLT3-ITD or with BA and HDI against AML cells resistant to FLT3-TKI.  Mol Cancer Ther; 13(10); 2315-27. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PTZkTs8dmLVg90H21EOLACvtfcHk0lgA8UJ98a5PPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI&md5=86b07b19b740ed314bd042a472507766</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0258%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%2BT.%26aulast%3DLeveque%26aufirst%3DC.%26aulast%3DPortier%26aufirst%3DB.%2BP.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DBET%2520Protein%2520Antagonist%2520JQ1%2520Is%2520Synergistically%2520Lethal%2520with%2520FLT3%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529%2520and%2520Overcomes%2520Resistance%2520to%2520FLT3-TKI%2520in%2520AML%2520Cells%2520Expressing%2520FLT-ITD%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2315%26epage%3D2327%26doi%3D10.1158%2F1535-7163.MCT-14-0258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&issue=1&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljeq4RnkVIkEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Sun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakshe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coarfa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devaraj, S. G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saenz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Synergistic Activity of BET Protein Antagonist-Based Combinations in Mantle Cell Lymphoma Cells Sensitive or Resistant to Ibrutinib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1182/blood-2015-04-639542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1182%2Fblood-2015-04-639542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1565-1574&author=B.+Sunauthor=B.+Shahauthor=W.+Fiskusauthor=J.+Qiauthor=K.+Rajapaksheauthor=C.+Coarfaauthor=L.+Liauthor=S.+G.+T.+Devarajauthor=S.+Sharmaauthor=L.+Zhangauthor=M.+L.+Wangauthor=D.+T.+Saenzauthor=S.+Kriegerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=Synergistic+Activity+of+BET+Protein+Antagonist-Based+Combinations+in+Mantle+Cell+Lymphoma+Cells+Sensitive+or+Resistant+to+Ibrutinib&doi=10.1182%2Fblood-2015-04-639542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-04-639542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-04-639542%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DRajapakshe%26aufirst%3DK.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%2BT.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DSaenz%26aufirst%3DD.%2BT.%26aulast%3DKrieger%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DSynergistic%2520Activity%2520of%2520BET%2520Protein%2520Antagonist-Based%2520Combinations%2520in%2520Mantle%2520Cell%2520Lymphoma%2520Cells%2520Sensitive%2520or%2520Resistant%2520to%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1565%26epage%3D1574%26doi%3D10.1182%2Fblood-2015-04-639542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Lu, J.</span><span> </span><span class="NLM_article-title">Palbociclib: A First-in-Class CDK4/CDK6 Inhibitor for the Treatment of Hormone-Receptor Positive Advanced Breast Cancer</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="refDoi"> DOI: 10.1186/s13045-015-0194-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1186%2Fs13045-015-0194-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26264704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC287it1Kltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=98&author=J.+Lu&title=Palbociclib%3A+A+First-in-Class+CDK4%2FCDK6+Inhibitor+for+the+Treatment+of+Hormone-Receptor+Positive+Advanced+Breast+Cancer&doi=10.1186%2Fs13045-015-0194-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer</span></div><div class="casAuthors">Lu Janice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy.  In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy.  This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeKTdzfqi8kjdblLE_E9PWfW6udTcc2eYugaLnHhgeTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287it1Kltw%253D%253D&md5=a731e76c3e3a0f4bb7610d9dd180a844</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0194-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0194-5%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DPalbociclib%253A%2520A%2520First-in-Class%2520CDK4%252FCDK6%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Hormone-Receptor%2520Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D98%26doi%3D10.1186%2Fs13045-015-0194-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arias, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faure, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisburd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span> </span><span class="NLM_article-title">Compensatory Induction of MYC Expression by Sustained CDK9 Inhibition via a BRD4-Dependent Mechanism</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.7554/eLife.06535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.7554%2FeLife.06535" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-26&author=H.+Luauthor=Y.+Xueauthor=G.+K.+Yuauthor=C.+Ariasauthor=J.+Linauthor=S.+Fongauthor=M.+Faureauthor=B.+Weisburdauthor=X.+Jiauthor=A.+Mercierauthor=J.+Suttonauthor=K.+Luoauthor=Z.+Gaoauthor=Q.+Zhou&title=Compensatory+Induction+of+MYC+Expression+by+Sustained+CDK9+Inhibition+via+a+BRD4-Dependent+Mechanism&doi=10.7554%2FeLife.06535"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.7554%2FeLife.06535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.06535%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DG.%2BK.%26aulast%3DArias%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DWeisburd%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DMercier%26aufirst%3DA.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DCompensatory%2520Induction%2520of%2520MYC%2520Expression%2520by%2520Sustained%2520CDK9%2520Inhibition%2520via%2520a%2520BRD4-Dependent%2520Mechanism%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D26%26doi%3D10.7554%2FeLife.06535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Arguello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterry, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalavar, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koss, W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stinson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvord, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klabansky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2282</span><span class="NLM_x">–</span> <span class="NLM_lpage">2490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1998&pages=2282-2490&author=F.+Arguelloauthor=M.+Alexanderauthor=J.+A.+Sterryauthor=G.+Tudorauthor=E.+M.+Smithauthor=N.+T.+Kalavarauthor=J.+F.+Greeneauthor=W.+Kossauthor=C.+D.+Morganauthor=S.+F.+Stinsonauthor=T.+J.+Sifordauthor=W.+G.+Alvordauthor=R.+L.+Klabanskyauthor=E.+A.+Sausville&title=Flavopiridol+Induces+Apoptosis+of+Normal+Lymphoid+Cells%2C+Causes+Immunosuppression%2C+and+Has+Potent+Antitumor+Activity+In+Vivo+Against+Human+Leukemia+and+Lymphoma+Xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArguello%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DSterry%26aufirst%3DJ.%2BA.%26aulast%3DTudor%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DKalavar%26aufirst%3DN.%2BT.%26aulast%3DGreene%26aufirst%3DJ.%2BF.%26aulast%3DKoss%26aufirst%3DW.%26aulast%3DMorgan%26aufirst%3DC.%2BD.%26aulast%3DStinson%26aufirst%3DS.%2BF.%26aulast%3DSiford%26aufirst%3DT.%2BJ.%26aulast%3DAlvord%26aufirst%3DW.%2BG.%26aulast%3DKlabansky%26aufirst%3DR.%2BL.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DFlavopiridol%2520Induces%2520Apoptosis%2520of%2520Normal%2520Lymphoid%2520Cells%252C%2520Causes%2520Immunosuppression%252C%2520and%2520Has%2520Potent%2520Antitumor%2520Activity%2520In%2520Vivo%2520Against%2520Human%2520Leukemia%2520and%2520Lymphoma%2520Xenografts%26jtitle%3DBlood%26date%3D1998%26volume%3D91%26spage%3D2282%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Parry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanahan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabhavalkar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paruch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oft, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees, E. M.</span><span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+Novel+and+Potent+Cyclin-Dependent+Kinase+Inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lilCOWQktD70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Baker, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannettino, A. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkley, C. R.</span><span> </span><span class="NLM_article-title">BET Inhibitors Induce Apoptosis through a MYC Independent Mechanism and Synergise with CDK Inhibitors to Kill Osteosarcoma Cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10120</span><span class="refDoi"> DOI: 10.1038/srep10120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsrep10120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25944566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10120&author=E.+K.+Bakerauthor=S.+Taylorauthor=A.+Gupteauthor=P.+P.+Sharpauthor=M.+Waliaauthor=N.+C.+Walshauthor=A.+C.+W.+Zannettinoauthor=A.+M.+Chalkauthor=C.+J.+Burnsauthor=C.+R.+Walkley&title=BET+Inhibitors+Induce+Apoptosis+through+a+MYC+Independent+Mechanism+and+Synergise+with+CDK+Inhibitors+to+Kill+Osteosarcoma+Cells&doi=10.1038%2Fsrep10120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells</span></div><div class="casAuthors">Baker, Emma K.; Taylor, Scott; Gupte, Ankita; Sharp, Phillip P.; Walia, Mannu; Walsh, Nicole C.; Zannettino, Andrew C. W.; Chalk, Alistair M.; Burns, Christopher J.; Walkley, Carl R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10120</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osteosarcoma (OS) survival rates have plateaued in part due to a lack of new therapeutic options.  Here we demonstrate that bromodomain inhibitors (BETi), JQ1, I-BET151, I-BET762, exert potent anti-tumor activity against primary and established OS cell lines, mediated by inhibition of BRD4.  Strikingly, unlike previous observations in long-term established human OS cell lines, the antiproliferative activity of JQ1 in primary OS cells was driven by the induction of apoptosis, not cell cycle arrest.  In further contrast, JQ1 activity in OS was mediated independently of MYC downregulation.  We identified that JQ1 suppresses the transcription factor FOSL1 by displacement of BRD4 from its locus.  Loss of FOSL1 phenocopied the antiproliferative effects of JQ1, identifying FOSL1 suppression as a potential novel therapeutic approach for OS.  As a monotherapy JQ1 demonstrated significant anti-tumor activity in vivo in an OS graft model.  Further, combinatorial treatment approaches showed that JQ1 increased the sensitivity of OS cells to doxorubicin and induced potent synergistic activity when rationally combined with CDK inhibitors.  The greater level of activity achieved with the combination of BETi with CDK inhibitors demonstrates the efficacy of this combination therapy.  Taken together, our studies show that BET inhibitors are a promising new therapeutic for OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiy0tg8DWClLVg90H21EOLACvtfcHk0lilCOWQktD70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrsL7I&md5=c95d487ed91b342bd426413430ba36ee</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fsrep10120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10120%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DE.%2BK.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGupte%26aufirst%3DA.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWalia%26aufirst%3DM.%26aulast%3DWalsh%26aufirst%3DN.%2BC.%26aulast%3DZannettino%26aufirst%3DA.%2BC.%2BW.%26aulast%3DChalk%26aufirst%3DA.%2BM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DWalkley%26aufirst%3DC.%2BR.%26atitle%3DBET%2520Inhibitors%2520Induce%2520Apoptosis%2520through%2520a%2520MYC%2520Independent%2520Mechanism%2520and%2520Synergise%2520with%2520CDK%2520Inhibitors%2520to%2520Kill%2520Osteosarcoma%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10120%26doi%3D10.1038%2Fsrep10120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Tacar, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sriamornsak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dass, C. R.</span><span> </span><span class="NLM_article-title">Doxorubicin: an Update on Anticancer Molecular Action, Toxicity and Novel Drug Delivery Systems</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1111/j.2042-7158.2012.01567.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.2042-7158.2012.01567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=23278683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=157-170&author=O.+Tacarauthor=P.+Sriamornsakauthor=C.+R.+Dass&title=Doxorubicin%3A+an+Update+on+Anticancer+Molecular+Action%2C+Toxicity+and+Novel+Drug+Delivery+Systems&doi=10.1111%2Fj.2042-7158.2012.01567.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems</span></div><div class="casAuthors">Tacar, Oktay; Sriamornsak, Pornsak; Dass, Crispin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-170</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Objectives The frontline drug doxorubicin has been used for treating cancer for over 30 years.  While providing a cure in select cases, doxorubicin causes toxicity to most major organs, esp. life-threatening cardiotoxicity, which forces the treatment to become dose-limiting.  Key findings Doxorubicin is known to bind to DNA-assocd. enzymes, intercalate with DNA base pairs, and target multiple mol. targets to produce a range of cytotoxic effects.  For instance, it causes the activation of various mol. signals from AMPK (AMP-activated protein kinase inducing apoptosis) to influence the Bcl-2/Bax apoptosis pathway.  By altering the Bcl-2/Bax ratio, downstream activation of different caspases can occur resulting in apoptosis.  Doxorubicin also induces apoptosis and necrosis in healthy tissue causing toxicity in the brain, liver, kidney and heart.  Over the years, many studies have been conducted to devise a drug delivery system that would eliminate these adverse affects including liposomes, hydrogel and nanoparticulate systems, and we highlight the pros and cons of these drug delivery systems.  Summary Overall the future for the continued use of doxorubicin clin. against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chem., delivery and toxicity.  Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ULJ-J2uxgrVg90H21EOLACvtfcHk0lhqOUlpFCQY6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGitb4%253D&md5=fca40d4f8ee61dcdd6216a694cf44548</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2012.01567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2012.01567.x%26sid%3Dliteratum%253Aachs%26aulast%3DTacar%26aufirst%3DO.%26aulast%3DSriamornsak%26aufirst%3DP.%26aulast%3DDass%26aufirst%3DC.%2BR.%26atitle%3DDoxorubicin%253A%2520an%2520Update%2520on%2520Anticancer%2520Molecular%2520Action%252C%2520Toxicity%2520and%2520Novel%2520Drug%2520Delivery%2520Systems%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D157%26epage%3D170%26doi%3D10.1111%2Fj.2042-7158.2012.01567.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Janeway, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grier, H. E.</span><span> </span><span class="NLM_article-title">Sequelae of Osteosarcoma Medical Therapy: a Review of Rare Acute Toxicities and Late Effects</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span><span class="refDoi"> DOI: 10.1016/S1470-2045(10)70062-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1470-2045%2810%2970062-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20347613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsVCntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=670-678&author=K.+A.+Janewayauthor=H.+E.+Grier&title=Sequelae+of+Osteosarcoma+Medical+Therapy%3A+a+Review+of+Rare+Acute+Toxicities+and+Late+Effects&doi=10.1016%2FS1470-2045%2810%2970062-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects</span></div><div class="casAuthors">Janeway Katherine A; Grier Holcombe E</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">670-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the introduction of multi-agent chemotherapy for osteosarcoma over 30 years ago, overall survival has exceeded 50%.  A clear understanding of the acute complications and late effects of osteosarcoma therapy is required to care effectively for patients with osteosarcoma undergoing active treatment, and for the increasing number of osteosarcoma survivors.  There has now been sufficient cumulative experience treating patients with osteosarcoma with active anti-osteosarcoma chemotherapy agents, high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, and etoposide to recognise and understand rare toxicities associated with these agents, and to identify the late effects of osteosarcoma therapy.  Late effects and rare toxicities of osteosarcoma include cardiac toxicity, acute and chronic nephrotoxicity, neurotoxicity, hearing loss, infertility, and second malignant neoplasms.  Reducing the complications of osteosarcoma therapy is an important goal that will require the identification of clear prognostic indicators, the development of biologically-based therapies, and improved antidotes for the active anti-osteosarcoma cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS1i4bhTL7itbHMBt0mMIXfW6udTcc2eba0cmW_8L8Pbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsVCntQ%253D%253D&md5=198e9dc9d8d00a77edc5d743b2d53efe</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970062-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970062-0%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DGrier%26aufirst%3DH.%2BE.%26atitle%3DSequelae%2520of%2520Osteosarcoma%2520Medical%2520Therapy%253A%2520a%2520Review%2520of%2520Rare%2520Acute%2520Toxicities%2520and%2520Late%2520Effects%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D670%26epage%3D678%26doi%3D10.1016%2FS1470-2045%2810%2970062-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doan, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forscher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span> </span><span class="NLM_article-title">Synergistic Effect of JQ1 and Rapamycin for Treatment of Human Osteosarcoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">2055</span><span class="NLM_x">–</span> <span class="NLM_lpage">2064</span><span class="refDoi"> DOI: 10.1002/ijc.29269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fijc.29269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25307878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislegt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=2055-2064&author=D.+H.+Leeauthor=J.+Qiauthor=J.+E.+Bradnerauthor=J.+W.+Saidauthor=N.+B.+Doanauthor=C.+Forscherauthor=H.+Yangauthor=H.+P.+Koeffler&title=Synergistic+Effect+of+JQ1+and+Rapamycin+for+Treatment+of+Human+Osteosarcoma&doi=10.1002%2Fijc.29269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma</span></div><div class="casAuthors">Lee, Dhong Hyun; Qi, Jun; Bradner, James E.; Said, Jonathan W.; Doan, Ngan B.; Forscher, Charles; Yang, Henry; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2055-2064</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Bromodomain and extra terminal domain (BET) proteins are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones.  JQ1, a BET protein inhibitor, has antiproliferative activity against many cancers, mainly through inhibition of c-MYC and upregulation of p21.  In this research, we investigated the use of JQ1 for human osteosarcoma (OS) treatment.  JQ1 significantly inhibited the proliferation and survival of OS cells inducing G1 cell cycle arrest, premature senescence, but little effect on apoptosis.  Interestingly, c-MYC protein levels in JQ1-treated cells remained unchanged, whereas the upregulation of p21 protein was still observable.  Although effective in vitro, JQ1 alone failed to reduce the size of the MNNG/HOS xenografts in immunocompromised mice.  To overcome the resistance of OS cells to JQ1 treatment, we combined JQ1 with rapamycin, an mammalian target of rapamycin (mTOR) inhibitor.  JQ1 and rapamycin synergistically inhibited the growth and survival of OS cells in vitro and in vivo.  We also identified that RUNX2 is a direct target of bromodomain-contg. protein 4 (BRD4) inhibition by JQ1 in OS cells.  Chromatin immunopptn. (ChIP) showed that enrichment of BRD4 protein around RUNX2 transcription start sites diminished with JQ1 treatment in MNNG/HOS cells.  Overexpression of RUNX2 protected JQ1-sensitive OS cells from the effect of JQ1, and siRNA-mediated inhibition of RUNX2 sensitized the same cells to JQ1.  In conclusion, our findings suggest that JQ1, in combination with rapamycin, is an effective chemotherapeutic option for OS treatment.  We also show that inhibition of RUNX2 expression by JQ1 partly explains the antiproliferative activity of JQ1 in OS cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0-M1_Sb11LVg90H21EOLACvtfcHk0lgWumGqG7CQNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislegt70%253D&md5=71971e482ce634ae9de6047e94557460</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fijc.29269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29269%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DSaid%26aufirst%3DJ.%2BW.%26aulast%3DDoan%26aufirst%3DN.%2BB.%26aulast%3DForscher%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DSynergistic%2520Effect%2520of%2520JQ1%2520and%2520Rapamycin%2520for%2520Treatment%2520of%2520Human%2520Osteosarcoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D2055%26epage%3D2064%26doi%3D10.1002%2Fijc.29269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Stratikopoulos, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dendy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabolcs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaykin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, R.</span><span> </span><span class="NLM_article-title">Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">851</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.ccell.2015.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26058079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=837-851&author=E.+E.+Stratikopoulosauthor=M.+Dendyauthor=M.+Szabolcsauthor=A.+J.+Khaykinauthor=C.+Lefebvreauthor=M.+M.+Zhouauthor=R.+Parsons&title=Kinase+and+BET+Inhibitors+Together+Clamp+Inhibition+of+PI3K+Signaling+and+Overcome+Resistance+to+Therapy&doi=10.1016%2Fj.ccell.2015.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy</span></div><div class="casAuthors">Stratikopoulos, Elias E.; Dendy, Meaghan; Szabolcs, Matthias; Khaykin, Alan J.; Lefebvre, Celine; Zhou, Ming-Ming; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">837-851</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Unsustained enzyme inhibition is a barrier to targeted therapy for cancer.  Here, resistance to a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was assocd. with feedback activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC.  Inhibitors of bromodomain and extra terminal domain (BET) proteins also failed to affect tumor growth.  Interestingly, BET inhibitors lowered PI3K signaling and dissocd. BRD4 from chromatin at regulatory regions of insulin receptor and EGFR family RTKs to reduce their expression.  Combined PI3K and BET inhibition induced cell death, tumor regression, and clamped inhibition of PI3K signaling in a broad range of tumor cell lines to provide a strategy to overcome resistance to kinase inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmdX2xaXkHjbVg90H21EOLACvtfcHk0lgWumGqG7CQNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejurbK&md5=91cca562c9bff9e11e94535916583867</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DStratikopoulos%26aufirst%3DE.%2BE.%26aulast%3DDendy%26aufirst%3DM.%26aulast%3DSzabolcs%26aufirst%3DM.%26aulast%3DKhaykin%26aufirst%3DA.%2BJ.%26aulast%3DLefebvre%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DKinase%2520and%2520BET%2520Inhibitors%2520Together%2520Clamp%2520Inhibition%2520of%2520PI3K%2520Signaling%2520and%2520Overcome%2520Resistance%2520to%2520Therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D837%26epage%3D851%26doi%3D10.1016%2Fj.ccell.2015.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tinsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meja, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khwaja, A.</span><span> </span><span class="NLM_article-title">Synergistic Induction of Cell Death in Haematological Malignancies by Combined Phosphoinositide-3-Kinase and BET Bromodomain Inhibition</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1111/bjh.13283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fbjh.13283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25640480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A280%3ADC%252BC2MrhsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=275-278&author=S.+Tinsleyauthor=K.+Mejaauthor=C.+Shepherdauthor=A.+Khwaja&title=Synergistic+Induction+of+Cell+Death+in+Haematological+Malignancies+by+Combined+Phosphoinositide-3-Kinase+and+BET+Bromodomain+Inhibition&doi=10.1111%2Fbjh.13283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition</span></div><div class="casAuthors">Tinsley Steven; Meja Koremu; Shepherd Clare; Khwaja Asim</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcfO8VmViEKF1C8OJBvdfbfW6udTcc2eaeCOWuF7zFtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrhsVKmsg%253D%253D&md5=1bd85235d6627429aeac4ddf745cd266</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13283%26sid%3Dliteratum%253Aachs%26aulast%3DTinsley%26aufirst%3DS.%26aulast%3DMeja%26aufirst%3DK.%26aulast%3DShepherd%26aufirst%3DC.%26aulast%3DKhwaja%26aufirst%3DA.%26atitle%3DSynergistic%2520Induction%2520of%2520Cell%2520Death%2520in%2520Haematological%2520Malignancies%2520by%2520Combined%2520Phosphoinositide-3-Kinase%2520and%2520BET%2520Bromodomain%2520Inhibition%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D170%26spage%3D275%26epage%3D278%26doi%3D10.1111%2Fbjh.13283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Widakowich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-12-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1634%2Ftheoncologist.12-12-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18165622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1443-1455&author=C.+Widakowichauthor=G.+de+Castroauthor=E.+de+Azambujaauthor=P.+Dinhauthor=A.+Awada&title=Review%3A+Side+Effects+of+Approved+Molecular+Targeted+Therapies+in+Solid+Cancers&doi=10.1634%2Ftheoncologist.12-12-1443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Review: side effects of approved molecular targeted therapies in solid cancers</span></div><div class="casAuthors">Widakowich, Christian; de Castro, Gilberto, Jr.; de Azambuja, Evandro; Dinh, Phuong; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1443-1455</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Major advances have been achieved in the field of biol. based therapies for cancer in the last few years, and some of the recently approved mol.-targeted therapies are now being used in daily clin. practice.  These mol. targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function.  In general, targeted mol. therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities.  In this article, we review the toxicity and safety of various small mols. and monoclonal antibodies used in solid tumors, with discussion of the pathophysiol., correlation with response, and strategies for prevention and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQLiiHG_Az7Vg90H21EOLACvtfcHk0lgBatyrTHZn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D&md5=56e9026df40a921510114079777e84b7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-12-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-12-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWidakowich%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DDinh%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DReview%253A%2520Side%2520Effects%2520of%2520Approved%2520Molecular%2520Targeted%2520Therapies%2520in%2520Solid%2520Cancers%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1443%26epage%3D1455%26doi%3D10.1634%2Ftheoncologist.12-12-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olesen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schönbrunn, E.</span><span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2360</span><span class="NLM_x">–</span> <span class="NLM_lpage">2365</span><span class="refDoi"> DOI: 10.1021/cb4003283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4003283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2rtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2360-2365&author=M.+P.+Martinauthor=S.+H.+Olesenauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Cyclin-Dependent+Kinase+Inhibitor+Dinaciclib+Interacts+with+the+Acetyl-Lysine+Recognition+Site+of+Bromodomains&doi=10.1021%2Fcb4003283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains</span></div><div class="casAuthors">Martin, Mathew P.; Olesen, Sanne H.; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2360-2365</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. proteins are considered atypical kinases, but their potential to interact with kinase inhibitors is unknown.  Dinaciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), which recently advanced to Phase III clin. trials for the treatment of leukemia.  The authors detd. the crystal structure of dinaciclib in complex with CDK2 at 1.7 Å resoln., revealing an elaborate network of binding interactions in the ATP site, which explains the extraordinary potency and selectivity of this inhibitor.  Remarkably, dinaciclib also interacted with the acetyl-lysine recognition site of the bromodomain testis-specific protein BRDT, a member of the BET family of bromodomains.  The binding mode of dinaciclib to BRDT at 2.0 Å resoln. suggests that general kinase inhibitors (hinge binders) possess a previously unrecognized potential to act as protein-protein inhibitors of bromodomains.  The findings may provide a new structural framework for the design of next-generation bromodomain inhibitors using the vast chem. space of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonrxl9QUxkE7Vg90H21EOLACvtfcHk0lgBatyrTHZn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2rtbvN&md5=1ae089e8e571ad11aadcdc4a1a5769b5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fcb4003283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4003283%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitor%2520Dinaciclib%2520Interacts%2520with%2520the%2520Acetyl-Lysine%2520Recognition%2520Site%2520of%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D2360%26epage%3D2365%26doi%3D10.1021%2Fcb4003283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitors Move into Phase III</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">892</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span><span class="refDoi"> DOI: 10.1038/nrd3908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnrd3908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=892-894&author=M.+Guha&title=Cyclin-Dependent+Kinase+Inhibitors+Move+into+Phase+III&doi=10.1038%2Fnrd3908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrd3908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3908%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitors%2520Move%2520into%2520Phase%2520III%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D892%26epage%3D894%26doi%3D10.1038%2Fnrd3908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Ember, S. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olesen, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schönbrunn, E.</span><span> </span><span class="NLM_article-title">Acetyl-Lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1171</span><span class="refDoi"> DOI: 10.1021/cb500072z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500072z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1160-1171&author=S.+W.+J.+Emberauthor=J.+Y.+Zhuauthor=S.+H.+Olesenauthor=M.+P.+Martinauthor=A.+Beckerauthor=N.+Berndtauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Acetyl-Lysine+Binding+Site+of+Bromodomain-Containing+Protein+4+%28BRD4%29+Interacts+with+Diverse+Kinase+Inhibitors&doi=10.1021%2Fcb500072z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span></div><div class="casAuthors">Ember, Stuart W. J.; Zhu, Jin-Yi; Olesen, Sanne H.; Martin, Mathew P.; Becker, Andreas; Berndt, Norbert; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1171</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research.  In co-crystn. screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and characterized 14 kinase inhibitors (10 distinct chem. scaffolds) as ligands of the KAc binding site.  Among these, the PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 displayed strongest inhibitory potential against BRD4 (IC50 = 25 nM and 130 nM, resp.) and high selectivity for BET bromodomains.  Comparative structural anal. revealed markedly different binding modes of kinase hinge-binding scaffolds in the KAc binding site, suggesting that BET proteins are potential off-targets of diverse kinase inhibitors.  Combined, these findings provide a new structural framework for the rational design of next-generation BET-selective and dual-activity BET-kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0X1hjt7cBbVg90H21EOLACvtfcHk0lgBatyrTHZn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D&md5=5ca37df00cdaa0ba81c0cb4a0f70ba5d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fcb500072z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500072z%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DAcetyl-Lysine%2520Binding%2520Site%2520of%2520Bromodomain-Containing%2520Protein%25204%2520%2528BRD4%2529%2520Interacts%2520with%2520Diverse%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1160%26epage%3D1171%26doi%3D10.1021%2Fcb500072z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Matzuk, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agno, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span> </span><span class="NLM_article-title">Small-Molecule Inhibition of BRDT for Male Contraception</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cell.2012.06.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22901802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aktrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2012&pages=673-684&author=M.+M.+Matzukauthor=M.+R.+McKeownauthor=P.+Filippakopoulosauthor=Q.+Liauthor=L.+Maauthor=J.+E.+Agnoauthor=M.+E.+Lemieuxauthor=S.+Picaudauthor=R.+N.+Yuauthor=J.+Qiauthor=S.+Knappauthor=J.+E.+Bradner&title=Small-Molecule+Inhibition+of+BRDT+for+Male+Contraception&doi=10.1016%2Fj.cell.2012.06.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibition of BRDT for Male Contraception</span></div><div class="casAuthors">Matzuk, Martin M.; McKeown, Michael R.; Filippakopoulos, Panagis; Li, Qinglei; Ma, Lang; Agno, Julio E.; Lemieux, Madeleine E.; Picaud, Sarah; Yu, Richard N.; Qi, Jun; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">673-684</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A pharmacol. approach to male contraception remains a longstanding challenge in medicine.  Toward this objective, the authors explored the spermatogenic effects of a selective small-mol. inhibitor (JQ1) of the bromodomain and extraterminal (BET) subfamily of epigenetic reader proteins.  Here, the authors report potent inhibition of the testis-specific member BRDT, which is essential for chromatin remodeling during spermatogenesis.  Biochem. and crystallog. studies confirm that occupancy of the BRDT acetyl-lysine binding pocket by JQ1 prevents recognition of acetylated histone H4.  Treatment of mice with JQ1 reduced seminiferous tubule area, testis size, and spermatozoa no. and motility without affecting hormone levels.  Although JQ1-treated males mate normally, inhibitory effects of JQ1 evident at the spermatocyte and round spermatid stages cause a complete and reversible contraceptive effect.  These data establish a new contraceptive that can cross the blood:testis boundary and inhibit bromodomain activity during spermatogenesis, providing a lead compd. targeting the male germ cell for contraception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVWUgXTC77Vg90H21EOLACvtfcHk0liy4keoEnwiCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aktrbO&md5=ccfa1b443c156612714e4b7f88590041</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DMatzuk%26aufirst%3DM.%2BM.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DAgno%26aufirst%3DJ.%2BE.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%2BN.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520BRDT%2520for%2520Male%2520Contraception%26jtitle%3DCell%26date%3D2012%26volume%3D150%26spage%3D673%26epage%3D684%26doi%3D10.1016%2Fj.cell.2012.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimlinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haug, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halling, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkumar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span> </span><span class="NLM_article-title">TG101209, a Novel JAK2 Inhibitor, Has Significant in Vitro Activity in Multiple Myeloma and Displays Preferential Cytotoxicity for CD45+ Myeloma Cells</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span><span class="refDoi"> DOI: 10.1002/ajh.21785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1002%2Fajh.21785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20652971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Sqtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2010&pages=675-686&author=V.+Ramakrishnanauthor=T.+Kimlingerauthor=J.+Haugauthor=M.+Timmauthor=L.+Wellikauthor=T.+Hallingauthor=A.+Pardananiauthor=A.+Tefferiauthor=S.+V.+Rajkumarauthor=S.+Kumar&title=TG101209%2C+a+Novel+JAK2+Inhibitor%2C+Has+Significant+in+Vitro+Activity+in+Multiple+Myeloma+and+Displays+Preferential+Cytotoxicity+for+CD45%2B+Myeloma+Cells&doi=10.1002%2Fajh.21785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells</span></div><div class="casAuthors">Ramakrishnan, Vijay; Kimlinger, Teresa; Haug, Jessica; Timm, Michael; Wellik, Linda; Halling, Timothy; Pardanani, Animesh; Tefferi, Ayalew; Rajkumar, Sundararasan Vincent; Kumar, Shaji</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">675-686</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Interaction of myeloma cells with the bone marrow microenvironment is mediated in large part through different cytokines, esp. VEGF and IL6.  These cytokines, esp. IL6, leads to upregulation of the JAK/STAT pathway in myeloma cell, contributing to increased proliferation, decreased apoptosis, and acquired drug resistance.  Here, we examd. the preclin. activity of a novel JAK2 inhibitor TG101209.  TG101209 induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines.  The induction of cytotoxicity was assocd. with inhibition of cell cycle progression and induction of apoptosis in myeloma cell lines and patient-derived plasma cells.  Evaluation of U266 cell lines and patient cells, which have a mix of CD45 pos. and neg. cells, demonstrated more profound cytotoxicity and antiproliferative activity of the drug on the CD45+ population relative to the CD45- cells.  Exploring the mechanism of action of TG101209 indicated downregulation of pJak2, pStat3, and Bcl-xl levels with upregulation of pErk and pAkt levels Indicating cross talk between signaling pathways.  TG101209, when used in combination with the PI3K inhibitor LY294002, demonstrated synergistic cytotoxicity against myeloma cells.  Our results provide the rationale for clin. evaluation of TG101209 alone or in combination with PI3K/Akt inhibitors in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiSxKDxqSHLVg90H21EOLACvtfcHk0liy4keoEnwiCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Sqtb7I&md5=127140bd409441550327c0e32eb67fc3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fajh.21785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21785%26sid%3Dliteratum%253Aachs%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DKimlinger%26aufirst%3DT.%26aulast%3DHaug%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DWellik%26aufirst%3DL.%26aulast%3DHalling%26aufirst%3DT.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DRajkumar%26aufirst%3DS.%2BV.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DTG101209%252C%2520a%2520Novel%2520JAK2%2520Inhibitor%252C%2520Has%2520Significant%2520in%2520Vitro%2520Activity%2520in%2520Multiple%2520Myeloma%2520and%2520Displays%2520Preferential%2520Cytotoxicity%2520for%2520CD45%252B%2520Myeloma%2520Cells%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2010%26volume%3D85%26spage%3D675%26epage%3D686%26doi%3D10.1002%2Fajh.21785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+Selective+JAK2+Inhibitor%2C+in+Treatment+of+a+Murine+Model+of+JAK2V617F-Induced+Polycythemia+Vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lgb_HgAry_Tog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520Selective%2520JAK2%2520Inhibitor%252C%2520in%2520Treatment%2520of%2520a%2520Murine%2520Model%2520of%2520JAK2V617F-Induced%2520Polycythemia%2520Vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lénárt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssák, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gürtler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Krss%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+In+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0lgb_HgAry_Tog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKrss%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurie, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyorffy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munzert, G.</span><span> </span><span class="NLM_article-title">A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together with Pemetrexed in Previously Treated Patients with Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.cllc.2012.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cllc.2012.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=22658814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFSktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=19-27&author=P.+M.+Ellisauthor=Q.+S.+Chuauthor=N.+Leighlauthor=S.+A.+Laurieauthor=H.+Fritschauthor=B.+Gaschler-Markefskiauthor=S.+Gyorffyauthor=G.+Munzert&title=A+Phase+I+Open-Label+Dose-Escalation+Study+of+Intravenous+BI+2536+Together+with+Pemetrexed+in+Previously+Treated+Patients+with+Non-Small-Cell+Lung+Cancer&doi=10.1016%2Fj.cllc.2012.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Ellis, Peter M.; Chu, Quincy S.; Leighl, Natasha; Laurie, Scott A.; Fritsch, Holger; Gaschler-Markefski, Birgit; Gyorffy, Steve; Munzert, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1.  This open-label, phase I study investigated the max. tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with std.-dose pemetrexed in previously treated advanced or metastatic non-small-cell lung cancer.  A std. 3 + 3 design was used.  The patients received 500 mg/m2 pemetrexed and escalating doses of BI 2536 on day 1 every 3 wk.  The primary objective was the MTD of BI 2536 combined with pemetrexed.  Secondary endpoints were response rate (Response Evaluation Criteria in Solid Tumors), overall safety, and PK.  Forty-one patients received BI 2536 (100-325 mg).  Two dose-limiting toxicities (DLT) occurred at BI 2536 325 mg (grade 3 pruritus and rash; grade 4 neutropenia).  Therefore, the MTD for BI 2536 in combination with pemetrexed was 300 mg.  After expanding the MTD dose level, 3 addnl. patients experienced DLTs, which resulted in expansion of the 250 mg cohort, in which 4 of the 13 addnl. patients experienced DLTs.  Therefore, the recommended dose of BI 2536 was 200 mg.  Most frequently reported drug-related adverse events were fatigue (71%), nausea (37%), and rash (34%).  Two patients had durable confirmed partial responses; 21 (54%) patients had stable disease after the treatment cycle 2.  PK anal. showed that BI 2536 and pemetrexed exposure were not altered when coadministered.  BI 2536 200 mg combined with std.-dose pemetrexed has an acceptable safety profile in relapsed non-small-cell lung cancer.  The antitumor activity obsd. is encouraging and supports further investigation of Plk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwPCdEZCOOD7Vg90H21EOLACvtfcHk0lgb_HgAry_Tog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFSktrrI&md5=35a269b8c6c75aba0578ea3bfc441d43</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2012.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2012.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DChu%26aufirst%3DQ.%2BS.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DGyorffy%26aufirst%3DS.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Open-Label%2520Dose-Escalation%2520Study%2520of%2520Intravenous%2520BI%25202536%2520Together%2520with%2520Pemetrexed%2520in%2520Previously%2520Treated%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2013%26volume%3D14%26spage%3D19%26epage%3D27%26doi%3D10.1016%2Fj.cllc.2012.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Dittmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitski, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fälth Savitski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewes, G.</span><span> </span><span class="NLM_article-title">The Commonly Used PI3-Kinase Probe LY294002 is an Inhibitor of BET Bromodomains</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1021/cb400789e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400789e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=495-502&author=A.+Dittmannauthor=T.+Wernerauthor=C.+W.+Chungauthor=M.+M.+Savitskiauthor=M.+F%C3%A4lth+Savitskiauthor=P.+Grandiauthor=C.+Hopfauthor=M.+Lindonauthor=G.+Neubauerauthor=R.+K.+Prinjhaauthor=M.+Bantscheffauthor=G.+Drewes&title=The+Commonly+Used+PI3-Kinase+Probe+LY294002+is+an+Inhibitor+of+BET+Bromodomains&doi=10.1021%2Fcb400789e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span></div><div class="casAuthors">Dittmann, Antje; Werner, Thilo; Chung, Chun-Wa; Savitski, Mikhail M.; Faelth Savitski, Maria; Grandi, Paola; Hopf, Carsten; Lindon, Matthew; Neubauer, Gitte; Prinjha, Rabinder K.; Bantscheff, Marcus; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A commonly used small-mol. probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002.  Quant. chemoproteomic profiling shows that LY294002 and LY303511, a close analog devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.  Both compds. competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell exts.  X-ray crystallog. shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbIVXFQARTKLVg90H21EOLACvtfcHk0lg3yeHErmOvAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO&md5=13435c7d6a6747dc5699e3c3865c8243</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fcb400789e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400789e%26sid%3Dliteratum%253Aachs%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DF%25C3%25A4lth%2BSavitski%26aufirst%3DM.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThe%2520Commonly%2520Used%2520PI3-Kinase%2520Probe%2520LY294002%2520is%2520an%2520Inhibitor%2520of%2520BET%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D495%26epage%3D502%26doi%3D10.1021%2Fcb400789e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&author=P.+Ciceriauthor=S.+M%C3%BCllerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+a+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0lg3yeHErmOvAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2Ba%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Sapkota, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">BI-D1870 is a Specific Inhibitor of the p90 RSK (Ribosomal S6 Kinase) Isoforms in Vitro and in Vivo</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1042/BJ20061088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1042%2FBJ20061088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2007&pages=29-38&author=G.+P.+Sapkotaauthor=L.+Cummingsauthor=F.+S.+Newellauthor=C.+Armstrongauthor=J.+Bainauthor=M.+Frodinauthor=M.+Grauertauthor=M.+Hoffmannauthor=G.+Schnappauthor=M.+Steegmaierauthor=P.+Cohenauthor=D.+R.+Alessi&title=BI-D1870+is+a+Specific+Inhibitor+of+the+p90+RSK+%28Ribosomal+S6+Kinase%29+Isoforms+in+Vitro+and+in+Vivo&doi=10.1042%2FBJ20061088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1042%2FBJ20061088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20061088%26sid%3Dliteratum%253Aachs%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26aulast%3DCummings%26aufirst%3DL.%26aulast%3DNewell%26aufirst%3DF.%2BS.%26aulast%3DArmstrong%26aufirst%3DC.%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DFrodin%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DSchnapp%26aufirst%3DG.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DBI-D1870%2520is%2520a%2520Specific%2520Inhibitor%2520of%2520the%2520p90%2520RSK%2520%2528Ribosomal%2520S6%2520Kinase%2529%2520Isoforms%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D401%26spage%3D29%26epage%3D38%26doi%3D10.1042%2FBJ20061088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span> </span><span class="NLM_article-title">Selectivity-Determining Residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.+H.+Ding&title=Selectivity-Determining+Residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0lh770ho-ynGjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%2BH.%26atitle%3DSelectivity-Determining%2520Residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shorr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1200/JCO.2010.32.8021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1200%2FJCO.2010.32.8021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=21220608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlelsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=789-796&author=A.+Pardananiauthor=J.+R.+Gotlibauthor=C.+Jamiesonauthor=J.+E.+Cortesauthor=M.+Talpazauthor=R.+M.+Stoneauthor=M.+H.+Silvermanauthor=D.+G.+Gillilandauthor=J.+Shorrauthor=A.+Tefferi&title=Safety+and+Efficacy+of+TG101348%2C+a+Selective+JAK2+Inhibitor%2C+in+Myelofibrosis&doi=10.1200%2FJCO.2010.32.8021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Pardanani, Animesh; Gotlib, Jason R.; Jamieson, Catriona; Cortes, Jorge E.; Talpaz, Moshe; Stone, Richard M.; Silverman, Michael H.; Gilliland, D. Gary; Shorr, Jolene; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-796</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Myelofibrosis is a myeloid malignancy assocd. with anemia, splenomegaly, and constitutional symptoms.  Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-mol. Janus kinase 2 (JAK2) inhibitor.  Patients and Methods In a multicenter phase I trial, oral TG101348 was administered once a day to patients with high- or intermediate-risk primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.  Results Fifty-nine patients were treated, including 28 in the dose-escalation phase.  The max.-tolerated dose was 680 mg/d, and dose-limiting toxicity was a reversible and asymptomatic increase in the serum amylase level.  Forty-three patients (73%) continued treatment beyond six cycles; the median cumulative exposure to TG101348 was 380 days.  Adverse events included nausea, vomiting, diarrhea, anemia, and thrombocytopenia; corresponding grades 3 to 4 incidence rates were 3%, 3%, 10%, 35%, and 24%.  TG101348 treatment had modest effect on serum cytokine levels, but greater than half of the patients with early satiety, night sweats, fatigue, pruritus, and cough achieved rapid and durable improvement in these symptoms.  By six and 12 cycles of treatment, 39% and 47% of patients, resp., had achieved a spleen response per International Working Group criteria.  The majority of patients with leukocytosis or thrombocytosis at baseline (n = 28 and n = 10, resp.) achieved normalization of blood counts after six (57% and 90%, resp.) and 12 (56% and 88%, resp.) cycles.  A significant decrease in JAK2 V617F allele burden was obsd. at 6 mo in mutation-pos. patients (n = 51; P = .04), particularly in the subgroup with allele burden greater than 20% (n = 23; P < .01); the decrease was durable at 12 mo.  Conclusion TG101348 is well tolerated and produces significant redn. in disease burden and durable clin. benefit in patients with myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH4BD7RVGmfLVg90H21EOLACvtfcHk0lh770ho-ynGjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlelsL0%253D&md5=8b69a31d9dcf09b3b121e477f98d103b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.8021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.8021%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DGotlib%26aufirst%3DJ.%2BR.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSilverman%26aufirst%3DM.%2BH.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DShorr%26aufirst%3DJ.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520TG101348%252C%2520a%2520Selective%2520JAK2%2520Inhibitor%252C%2520in%2520Myelofibrosis%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D789%26epage%3D796%26doi%3D10.1200%2FJCO.2010.32.8021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanning, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountain, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheenstra, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strovel, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=764-769&author=L.+Chenauthor=J.+L.+Yapauthor=M.+Yoshiokaauthor=M.+E.+Lanningauthor=R.+N.+Fountainauthor=M.+Rajeauthor=J.+A.+Scheenstraauthor=J.+W.+Strovelauthor=S.+Fletcher&title=BRD4+Structure%E2%80%93Activity+Relationships+of+Dual+PLK1+Kinase%2FBRD4+Bromodomain+Inhibitor+BI-2536&doi=10.1021%2Facsmedchemlett.5b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span></div><div class="casAuthors">Chen, Lijia; Yap, Jeremy L.; Yoshioka, Makoto; Lanning, Maryanna E.; Fountain, Rachel N.; Raje, Mithun; Scheenstra, Jacob A.; Strovel, Jeffrey W.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">764-769</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused library of analogs of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepd. and then analyzed for BRD4 and PLK1 inhibitory activities.  Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiety afforded the most potent BRD4 inhibitor of the series (39j) with a Ki = 8.7 nM, which was equipotent against PLK1.  The superior affinity of 39j over the parental compd. to BRD4 possibly derives from improved interactions with the WPF shelf.  Meanwhile, substitution of the pyrimidine NH with an oxygen atom reversed the PLK1/BRD4 selectivity to convert BI-2536 into a BRD4-selective inhibitor, likely owing to the loss of a crit. hydrogen bond in PLK1.  We believe further fine-tuning will furnish a BRD4 "magic bullet" or an even more potent PLK1/BRD4 dual inhibitor toward the expansion and improved efficacy of the chemotherapy arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5UnNSmf1L17Vg90H21EOLACvtfcHk0lg3VF7XuK9pwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D&md5=f39070e652bca20c03a3bc5fe070a7fc</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DYoshioka%26aufirst%3DM.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DFountain%26aufirst%3DR.%2BN.%26aulast%3DRaje%26aufirst%3DM.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DStrovel%26aufirst%3DJ.%2BW.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DBRD4%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Dual%2520PLK1%2520Kinase%252FBRD4%2520Bromodomain%2520Inhibitor%2520BI-2536%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D764%26epage%3D769%26doi%3D10.1021%2Facsmedchemlett.5b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Allen, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ember, S. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbrunn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schürer, S. C.</span><span> </span><span class="NLM_article-title">Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">16924</span><span class="refDoi"> DOI: 10.1038/srep16924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsrep16924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26596901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFentrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16924&author=B.+K.+Allenauthor=S.+Mehtaauthor=S.+W.+J.+Emberauthor=E.+Schonbrunnauthor=N.+Ayadauthor=S.+C.+Sch%C3%BCrer&title=Large-Scale+Computational+Screening+Identifies+First+in+Class+Multitarget+Inhibitor+of+EGFR+Kinase+and+BRD4&doi=10.1038%2Fsrep16924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4</span></div><div class="casAuthors">Allen, Bryce K.; Mehta, Saurabh; Ember, Stewart W. J.; Schonbrunn, Ernst; Ayad, Nagi; Schurer, Stephan C.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16924</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common.  One way to overcome resistance is to target orthogonal cancer-promoting pathways.  Bromo and Extra-Terminal (BET) domain proteins, which belong to the family of epigenetic readers, have recently emerged as promising therapeutic targets in multiple cancers.  The development of multitarget drugs that inhibit kinase and BET proteins therefore may be a promising strategy to overcome tumor resistance and prolong therapeutic efficacy in the clinic.  We developed a general computational screening approach to identify novel dual kinase/bromodomain inhibitors from millions of com. available small mols.  Our method integrated machine learning using big datasets of kinase inhibitors and structure-based drug design.  Here we describe the computational methodol., including validation and characterization of our models and their application and integration into a scalable virtual screening pipeline.  We screened over 6 million com. available compds. and selected 24 for testing in BRD4 and EGFR biochem. assays.  We identified several novel BRD4 inhibitors, among them a first in class dual EGFR-BRD4 inhibitor.  Our studies suggest that this computational screening approach may be broadly applicable for identifying dual kinase/BET inhibitors with potential for treating various cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2LBJWDL9se7Vg90H21EOLACvtfcHk0lg3VF7XuK9pwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFentrrI&md5=341f9fedbdfd9e66829e5c43d602d510</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fsrep16924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16924%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DB.%2BK.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DAyad%26aufirst%3DN.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26atitle%3DLarge-Scale%2520Computational%2520Screening%2520Identifies%2520First%2520in%2520Class%2520Multitarget%2520Inhibitor%2520of%2520EGFR%2520Kinase%2520and%2520BRD4%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16924%26doi%3D10.1038%2Fsrep16924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Burris, A. H.,  III</span><span> </span><span class="NLM_article-title">Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1634/theoncologist.9-suppl_3-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1634%2Ftheoncologist.9-suppl_3-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15163842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=10-15&author=A.+H.+Burris&title=Dual+Kinase+Inhibition+in+the+Treatment+of+Breast+Cancer%3A+Initial+Experience+with+the+EGFR%2FErbB-2+Inhibitor+Lapatinib&doi=10.1634%2Ftheoncologist.9-suppl_3-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib</span></div><div class="casAuthors">Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">10-15</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Dual inhibition of ErbB-1 (EGFR) and ErbB-2 (HER-2) tyrosine kinases has been found to exert greater biol. effects in the inhibition of signaling pathways promoting cancer cell proliferation and survival than inhibition of either receptor alone.  The novel dual EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; Research Triangle Park, NC) has been shown to inhibit tumor cell growth in vitro and in xenograft models for a variety of human tumors.  Preliminary findings in a phase I study of lapatinib in patients with solid tumors indicate doses up to 1,800 mg per day are well tolerated.  No grade 4 toxicities were obsd. and only two of 43 patients had grade 3 toxicity (diarrhea).  Clin. activity of lapatinib was obsd. in these patients; nine patients with a variety of tumors remained on study for ≥4 mo, one with a complete response (head and neck cancer).  In a phase IB study in pretreated metastatic cancer patients with disease that could be biopsied, grade 1 or 2 diarrhea and rash were the most common adverse events.  Three patients with breast cancer refractory to trastuzumab (Herceptin; Genentech, Inc.; South San Francisco, CA) had partial responses and 12 patients with a variety of tumors had stable disease.  Assessment of biol. correlates in these patients indicates that increased tumor cell apoptosis on the terminal deoxynucleotide transferase-mediated dUTP nick-end labeling assay correlates with clin. response.  Lapatinib currently is being evaluated in phase II and phase III trials in patients with metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynMnAi22a_rVg90H21EOLACvtfcHk0lg3VF7XuK9pwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFOju7g%253D&md5=b1b91091896f42356f369ba20f6c39de</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.9-suppl_3-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.9-suppl_3-10%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DA.%2BH.%26atitle%3DDual%2520Kinase%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520Breast%2520Cancer%253A%2520Initial%2520Experience%2520with%2520the%2520EGFR%252FErbB-2%2520Inhibitor%2520Lapatinib%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D10%26epage%3D15%26doi%3D10.1634%2Ftheoncologist.9-suppl_3-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Stuhlmiller, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistowski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, K. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuther, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuan, P.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. L.</span><span> </span><span class="NLM_article-title">Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.celrep.2015.03.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=25865888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVCjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=390-404&author=T.+J.+Stuhlmillerauthor=S.+M.+Millerauthor=J.+S.+Zawistowskiauthor=K.+Nakamuraauthor=A.+S.+Beltranauthor=J.+S.+Duncanauthor=S.+P.+Angusauthor=K.+A.+L.+Collinsauthor=D.+A.+Grangerauthor=R.+A.+Reutherauthor=L.+M.+Gravesauthor=S.+M.+Gomezauthor=P.-F.+Kuanauthor=J.+S.+Parkerauthor=X.+Chenauthor=N.+Sciakyauthor=L.+A.+Careyauthor=H.+S.+Earpauthor=J.+Jinauthor=G.+L.+Johnson&title=Inhibition+of+Lapatinib-Induced+Kinome+Reprogramming+in+ERBB2-Positive+Breast+Cancer+by+Targeting+BET+Family+Bromodomains&doi=10.1016%2Fj.celrep.2015.03.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains</span></div><div class="casAuthors">Stuhlmiller, Timothy J.; Miller, Samantha M.; Zawistowski, Jon S.; Nakamura, Kazuhiro; Beltran, Adriana S.; Duncan, James S.; Angus, Steven P.; Collins, Kyla A. L.; Granger, Deborah A.; Reuther, Rachel A.; Graves, Lee M.; Gomez, Shawn M.; Kuan, Pei-Fen; Parker, Joel S.; Chen, Xin; Sciaky, Noah; Carey, Lisa A.; Earp, H. Shelton; Jin, Jian; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-404</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Therapeutics that target ERBB2, such as lapatinib, often provide initial clin. benefit, but resistance frequently develops.  Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activation of multiple tyrosine kinases.  The heterogeneity of induced kinases prevents their targeting by a single kinase inhibitor, underscoring the challenge of predicting effective kinase inhibitor combination therapies.  We hypothesized that, to make the tumor response to single kinase inhibitors durable, the adaptive kinome response itself must be inhibited.  Genetic and chem. inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.  Combining inhibitors of kinases and chromatin readers prevents kinome adaptation by blocking transcription, generating a durable response to lapatinib, and overcoming the dilemma of heterogeneity in the adaptive response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroE3zQ9yBs3LVg90H21EOLACvtfcHk0lgqdhhvfJRpxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVCjsr4%253D&md5=c1f91643c2ff7034d7c44aa93653ab27</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DS.%2BM.%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DCollins%26aufirst%3DK.%2BA.%2BL.%26aulast%3DGranger%26aufirst%3DD.%2BA.%26aulast%3DReuther%26aufirst%3DR.%2BA.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DGomez%26aufirst%3DS.%2BM.%26aulast%3DKuan%26aufirst%3DP.-F.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DInhibition%2520of%2520Lapatinib-Induced%2520Kinome%2520Reprogramming%2520in%2520ERBB2-Positive%2520Breast%2520Cancer%2520by%2520Targeting%2520BET%2520Family%2520Bromodomains%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D11%26spage%3D390%26epage%3D404%26doi%3D10.1016%2Fj.celrep.2015.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+Determinants+of+Phosphoinositide+3-Kinase+Inhibition+by+Wortmannin%2C+LY294002%2C+Quercetin%2C+Myricetin%2C+and+Staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lgqdhhvfJRpxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520Determinants%2520of%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520by%2520Wortmannin%252C%2520LY294002%252C%2520Quercetin%252C%2520Myricetin%252C%2520and%2520Staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Morales, G. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlich, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newblom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durden, D. L.</span><span> </span><span class="NLM_article-title">Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-B]pyran-7-Ones Designed as next Generation PI3K Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1922</span><span class="NLM_x">–</span> <span class="NLM_lpage">1939</span><span class="refDoi"> DOI: 10.1021/jm301522m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301522m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1922-1939&author=G.+a+Moralesauthor=J.+R.+Garlichauthor=J.+Suauthor=X.+Pengauthor=J.+Newblomauthor=K.+Weberauthor=D.+L.+Durden&title=Synthesis+and+Cancer+Stem+Cell-Based+Activity+of+Substituted+5-Morpholino-7H-thieno%5B3%2C2-B%5Dpyran-7-Ones+Designed+as+next+Generation+PI3K+Inhibitors&doi=10.1021%2Fjm301522m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm301522m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301522m%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DG.%2Ba%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DNewblom%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DK.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DSynthesis%2520and%2520Cancer%2520Stem%2520Cell-Based%2520Activity%2520of%2520Substituted%25205-Morpholino-7H-thieno%255B3%252C2-B%255Dpyran-7-Ones%2520Designed%2520as%2520next%2520Generation%2520PI3K%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1922%26epage%3D1939%26doi%3D10.1021%2Fjm301522m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span>SignalRX Pharmaceuticals. Product Candidates, PI3K Pipeline. 2015. <a href="http://www.signalrx.com/signal-Rx/product-candidates/pi3k/" class="extLink">http://www.signalrx.com/signal-Rx/product-candidates/pi3k/</a> (accessed January 16,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SignalRX+Pharmaceuticals.+Product+Candidates%2C+PI3K+Pipeline.+2015.+http%3A%2F%2Fwww.signalrx.com%2Fsignal-Rx%2Fproduct-candidates%2Fpi3k%2F+%28accessed+January+16%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Singh, A. R.; Joshi, S.; Garlich, J. R.; Morales, G. A.; Durden, D. L.</span><span> </span><span class="NLM_article-title">Dual PI3K/BRD4 (Kinase/Epigenetic) Inhibitors for Maximal MYC Control in Cancer Therapeutics</span>. AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Philadelphia, PA, September 14–17,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract A27. <a href="http://mct.aacrjournals.org/content/14/7_Supplement/A27.abstract/" class="extLink">http://mct.aacrjournals.org/content/14/7_Supplement/A27.abstract/</a> (accessed January 16, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+R.+Singh&author=S.+Joshi&author=J.+R.+Garlich&author=G.+A.+Morales&author=D.+L.+Durden&title=Dual+PI3K%2FBRD4+%28Kinase%2FEpigenetic%29+Inhibitors+for+Maximal+MYC+Control+in+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BR.%26atitle%3DDual%2520PI3K%252FBRD4%2520%2528Kinase%252FEpigenetic%2529%2520Inhibitors%2520for%2520Maximal%2520MYC%2520Control%2520in%2520Cancer%2520Therapeutics%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Morales, G. A.; Weber, K. T.; Newblom, J. M.; Peng, X.; Su, J.; Garlich, J. R.</span><span> </span><span class="NLM_article-title">Thienopyranones as Kinase Inhibitors</span>. U.S. Patent 8557807, October 15,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+A.+Morales&author=K.+T.+Weber&author=J.+M.+Newblom&author=X.+Peng&author=J.+Su&author=J.+R.+Garlich&title=Thienopyranones+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DG.%2BA.%26atitle%3DThienopyranones%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, L.</span><span> </span><span class="NLM_article-title">Computational Polypharmacology Comes of Age</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.3389/fphar.2015.00157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.3389%2Ffphar.2015.00157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=26283966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=157&author=G.+Rastelliauthor=L.+Pinzi&title=Computational+Polypharmacology+Comes+of+Age&doi=10.3389%2Ffphar.2015.00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Computational polypharmacology comes of age</span></div><div class="casAuthors">Rastelli, Giulio; Pinzi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/4</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the predicting drug polypharmacol., the raising no. of computational strategies, frameworks developed at testify that computational polypharmacol. has come of age and increasingly important role in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiapZ3lz9l4rVg90H21EOLACvtfcHk0lgkZe9yOSZOhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI&md5=4444f48a7d9c80f30a4d9dbf3f6ba2be</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00157%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DPinzi%26aufirst%3DL.%26atitle%3DComputational%2520Polypharmacology%2520Comes%2520of%2520Age%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D157%26doi%3D10.3389%2Ffphar.2015.00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Dixon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smondyrev, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening: 1. Methodology and Preliminary Results</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span><span class="refDoi"> DOI: 10.1007/s10822-006-9087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1007%2Fs10822-006-9087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17124629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCksbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=647-671&author=S.+L.+Dixonauthor=A.+M.+Smondyrevauthor=E.+H.+Knollauthor=S.+N.+Raoauthor=D.+E.+Shawauthor=R.+A.+Friesner&title=PHASE%3A+A+New+Engine+for+Pharmacophore+Perception%2C+3D+QSAR+Model+Development%2C+and+3D+Database+Screening%3A+1.+Methodology+and+Preliminary+Results&doi=10.1007%2Fs10822-006-9087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">PHASE: A new design for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results</span></div><div class="casAuthors">Dixon, Steven L.; Smondyrev, Alexander M.; Knoll, Eric H.; Rao, Shashidhar N.; Shaw, David E.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10/11</span>),
    <span class="NLM_cas:pages">647-671</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We introduce PHASE, a highly flexible system for common pharmacophore identification and assessment, 3D QSAR model development, and 3D database creation and searching.  The primary workflows and tasks supported by PHASE are described, and details of the underlying scientific methodologies are provided. Using results from previously published investigations, PHASE is compared directly to other ligand-based software for its ability to identify target pharmacophores, rationalize structure-activity data, and predict activities of external compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof5WS3oFk3MLVg90H21EOLACvtfcHk0lgkZe9yOSZOhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCksbvE&md5=512f55e6e3c3dfbae3fc94886482b69a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1007%2Fs10822-006-9087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-006-9087-6%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DS.%2BL.%26aulast%3DSmondyrev%26aufirst%3DA.%2BM.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DRao%26aufirst%3DS.%2BN.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DPHASE%253A%2520A%2520New%2520Engine%2520for%2520Pharmacophore%2520Perception%252C%25203D%2520QSAR%2520Model%2520Development%252C%2520and%25203D%2520Database%2520Screening%253A%25201.%2520Methodology%2520and%2520Preliminary%2520Results%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2006%26volume%3D20%26spage%3D647%26epage%3D671%26doi%3D10.1007%2Fs10822-006-9087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Dixon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smondyrev, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. N.</span><span> </span><span class="NLM_article-title">PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2006.00384.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1111%2Fj.1747-0285.2006.00384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=16784462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVeqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=370-372&author=S.+L.+Dixonauthor=A.+M.+Smondyrevauthor=S.+N.+Rao&title=PHASE%3A+A+Novel+Approach+to+Pharmacophore+Modeling+and+3D+Database+Searching&doi=10.1111%2Fj.1747-0285.2006.00384.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approach to pharmacophore modeling and 3D database searching</span></div><div class="casAuthors">Dixon, Steven L.; Smondyrev, Alexander M.; Rao, Shashidhar N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">370-372</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Pharmacophore modeling and 3D database searching are now recognized as integral components of lead discovery and lead optimization, and the continuing need for improved pharmacophore-based tools has driven the development of PHASE.  PHASE pharmacophore and 3D QSAR models provide a means for rationalizing structure-activity data, predicting the activity of new compds., and efficiently extg. actives from a prototypical database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50KpRHTGgAbVg90H21EOLACvtfcHk0lgkZe9yOSZOhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVeqsbg%253D&md5=30d06fe99776e203eed35b0f774bbe64</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2006.00384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2006.00384.x%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DS.%2BL.%26aulast%3DSmondyrev%26aufirst%3DA.%2BM.%26aulast%3DRao%26aufirst%3DS.%2BN.%26atitle%3DPHASE%253A%2520A%2520Novel%2520Approach%2520to%2520Pharmacophore%2520Modeling%2520and%25203D%2520Database%2520Searching%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D370%26epage%3D372%26doi%3D10.1111%2Fj.1747-0285.2006.00384.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Friesner, R. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. a</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+a+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+a+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+New+Approach+for+Rapid%2C+Accurate+Docking+and+Scoring.+1.+Method+and+Assessment+of+Docking+Accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lgTrkkK7H-lwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2Ba%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2Ba%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520New%2520Approach%2520for%2520Rapid%252C%2520Accurate%2520Docking%2520and%2520Scoring.%25201.%2520Method%2520and%2520Assessment%2520of%2520Docking%2520Accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Muvva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singam, E. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raman, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, V.</span><span> </span><span class="NLM_article-title">Structure-Based Virtual Screening of Novel, High-Affinity BRD4 Inhibitors</span> <span class="citation_source-journal">Mol. BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2397</span><span class="refDoi"> DOI: 10.1039/C4MB00243A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1039%2FC4MB00243A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=24976024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOis7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=2384-2397&author=C.+Muvvaauthor=E.+R.+A.+Singamauthor=S.+S.+Ramanauthor=V.+Subramanian&title=Structure-Based+Virtual+Screening+of+Novel%2C+High-Affinity+BRD4+Inhibitors&doi=10.1039%2FC4MB00243A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based virtual screening of novel, high-affinity BRD4 inhibitors</span></div><div class="casAuthors">Muvva, Charuvaka; Singam, E. R. Azhagiya; Raman, S. Sundar; Subramanian, V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2384-2397</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are a diverse family of evolutionarily conserved protein-interaction modules.  Among various members of the bromodomain and extra terminal domain family, BRD4 is found to be an important target for many diseases such as cancer, acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, etc.  Therefore, in this study an attempt has been made to screen compds. from NCI Diversity, Drug Bank and Toslab Databases targeting the Kac binding site of BRD4 using mol. docking, mol. dynamics simulations, MM-PB/GBSA binding free energy calcns. and steered mol. dynamics simulations.  Using virtual screening and docking, we have identified 11 inhibitors.  These new inhibitors exhibit binding energy values higher than that of the (+)JQ1 inhibitor which is effective against BRD4.  However, due to the toxicity of (+)JQ1, the designing of new inhibitors becomes significantly important.  Thus, these new 11 ligands were systematically analyzed using other computational investigations.  Results reveal that the compds. ZINC01411240, ZINC19632618 and ZINC04818522 could be potential drug candidates for targeting BRD4.  It can also be seen from the results that there is a linear relationship between the results obtained from the SMD simulation and free energy obtained from the MM-PBSA/GBSA approach.  This study clearly illustrates that the steered mol. dynamics can be effectively used for the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3go7Pz1QUrVg90H21EOLACvtfcHk0lgTrkkK7H-lwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOis7nP&md5=81005695a0cb0efa88b6b7fefaa768c7</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1039%2FC4MB00243A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MB00243A%26sid%3Dliteratum%253Aachs%26aulast%3DMuvva%26aufirst%3DC.%26aulast%3DSingam%26aufirst%3DE.%2BR.%2BA.%26aulast%3DRaman%26aufirst%3DS.%2BS.%26aulast%3DSubramanian%26aufirst%3DV.%26atitle%3DStructure-Based%2520Virtual%2520Screening%2520of%2520Novel%252C%2520High-Affinity%2520BRD4%2520Inhibitors%26jtitle%3DMol.%2520BioSyst.%26date%3D2014%26volume%3D10%26spage%3D2384%26epage%3D2397%26doi%3D10.1039%2FC4MB00243A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Duffy, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsia, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharenko, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesner, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLure, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshminarasimhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D. B.</span><span> </span><span class="NLM_article-title">Discovery of a New Chemical Series of BRD4(1) Inhibitors Using Protein-Ligand Docking and Structure-Guided Design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2818</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2015.04.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2818-2823&author=B.+C.+Duffyauthor=S.+Liuauthor=G.+S.+Martinauthor=R.+Wangauthor=M.+M.+Hsiaauthor=H.+Zhaoauthor=C.+Guoauthor=M.+Ellisauthor=J.+F.+Quinnauthor=O.+A.+Kharenkoauthor=K.+Norekauthor=E.+M.+Gesnerauthor=P.+R.+Youngauthor=K.+G.+McLureauthor=G.+S.+Wagnerauthor=D.+Lakshminarasimhanauthor=A.+Whiteauthor=R.+K.+Sutoauthor=H.+C.+Hansenauthor=D.+B.+Kitchen&title=Discovery+of+a+New+Chemical+Series+of+BRD4%281%29+Inhibitors+Using+Protein-Ligand+Docking+and+Structure-Guided+Design&doi=10.1016%2Fj.bmcl.2015.04.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.107%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DB.%2BC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DHsia%26aufirst%3DM.%2BM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DEllis%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DKharenko%26aufirst%3DO.%2BA.%26aulast%3DNorek%26aufirst%3DK.%26aulast%3DGesner%26aufirst%3DE.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DMcLure%26aufirst%3DK.%2BG.%26aulast%3DWagner%26aufirst%3DG.%2BS.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DSuto%26aufirst%3DR.%2BK.%26aulast%3DHansen%26aufirst%3DH.%2BC.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Chemical%2520Series%2520of%2520BRD4%25281%2529%2520Inhibitors%2520Using%2520Protein-Ligand%2520Docking%2520and%2520Structure-Guided%2520Design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2818%26epage%3D2823%26doi%3D10.1016%2Fj.bmcl.2015.04.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartenmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Discovery of BRD4 Bromodomain Inhibitors by Fragment-Based High-Throughput Docking</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2496</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2014.04.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2493-2496&author=H.+Zhaoauthor=L.+Gartenmannauthor=J.+Dongauthor=D.+Spiliotopoulosauthor=A.+Caflisch&title=Discovery+of+BRD4+Bromodomain+Inhibitors+by+Fragment-Based+High-Throughput+Docking&doi=10.1016%2Fj.bmcl.2014.04.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGartenmann%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520BRD4%2520Bromodomain%2520Inhibitors%2520by%2520Fragment-Based%2520High-Throughput%2520Docking%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2493%26epage%3D2496%26doi%3D10.1016%2Fj.bmcl.2014.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Discovery of Benzo[cd]indol-2(1H)-Ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization and Biological Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1565</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01511</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01511" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1565-1579&author=X.+Xueauthor=Y.+Zhangauthor=Z.+Liuauthor=M.+Songauthor=Y.+Xingauthor=Q.+Xiangauthor=Z.+Wangauthor=Z.-C.+Tuauthor=Y.+Zhouauthor=K.+Dingauthor=Y.+Xu&title=Discovery+of+Benzo%5Bcd%5Dindol-2%281H%29-Ones+as+Potent+and+Specific+BET+Bromodomain+Inhibitors%3A+Structure-Based+Virtual+Screening%2C+Optimization+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.5b01511"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01511%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Benzo%255Bcd%255Dindol-2%25281H%2529-Ones%2520as%2520Potent%2520and%2520Specific%2520BET%2520Bromodomain%2520Inhibitors%253A%2520Structure-Based%2520Virtual%2520Screening%252C%2520Optimization%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1565%26epage%3D1579%26doi%3D10.1021%2Facs.jmedchem.5b01511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Hügle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostrovskyi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breit, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einsle, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlwend, D.</span><span> </span><span class="NLM_article-title">4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1518</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1518-1530&author=M.+H%C3%BCgleauthor=X.+Lucasauthor=G.+Weitzelauthor=D.+Ostrovskyiauthor=B.+Breitauthor=S.+Gerhardtauthor=O.+Einsleauthor=S.+G%C3%BCntherauthor=D.+Wohlwend&title=4-Acyl+Pyrrole+Derivatives+Yield+Novel+Vectors+for+Designing+Inhibitors+of+the+Acetyl-Lysine+Recognition+Site+of+BRD4%281%29&doi=10.1021%2Facs.jmedchem.5b01267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1)</span></div><div class="casAuthors">Huegle, Martin; Lucas, Xavier; Weitzel, Gerhard; Ostrovskyi, Dmytro; Breit, Bernhard; Gerhardt, Stefan; Einsle, Oliver; Guenther, Stefan; Wohlwend, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1518-1530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several human diseases, including cancer, show altered signaling pathways resulting from changes in the activity levels of epigenetic modulators.  In the past few years, small-mol. inhibitors against specific modulators, including the bromodomain and extra-terminal (BET) bromodomain family of acetylation readers, have shown early promise in the treatment of the genetically defined midline carcinoma and hematopoietic malignancies.  We have recently developed a novel potent inhibitor of BET proteins, 1 (XD14), which exerts a strong inhibitory potential on the proliferation of specific leukemia cell lines.  In the study presented here, we designed analogs of 1 to study the potential of substitutions on the 4-acyl pyrrole backbone to occupy addnl. sites within the substrate recognition site of BRD4(1).  The compds. were profiled using ITC, DSF, and X-ray crystallog.  We could introduce several substitutions that address previously untargeted areas of the substrate recognition site.  This work may substantially contribute to the development of therapeutics with increased target specificity against BRD4-related malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwg6psp_B35bVg90H21EOLACvtfcHk0lhOa_EgYft1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yksA%253D%253D&md5=07296d23042a3ce2f2ecc1b6ae691e30</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01267%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCgle%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DX.%26aulast%3DWeitzel%26aufirst%3DG.%26aulast%3DOstrovskyi%26aufirst%3DD.%26aulast%3DBreit%26aufirst%3DB.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DEinsle%26aufirst%3DO.%26aulast%3DG%25C3%25BCnther%26aufirst%3DS.%26aulast%3DWohlwend%26aufirst%3DD.%26atitle%3D4-Acyl%2520Pyrrole%2520Derivatives%2520Yield%2520Novel%2520Vectors%2520for%2520Designing%2520Inhibitors%2520of%2520the%2520Acetyl-Lysine%2520Recognition%2520Site%2520of%2520BRD4%25281%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1518%26epage%3D1530%26doi%3D10.1021%2Facs.jmedchem.5b01267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Vidler, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8073</span><span class="NLM_x">–</span> <span class="NLM_lpage">8088</span><span class="refDoi"> DOI: 10.1021/jm4011302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOjurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8073-8088&author=L.+R.+Vidlerauthor=P.+Filippakopoulosauthor=O.+Fedorovauthor=S.+Picaudauthor=S.+Martinauthor=M.+Tomsettauthor=H.+Woodwardauthor=N.+Brownauthor=S.+Knappauthor=S.+Hoelder&title=Discovery+of+Novel+Small-Molecule+Inhibitors+of+BRD4+Using+Structure-Based+Virtual+Screening&doi=10.1021%2Fjm4011302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening</span></div><div class="casAuthors">Vidler, Lewis R.; Filippakopoulos, Panagis; Fedorov, Oleg; Picaud, Sarah; Martin, Sarah; Tomsett, Michael; Woodward, Hannah; Brown, Nathan; Knapp, Stefan; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8073-8088</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains (BRDs) are epigenetic readers that recognize acetylated-lysine (KAc) on proteins and are implicated in a no. of diseases.  We describe a virtual screening approach to identify BRD inhibitors.  Key elements of this approach are the extensive design and use of substructure queries to compile a set of com. available compds. featuring novel putative KAc mimetics and docking this set for final compd. selection.  We describe the validation of this approach by applying it to the first BRD of BRD4.  The selection and testing of 143 compds. lead to the discovery of six novel hits, including four unprecedented KAc mimetics.  We solved the crystal structure of four hits, detd. their binding mode, and improved their potency through synthesis and the purchase of derivs.  This work provides a validated virtual screening approach that is applicable to other BRDs and describes novel KAc mimetics that can be further explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow5yj8bnohUbVg90H21EOLACvtfcHk0lhOa_EgYft1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOjurrI&md5=c1f76e4838713335be7a93ebe4c68701</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm4011302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011302%26sid%3Dliteratum%253Aachs%26aulast%3DVidler%26aufirst%3DL.%2BR.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DTomsett%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Small-Molecule%2520Inhibitors%2520of%2520BRD4%2520Using%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8073%26epage%3D8088%26doi%3D10.1021%2Fjm4011302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Ran, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meagher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaswamy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4927</span><span class="NLM_x">–</span> <span class="NLM_lpage">4939</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4927-4939&author=X.+Ranauthor=Y.+Zhaoauthor=L.+Liuauthor=L.+Baiauthor=C.+Y.+Yangauthor=B.+Zhouauthor=J.+L.+Meagherauthor=K.+Chinnaswamyauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-Based+Design+of+%CE%B3-Carboline+Analogues+as+Potent+and+Specific+BET+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors</span></div><div class="casAuthors">Ran, Xu; Zhao, Yujun; Liu, Liu; Bai, Longchuan; Yang, Chao-Yie; Zhou, Bing; Meagher, Jennifer L.; Chinnaswamy, Krishnapriya; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4927-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of bromodomain and extra terminal proteins (BET), including BRD2, BRD3, and BRD4 proteins have therapeutic potential for the treatment of human cancers and other diseases and conditions.  In this paper, the authors report the design, synthesis, and evaluation of γ-carboline-contg. compds. as a new class of small-mol. BET inhibitors.  The most potent inhibitor I (RX-37) obtained from this study binds to BET bromodomain proteins (BRD2, BRD3, and BRD4) with Ki values of 3.2-24.7 nM and demonstrates high selectivity over other non-BET bromodomain-contg. proteins.  Compd. I potently and selectively inhibits cell growth in human acute leukemia cell lines harboring the rearranged mixed lineage leukemia 1 gene.  The authors have detd. a cocrystal structure of I in complex with BRD4 BD2 at 1.4 Å resoln., which provides a solid structural basis for the compd.'s high binding affinity and for its further structure-based optimization.  Compd. I represents a promising lead compd. for the development of a new class of therapeutics for the treatment of human cancer and other conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-VCfWLBWYLVg90H21EOLACvtfcHk0lhT5b1Fft1DqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7rM&md5=e6e150169812e439c1d7d91416eb3ee9</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00613%26sid%3Dliteratum%253Aachs%26aulast%3DRan%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-Based%2520Design%2520of%2520%25CE%25B3-Carboline%2520Analogues%2520as%2520Potent%2520and%2520Specific%2520BET%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4927%26epage%3D4939%26doi%3D10.1021%2Facs.jmedchem.5b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Misra, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Activity of N-aryl-2-aminothiazoles: Potent Pan Inhibitors of Cyclin-Dependent Kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2973</span><span class="NLM_x">–</span> <span class="NLM_lpage">2977</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2004.02.105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2973-2977&author=R.+J.+Misraauthor=H.+J.+Xiaoauthor=D.+K.+Williamsauthor=K.+S.+Kimauthor=S.+Luauthor=K.+A.+Kellerauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=J.+S.+Tokarskiauthor=J.+S.+Sackauthor=S.+D.+Kimballauthor=F.+J.+Leeauthor=K.+R.+Webster&title=Synthesis+and+Biological+Activity+of+N-aryl-2-aminothiazoles%3A+Potent+Pan+Inhibitors+of+Cyclin-Dependent+Kinases&doi=10.1016%2Fj.bmcl.2004.02.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.105%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BJ.%26aulast%3DXiao%26aufirst%3DH.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DLee%26aufirst%3DF.%2BJ.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520N-aryl-2-aminothiazoles%253A%2520Potent%2520Pan%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2973%26epage%3D2977%26doi%3D10.1016%2Fj.bmcl.2004.02.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">TG101209, a Small Molecule JAK2-Selective Kinase Inhibitor Potently Inhibits Myeloproliferative Disorder-Associated JAK2V617F and MPLW515L/K Mutations</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1668</span><span class="refDoi"> DOI: 10.1038/sj.leu.2404750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fsj.leu.2404750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17541402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1658-1668&author=A.+Pardananiauthor=J.+Hoodauthor=T.+Lashoauthor=R.+L.+Levineauthor=M.+B.+Martinauthor=G.+Noronhaauthor=C.+Finkeauthor=C.+C.+Makauthor=R.+Mesaauthor=H.+Zhuauthor=R.+Sollauthor=D.+G.+Gillilandauthor=A.+Tefferi&title=TG101209%2C+a+Small+Molecule+JAK2-Selective+Kinase+Inhibitor+Potently+Inhibits+Myeloproliferative+Disorder-Associated+JAK2V617F+and+MPLW515L%2FK+Mutations&doi=10.1038%2Fsj.leu.2404750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations</span></div><div class="casAuthors">Pardanani, A.; Hood, J.; Lasho, T.; Levine, R. L.; Martin, M. B.; Noronha, G.; Finke, C.; Mak, C. C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D. G.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1658-1668</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis.  The authors developed TG101209, an orally bioavailable small mol. that potently inhibits JAK2 (IC50 = 6 nM), FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC50 = 169 nM).  TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of ∼200 nM.  In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209-induced cell cycle arrest and apoptosis, and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3.  Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model.  Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFcz0joQsNbVg90H21EOLACvtfcHk0lhT5b1Fft1DqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D&md5=784ff4ff7d65097052d9d864c90e8138</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404750%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BB.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DTG101209%252C%2520a%2520Small%2520Molecule%2520JAK2-Selective%2520Kinase%2520Inhibitor%2520Potently%2520Inhibits%2520Myeloproliferative%2520Disorder-Associated%2520JAK2V617F%2520and%2520MPLW515L%252FK%2520Mutations%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1658%26epage%3D1668%26doi%3D10.1038%2Fsj.leu.2404750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Lénárt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipp, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J. M.</span><span> </span><span class="NLM_article-title">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.cub.2006.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=17291761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=304-315&author=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Steegmaierauthor=B.+Di+Fioreauthor=J.+J.+Lippauthor=M.+Hoffmannauthor=W.+J.+Rettigauthor=N.+Krautauthor=J.+M.+Peters&title=The+Small-Molecule+Inhibitor+BI+2536+Reveals+Novel+Insights+into+Mitotic+Roles+of+Polo-like+Kinase+1&doi=10.1016%2Fj.cub.2006.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span></div><div class="casAuthors">Lenart, Peter; Petronczki, Mark; Steegmaier, Martin; Di Fiore, Barbara; Lipp, Jesse J.; Hoffmann, Matthias; Rettig, Wolfgang J.; Kraut, Norbert; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensively to further understanding of mitotic mechanisms and as potential targets for cancer therapy.  Cdk1 and Aurora kinase studies have been facilitated by small-mol. inhibitors, but few if any potent Plk1 inhibitors have been identified.  We describe the cellular effects of a novel compd., BI 2536, a potent and selective inhibitor of Plk1.  The fact that BI 2536 blocks Plk1 activity fully and instantaneously enabled us to study controversial and unknown functions of Plk1.  Cells treated with BI 2536 are delayed in prophase but eventually import Cdk1-cyclin B into the nucleus, enter prometaphase, and degrade cyclin A, although BI 2536 prevents degrdn. of the APC/C inhibitor Emi1.  BI 2536-treated cells lack prophase microtubule asters and thus polymerize mitotic microtubules only after nuclear-envelope breakdown and form monopolar spindles that do not stably attach to kinetochores.  Mad2 accumulates at kinetochores, and cells arrest with an activated spindle-assembly checkpoint.  BI 2536 prevents Plk1's enrichment at kinetochores and centrosomes, and when added to metaphase cells, it induces detachment of microtubules from kinetochores and leads to spindle collapse.  Our results suggest that Plk1's accumulation at centrosomes and kinetochores depends on its own activity and that this activity is required for maintaining centrosome and kinetochore function.  Our data also show that Plk1 is not required for prophase entry, but delays transition to prometaphase, and that Emi1 destruction in prometaphase is not essential for APC/C-mediated cyclin A degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmCcyKwjrX7Vg90H21EOLACvtfcHk0liMZMndjvlYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D&md5=4f0bc426138f64db93e17bf10a5f4db9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DB.%26aulast%3DLipp%26aufirst%3DJ.%2BJ.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Small-Molecule%2520Inhibitor%2520BI%25202536%2520Reveals%2520Novel%2520Insights%2520into%2520Mitotic%2520Roles%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.cub.2006.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Boehm, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bower, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span> </span><span class="NLM_article-title">Phenoxypyrimidine Inhibitors of p38α Kinase: Synthesis and Statistical Evaluation of the p38 Inhibitory Potencies of a Series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00163-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2FS0960-894X%2801%2900163-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1123-1126&issue=9&author=J.+C.+Boehmauthor=M.+J.+Bowerauthor=T.+F.+Gallagherauthor=S.+Kassisauthor=S.+R.+Johnsonauthor=J.+R.+Adams&title=Phenoxypyrimidine+Inhibitors+of+p38%CE%B1+Kinase%3A+Synthesis+and+Statistical+Evaluation+of+the+p38+Inhibitory+Potencies+of+a+Series+of+1-%28piperidin-4-yl%29-4-%284-fluorophenyl%29-5-%282-phenoxypyrimidin-4-yl%29+imidazoles&doi=10.1016%2FS0960-894X%2801%2900163-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900163-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900163-9%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DJ.%2BC.%26aulast%3DBower%26aufirst%3DM.%2BJ.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DKassis%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26atitle%3DPhenoxypyrimidine%2520Inhibitors%2520of%2520p38%25CE%25B1%2520Kinase%253A%2520Synthesis%2520and%2520Statistical%2520Evaluation%2520of%2520the%2520p38%2520Inhibitory%2520Potencies%2520of%2520a%2520Series%2520of%25201-%2528piperidin-4-yl%2529-4-%25284-fluorophenyl%2529-5-%25282-phenoxypyrimidin-4-yl%2529%2520imidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D9%26spage%3D1123%26epage%3D1126%26doi%3D10.1016%2FS0960-894X%2801%2900163-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Leahy, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigoreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span> </span><span class="NLM_article-title">Identification of a Highly Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor (NU7441) by Screening of Chromenone Libraries</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6083</span><span class="NLM_x">–</span> <span class="NLM_lpage">6087</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2004.09.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=15546735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps1Okurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=6083-6087&issue=24&author=J.+J.+J.+Leahyauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=I.+R.+Hardcastleauthor=C.+Richardsonauthor=L.+Rigoreauauthor=G.+C.+M.+Smith&title=Identification+of+a+Highly+Potent+and+Selective+DNA-Dependent+Protein+Kinase+%28DNA-PK%29+Inhibitor+%28NU7441%29+by+Screening+of+Chromenone+Libraries&doi=10.1016%2Fj.bmcl.2004.09.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries</span></div><div class="casAuthors">Leahy, Justin J. J.; Golding, Bernard T.; Griffin, Roger J.; Hardcastle, Ian R.; Richardson, Caroline; Rigoreau, Laurent; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6083-6087</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A soln.-phase multiple-parallel synthesis approach was employed for the prepn. of 6-, 7- and 8-aryl-substituted chromenone libraries, which were screened as inhibitors of the DNA repair enzyme DNA-dependent protein kinase (DNA-PK).  These studies resulted in the identification of 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (I; NU7441) as a highly potent and selective DNA-PK inhibitor (IC50 = 14 nM), exhibiting ATP-competitive inhibition kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIxqS9nsWG9rVg90H21EOLACvtfcHk0liMZMndjvlYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps1Okurg%253D&md5=f2a980013b9943f93a6c9e5f6897cf8a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.060%26sid%3Dliteratum%253Aachs%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26atitle%3DIdentification%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520DNA-Dependent%2520Protein%2520Kinase%2520%2528DNA-PK%2529%2520Inhibitor%2520%2528NU7441%2529%2520by%2520Screening%2520of%2520Chromenone%2520Libraries%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D24%26spage%3D6083%26epage%3D6087%26doi%3D10.1016%2Fj.bmcl.2004.09.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Davies, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caivano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0liMZMndjvlYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Rudolph, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3094</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+A+Polo-like+Kinase+Inhibitor+with+Improved+Pharmacokinetic+Profile+and+Broad+Antitumor+Activity&doi=10.1158%2F1078-0432.CCR-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0lisJ6viqFIPrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520A%2520Polo-like%2520Kinase%2520Inhibitor%2520with%2520Improved%2520Pharmacokinetic%2520Profile%2520and%2520Broad%2520Antitumor%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26doi%3D10.1158%2F1078-0432.CCR-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Hewitt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tighe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santaguida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musacchio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span> </span><span class="NLM_article-title">Sustained Mps1 Activity is Required in Mitosis to Recruit O-Mad2 to the Mad1–C-Mad2 Core Complex</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1083/jcb.201002133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1083%2Fjcb.201002133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=20624899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2010&pages=25-34&author=L.+Hewittauthor=A.+Tigheauthor=S.+Santaguidaauthor=A.+M.+Whiteauthor=C.+D.+Jonesauthor=A.+Musacchioauthor=S.+Greenauthor=S.+S.+Taylor&title=Sustained+Mps1+Activity+is+Required+in+Mitosis+to+Recruit+O-Mad2+to+the+Mad1%E2%80%93C-Mad2+Core+Complex&doi=10.1083%2Fjcb.201002133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex</span></div><div class="casAuthors">Hewitt, Laura; Tighe, Anthony; Santaguida, Stefano; White, Anne M.; Jones, Clifford D.; Musacchio, Andrea; Green, Stephen; Taylor, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mps1 is an essential component of the spindle assembly checkpoint.  In this study, we describe a novel Mps1 inhibitor, AZ3146, and use it to probe the role of Mps1's catalytic activity during mitosis.  When Mps1 is inhibited before mitotic entry, subsequent recruitment of Mad1 and Mad2 to kinetochores is abolished.  However, if Mps1 is inhibited after mitotic entry, the Mad1-C-Mad2 core complex remains kinetochore bound, but O-Mad2 is not recruited to the core.  Although inhibiting Mps1 also interferes with chromosome alignment, we see no obvious effect on aurora B activity.  In contrast, kinetochore recruitment of centromere protein E (CENP-E), a kinesin-related motor protein, is severely impaired.  Strikingly, inhibition of Mps1 significantly increases its own abundance at kinetochores.  Furthermore, we show that Mps1 can dimerize and transphosphorylate in cells.  We propose a model whereby Mps1 transphosphorylation results in its release from kinetochores, thus facilitating recruitment of O-Mad2 and CENP-E and thereby simultaneously promoting checkpoint signaling and chromosome congression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40BfrYS2Vu7Vg90H21EOLACvtfcHk0lisJ6viqFIPrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D&md5=2b95cfba4b228bada877bdb6dc95be1f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201002133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201002133%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DL.%26aulast%3DTighe%26aufirst%3DA.%26aulast%3DSantaguida%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DSustained%2520Mps1%2520Activity%2520is%2520Required%2520in%2520Mitosis%2520to%2520Recruit%2520O-Mad2%2520to%2520the%2520Mad1%25E2%2580%2593C-Mad2%2520Core%2520Complex%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D190%26spage%3D25%26epage%3D34%26doi%3D10.1083%2Fjcb.201002133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Allen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, P.</span><span> </span><span class="NLM_article-title">Emerging Targets in Osteoporosis Disease Modification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4332</span><span class="NLM_x">–</span> <span class="NLM_lpage">4353</span><span class="refDoi"> DOI: 10.1021/jm9018756</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018756" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVyht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4332-4353&author=J.+G.+Allenauthor=C.+Fotschauthor=P.+Babij&title=Emerging+Targets+in+Osteoporosis+Disease+Modification&doi=10.1021%2Fjm9018756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Targets in Osteoporosis Disease Modification</span></div><div class="casAuthors">Allen, John G.; Fotsch, Christopher; Babij, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4332-4353</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolnqRUQFya4bVg90H21EOLACvtfcHk0lisJ6viqFIPrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVyht74%253D&md5=78e247d0cddbbba4635209fa030d688f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm9018756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018756%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DBabij%26aufirst%3DP.%26atitle%3DEmerging%2520Targets%2520in%2520Osteoporosis%2520Disease%2520Modification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4332%26epage%3D4353%26doi%3D10.1021%2Fjm9018756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Z.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0liuiJp40HYAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%2BZ.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span><span class="refDoi"> DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0liuiJp40HYAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claiborne, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libby, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitzenberger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selnick, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancheck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanlon, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofsess, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orevillo, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolando, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahly, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2180</span><span class="NLM_x">–</span> <span class="NLM_lpage">2190</span><span class="refDoi"> DOI: 10.1021/jm9805236</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9805236" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADyaK1MXjt1aqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2180-2190&author=N.+J.+Livertonauthor=J.+W.+Butcherauthor=C.+F.+Claiborneauthor=D.+A.+Claremonauthor=B.+E.+Libbyauthor=K.+T.+Nguyenauthor=S.+M.+Pitzenbergerauthor=H.+G.+Selnickauthor=G.+R.+Smithauthor=A.+Tebbenauthor=J.+P.+Vaccaauthor=S.+L.+Vargaauthor=L.+Agarwalauthor=K.+Dancheckauthor=A.+J.+Forsythauthor=D.+S.+Fletcherauthor=B.+Frantzauthor=W.+A.+Hanlonauthor=C.+F.+Harperauthor=S.+J.+Hofsessauthor=M.+Kosturaauthor=J.+Linauthor=S.+Luellauthor=E.+A.+O%E2%80%99Neillauthor=C.+J.+Orevilloauthor=M.+Pangauthor=J.+Parsonsauthor=A.+Rolandoauthor=Y.+Sahlyauthor=D.+M.+Viscoauthor=S.+J.+O%E2%80%99Keefe&title=Design+and+Synthesis+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Tetrasubstituted+Imidazole+Inhibitors+of+p38+Mitogen-Activated+Protein+Kinase&doi=10.1021%2Fjm9805236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase</span></div><div class="casAuthors">Liverton, Nigel J.; Butcher, John W.; Claiborne, Christopher F.; Claremon, David A.; Libby, Brian E.; Nguyen, Kevin T.; Pitzenberger, Steven M.; Selnick, Harold G.; Smith, Garry R.; Tebben, Andrew; Vacca, Joseph P.; Varga, Sandor L.; Agarwal, Lily; Dancheck, Kim; Forsyth, Amy J.; Fletcher, Daniel S.; Frantz, Betsy; Hanlon, William A.; Harper, Coral F.; Hofsess, Scott J.; Kostura, Matthew; Lin, Jiunn; Luell, Sylvie; O'Neill, Edward A.; Orevillo, Chad J.; Pang, Margaret; Parsons, Janey; Rolando, Anna; Sahly, Yousif; Visco, Denise M.; O'Keefe, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2180-2190</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-α (TNF-α) release and an animal model of rheumatoid arthritis.  The SAR leading to the development of selectivity against c-Raf and JNK2α1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a 2-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aq. soly.  In general, oral bioavailability of this class of compds. was found to be poor unless the imidazole was methylated on nitrogen.  This work led to identification of 4-[1-methyl-2-(4-piperidinyl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]-2-pyridinamine sulfate salt, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-α from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCz5nW0Ifnt7Vg90H21EOLACvtfcHk0lgNtrFgMLX8VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjt1aqsrY%253D&md5=1a8e8710ce6ab0c3928077a29029938d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm9805236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9805236%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DLibby%26aufirst%3DB.%2BE.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DPitzenberger%26aufirst%3DS.%2BM.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DVarga%26aufirst%3DS.%2BL.%26aulast%3DAgarwal%26aufirst%3DL.%26aulast%3DDancheck%26aufirst%3DK.%26aulast%3DForsyth%26aufirst%3DA.%2BJ.%26aulast%3DFletcher%26aufirst%3DD.%2BS.%26aulast%3DFrantz%26aufirst%3DB.%26aulast%3DHanlon%26aufirst%3DW.%2BA.%26aulast%3DHarper%26aufirst%3DC.%2BF.%26aulast%3DHofsess%26aufirst%3DS.%2BJ.%26aulast%3DKostura%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuell%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%2BA.%26aulast%3DOrevillo%26aufirst%3DC.%2BJ.%26aulast%3DPang%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DRolando%26aufirst%3DA.%26aulast%3DSahly%26aufirst%3DY.%26aulast%3DVisco%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Tetrasubstituted%2520Imidazole%2520Inhibitors%2520of%2520p38%2520Mitogen-Activated%2520Protein%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2180%26epage%3D2190%26doi%3D10.1021%2Fjm9805236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Padilla, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowrie, L. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O-Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span> </span><span class="NLM_article-title">Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1677</span><span class="NLM_x">–</span> <span class="NLM_lpage">1692</span><span class="refDoi"> DOI: 10.1021/jm301720p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301720p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFaqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1677-1692&author=F.+Padillaauthor=N.+Bhagirathauthor=S.+Chenauthor=R.+Chiaoauthor=D.+M.+Goldsteinauthor=J.+C.+Hermannauthor=J.+Hsuauthor=J.+J.+Kennedy-Smithauthor=A.+Kuglstatterauthor=C.+Liaoauthor=W.+Liuauthor=L.+E.+Lowrieauthor=K.+C.+Lukauthor=S.+M.+Lynchauthor=J.+M.+Menkeauthor=L.+Niuauthor=T.+D.+Owensauthor=C.+O-Yangauthor=A.+Railkarauthor=R.+C.+Schoenfeldauthor=M.+Sladeauthor=S.+Steinerauthor=Y.+C.+Tanauthor=A.+G.+Villasenorauthor=C.+Wangauthor=J.+Wannerauthor=W.+Xieauthor=D.+Xuauthor=X.+Zhangauthor=M.+Zhouauthor=M.+C.+Lucas&title=Pyrrolopyrazines+as+Selective+Spleen+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Fjm301720p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Padilla, Fernando; Bhagirath, Niala; Chen, Shaoqing; Chiao, Eric; Goldstein, David M.; Hermann, Johannes C.; Hsu, Jonathan; Kennedy-Smith, Joshua J.; Kuglstatter, Andreas; Liao, Cheng; Liu, Wenjian; Lowrie, Lee E., Jr.; Luk, Kin Chun; Lynch, Stephen M.; Menke, John; Niu, Linghao; Owens, Timothy D.; O-Yang, Counde; Railkar, Aruna; Schoenfeld, Ryan C.; Slade, Michelle; Steiner, Sandra; Tan, Yun-Chou; Villasenor, Armando G.; Wang, Ce; Wanner, Jutta; Xie, Wenwei; Xu, Daigen; Zhang, Xiaohu; Zhou, Mingyan; Lucas, Matthew C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1677-1692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochem. properties and human whole blood potencies.  Ultimately, the mouse model revealed unexpected toxicity of compd. I that precluded the further advancement of this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPn6yiWDGRMbVg90H21EOLACvtfcHk0lgNtrFgMLX8VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFaqurs%253D&md5=2ab3e28de06e6300547d2a474bd14aef</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm301720p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301720p%26sid%3Dliteratum%253Aachs%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChiao%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLowrie%26aufirst%3DL.%2BE.%26aulast%3DLuk%26aufirst%3DK.%2BC.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DMenke%26aufirst%3DJ.%2BM.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DO-Yang%26aufirst%3DC.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWanner%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26atitle%3DPyrrolopyrazines%2520as%2520Selective%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1677%26epage%3D1692%26doi%3D10.1021%2Fjm301720p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Taha, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bustanji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ghussein, M. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalloum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Masri, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, N.</span><span> </span><span class="NLM_article-title">Pharmacophore Modeling, Quantitative Structure–Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2062</span><span class="NLM_x">–</span> <span class="NLM_lpage">2077</span><span class="refDoi"> DOI: 10.1021/jm7009765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2062-2077&author=M.+O.+Tahaauthor=Y.+Bustanjiauthor=M.+A.+S.+Al-Ghusseinauthor=M.+Mohammadauthor=H.+Zalloumauthor=I.+M.+Al-Masriauthor=N.+Atallah&title=Pharmacophore+Modeling%2C+Quantitative+Structure%E2%80%93Activity+Relationship+Analysis%2C+and+in+Silico+Screening+Reveal+Potent+Glycogen+Synthase+Kinase-3%CE%B2+Inhibitory+Activities+for+Cimetidine%2C+Hydroxychloroquine%2C+and+Gemifloxacin&doi=10.1021%2Fjm7009765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin</span></div><div class="casAuthors">Taha, Mutasem O.; Bustanji, Yasser; Al-Ghussein, Mohamed A. S.; Mohammad, Mohammad; Zalloum, Hiba; Al-Masri, Ihab M.; Atallah, Naji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2062-2077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacophoric space of glycogen synthase kinase-3β (GSK-3β) was explored using two diverse sets of inhibitors.  Subsequently, genetic algorithm and multiple linear regression anal. were employed to select optimal combination of pharmacophores and physicochem. descriptors that access self-consistent and predictive quant. structure-activity relationship (QSAR) against 132 training compds. (r2123 = 0.663, F = 24.6, r2LOO = 0.592, r2PRESS against 29 external test inhibitors = 0.695).  Two orthogonal pharmacophores emerged in the QSAR, suggesting the existence of at least two distinct binding modes accessible to ligands within GSK-3β binding pocket.  The validity of the QSAR equation and the assocd. pharmacophores was established by the identification of three nanomolar GSK-3β inhibitors retrieved from our inhouse-built structural database of established drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin.  Docking studies supported the binding modes suggested by the pharmacophore/QSAR anal.  In addn. to being excellent leads for subsequent optimization, the anti-GSK-3β activities of these drugs should have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEh_csUf5KYLVg90H21EOLACvtfcHk0lgNtrFgMLX8VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOnur0%253D&md5=60a909c0c66603e68e29bddfb3518a36</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm7009765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009765%26sid%3Dliteratum%253Aachs%26aulast%3DTaha%26aufirst%3DM.%2BO.%26aulast%3DBustanji%26aufirst%3DY.%26aulast%3DAl-Ghussein%26aufirst%3DM.%2BA.%2BS.%26aulast%3DMohammad%26aufirst%3DM.%26aulast%3DZalloum%26aufirst%3DH.%26aulast%3DAl-Masri%26aufirst%3DI.%2BM.%26aulast%3DAtallah%26aufirst%3DN.%26atitle%3DPharmacophore%2520Modeling%252C%2520Quantitative%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Analysis%252C%2520and%2520in%2520Silico%2520Screening%2520Reveal%2520Potent%2520Glycogen%2520Synthase%2520Kinase-3%25CE%25B2%2520Inhibitory%2520Activities%2520for%2520Cimetidine%252C%2520Hydroxychloroquine%252C%2520and%2520Gemifloxacin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2062%26epage%3D2077%26doi%3D10.1021%2Fjm7009765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieffine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalisz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M.</span><span> </span><span class="NLM_article-title">Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1016/j.jmb.2003.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.jmb.2003.08.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2003&pages=393-407&issue=2&author=J.+A.+Bertrandauthor=S.+Thieffineauthor=A.+Vulpettiauthor=C.+Cristianiauthor=B.+Valsasinaauthor=S.+Knappauthor=H.+M.+Kaliszauthor=M.+Flocco&title=Structural+Characterization+of+the+GSK-3%CE%B2+Active+Site+Using+Selective+and+Non-selective+ATP-mimetic+Inhibitors&doi=10.1016%2Fj.jmb.2003.08.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKalisz%26aufirst%3DH.%2BM.%26aulast%3DFlocco%26aufirst%3DM.%26atitle%3DStructural%2520Characterization%2520of%2520the%2520GSK-3%25CE%25B2%2520Active%2520Site%2520Using%2520Selective%2520and%2520Non-selective%2520ATP-mimetic%2520Inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D333%26issue%3D2%26spage%3D393%26epage%3D407%26doi%3D10.1016%2Fj.jmb.2003.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamford, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaiba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, J. GA.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The Identification of Potent, Selective and CNS Penetrant Furan-Based Inhibitors of B-Raf Kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4373</span><span class="NLM_x">–</span> <span class="NLM_lpage">4376</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;key=10.1016%2Fj.bmcl.2008.06.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4373-4376&issue=15&author=A.+K.+Takleauthor=M.+J.+Bamfordauthor=S.+Daviesauthor=R.+P.+Davisauthor=D.+K.+Deanauthor=A.+Gaibaauthor=E.+A.+Irvingauthor=F.+D.+Kingauthor=A.+Naylorauthor=C.+A.+Parrauthor=A.+M.+Rayauthor=A.+D.+Reithauthor=B.+B.+Smithauthor=P.+C.+Statonauthor=J.+GA.+Steadmanauthor=T.+O.+Steanauthor=D.+M.+Wilson&title=The+Identification+of+Potent%2C+Selective+and+CNS+Penetrant+Furan-Based+Inhibitors+of+B-Raf+Kinase&doi=10.1016%2Fj.bmcl.2008.06.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DIrving%26aufirst%3DE.%2BA.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DRay%26aufirst%3DA.%2BM.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DB.%2BB.%26aulast%3DStaton%26aufirst%3DP.%2BC.%26aulast%3DSteadman%26aufirst%3DJ.%2BGA.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520Identification%2520of%2520Potent%252C%2520Selective%2520and%2520CNS%2520Penetrant%2520Furan-Based%2520Inhibitors%2520of%2520B-Raf%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D15%26spage%3D4373%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2008.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KD1','PDB','4KD1'); return false;">PDB: 4KD1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KCX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KCX','PDB','4KCX'); return false;">PDB: 4KCX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O70','PDB','4O70'); return false;">PDB: 4O70</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF','PDB','3MXF'); return false;">PDB: 3MXF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YEL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YEL','PDB','2YEL'); return false;">PDB: 2YEL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLP','PDB','4FLP'); return false;">PDB: 4FLP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O76','PDB','4O76'); return false;">PDB: 4O76</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7F','PDB','4O7F'); return false;">PDB: 4O7F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O74','PDB','4O74'); return false;">PDB: 4O74</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CFK','PDB','4CFK'); return false;">PDB: 4CFK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O72','PDB','4O72'); return false;">PDB: 4O72</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P5O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P5O','PDB','3P5O'); return false;">PDB: 3P5O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O71" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O71','PDB','4O71'); return false;">PDB: 4O71</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR','PDB','3BLR'); return false;">PDB: 3BLR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JI9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JI9','PDB','4JI9'); return false;">PDB: 4JI9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O73" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O73','PDB','4O73'); return false;">PDB: 4O73</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU','PDB','2RKU'); return false;">PDB: 2RKU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2','PDB','4FA2'); return false;">PDB: 4FA2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V','PDB','1E7V'); return false;">PDB: 1E7V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O77" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O77','PDB','4O77'); return false;">PDB: 4O77</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZS5','PDB','3ZS5'); return false;">PDB: 3ZS5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D9K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D9K','PDB','5D9K'); return false;">PDB: 5D9K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FC2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FC2','PDB','3FC2'); return false;">PDB: 3FC2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FZR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FZR','PDB','3FZR'); return false;">PDB: 3FZR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT5','PDB','4JT5'); return false;">PDB: 4JT5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O78" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O78','PDB','4O78'); return false;">PDB: 4O78</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CIF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CIF','PDB','3CIF'); return false;">PDB: 3CIF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7B','PDB','4O7B'); return false;">PDB: 4O7B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7E','PDB','4O7E'); return false;">PDB: 4O7E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O75" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O75','PDB','4O75'); return false;">PDB: 4O75</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PIY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PIY','PDB','3PIY'); return false;">PDB: 3PIY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7A','PDB','4O7A'); return false;">PDB: 4O7A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L','PDB','1Q4L'); return false;">PDB: 1Q4L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O7C','PDB','4O7C'); return false;">PDB: 4O7C</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00438&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00438%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-20%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00438" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ab23088a03c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
